<SEC-DOCUMENT>0001701541-23-000032.txt : 20230509
<SEC-HEADER>0001701541-23-000032.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509074547
ACCESSION NUMBER:		0001701541-23-000032
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Black Diamond Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001701541
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39200
		FILM NUMBER:		23900021

	BUSINESS ADDRESS:	
		STREET 1:		ONE MAIN STREET, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-417-5868

	MAIL ADDRESS:	
		STREET 1:		ONE MAIN STREET, 14TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aset Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170321
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bdtx-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:73ec13c2-272f-4624-b8c8-b5925ba5540a,g:c0252310-7c05-47ef-aa9c-a55e1f9856cd,d:c06fdbc868994781830cfb9f962306b5--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:bdtx="http://www.blackdiamondtherapeutics.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bdtx-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80L2ZyYWc6NWM4OWRjOTQ1YjM4NGI1MWI2MDQ4NTJiYWFhNmVhNzkvdGFibGU6ZDUyZGQ0OTcyM2I5NGYzMDk4ODM4MDE3YWI4MmMzNzMvdGFibGVyYW5nZTpkNTJkZDQ5NzIzYjk0ZjMwOTg4MzgwMTdhYjgyYzM3M18yLTEtMS0xLTI4MzI4_dcae7fe2-1a28-4f51-bef1-12f033ef0509">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80L2ZyYWc6NWM4OWRjOTQ1YjM4NGI1MWI2MDQ4NTJiYWFhNmVhNzkvdGFibGU6ZDUyZGQ0OTcyM2I5NGYzMDk4ODM4MDE3YWI4MmMzNzMvdGFibGVyYW5nZTpkNTJkZDQ5NzIzYjk0ZjMwOTg4MzgwMTdhYjgyYzM3M18zLTEtMS0xLTI4MzI4_fb1317ae-7e7f-4634-90ff-f377080ea7ce">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80L2ZyYWc6NWM4OWRjOTQ1YjM4NGI1MWI2MDQ4NTJiYWFhNmVhNzkvdGFibGU6ZDUyZGQ0OTcyM2I5NGYzMDk4ODM4MDE3YWI4MmMzNzMvdGFibGVyYW5nZTpkNTJkZDQ5NzIzYjk0ZjMwOTg4MzgwMTdhYjgyYzM3M180LTEtMS0xLTI4MzI4_948289de-1409-408d-a855-1a20bf67770d">2023</ix:nonNumeric><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80L2ZyYWc6NWM4OWRjOTQ1YjM4NGI1MWI2MDQ4NTJiYWFhNmVhNzkvdGFibGU6ZDUyZGQ0OTcyM2I5NGYzMDk4ODM4MDE3YWI4MmMzNzMvdGFibGVyYW5nZTpkNTJkZDQ5NzIzYjk0ZjMwOTg4MzgwMTdhYjgyYzM3M181LTEtMS0xLTI4MzI4_bd19ea92-5a76-477a-a5de-13c9cb493f7d">0001701541</ix:nonNumeric><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80L2ZyYWc6NWM4OWRjOTQ1YjM4NGI1MWI2MDQ4NTJiYWFhNmVhNzkvdGFibGU6ZDUyZGQ0OTcyM2I5NGYzMDk4ODM4MDE3YWI4MmMzNzMvdGFibGVyYW5nZTpkNTJkZDQ5NzIzYjk0ZjMwOTg4MzgwMTdhYjgyYzM3M182LTEtMS0xLTI4MzI4_3757cd07-c175-4a78-b1a2-cc237b135885">12-31</ix:nonNumeric><ix:nonNumeric contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_5102cdaa-2077-4a92-ad76-9ae9e3ad93f1">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_fd6e36e0-6ca5-4d7c-bac0-99a6f8cd4f37">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i09dbac4b37d84e3eb2e7dad646327861_I20200731" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfNTMw_02522d54-356b-489e-ae5f-0345b2c059f0">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="id28a5be0a35d4bc881d156351fc61d4e_I20201231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMTY5OA_c306ce76-7222-412d-9933-d5323bf1972b">P5Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bdtx-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66226731c0624aabac4ffa6c672102e6_I20230501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if76381c49969430b8ee1ce9004b721ee_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i17eafc42a82d4f13904b976d1891eb47_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18236f10c6bb43fba2c9c3fbf41ce4ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9928ba02038f4ae78a1c4a0dd70f34fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5805f6a69cd441a69d534bb81c0e06da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68d16179c5a14c7ebdbc734b0382415d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i456bfd3daab443ea80542d825dc5fe07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08b218a8d5294a0cbed694379ad58ce2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e95a40d0c894120a1db7291d5cee4e2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94cc5dde32e24698bf33abd440aee5b4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1e742d729ce432ca0f35a2494585ade_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28226edd859e4dab945d64e22ffcaebf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ef21fb740fd4df29d87c63818a8be4f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i550bd7cfc5394510a5c782d6d944408a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58ce2b6758eb48fa96ddd6fc6e0b2a03_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dad2752f6d24f69beb01b7d41d018ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44fbc51eccac4780a51aa2110725c195_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aa33c9766164861a9a2941ebecacdc5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d19e2d7bf5648c0a1412530bc5a4c83_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3528e294eb84233bd324a45f9d5729f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0092b7cc057941c08850f1ad6c56a4d3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a14724cbb314a469c727f2b58faa85e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43d5ebddb1f54d71b47373c1b912f7e9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1759f611756a4cffabc3f4c4fb8a6561_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4440f7aa29164195bfa74c860ee07235_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id112bbe0621046fca2f448c03c6b6480_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c4a9410dd2e40eb9adaf67022861157_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i759d4ddb3ad64fd38d5531cb44817594_D20221114-20221114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdtx:ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-14</xbrli:startDate><xbrli:endDate>2022-11-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f823a64b85d4ac7bd10d06b5df686fb_D20221114-20221114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdtx:OpenMarketSaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-14</xbrli:startDate><xbrli:endDate>2022-11-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb328d7ce3ad4166b5b61eefd59f420a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5277e7080f4af5bb25a652a809641e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6687f45413a4419bb690fef99015b01f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0274173257c24f579ec10811eeb0c81a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b0e3b7df6074918b33a2cdc71901202_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08fef76a1c7c437c9d1b3eda6db89dd3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55653debaf274b11b4ac7a51ce4696e4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a33cd0b3c4a4b16a14fe04651a86c84_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a75e0a6cc5a43a49aa062ef1bece4c0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84693306474940138214ef4e5288008e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0023816158b34fbdbb78091138c96439_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92484769461f4b74b3d02cb2e1f9e9a2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d84216f3a25460d9a88c52522dd8d6f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i206b8d6455b84e2f9f3f3b9a6c71a580_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3da457e1122144b4b86fe4e412be3000_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1de270b96e64e8d86b7cbcec1f81067_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b518c619fde4699bb430693ce9bb402_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0954e4764df9420ca7f966a581b88ab5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3bdbcb5dab7449a919d62bf333c2769_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifff94a18639d4cc9ace4b7980f18491b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea5548dbdcc84e34b38db41da417d969_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie47787450b694b2ea0d0a633fb578e87_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i143f2d561c544650ae4cec160b40d837_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i559c92eb9a82422882d92a40b4732e87_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c4d688c720846d2a8ca1d0ef6ad503a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55878f702cbe4a6785d7165f6bc9ba1b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf6167cc94b8412da93063def658ef27_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76c3bea13eeb4df78dbeccc4af6e9ef1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i694eac40ab4244e99565a2f9e0787907_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2134d67ef3194c7486e8e79dbdced6a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i885123a2113040f3b1921f9e90183ed4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70fe665f9b0b4d5f97f1dd8448e2e411_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38fd7a41430b45bb87c13424399f3a46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9f1757297d34af5b00fef34b103aa0a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b0d8ea13e94b30a9276dd91f107156_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i939ee62047f64d468543c94f23dee9b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9351ba53ff254b0f88999f498b0319e9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8f2c21f696d4b7da626acb69831ccb0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e1463d111734f7ba01a42c102369654_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04d9627eeb7e470e8198fa77f00eba51_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5395e8eff10344b5ac2d2b3de662edb3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i700858d5fb2842d8aa731adad03358f0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f6c4be62384e909f6b4e404ead2edc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93b69b82ac6a4bb9a460d33085d57f68_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i521fe07ef68d4b4a935d05639717ad02_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2982e6cbd8454350b0195b786784f14a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a98c5b77af845f1970750ebfc01cbf6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c3fa369595f4fd88697523852da9e92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i758366b058d642888997dc00f48056d1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic51c923c2ba142dca072c9813d731cae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13adc33a304f4c00a11e5a74299bae27_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bdtx:LaunchpadTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd3f10ee0c2541fd9d0fc8361fe6a9e4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bdtx:LaunchpadTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if35bb4b182804be19ee91c94ba0ca241_I20221201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bdtx:LaunchpadTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i865dd29de11f4df59827ccfa2b07a604_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bdtx:LaunchpadTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53da331621624cf18bde372f78562fe5_I20200114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae929b9e760640749d3650b763b62da4_D20230101-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeabbd2a73b145ea98866ff29f77c989_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7a453a75f14538a02a138efbfaf7a5_I20200114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4476e554da044810af3f1a45eaa2a804_D20230101-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i549acd543c9a4b5aa7c94abf409f84da_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f33b8615f184762bdde93307f038957_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89b78b326fe4b0a997b225ea39acef4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ab72299068b42fdbaa9a32deddc9c0d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd05de7566d7485c87c6e0a63d1068f1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:OtherAwardTypeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf76fbfd9fad48fbafde9bd4d08feef3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:OtherAwardTypeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531627ec9aa54ef1ba96e5c5b9e70e77_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a68a37a9356497ebf39ad08f89e5202_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40eacd0ad8714a8b8f4aa9d78df3b014_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie179c4253b6c47ac8c91e9c01f937de2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b7e706f65f045e882a5da0982835947_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e69e52e4e6d406fb3c05c1f565e0fc4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ba383758bc7459cbba65c787855cd79_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bbb31a5e28c45da9f270f4b2a17dc96_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1dd1836d0a04ec5916ed35f6b8154f9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6665b2a485470da5f751271274fa6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id72ab97139f6499186284a9e549e2dcd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b8ca7e990664a5b82b28aaeab2809ac_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f5dc11878354eceb96d35803df03196_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaedbd1575db640bfa3b1a3840d2f60c1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92885a5fac644e64800d5f746f26e823_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34860dd43a7c4f3385bb39b1b3cce7d7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i655a42e7d5614f70874d9d99b077d0ca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e956203346c4f019b41b2e8a5ca63b5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i480b155b6e9e4eb7bb0b1e836d5e7afb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54c6774cffa04e968e001d62f8b99a07_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib89eee0073ef4f748054dcd1018afcb4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf82d51205674d83a503b0e61adba697_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id425a5500c184a08bd09e08bff211884_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812984cbee954504a8f1cb1007753038_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if98a5e733c4c466b9290ddc071d57eb2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c4704e3cd5b4f9ca3f745afab97bcbc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec9bf005920e479db53ec4495d3c9605_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="contract"><xbrli:measure>bdtx:contract</xbrli:measure></xbrli:unit><xbrli:context id="i09dbac4b37d84e3eb2e7dad646327861_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bdtx:OperatingLeasePrincipalOfficeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="id28a5be0a35d4bc881d156351fc61d4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001701541</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bdtx:OperatingLeaseOfficeAndLaboratorySpaceNYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic06fdbc868994781830cfb9f962306b5_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">___________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18xMjY_33a4d7c0-2487-4268-a914-065efa49d5e1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NjY4MmI4OTk3MzI4NDM5NGJlNGFiMmJiODU2MGQ0NmYvdGFibGVyYW5nZTo2NjgyYjg5OTczMjg0Mzk0YmU0YWIyYmI4NTYwZDQ2Zl8wLTAtMS0xLTI4MzI4_acedc0cd-ce1a-41c8-a2e1-f9f3cec829cf">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18yNDE_ff9b8032-1538-447b-9596-891736548edb">March&#160;31, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6MjI1ZGE2NjA3Mjk4NGM3OGI0NDMwYzJjYTE3YmEyNWYvdGFibGVyYW5nZToyMjVkYTY2MDcyOTg0Yzc4YjQ0MzBjMmNhMTdiYTI1Zl8wLTAtMS0xLTI4MzI4_89d16f49-ab5b-4a2b-9a3b-024701049a52">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM _ TO _</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18zMDk_1e7edf8f-8ec3-47d1-8046-ca15cc8c32aa">001-38501</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">___________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18zNTY_ec7ad3b4-e244-4ad4-97f5-decb0a3ba89d">BLACK DIAMOND THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> ________________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8wLTAtMS0xLTI4MzI4_b8f23498-4914-413e-9878-8c0eab394bbf">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8wLTEtMS0xLTI4MzI4_ec8207c1-9d3f-4003-afdf-ecf8f6b2edfe">81-4254660</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(State or other jurisdiction</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(I.R.S. Employer</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8yLTAtMS0xLTI4MzI4L3RleHRyZWdpb246NjQ5MzVlZTYzMmMxNDk3YThhZGRmOThiNDRmMDgzZDJfNQ_62ac466c-a214-4f80-931f-eaeb5c9ba9e5">One Main Street, 14th Floor</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8yLTAtMS0xLTI4MzI4L3RleHRyZWdpb246NjQ5MzVlZTYzMmMxNDk3YThhZGRmOThiNDRmMDgzZDJfOQ_f2d250fd-86bf-4d88-90de-e67d60821ebb">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8yLTAtMS0xLTI4MzI4L3RleHRyZWdpb246NjQ5MzVlZTYzMmMxNDk3YThhZGRmOThiNDRmMDgzZDJfMTM_5fcf9a54-0908-4652-a465-7f3ccb325f8f">Massachusetts</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8yLTEtMS0xLTI4MzI4L3RleHRyZWdpb246ZmM5NTM5YjVlZmEyNDJmMWJkZDliZmVjODBmMjdkZGJfNQ_08d89c60-a1b5-48f1-8a46-2722e2ca7cf0">02142</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(Zip Code)</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8zLTAtMS0xLTI4MzI4L3RleHRyZWdpb246MDE4YWI2MDYyYmZiNDQ4NzlkYWM4N2EzMmNmN2QxMDlfNQ_12dd326b-42cd-4ae8-a024-e6e2fe125334">(617)</ix:nonNumeric> <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8zLTAtMS0xLTI4MzI4L3RleHRyZWdpb246MDE4YWI2MDYyYmZiNDQ4NzlkYWM4N2EzMmNmN2QxMDlfOA_b28f64b4-6b3f-4011-8aa9-2a14fd5f3562">252-0848</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%">(Registrant&#8217;s telephone number, including area code)</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Former name, former address and former fiscal year, if changed since last report)</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td></tr></table></div><div><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NWE0ZmYyNTE1NWE1NGQzNTg5ZmUxZDgyZmNhZGVmZjYvdGFibGVyYW5nZTo1YTRmZjI1MTU1YTU0ZDM1ODlmZTFkODJmY2FkZWZmNl8xLTAtMS0xLTI4MzI4_676932de-e657-4f28-8d86-8a6ab96dab72">Common stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NWE0ZmYyNTE1NWE1NGQzNTg5ZmUxZDgyZmNhZGVmZjYvdGFibGVyYW5nZTo1YTRmZjI1MTU1YTU0ZDM1ODlmZTFkODJmY2FkZWZmNl8xLTEtMS0xLTI4MzI4_14c1826e-053f-46ca-a951-dc5a28be52f9">BDTX</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NWE0ZmYyNTE1NWE1NGQzNTg5ZmUxZDgyZmNhZGVmZjYvdGFibGVyYW5nZTo1YTRmZjI1MTU1YTU0ZDM1ODlmZTFkODJmY2FkZWZmNl8xLTItMS0xLTI4MzI4_9a1d8a00-059e-4d6a-bffb-f0827d61ace6">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY185MDc_1dc39f0c-ac97-4a33-9158-1acaeec58531">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18xMjM0_d32475e4-d05f-4888-99b8-dfc02092aae1">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Large&#160;accelerated&#160;filer</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NWQwOGNlNjRlYWU2NDJkZjkxZjU0ZGRlODQxYTFlMDMvdGFibGVyYW5nZTo1ZDA4Y2U2NGVhZTY0MmRmOTFmNTRkZGU4NDFhMWUwM18yLTAtMS0xLTI4MzI4_88ac8518-ed5a-4904-a7e1-eecbbe863631">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NWQwOGNlNjRlYWU2NDJkZjkxZjU0ZGRlODQxYTFlMDMvdGFibGVyYW5nZTo1ZDA4Y2U2NGVhZTY0MmRmOTFmNTRkZGU4NDFhMWUwM18yLTMtMS0xLTI4MzI4_3b17a3c1-9876-4a3c-a643-143c0521638a">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NWQwOGNlNjRlYWU2NDJkZjkxZjU0ZGRlODQxYTFlMDMvdGFibGVyYW5nZTo1ZDA4Y2U2NGVhZTY0MmRmOTFmNTRkZGU4NDFhMWUwM180LTMtMS0xLTI4MzI4_43db3659-834c-478e-8f7b-fa389dd70a31">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18xODQ5_bfa634fc-5761-4c51-804e-780446d10d6f">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18xOTcz_63cdf7ef-7884-44cb-8b67-a86f407c03d8">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;1, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="i66226731c0624aabac4ffa6c672102e6_I20230501" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18yMDE0_d2e10d66-1b03-4385-b0a1-ce9b52543be0">36,512,572</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q (this Quarterly Report) contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;could&#8221;, &#8220;should&#8221;, &#8220;expects&#8221;, &#8220;intends&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221;, &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the progress, timing and success of preclinical studies and our clinical trials of BDTX-1535, BDTX-4933 and any other product candidates, including the availability, timing and announcement of data and results of such studies and trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug (IND) applications and other regulatory submissions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the continued development and advancement of our fibroblast growth factor receptor (FGFR) program and nomination of BDTX-4876 as our development candidate; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain and maintain regulatory approval for BDTX-1535 and BDTX-4933 or any of our other current or future product candidates that we may identify or develop; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our need to raise additional funding before we can expect to generate any revenues from product sales; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to identify future product candidates for treatment of additional disease indications; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to develop our current product candidates for the treatment of various cancers; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the rate and degree of market acceptance and clinical utility for any current or future product candidates we may develop; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the effects of competition with respect to BDTX-1535, BDTX-4933 or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the implementation of our strategic plans for our business, any product candidates we may develop and our Mutation-Allostery-Pharmacology (MAP) drug discovery engine; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully develop companion diagnostics for use with our current or future product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our intellectual property position, including the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering our product candidates and MAP drug discovery engine; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain additional funding for our operations, when needed, including funding necessary to complete further development and commercialization of our product candidates, if approved, and to further expand our MAP drug discovery engine;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the period over which we expect our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">our future financial performance and our ability to effectively manage our anticipated growth; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our estimates regarding the market opportunities for our product candidates, including our competitive position and the success of competing therapies that are or may become available; </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our need for and ability to attract and retain key scientific, management and other personnel and to identify, hire and retain additional qualified professionals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the potential for our business development efforts to maximize the value of our platform and product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets, either alone or in partnership with others;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to establish or maintain collaborations or strategic relationships and the ability and willingness of our third-party strategic collaborators to undertake research and development activities relating to our current or future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our expectations regarding the period during which we will remain an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the JOBS Act); </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to maintain an effective system of internal controls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the impact of global economic and political developments on our business, including rising inflation and capital market disruptions, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our common stock and our ability to access capital markets; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the ultimate impact of the ongoing coronavirus (COVID-19) pandemic, or any other health epidemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our clinical trials, our research programs, healthcare systems or the global economy as a whole.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part I, Item 1A, &#8220;Risk Factors&#8221; and elsewhere in our most recent Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the Annual Report) and in other Securities and Exchange Commission (SEC) filings. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic, including as a result of the emergence of new variants or subvariants, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Quarterly Report contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed as exhibits to this Quarterly Report. In this Quarterly Report, the terms &#8220;Black Diamond Therapeutics&#8221;, &#8220;Black Diamond&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; and similar designations refer to Black Diamond Therapeutics, Inc. and, where appropriate, our subsidiaries. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">4</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_13">PART I</a> - FINANCIAL INFORMATION</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_13">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_13">Item 1. Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_13">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_19">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_22">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_22">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_25">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_25">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:60pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_28">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_28">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_64">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_64">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_91">Item 3. Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_91">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_94">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_94">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_97">PART II</a> - OTHER INFORMATION</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_97">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_100">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_100">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_103">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_103">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_106">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_106">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_109">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_109">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_112">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_112">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_115">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_115">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_118">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_118">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:66pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_121">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#ic06fdbc868994781830cfb9f962306b5_121">36</a></span></div></td></tr></table></div><div style="margin-top:21pt"><span><br/></span></div><div style="margin-top:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have applied for various trademarks that we use in connection with the operation of our business. This Quarterly Report may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#8217; trademarks, service marks, trade names or products in this Quarterly Report is not intended to, and does not, imply a relationship with, or endorsement or sponsorship by, us. Solely for convenience, the trademarks, service marks and trade names referred to in this Quarterly Report may appear without the &#174;, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner of these trademarks, service marks and trade names will not assert, to the fullest extent under applicable law, its rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this Quarterly Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Part I - FINANCIAL INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item I. Condensed Consolidated Financial Statements (Unaudited)</span></div><div id="ic06fdbc868994781830cfb9f962306b5_16"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNC0xLTEtMS0yODMyOA_4b42d27d-34ae-42a9-89cd-aaf6b92eceb4">39,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNC0zLTEtMS0yODMyOA_45c9e7a4-979f-42e5-a4d5-49bf43276df4">34,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNS0xLTEtMS0yODMyOA_36d10e21-611e-43fc-bde6-7d69723cffe9">64,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNS0zLTEtMS0yODMyOA_0ff55300-c0cd-425f-b18d-f6ad737f91fd">88,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNi0xLTEtMS0yODMyOA_17a92ed0-27e0-46ce-afd1-f655f1d78d88">4,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNi0zLTEtMS0yODMyOA_80ac6d49-d97d-4213-be6e-3d77d25ae43e">4,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNy0xLTEtMS0yODMyOA_138253ee-5974-4e09-8569-366f1fcf39af">107,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNy0zLTEtMS0yODMyOA_58207be5-cffc-491f-b427-daeb80907798">127,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfOC0xLTEtMS0yODMyOA_c94f4f54-0851-42dc-b39d-19c805743ad4">2,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfOC0zLTEtMS0yODMyOA_25d2451d-3c7b-482f-9735-4dfc0f41a071">2,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfOS0xLTEtMS0yODMyOA_43d5c31b-1724-41d5-9502-69dec207d887">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfOS0zLTEtMS0yODMyOA_0c301850-7736-48a2-aa5a-56be8baba020">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTAtMS0xLTEtMjgzMjg_bef4dc73-3ae2-4456-a664-4c30ac23ca9f">24,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTAtMy0xLTEtMjgzMjg_743b4bbb-c52f-4ffa-99af-1630fae39367">24,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTItMS0xLTEtMjgzMjg_7b1c5c34-4dfc-48b3-9f63-90e8bf6c38c0">135,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTItMy0xLTEtMjgzMjg_3af1376e-b30a-401b-851e-4ea4d3b09dec">156,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTUtMS0xLTEtMjgzMjg_e28c6c3a-d094-4e61-8f92-dd4a29f3781e">3,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTUtMy0xLTEtMjgzMjg_5d28fc83-558b-4d1c-8e33-f95638165774">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTctMS0xLTEtMjgzMjg_54facc15-787f-4218-8360-322d8f5cbb65">9,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTctMy0xLTEtMjgzMjg_ef879022-8704-464e-92c1-0de07a623076">13,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTgtMS0xLTEtMjgzMjg_e3c23c2c-06e4-4945-b214-bab771b3a3ee">12,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTgtMy0xLTEtMjgzMjg_3e83744f-2b8b-484c-be6a-4324a45e4d2d">15,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTktMS0xLTEtMjgzMjg_3136736c-b4ca-4a59-b70c-1f0aabd82f08">24,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTktMy0xLTEtMjgzMjg_2da48658-574f-4eea-b42e-a96f29e53203">25,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjAtMS0xLTEtMjgzMjg_48fac619-3ada-4568-8322-0afd6463a9b5">37,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjAtMy0xLTEtMjgzMjg_4633c475-42fb-411b-b506-775b8f88ea32">40,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commitments and contingencies (Note&#160;11)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjEtMS0xLTEtMjgzMjg_e98e52e1-bb4b-499d-94e0-ab283c674332"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjEtMy0xLTEtMjgzMjg_305826f5-a298-4351-9d78-97a9ec19d47c"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="4" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF8yMQ_3d80c300-76e3-49ff-b282-74bcb8b5ae13"><ix:nonFraction unitRef="usdPerShare" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="4" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF8yMQ_fd298202-2c06-4634-b463-c16c58b8c918">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF8zNQ_5246d909-b43e-42d1-8b93-7dbcf758d93e"><ix:nonFraction unitRef="shares" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF8zNQ_a57f59bb-1ffa-4618-9d05-386a59e05239">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="0" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF83MA_1af2c3e4-4a71-4972-b898-7821b4b29da5"><ix:nonFraction unitRef="shares" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF83MA_b2ff6bd9-6588-49be-af4d-5dfff729062f"><ix:nonFraction unitRef="shares" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF83MA_b4c35379-6a37-4b5f-bfb2-e80f1314d585"><ix:nonFraction unitRef="shares" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="0" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF83MA_d357dbb0-395c-46b4-8d3d-1f685e97e45a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at March&#160;31, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMS0xLTEtMjgzMjg_3cbd3a53-8147-4589-93ff-826a68b9223f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMy0xLTEtMjgzMjg_7b2902dc-8f15-49f9-b963-5c39bd637ab7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV8xOA_891035ff-045a-4cac-9a5b-6670ccfeaa43"><ix:nonFraction unitRef="usdPerShare" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV8xOA_aaa899fd-1e54-42a4-aa1c-251721ceb271">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV8zMg_36aaa981-a150-461d-bd5f-79a30daca807"><ix:nonFraction unitRef="shares" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV8zMg_e0655524-cd66-4905-8997-694af4d00b1e">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV82Nw_17c433ab-06af-4828-8294-95c17a5d9c58"><ix:nonFraction unitRef="shares" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV82Nw_9f1887d9-a5f4-4ccc-815c-27cc696726fb">36,511,947</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV8xMTA_06fbd806-3b89-4e4f-947e-46dca713154e"><ix:nonFraction unitRef="shares" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV8xMTA_7b81b0ce-2932-41f2-b931-d0b8280dd611">36,434,297</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMS0xLTEtMjgzMjg_780b5be8-a73c-48f7-be3a-5cdab70d9c5a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMy0xLTEtMjgzMjg_8983b37f-e0a3-482e-8cc5-2eb0ce9c00f4">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjYtMS0xLTEtMjgzMjg_ca9fc1ae-6786-4db4-8e10-90877756049f">455,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjYtMy0xLTEtMjgzMjg_446f6f0e-1179-4b4c-a644-a272088d3bb0">452,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjctMS0xLTEtMjgzMjg_26d9a5e4-69b9-45d3-aedf-fffe73bb6301">1,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjctMy0xLTEtMjgzMjg_89bbd50f-2f40-4471-977f-80311139eccf">1,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjgtMS0xLTEtMjgzMjg_af2e28ad-be48-4292-a764-00ba0b635717">355,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjgtMy0xLTEtMjgzMjg_b702b26d-2a34-4989-9824-d6ee54364ebe">334,989</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjktMS0xLTEtMjgzMjg_b9d6ab3a-1298-46f3-b89e-c4753f94a2df">98,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjktMy0xLTEtMjgzMjg_bb3a6c97-56c5-4504-99ee-1651fd42be8a">115,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMzAtMS0xLTEtMjgzMjg_a842bc5b-4cf4-4738-a65d-132478be889a">135,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMzAtMy0xLTEtMjgzMjg_6da0b855-1d7c-467c-9318-aa4202a52d2e">156,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">6</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.528%"><tr><td style="width:1.0%"></td><td style="width:68.309%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMy01LTEtMS0yODMyOA_aac5c777-cabb-4b60-822c-d9385105b235">14,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMy03LTEtMS0yODMyOA_00d8f501-30c3-4ad6-abcc-e9fa5cec349d">17,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfNC01LTEtMS0yODMyOA_30e29c0c-076c-46c2-8052-5b7f1c471014">6,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfNC03LTEtMS0yODMyOA_39947f0d-98d4-42f4-b3e1-0e0ab43218f7">7,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfNS01LTEtMS0yODMyOA_10540da1-288f-40c3-b9c0-8b10ac1d88a7">21,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfNS03LTEtMS0yODMyOA_f9f52497-b47a-44fe-8184-3cd6ffb5c38d">25,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfNi01LTEtMS0yODMyOA_73c8cf08-faac-44fb-a7fe-d35c68572ce0">21,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfNi03LTEtMS0yODMyOA_7c8bd6cc-cbc4-40d6-91fa-20729c5eb671">25,679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfOS01LTEtMS0yODMyOA_3e20412c-894c-4184-a43a-81e4169191cc">622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfOS03LTEtMS0yODMyOA_d1e88c6c-4588-491a-acf6-0b39a1b891db">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other (expense) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTAtNS0xLTEtMjgzMjg_1f664478-2672-42b7-af2e-405586df0691">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTAtNy0xLTEtMjgzMjg_07a11c6f-80d2-4794-89b9-322b90bc2bad">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTEtNS0xLTEtMjgzMjg_ee53a4ab-3287-419f-a763-ea463a59968f">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTEtNy0xLTEtMjgzMjg_fe09fa7c-77b9-411d-aa88-6537ac3a0741">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTItNS0xLTEtMjgzMjg_619db430-cdf9-423f-b67a-9e4e8d43739c">20,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTItNy0xLTEtMjgzMjg_1af97a28-7010-4afa-98de-529110b0e973">25,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTMtNS0xLTEtMjgzMjg_1db7baa0-dde5-4435-8834-068a7d2c922f"><ix:nonFraction unitRef="usdPerShare" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTMtNS0xLTEtMjgzMjg_c3667fa9-7f3b-48c6-a85d-ef28c0ad1930">0.57</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTMtNy0xLTEtMjgzMjg_05330ddd-6f54-40c1-8410-9cccc1dabf9d"><ix:nonFraction unitRef="usdPerShare" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTMtNy0xLTEtMjgzMjg_8f963f13-fcc2-4d29-b632-dc8707c9d44d">0.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTQtNS0xLTEtMjgzMjg_140c5106-86be-416d-a53c-694c03aad9ec"><ix:nonFraction unitRef="shares" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTQtNS0xLTEtMjgzMjg_5a2341d7-a90d-46c3-a11a-2aefce5b150b">36,483,878</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTQtNy0xLTEtMjgzMjg_d272ed3c-face-47a7-9cc0-a87690669ea9"><ix:nonFraction unitRef="shares" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTQtNy0xLTEtMjgzMjg_f40aca61-65e9-4527-a7eb-26e51c421265">36,271,291</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTctNS0xLTEtMjgzMjg_0dc72721-0ed4-45ab-ad69-f7a207059c80">20,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTctNy0xLTEtMjgzMjg_32102d79-2698-4966-9e1b-7c51085b276c">25,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other comprehensive income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unrealized gain (loss) on investments, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTktNS0xLTEtMjgzMjg_737bfecf-42f0-442c-bde2-19afe400991e">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTktNy0xLTEtMjgzMjg_c64d582f-2297-4267-a413-9c4e0e1f0dbc">1,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMjAtNS0xLTEtMjgzMjg_2b46a7f8-8e01-4579-a9bf-993cef921f24">20,227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMjAtNy0xLTEtMjgzMjg_e43556eb-35de-4635-816c-2d17d6615e95">26,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">7</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_22"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:73.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMy0xLTEtMS0yODMyOA_b1fe9fb7-b946-424a-a1cf-2ff5c6e2d015">20,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMy0zLTEtMS0yODMyOA_f71427f1-5e02-44fc-97f8-41b3d2182841">25,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adjustment to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNS0xLTEtMS0yODMyOA_0ff6df5e-da06-4bab-9600-cf9f3d262979">2,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNS0zLTEtMS0yODMyOA_679b9ac6-cf74-41fa-8a2a-20a90efa4b3d">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNi0xLTEtMS0yODMyOA_2d58cd27-5eda-4fba-b91b-be600327e612">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNi0zLTEtMS0yODMyOA_64d39116-ee73-4a63-9da4-656758c3e860">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amortization of premium on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNy0xLTEtMS0yODMyOA_e1198b93-a8d7-4c95-8943-dcd17af04528">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNy0zLTEtMS0yODMyOA_a72bb456-b274-4f0c-955a-c6bd42cb4a0b">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Noncash rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="bdtx:RentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfOS0xLTEtMS0yODMyOA_b384aea4-0b87-40a4-988a-027fb5c62c92">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="bdtx:RentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfOS0zLTEtMS0yODMyOA_340570e9-40d8-4cdc-9daf-0cf59bbb280b">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loss on sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTItMS0xLTEtMzAxMzk_c9cf4c6b-f2ed-4ccf-bdf6-092a47d3d61c">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTItMy0xLTEtMzAxMzk_426e7716-7419-4495-95c3-f49b26c03626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in current assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTMtMS0xLTEtMjgzMjg_be7ea442-d5e5-45bf-aedf-7b9b3c416d71">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTMtMy0xLTEtMjgzMjg_a365aea0-c481-457b-b004-1299c2315d62">2,648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTQtMS0xLTEtMjgzMjg_c5b0a80e-c52a-4ce9-afea-d239a2ea9720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTQtMy0xLTEtMjgzMjg_52e1797a-0ff1-46d8-892f-29be58ea51e9">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTUtMS0xLTEtMjgzMjg_f8a345e3-7a88-44c4-9995-4ff4592761bd">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTUtMy0xLTEtMjgzMjg_7be72bf9-4e4b-4a30-9abf-64bbaf881d16">2,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTYtMS0xLTEtMjgzMjg_2285770b-8c4c-492f-b25f-7bb39b86c32d">3,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTYtMy0xLTEtMjgzMjg_ce7116b3-f6d0-496f-91a6-c6c7068afa06">1,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="bdtx:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTctMS0xLTEtMjgzMjg_68ba4115-f4c0-43ed-bf57-5dc2ef5e0e5d">754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="bdtx:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTctMy0xLTEtMjgzMjg_e40d2a79-2393-4aa5-b665-d784989292f8">687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTgtMS0xLTEtMjgzMjg_1076eee5-0932-4e8d-a803-15dda6d0704c">20,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTgtMy0xLTEtMjgzMjg_ddca5cb4-63f7-469d-a097-ed40ccb5827d">28,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Purchases of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjEtMS0xLTEtMjgzMjg_cfc66b69-b0fd-44fe-8884-5fc8b74c261b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjEtMy0xLTEtMjgzMjg_f3f56140-8eda-4c7c-bb66-a1e749b1cd67">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjItMS0xLTEtMjgzMjg_1e891ad0-a966-4889-b434-6cd7346f4e36">24,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjItMy0xLTEtMjgzMjg_3f2bfd1d-adf4-40ce-ad4e-90d4c0cfd605">37,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjMtMS0xLTEtMjgzMjg_af707127-1e41-4d58-b454-004717244880">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjMtMy0xLTEtMjgzMjg_a3047a90-2486-4eae-b5c8-7f7fb01b01bb">20,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjQtMS0xLTEtMjgzMjg_035104b9-265b-4ef9-82fd-caadaeeb6216">24,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjQtMy0xLTEtMjgzMjg_a5bcfc15-53c9-4842-9571-8817ea09cd60">16,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Proceeds from exercise of common stock options and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjctMS0xLTEtMjgzMjg_a4fcc066-a894-4c9a-91e3-6eebf5b81f86">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjctMy0xLTEtMjgzMjg_ef41d0aa-5d53-4f68-a4cb-a0e21669c29b">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzAtMS0xLTEtMjgzMjg_c9e575f5-7be5-496a-8869-5f6869b58895">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzAtMy0xLTEtMjgzMjg_4a36b67a-2157-4cec-b67c-88a60d02e9e2">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzEtMS0xLTEtMjgzMjg_d0ff5ae6-d812-4e23-a803-51a22fddaabb">4,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzEtMy0xLTEtMjgzMjg_b3372ba7-89ba-4acc-a006-248aba0cbcf1">11,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzItMS0xLTEtMjgzMjg_dee0c3e4-3846-43fc-b71b-0f3ea5cbe30b">35,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i18236f10c6bb43fba2c9c3fbf41ce4ce_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzItMy0xLTEtMjgzMjg_1bae7717-fa95-4501-bae1-5eaaff5b4420">67,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzMtMS0xLTEtMjgzMjg_556f099d-5c30-4326-9558-173845f64b61">40,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzMtMy0xLTEtMjgzMjg_1ee0eb54-d70c-4498-a7aa-140fa1689916">55,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzUtMS0xLTEtMjgzMjg_f318e46f-c4b5-4217-a239-7b25b135cd50">39,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzUtMy0xLTEtMjgzMjg_5add4f79-8835-4d22-8fae-9c84708fc483">54,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted cash, end of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzYtMS0xLTEtMjgzMjg_9d80d442-9982-45c3-9216-6da3e344dae1">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzYtMy0xLTEtMjgzMjg_2fe692ea-9b62-4bd1-9adf-24a1025d8765">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzctMS0xLTEtMjgzMjg_cdfcc680-3490-4b3e-b627-c51f122fc0ee">40,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzctMy0xLTEtMjgzMjg_716d6289-8535-4694-93ab-6eb2a75145fe">55,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sale of equipment included in prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="bdtx:SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNDMtMS0xLTEtMzAxNzA_34907199-cc59-4e4b-ad2c-c3be3430820f">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="bdtx:SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNDMtMy0xLTEtMzAxNzA_52e84414-1f61-41a3-b17e-3b5f0d189409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for operating lease obligation </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="bdtx:IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNDItMS0xLTEtMjgzMjg_375843df-79ce-4340-96e0-9337052d8983">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="bdtx:IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNDItMy0xLTEtMjgzMjg_fe6062a1-17be-4cba-b2bc-798d97a0498b">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:20.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">8</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_25"></div><hr style="page-break-after:always"/><div style="min-height:29.25pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.064%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Additional</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">paid-in capital</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">stockholders&#8217;</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Par Value</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE - December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9928ba02038f4ae78a1c4a0dd70f34fe_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMy0xLTEtMS0yODMyOA_db616723-c1d2-4243-ba02-49ed2eb9048e">36,234,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9928ba02038f4ae78a1c4a0dd70f34fe_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMy0zLTEtMS0yODMyOA_24e26e91-1911-4fdb-9b8e-590c1a51df88">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5805f6a69cd441a69d534bb81c0e06da_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMy01LTEtMS0yODMyOA_6a10c35b-9ba1-4665-aa6d-269ec2d3de81">440,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i68d16179c5a14c7ebdbc734b0382415d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMy03LTEtMS0yODMyOA_e0c81dfc-0ba5-47d2-b3a3-b9cec6a9b497">414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i456bfd3daab443ea80542d825dc5fe07_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMy05LTEtMS0yODMyOA_1c2f0e0c-952d-497c-8e13-df72ceb6ea01">243,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i18236f10c6bb43fba2c9c3fbf41ce4ce_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMy0xMS0xLTEtMjgzMjg_c01b1098-61c9-4c4e-86d5-47d1df219c45">195,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i08b218a8d5294a0cbed694379ad58ce2_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNC0xLTEtMS0yODMyOA_7ff9d1a6-7203-4c33-adbd-08c8162318c6">3,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95a40d0c894120a1db7291d5cee4e2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNC01LTEtMS0yODMyOA_b0a0be93-3db4-4a32-a4cf-b596778acb2a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNC0xMS0xLTEtMjgzMjg_a91b13b1-b7f7-45c9-8979-a58c6b1c5626">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i08b218a8d5294a0cbed694379ad58ce2_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNS0xLTEtMS0yODMyOA_ed789315-cf89-40a0-a0f2-56920545bb8e">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock related to ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i08b218a8d5294a0cbed694379ad58ce2_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNi0xLTEtMS0yODc3Nw_dc3de71d-f860-4bb8-ad57-c33d5afb48b3">31,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95a40d0c894120a1db7291d5cee4e2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNi01LTEtMS0yODc3Nw_55dd451f-01f0-4f8c-b47e-fa97572a93c9">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNi0xMS0xLTEtMjg3Nzc_0f6e2367-e43a-4389-b260-39700bd581fe">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i08b218a8d5294a0cbed694379ad58ce2_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNi0xLTEtMS0yODMyOA_ca4c724e-a6c3-43a4-9388-1695d7b53fb9">13,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3e95a40d0c894120a1db7291d5cee4e2_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNi01LTEtMS0yODMyOA_bf047aa1-60f2-476a-8a64-717072717e81">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNi0xMS0xLTEtMjgzMjg_f39db605-77de-451d-86fe-9fdb01c3edac">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i94cc5dde32e24698bf33abd440aee5b4_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNy03LTEtMS0yODMyOA_e2681f61-cc96-4d65-bb1b-d863b2dcfe44">1,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNy0xMS0xLTEtMjgzMjg_326e9944-edf3-4e11-9515-12ceab43708d">1,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic1e742d729ce432ca0f35a2494585ade_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOC05LTEtMS0yODMyOA_79158554-d1f8-4362-8d32-2c0233566c31">25,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOC0xMS0xLTEtMjgzMjg_69c20bc0-274e-4ff4-b931-42682d759b72">25,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE - March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i28226edd859e4dab945d64e22ffcaebf_I20220331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOS0xLTEtMS0yODMyOA_ecd62544-a8de-42c4-85a1-fd1870377e0c">36,287,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28226edd859e4dab945d64e22ffcaebf_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOS0zLTEtMS0yODMyOA_f83bcf27-70c5-4acd-900f-245687f6f092">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ef21fb740fd4df29d87c63818a8be4f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOS01LTEtMS0yODMyOA_fb45e474-bf9d-47bf-a236-8a8b068a7c48">443,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i550bd7cfc5394510a5c782d6d944408a_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOS03LTEtMS0yODMyOA_3faca209-11ea-470a-a226-fd56d27a6c52">1,775</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i58ce2b6758eb48fa96ddd6fc6e0b2a03_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOS05LTEtMS0yODMyOA_7f618d77-d003-4a5c-90d3-827a66737853">269,327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOS0xMS0xLTEtMjgzMjg_c8a2726c-d722-4272-8c75-a38525ac2fcf">172,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE - December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7dad2752f6d24f69beb01b7d41d018ea_I20221231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjYtMS0xLTEtMjgzMjg_7139c44f-f0c0-4340-ab15-299014767b07">36,434,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7dad2752f6d24f69beb01b7d41d018ea_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjYtMy0xLTEtMjgzMjg_9d9e671f-84eb-46fe-b27b-858ae326ce0a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i44fbc51eccac4780a51aa2110725c195_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjYtNS0xLTEtMjgzMjg_ee135480-fb04-4b78-968b-872847a57b3c">452,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3aa33c9766164861a9a2941ebecacdc5_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjYtNy0xLTEtMjgzMjg_0e0f2c67-3c12-4a66-8c7e-16a93a8461f1">1,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d19e2d7bf5648c0a1412530bc5a4c83_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjYtOS0xLTEtMjgzMjg_45b0f622-6d5f-4579-8456-e864bf186723">334,989</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjYtMTEtMS0xLTI4MzI4_8cdcc683-b23b-4d16-b3db-68797a0d46cb">115,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if3528e294eb84233bd324a45f9d5729f_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjgtMS0xLTEtMjgzMjg_475d7ad1-57cb-4e71-aca9-d0dcc7bdf235">23,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Surrender of shares for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="if3528e294eb84233bd324a45f9d5729f_D20230101-20230331" decimals="0" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzEtMS0xLTEtMzEyNDc_693f4272-6a6a-48cb-9186-1403b97c80e0">3,903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock related to ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if3528e294eb84233bd324a45f9d5729f_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjktMS0xLTEtMjgzMjg_42648c00-0924-4ec6-867a-34b0bf1468d1">33,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0092b7cc057941c08850f1ad6c56a4d3_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjktNS0xLTEtMjgzMjg_44aab3c7-03ec-4d99-a8f5-7681e0957141">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjktMTEtMS0xLTI4MzI4_99724132-caee-4c30-b4cd-67912fad6883">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if3528e294eb84233bd324a45f9d5729f_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzAtMS0xLTEtMjgzMjg_a00ede78-f3c3-40b8-be88-6397c61c1ecf">24,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0092b7cc057941c08850f1ad6c56a4d3_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzAtNS0xLTEtMjgzMjg_8027ae7a-96d2-4746-9cc8-52599837f188">2,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzAtMTEtMS0xLTI4MzI4_fff23e3e-d38a-40d9-94ab-74d7f6b1cbfc">2,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gain (loss) on investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a14724cbb314a469c727f2b58faa85e_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzEtNy0xLTEtMjgzMjg_a5592a09-04e2-46f2-8a70-46ee7e5da32c">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzEtMTEtMS0xLTI4MzI4_0d165030-d1ed-4f04-8f7d-fdeca1d1a08b">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i43d5ebddb1f54d71b47373c1b912f7e9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzItOS0xLTEtMjgzMjg_e4d97407-4fbd-40e2-a282-c5b7edc63aad">20,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzItMTEtMS0xLTI4MzI4_e5de7be7-8645-49ee-9c4d-d5fc267a8dfa">20,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE - March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1759f611756a4cffabc3f4c4fb8a6561_I20230331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzMtMS0xLTEtMjgzMjg_1f86151c-8736-4961-9585-26a60f532fe5">36,511,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1759f611756a4cffabc3f4c4fb8a6561_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzMtMy0xLTEtMjgzMjg_3ca0d9ed-1457-4708-a5e1-cfda26344fa6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4440f7aa29164195bfa74c860ee07235_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzMtNS0xLTEtMjgzMjg_5cd1e669-8c86-420d-a22a-d08f5bebc97b">455,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id112bbe0621046fca2f448c03c6b6480_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzMtNy0xLTEtMjgzMjg_80327be0-a386-401d-82b5-9438a6fcdb01">1,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4c4a9410dd2e40eb9adaf67022861157_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzMtOS0xLTEtMjgzMjg_ce3e5137-cf2a-48a4-819c-61086c509d38">355,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzMtMTEtMS0xLTI4MzI4_d0db7a7b-f6ef-4f81-a0b5-37580125fc4f">98,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">9</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share amounts)</span></div><div id="ic06fdbc868994781830cfb9f962306b5_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zMS9mcmFnOjc2MGE2N2U0OTAxNjQwMDc4OGZhZDFmZjQ0ZDhiOGU1L3RleHRyZWdpb246NzYwYTY3ZTQ5MDE2NDAwNzg4ZmFkMWZmNDRkOGI4ZTVfNzA0NA_6cb709d6-4a00-442f-b641-48016514a9ab" continuedAt="i5500897ea3294a599f6cc9920cdbbb25" escape="true">NATURE OF BUSINESS AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i5500897ea3294a599f6cc9920cdbbb25"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zMS9mcmFnOjc2MGE2N2U0OTAxNjQwMDc4OGZhZDFmZjQ0ZDhiOGU1L3RleHRyZWdpb246NzYwYTY3ZTQ5MDE2NDAwNzg4ZmFkMWZmNDRkOGI4ZTVfNzA0NQ_958d29bc-5a10-4453-95a1-8ff098e354fb" continuedAt="i15511feb1ea24bac81a741b75d3431cf" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the Company) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development of its mutation, allostery, and pharmacology drug discovery engine. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 14, 2022, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement), with the Securities and Exchange Commission (the SEC), which covers the offering, issuance and sale of the Company&#8217;s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum offering price of $<ix:nonFraction unitRef="usd" contextRef="i759d4ddb3ad64fd38d5531cb44817594_D20221114-20221114" decimals="-6" name="bdtx:SaleOfStockAuthorizedConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zMS9mcmFnOjc2MGE2N2U0OTAxNjQwMDc4OGZhZDFmZjQ0ZDhiOGU1L3RleHRyZWdpb246NzYwYTY3ZTQ5MDE2NDAwNzg4ZmFkMWZmNDRkOGI4ZTVfMTY0OTI2NzQ1MjE4NA_e66eba25-f1af-4173-a434-e634c461c573">500</ix:nonFraction>&#160;million. The Company simultaneously entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by the Company of up to $<ix:nonFraction unitRef="usd" contextRef="i5f823a64b85d4ac7bd10d06b5df686fb_D20221114-20221114" decimals="-6" name="bdtx:SaleOfStockAuthorizedConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zMS9mcmFnOjc2MGE2N2U0OTAxNjQwMDc4OGZhZDFmZjQ0ZDhiOGU1L3RleHRyZWdpb246NzYwYTY3ZTQ5MDE2NDAwNzg4ZmFkMWZmNDRkOGI4ZTVfMjE4NQ_998365e7-a5af-4fa8-81a6-6c7784164024">150</ix:nonFraction> million of its common stock from time to time through Jefferies (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. As of March&#160;31, 2023, no sales have been made pursuant to the ATM Program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred stock and common stock. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of May&#160;9, 2023, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, or reduce headcount and general and administrative costs, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">10</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNC9mcmFnOjJhNzU1OWY1NWRkZDRmNzBiM2ExYzJlYWE4MzFiOTAyL3RleHRyZWdpb246MmE3NTU5ZjU1ZGRkNGY3MGIzYTFjMmVhYTgzMWI5MDJfMzY3MQ_bbf90c69-0e79-4231-9346-9b104f590f5e" continuedAt="ic85039d0c4a9413d914166be5a1efe66" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ic85039d0c4a9413d914166be5a1efe66"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.</span></div><ix:continuation id="i15511feb1ea24bac81a741b75d3431cf"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNC9mcmFnOjJhNzU1OWY1NWRkZDRmNzBiM2ExYzJlYWE4MzFiOTAyL3RleHRyZWdpb246MmE3NTU5ZjU1ZGRkNGY3MGIzYTFjMmVhYTgzMWI5MDJfMzY2NQ_b1b130ea-ec60-4b48-a554-dfe7adbf7faa" continuedAt="i8eaa8f44645c41b3a951a35f566eb8dd" escape="true">Principles of consolidation </ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:continuation id="i8eaa8f44645c41b3a951a35f566eb8dd">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNC9mcmFnOjJhNzU1OWY1NWRkZDRmNzBiM2ExYzJlYWE4MzFiOTAyL3RleHRyZWdpb246MmE3NTU5ZjU1ZGRkNGY3MGIzYTFjMmVhYTgzMWI5MDJfMzY2OQ_79f59514-5b19-423f-911a-50e09a4a902a" continuedAt="ia1a1a3f6cf5d4a178f2c8fb221a837d3" escape="true">Use of estimates </ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:continuation id="ia1a1a3f6cf5d4a178f2c8fb221a837d3">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company continues to monitor the impact of global economic developments, political unrest, high inflation, the recent failure of certain banks and financial institutions, and health crises, such as the COVID-19 pandemic, on all aspects of its business, and has considered the impact of these factors on estimates within its financial statements. The extent to which future developments may impact the Company&#8217;s business, results of operations or financial condition are uncertain and cannot be predicted with confidence and there may be changes to estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of these factors and is not aware of any specific related event or circumstance that would require it to update its estimates.</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">11</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RleHRyZWdpb246YTlhZTNhZDRjNTU0NDhmY2FhM2FlZjg4ZjViMTI3OWFfMTE5OQ_f6bef67d-c5c5-42fd-8dfe-7571975af16e" continuedAt="i9e08eef00c02483ca1586f33d9036ccb" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i9e08eef00c02483ca1586f33d9036ccb"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RleHRyZWdpb246YTlhZTNhZDRjNTU0NDhmY2FhM2FlZjg4ZjViMTI3OWFfMTIwMA_19982715-8b10-4000-a4c2-250d7b76446b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at March 31, 2023 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibb328d7ce3ad4166b5b61eefd59f420a_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNC0xLTEtMS0yODMyOA_9195f23c-eded-40e7-a37e-7dee8932430d">15,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ice5277e7080f4af5bb25a652a809641e_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNC0zLTEtMS0yODMyOA_aa41793a-26a3-4de2-98aa-bb04e6ca108b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6687f45413a4419bb690fef99015b01f_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNC01LTEtMS0yODMyOA_b18b7e63-7881-4a07-b92f-29576756c931">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0274173257c24f579ec10811eeb0c81a_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNC03LTEtMS0yODMyOA_f10c3830-52d9-4783-98b0-2adf1b870f62">15,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7b0e3b7df6074918b33a2cdc71901202_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNy0xLTEtMS0yODMyOA_31b4caed-f104-43cb-98e5-4a529d24016d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i08fef76a1c7c437c9d1b3eda6db89dd3_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNy0zLTEtMS0yODMyOA_c919322f-2164-4011-bf17-c3d61f831caa">36,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55653debaf274b11b4ac7a51ce4696e4_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNy01LTEtMS0yODMyOA_f0bbc9e1-d0f0-428d-abc5-cb47789976b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7a33cd0b3c4a4b16a14fe04651a86c84_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNy03LTEtMS0yODMyOA_5195c55e-3e92-4eec-a34e-79c62a25704c">36,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0a75e0a6cc5a43a49aa062ef1bece4c0_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOC0xLTEtMS0yODMyOA_23d2d341-c5e1-4133-a659-900e72572fde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i84693306474940138214ef4e5288008e_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOC0zLTEtMS0yODMyOA_f814c2bb-26b9-4c51-aa9c-a9413c3666ca">27,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0023816158b34fbdbb78091138c96439_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOC01LTEtMS0yODMyOA_c84103e9-1180-4e58-8365-f5c438dd5b99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i92484769461f4b74b3d02cb2e1f9e9a2_I20230331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOC03LTEtMS0yODMyOA_cb7f14d6-2204-4811-81e1-43f238c802a0">27,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7d84216f3a25460d9a88c52522dd8d6f_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOS0xLTEtMS0yODMyOA_44b3cc76-383d-4ec0-a577-a0170e3e3815">15,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i206b8d6455b84e2f9f3f3b9a6c71a580_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOS0zLTEtMS0yODMyOA_1de0791b-d9b3-452a-859c-21268552f6aa">64,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3da457e1122144b4b86fe4e412be3000_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOS01LTEtMS0yODMyOA_9ae67d0a-4799-4525-976c-8115d6203345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie1de270b96e64e8d86b7cbcec1f81067_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOS03LTEtMS0yODMyOA_10a81cff-76a4-4948-81bd-b16fbef12f78">79,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at December 31, 2022 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4b518c619fde4699bb430693ce9bb402_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNC0xLTEtMS0yODMyOA_9c7fa682-dce9-4415-83e3-098824e60da8">32,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0954e4764df9420ca7f966a581b88ab5_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNC0zLTEtMS0yODMyOA_8152656d-49eb-451f-8c0f-5b3620752a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if3bdbcb5dab7449a919d62bf333c2769_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNC01LTEtMS0yODMyOA_ebb10b52-c811-4ae6-afe0-1b02a8701e5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifff94a18639d4cc9ace4b7980f18491b_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNC03LTEtMS0yODMyOA_8b8243fe-2714-4c03-a70e-c6fe81aae4e2">32,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iea5548dbdcc84e34b38db41da417d969_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNi0xLTEtMS0yODMyOA_d49c6298-3ba2-4b3e-8a6a-10422c14f0e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie47787450b694b2ea0d0a633fb578e87_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNi0zLTEtMS0yODMyOA_b8f4d2e5-b903-4857-bbad-892f83010ec7">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i143f2d561c544650ae4cec160b40d837_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNi01LTEtMS0yODMyOA_f3ff6638-efec-4143-8632-2d4e71070734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i559c92eb9a82422882d92a40b4732e87_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNi03LTEtMS0yODMyOA_50767c07-f470-4869-820f-ce657cf136b0">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c4d688c720846d2a8ca1d0ef6ad503a_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNy0xLTEtMS0yODMyOA_f68d3942-b53a-4975-bb2a-2a6bf8560176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i55878f702cbe4a6785d7165f6bc9ba1b_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNy0zLTEtMS0yODMyOA_8b61f8ab-43d7-4374-b2c4-99e99404a328">45,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idf6167cc94b8412da93063def658ef27_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNy01LTEtMS0yODMyOA_68d3a191-7e95-40fa-8952-2a7f277123a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76c3bea13eeb4df78dbeccc4af6e9ef1_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNy03LTEtMS0yODMyOA_3051bc79-9d15-4160-b97b-d8d82a8ed26a">45,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i694eac40ab4244e99565a2f9e0787907_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOC0xLTEtMS0yODMyOA_d0536e1a-e5be-4c48-852a-744458ce5e0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2134d67ef3194c7486e8e79dbdced6a3_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOC0zLTEtMS0yODMyOA_5f7baef7-a8bb-407f-9431-697d5b9e7f91">39,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i885123a2113040f3b1921f9e90183ed4_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOC01LTEtMS0yODMyOA_3877c651-83b2-4a37-af30-6d013cef769d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i70fe665f9b0b4d5f97f1dd8448e2e411_I20221231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOC03LTEtMS0yODMyOA_3d51901c-f6fc-4c22-872c-8814b27b77fa">39,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i38fd7a41430b45bb87c13424399f3a46_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOS0xLTEtMS0yODMyOA_7bf879a0-7010-4251-9831-495beb72564a">32,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9f1757297d34af5b00fef34b103aa0a_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOS0zLTEtMS0yODMyOA_1266b53e-b60f-4db9-8a04-49998954ddb9">88,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i75b0d8ea13e94b30a9276dd91f107156_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOS01LTEtMS0yODMyOA_0035ae77-e00e-4941-bcd9-a46f39e7e2ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i939ee62047f64d468543c94f23dee9b3_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOS03LTEtMS0yODMyOA_2990d23d-4d4b-462c-b0b7-a866bb9ada88">120,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no transfers in or out of Level 3 categories in the periods presented.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">12</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RleHRyZWdpb246M2JjOGQxMmE1MjRlNDU2Zjg0YzVkNmQ5OWVlNmRkOWJfMTYxNw_8f4d7a17-0c97-4410-a567-d4ac512a099b" continuedAt="ib533d461d5634c0daa1dc2fe06ca8165" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="ib533d461d5634c0daa1dc2fe06ca8165"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RleHRyZWdpb246M2JjOGQxMmE1MjRlNDU2Zjg0YzVkNmQ5OWVlNmRkOWJfMTYxOA_48faf8d3-7855-4a90-b9a3-6f965e54ab33" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9351ba53ff254b0f88999f498b0319e9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMi0xLTEtMS0yODMyOA_a954ef97-015f-4e0e-90d6-a04b3278592f">36,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9351ba53ff254b0f88999f498b0319e9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMi0zLTEtMS0yODMyOA_14caca5a-0580-43ba-9284-7c885d4bf589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9351ba53ff254b0f88999f498b0319e9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMi01LTEtMS0yODMyOA_1612e321-9bbc-4383-8150-1351ee24b24f">538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9351ba53ff254b0f88999f498b0319e9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMi03LTEtMS0yODMyOA_88fb8410-a65a-4f97-adb7-a648b2a8ba2e">36,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8f2c21f696d4b7da626acb69831ccb0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMy0xLTEtMS0yODMyOA_98e9e8b7-0100-4122-bdcf-06e563fd6b67">28,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8f2c21f696d4b7da626acb69831ccb0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMy0zLTEtMS0yODMyOA_cd250422-ced5-4618-92a7-da99bc470abb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia8f2c21f696d4b7da626acb69831ccb0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMy01LTEtMS0yODMyOA_ab5056d4-72ef-4fc8-aa55-20b9ba38a4dd">638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8f2c21f696d4b7da626acb69831ccb0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMy03LTEtMS0yODMyOA_7f38e395-c799-4882-a214-1c0b9958cbf4">27,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfNC0xLTEtMS0yODMyOA_a119e1b9-4426-406a-8133-41838ac2aa7e">65,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfNC0zLTEtMS0yODMyOA_23ccafc3-b2ac-446a-89e1-e8af03a80dd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfNC01LTEtMS0yODMyOA_0f3fb17e-42c4-42d7-b94d-f0b9eedce0a2">1,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfNC03LTEtMS0yODMyOA_dc982aa1-2831-466d-a202-a4bb5922fa15">64,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e1463d111734f7ba01a42c102369654_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMS0xLTEtMS0yODMyOA_f60983e9-47e8-415a-a533-1bac871cfcd3">3,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e1463d111734f7ba01a42c102369654_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMS0zLTEtMS0yODMyOA_56322659-817e-4e81-8a91-07ee9ec14acb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4e1463d111734f7ba01a42c102369654_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMS01LTEtMS0yODMyOA_82a3b1b0-75ab-42af-86e9-72efcc1caa1b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e1463d111734f7ba01a42c102369654_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMS03LTEtMS0yODMyOA_21063dcf-08d4-42d3-84a1-baf101dd1c79">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i04d9627eeb7e470e8198fa77f00eba51_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMi0xLTEtMS0yODMyOA_f0575909-eb31-42d6-b821-1327c8693aab">46,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i04d9627eeb7e470e8198fa77f00eba51_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMi0zLTEtMS0yODMyOA_040609d9-64f8-4a3c-ab20-5482f7c90f43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i04d9627eeb7e470e8198fa77f00eba51_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMi01LTEtMS0yODMyOA_f69f8f6e-5bbd-4810-855f-7d7ff493baff">800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i04d9627eeb7e470e8198fa77f00eba51_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMi03LTEtMS0yODMyOA_fe9e6615-b9eb-49e6-8dc9-04df58022f47">45,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5395e8eff10344b5ac2d2b3de662edb3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMy0xLTEtMS0yODMyOA_a2685213-5b6c-4473-990f-9a66394ba88a">40,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5395e8eff10344b5ac2d2b3de662edb3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMy0zLTEtMS0yODMyOA_c4218523-cd51-4847-bc6e-412f0eb12cb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5395e8eff10344b5ac2d2b3de662edb3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMy01LTEtMS0yODMyOA_a938861c-872f-4d89-842f-2280de9a7a89">1,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5395e8eff10344b5ac2d2b3de662edb3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMy03LTEtMS0yODMyOA_4be00f81-5e50-404d-87ef-e1cc15744754">39,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfNC0xLTEtMS0yODMyOA_7b61f4ba-42f6-470f-bc99-846336f88612">90,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfNC0zLTEtMS0yODMyOA_e9e35d62-861f-4ed5-ade4-79a806ddb94f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfNC01LTEtMS0yODMyOA_490bcd97-4bf6-4bbf-8856-a80315dd783e">1,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfNC03LTEtMS0yODMyOA_21a7581c-ff6b-44e9-bbaf-89f4989c26be">88,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for corporate bonds with a fair value of $<ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RleHRyZWdpb246M2JjOGQxMmE1MjRlNDU2Zjg0YzVkNmQ5OWVlNmRkOWJfMzQx_5916e45b-d1ee-4bcf-9d88-65b683412e98">1,983</ix:nonFraction> that had maturities of one to three years. As of March&#160;31, 2023, all marketable securities held by the Company were in a loss position. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds, and commercial paper with a fair value of $<ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RleHRyZWdpb246M2JjOGQxMmE1MjRlNDU2Zjg0YzVkNmQ5OWVlNmRkOWJfNTY4_b3972022-0c63-4c75-bb1d-73fefd7c289a">13,687</ix:nonFraction> that had maturities of one to three years. As of December&#160;31, 2022, all marketable securities held by the Company were in a loss position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company reviewed its investment portfolio to assess the unrealized losses on its available-for-sale investments.  The Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company also determined no portion of the unrealized losses relate to a credit loss.  There have been <ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RleHRyZWdpb246M2JjOGQxMmE1MjRlNDU2Zjg0YzVkNmQ5OWVlNmRkOWJfMTA5OTUxMTYzMDkzNg_0d6e3869-bcd4-447d-beeb-f25bdca4a572"><ix:nonFraction unitRef="usd" contextRef="i700858d5fb2842d8aa731adad03358f0_D20220101-20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RleHRyZWdpb246M2JjOGQxMmE1MjRlNDU2Zjg0YzVkNmQ5OWVlNmRkOWJfMTA5OTUxMTYzMDkzNg_697b67cd-035d-4aa2-b3a3-7b0ac8a1b915">no</ix:nonFraction></ix:nonFraction> impairments of the Company&#8217;s assets measured and carried at fair value during the three months ended March&#160;31, 2023 and the year ended December&#160;31, 2022.</span></div></ix:continuation><div id="ic06fdbc868994781830cfb9f962306b5_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RleHRyZWdpb246YWVjMjk4YjQ5MDRkNGFiY2JhODNhNGVlNWU0MmVjNjJfMTcx_079d7360-dae8-4828-af1c-6ac2a8de42ee" continuedAt="i74cfccac757a47d6b8ffaf7780c732be" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i74cfccac757a47d6b8ffaf7780c732be"><div style="margin-top:12pt"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RleHRyZWdpb246YWVjMjk4YjQ5MDRkNGFiY2JhODNhNGVlNWU0MmVjNjJfMTcy_00c1578c-5f29-40f8-a692-a9e7215a05af" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if5f6c4be62384e909f6b4e404ead2edc_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfMS0xLTEtMS0yODMyOA_e7d475a8-43be-4613-a8d1-dbaf30005e93">611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i93b69b82ac6a4bb9a460d33085d57f68_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfMS0zLTEtMS0yODMyOA_82fe5e45-da46-4604-b5b4-00ea0893d00d">770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i521fe07ef68d4b4a935d05639717ad02_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfMi0xLTEtMS0yODMyOA_669e5e4b-81c4-496e-ace0-46822e27498f">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2982e6cbd8454350b0195b786784f14a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfMi0zLTEtMS0yODMyOA_b764fe87-cbf5-4265-b58d-9eb117549ba5">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computer and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7a98c5b77af845f1970750ebfc01cbf6_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfMy0xLTEtMS0yODMyOA_8d05c33f-0ac6-4b32-9dd0-e1be64166a26">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4c3fa369595f4fd88697523852da9e92_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfMy0zLTEtMS0yODMyOA_914d98b9-39ad-42f6-b2a9-a8c1097686a6">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i758366b058d642888997dc00f48056d1_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfNC0xLTEtMS0yODMyOA_5959f065-564a-4d36-aa69-333eeddb3a8e">2,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic51c923c2ba142dca072c9813d731cae_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfNC0zLTEtMS0yODMyOA_0c5c89da-606a-4ca5-87bb-7a28711f399a">2,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfNi0xLTEtMS0yODMyOA_ebdd874c-0bae-4368-a9ec-8578efba22e4">3,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfNi0zLTEtMS0yODMyOA_787827b9-db0e-4caf-b034-6095f09be1f6">3,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfNy0xLTEtMS0yODMyOA_67b7206e-d3f8-4e0b-9b33-cc7ed375fd7a">845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfNy0zLTEtMS0yODMyOA_f438125e-9d40-47ce-8b4e-3d05a5dbb7d4">750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfOC0xLTEtMS0yODMyOA_7f94b373-c811-4f19-b0a3-5b548fcbc334">2,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfOC0zLTEtMS0yODMyOA_34a102d2-bf4c-4af4-a2a7-6e85223755b1">2,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RleHRyZWdpb246YWVjMjk4YjQ5MDRkNGFiY2JhODNhNGVlNWU0MmVjNjJfMTQ4_92aeb3cb-ca22-43ec-b702-3ae42244f7c4">122</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RleHRyZWdpb246YWVjMjk4YjQ5MDRkNGFiY2JhODNhNGVlNWU0MmVjNjJfMTU1_038794af-3d81-433b-917c-bfcd56e56dee">125</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">13</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_508"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzE2NDkyNjc0NDM3Mzg_f5f434a3-9b1c-48aa-b6ed-aa9f9fd091da" continuedAt="i773a57ac508c4d9d96500f42d6a8b10b" escape="true">EQUITY METHOD INVESTMENT</ix:nonNumeric></span></div><ix:continuation id="i773a57ac508c4d9d96500f42d6a8b10b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2022, the Company received <ix:nonFraction unitRef="shares" contextRef="i13adc33a304f4c00a11e5a74299bae27_I20221231" decimals="INF" name="bdtx:EquityMethodInvestmentSharesReceivedInNoncashExchange" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2Mjc4NDg_fee3cf8c-7d4d-43a2-a01d-77bc8c15abaf">9,000,000</ix:nonFraction> shares of common stock in a newly formed antibody-focused precision oncology company, Launchpad Therapeutics, Inc. (Launchpad), in exchange for contributing early discovery-stage antibody programs and granting Launchpad a license to use its MAP drug discovery engine to discover, develop and commercialize large molecule therapeutics. As of the transaction date and as of March&#160;31, 2023, the Company has a <ix:nonFraction unitRef="number" contextRef="ifd3f10ee0c2541fd9d0fc8361fe6a9e4_I20230331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2MjgyNDc_806f0bef-d47c-40fb-bf51-f3e485e85f43">39.1</ix:nonFraction>% voting interest in Launchpad and one seat on Launchpad&#8217;s Board of Directors which provide the Company with significant influence over Launchpad. The remaining voting interest in Launchpad is held by Versant Ventures and New Enterprise Associates (NEA), who are shareholders of the Company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company accounted for the transaction under the equity method and recorded the carrying value of the Company&#8217;s investment in Launchpad common shares of $<ix:nonFraction unitRef="usd" contextRef="if35bb4b182804be19ee91c94ba0ca241_I20221201" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2Mjg2OTg_9abde480-3cad-4469-8d4d-89543bb0a556">2,250</ix:nonFraction> in equity method investments in the consolidated balance sheets. The contributed in process research and development (IPR&amp;D) had zero basis on the Company&#8217;s books prior to the transaction, therefore the Company recognized a gain on sale of IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="i700858d5fb2842d8aa731adad03358f0_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2Mjg5MTM_f9bc06f3-7b94-4972-8b7e-8535448c58e2">2,232</ix:nonFraction> in the consolidated statements of operations and comprehensive loss. The Company also recognized a loss from investments in equity method investee of $<ix:nonFraction unitRef="usd" contextRef="i865dd29de11f4df59827ccfa2b07a604_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2MjkwNjc_3bbd30e2-0b95-4260-a15f-bd5e5a4ac3ad">1,540</ix:nonFraction> in the consolidated statement of operations and comprehensive loss, associated with the Company&#8217;s proportionate share of Launchpad&#8217;s losses. The assets contributed by the Company were principally IPR&amp;D and were not deemed a business by Launchpad, therefore the Company determined its remaining basis difference of $<ix:nonFraction unitRef="usd" contextRef="i700858d5fb2842d8aa731adad03358f0_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2MjkzODU_0ac6e924-2eaa-448a-93d2-d7b9d4716171">710</ix:nonFraction> was substantially related to IPR&amp;D and immediately expensed it. As of December&#160;31, 2022, the carrying value of the investment in Launchpad was reduced to <ix:nonFraction unitRef="usd" contextRef="i13adc33a304f4c00a11e5a74299bae27_I20221231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2Mjk1Mjk_69b3c36d-b360-4607-b1a3-c497cf3be104">zero</ix:nonFraction>. Since the Company has no obligation to provide financing support to Launchpad, the Company is not required to record further losses exceeding the carrying value of the investment. The Company also determined that its investment in Launchpad is not material or significant to its operations or financial position. As of March&#160;31, 2023, the carrying value of the investment in Launchpad was <ix:nonFraction unitRef="usd" contextRef="ifd3f10ee0c2541fd9d0fc8361fe6a9e4_I20230331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzU0OTc1NTgxNDExNTU_6bedc3c9-742d-4301-8e03-9d510b69241b">zero</ix:nonFraction>.</span></div></ix:continuation><div id="ic06fdbc868994781830cfb9f962306b5_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RleHRyZWdpb246MjI2N2Y1MzUxMTNlNDc4Yjg3ZGNmYTMwZWU4MTY4MjNfMTMx_6a53767e-9295-4be9-afcf-594a2606375f" continuedAt="i0c106e7e02154bd0bfe02a65464afaca" escape="true">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="i0c106e7e02154bd0bfe02a65464afaca"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RleHRyZWdpb246MjI2N2Y1MzUxMTNlNDc4Yjg3ZGNmYTMwZWU4MTY4MjNfMTMy_54867332-c4fc-44c6-8fd9-5b37b74aeb4d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="bdtx:AccruedContractResearchServiceFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfMS0xLTEtMS0yODMyOA_3734fccd-c380-48ed-95be-ff49cb4ff3cf">4,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="bdtx:AccruedContractResearchServiceFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfMS0zLTEtMS0yODMyOA_130cf368-683f-4e65-b58d-7dc0381582c7">4,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfMi0xLTEtMS0yODMyOA_deaf8bdd-6f89-47cc-893e-f62aa2f28300">1,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfMi0zLTEtMS0yODMyOA_46d25be5-c158-488a-82c3-4ec67fb3b53e">4,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfMy0xLTEtMS0yODMyOA_ad26e607-dbce-45bc-aa05-59de60d6d6e3">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfMy0zLTEtMS0yODMyOA_e510607f-e331-471d-a4e2-1116355cff32">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_5102cdaa-2077-4a92-ad76-9ae9e3ad93f1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_fd6e36e0-6ca5-4d7c-bac0-99a6f8cd4f37">Current portion of operating lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0xLTEtMS0yODMyOA_743426c3-f800-4ef3-b2be-c1b89ca2690c">2,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0zLTEtMS0yODMyOA_d250c297-261c-4cc8-a65f-dab46bf57b2d">2,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNS0xLTEtMS0yODMyOA_33fc3ef3-8ce1-48cd-8761-e90910914aa3">9,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNS0zLTEtMS0yODMyOA_014fb88b-7395-4c18-998b-b3d9c65c54a0">13,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div id="ic06fdbc868994781830cfb9f962306b5_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8. STOCK-BASED COMPENSATION</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Stock Option and Incentive Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Stock Option and Incentive Plan (the 2020 Plan) was approved by the Company&#8217;s board of directors on December 5, 2019, and the Company&#8217;s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company&#8217;s initial public offering (IPO) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to <ix:nonFraction unitRef="number" contextRef="i53da331621624cf18bde372f78562fe5_I20200114" decimals="2" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfODQx_bf454383-3e8a-4d52-a992-5932dce48037">4</ix:nonFraction>% of the Company&#8217;s outstanding shares of common stock as of the last day of the prior year. On January 1, 2023, <ix:nonFraction unitRef="shares" contextRef="iae929b9e760640749d3650b763b62da4_D20230101-20230101" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfOTU0_e7ebfa28-5fad-4bfb-b463-6ac246f7642c">1,457,371</ix:nonFraction> shares of common stock, representing <ix:nonFraction unitRef="number" contextRef="ibeabbd2a73b145ea98866ff29f77c989_I20230101" decimals="2" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfOTk0_c3b0d9aa-cbb9-4152-9350-9819c1db4e65">4</ix:nonFraction>% of the Company&#8217;s outstanding shares of common stock as of December 31, 2022, were added to the 2020 Plan.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">14</span></div></div></div><hr style="page-break-after:always"/><div style="background-color:#ffffff"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the 2020 ESPP) was approved by the Company&#8217;s board of directors on December 5, 2019, and the Company&#8217;s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company&#8217;s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to <ix:nonFraction unitRef="number" contextRef="iac7a453a75f14538a02a138efbfaf7a5_I20200114" decimals="2" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMTU2Ng_7e2a48b3-5203-4566-b6a2-140e81e133e9">1</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by <ix:nonFraction unitRef="shares" contextRef="i4476e554da044810af3f1a45eaa2a804_D20230101-20230101" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMTc2OA_46140c0d-93c0-4cf1-aebf-7a6c8a155111">326,364</ix:nonFraction> shares effective as of January 1, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense </span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTIzMQ_23af05fe-1926-4cb3-8671-3e46ff03079f" continuedAt="i2a73ad52106c4df39869f75f0c0c49b0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three Months Ended<br/>March 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i549acd543c9a4b5aa7c94abf409f84da_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfMi01LTEtMS0yODMyOA_d467a327-773d-41eb-9319-8bc37d758545">2,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3f33b8615f184762bdde93307f038957_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfMi03LTEtMS0yODMyOA_b379e31c-d9e7-40b9-8ca0-b78a1e4b3dc6">3,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie89b78b326fe4b0a997b225ea39acef4_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfMy01LTEtMS0yODMyOA_30d3ba52-ee44-489f-932c-a5e251246819">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2ab72299068b42fdbaa9a32deddc9c0d_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfMy03LTEtMS0yODMyOA_2979c4a8-53f6-476b-a505-5976a3394483">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan and Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icd05de7566d7485c87c6e0a63d1068f1_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfNC01LTEtMS0yODMyOA_6ee85c50-d43d-4b62-a7bd-970e0e9fd24c">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idf76fbfd9fad48fbafde9bd4d08feef3_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfNC03LTEtMS0yODMyOA_724a7f37-229a-427c-add9-117d49da133a">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfNS01LTEtMS0yODMyOA_e1cfc7c6-e26f-4d46-992e-aac317f177ee">2,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfNS03LTEtMS0yODMyOA_968f0aca-b841-43c4-beae-47f8d434fbff">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="i531627ec9aa54ef1ba96e5c5b9e70e77_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMjA3OA_8bf2ed1d-aae8-4e38-83b5-aa121ad8484e">24,776</ix:nonFraction> shares of common stock out of its 2020 Plan under its policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.</span></div><div style="margin-top:12pt"><ix:continuation id="i2a73ad52106c4df39869f75f0c0c49b0"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>March 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2a68a37a9356497ebf39ad08f89e5202_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOmM1NWI2YzVkZTBlMjQ4MDVhZjYwNTdkZmRiMGY4NmZjL3RhYmxlcmFuZ2U6YzU1YjZjNWRlMGUyNDgwNWFmNjA1N2RmZGIwZjg2ZmNfMi01LTEtMS0yODMyOA_f6fb55c0-ca64-4e4f-a9ef-1ab9511ab6b8">949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i40eacd0ad8714a8b8f4aa9d78df3b014_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOmM1NWI2YzVkZTBlMjQ4MDVhZjYwNTdkZmRiMGY4NmZjL3RhYmxlcmFuZ2U6YzU1YjZjNWRlMGUyNDgwNWFmNjA1N2RmZGIwZjg2ZmNfMi03LTEtMS0yODMyOA_2c252159-2cb4-44f2-aaec-f80177334c7a">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie179c4253b6c47ac8c91e9c01f937de2_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOmM1NWI2YzVkZTBlMjQ4MDVhZjYwNTdkZmRiMGY4NmZjL3RhYmxlcmFuZ2U6YzU1YjZjNWRlMGUyNDgwNWFmNjA1N2RmZGIwZjg2ZmNfMy01LTEtMS0yODMyOA_b4632845-740e-49e6-88d6-4d0cfa754f5f">1,722</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b7e706f65f045e882a5da0982835947_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOmM1NWI2YzVkZTBlMjQ4MDVhZjYwNTdkZmRiMGY4NmZjL3RhYmxlcmFuZ2U6YzU1YjZjNWRlMGUyNDgwNWFmNjA1N2RmZGIwZjg2ZmNfMy03LTEtMS0yODMyOA_b03bd36d-74bb-426d-b574-f0eee244361b">1,847</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOmM1NWI2YzVkZTBlMjQ4MDVhZjYwNTdkZmRiMGY4NmZjL3RhYmxlcmFuZ2U6YzU1YjZjNWRlMGUyNDgwNWFmNjA1N2RmZGIwZjg2ZmNfNC01LTEtMS0yODMyOA_f5de65a2-63ea-4650-ac04-a4ef3c2d6a1a">2,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOmM1NWI2YzVkZTBlMjQ4MDVhZjYwNTdkZmRiMGY4NmZjL3RhYmxlcmFuZ2U6YzU1YjZjNWRlMGUyNDgwNWFmNjA1N2RmZGIwZjg2ZmNfNC03LTEtMS0yODMyOA_8a0bc05d-ee4e-44ef-9cb8-112f69ef3e6a">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">15</span></div></div></div></div><hr style="page-break-after:always"/><div style="background-color:#ffffff"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Options </span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTIzMw_180daaaf-e8d3-48ed-827b-f2d9617cd610" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company&#8217;s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:46.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exercise</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfMS0xLTEtMS0yODMyOA_24e74873-c402-4369-8567-d78f4a488c48">5,359,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfMS0zLTEtMS0yODMyOA_4596386a-06df-4831-afb8-e75a30a63267">12.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i700858d5fb2842d8aa731adad03358f0_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfMS01LTEtMS0yODMyOA_a0d72043-080d-4374-8a07-ecc2396b230a">7.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfMS03LTEtMS0yODMyOA_7b801648-c148-457a-b1c4-c63ea2f661f6">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfMi0xLTEtMS0yODMyOA_f047549c-e147-49ef-a14b-8a1982acfc5b">2,659,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfMi0zLTEtMS0yODMyOA_4c619baf-d54a-412f-8322-51854de3cd88">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNC0xLTEtMS0yODMyOA_ff9ef850-6c37-4f4e-a85c-4ccdc0144c71">240,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNC0zLTEtMS0yODMyOA_29b3cf85-c7e6-4cf4-9f55-b539dd9e533e">11.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNS0xLTEtMS0zMDIzNw_fe563eb9-0bdc-4437-aa1b-a2767a126ebc">68,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNS0zLTEtMS0zMDIzNw_c1b846d2-57fd-4add-970f-8d9beb67b9d8">28.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNS0xLTEtMS0yODMyOA_51f46d59-eff0-4efc-8db8-28111a5ab86e">7,710,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNS0zLTEtMS0yODMyOA_dca8efe5-69e5-410b-8c99-291469050674">9.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNS01LTEtMS0yODMyOA_a85a4e27-43b5-48d1-b2c0-11283d3e4b26">8.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNS03LTEtMS0yODMyOA_037f2f21-8a8e-42bc-bedb-ef0ce700a3af">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options vested or expected to vest at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNi0xLTEtMS0yODMyOA_e5c6ca29-929b-4a7d-8069-171c4098333d">7,710,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNi0zLTEtMS0yODMyOA_f7e69f15-394f-412d-a198-befc359ab5ee">9.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNi01LTEtMS0yODMyOA_585482b0-aade-4758-9afc-eb7ef60e5db9">8.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNi03LTEtMS0yODMyOA_ec66378c-b0b3-410c-9b8c-67f06c7722c9">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNy0xLTEtMS0yODMyOA_e1448766-1747-431c-892b-d6525e5dd2bc">2,828,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNy0zLTEtMS0yODMyOA_4a66a8c4-6e13-4b31-9cf8-0d4ea668af3a">14.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNy01LTEtMS0yODMyOA_891b4a02-cf17-4836-a407-c90af8306773">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNy03LTEtMS0yODMyOA_ef59e1ba-c6e5-4146-b00c-48d1ac66e455">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, total unrecognized compensation cost related to the unvested stock-options was $<ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMjY0MQ_3625dfe2-9c7a-4436-b6ac-c43b413ccb6e">17,489</ix:nonFraction>, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i549acd543c9a4b5aa7c94abf409f84da_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMjcxNA_f6a15995-c020-4b25-b32a-f3dab5626db9">2.3</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair values of restricted stock units are based on the market value of the Company&#8217;s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTIzNA_cb4de927-770d-452d-bed3-4602e6a49093" continuedAt="idcab0084a45f4de8baeb302d78cd8e79" escape="true">The following table summarizes time-based restricted stock activity since January 1, 2023:</ix:nonNumeric></span><ix:continuation id="idcab0084a45f4de8baeb302d78cd8e79"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">average</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">grant&#160;date</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">fair value</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4e69e52e4e6d406fb3c05c1f565e0fc4_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfNS0xLTEtMS0yODMyOA_fbb73213-6044-48bd-af1e-bb556b2cf8cc">101,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e69e52e4e6d406fb3c05c1f565e0fc4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfNS0zLTEtMS0yODMyOA_fb217307-e6fb-4682-8365-725b274d1172">5.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i4ba383758bc7459cbba65c787855cd79_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfNy0xLTEtMS0yODMyOA_b6d6c4f9-386d-482d-8fcf-ca3e8460ab53">13,959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ba383758bc7459cbba65c787855cd79_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfNy0zLTEtMS0yODMyOA_0446430b-0410-43ae-bc24-b7249f8298fe">14.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i4ba383758bc7459cbba65c787855cd79_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfOC0xLTEtMS0yODMyOA_05ed9b63-31fa-416a-866e-56dda4c5aeed">1,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ba383758bc7459cbba65c787855cd79_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfOC0zLTEtMS0yODMyOA_e2f8ae55-4f99-4c0b-85fc-2db5c8a27019">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1bbb31a5e28c45da9f270f4b2a17dc96_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfOS0xLTEtMS0yODMyOA_2e02df7b-99eb-4c16-8173-331587521c0e">86,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1bbb31a5e28c45da9f270f4b2a17dc96_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfOS0zLTEtMS0yODMyOA_41e772b4-b7a9-4f25-a943-fb8df1674842">4.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The total fair value of time-based restricted stock units vested during the three months ended March&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="ie89b78b326fe4b0a997b225ea39acef4_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMzIwOA_4c313468-e3b5-4115-bfb2-5753680a0cb8">203</ix:nonFraction>. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, total unrecognized compensation cost related to the time-based unvested restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="id1dd1836d0a04ec5916ed35f6b8154f9_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMzM0MA_52cfda2d-518e-43a3-8bb8-cdde1d05cd7f">212</ix:nonFraction>, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ie89b78b326fe4b0a997b225ea39acef4_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMzQxMw_8dfc0846-2451-4df2-8ad8-b7c9f4f0cbe7">0.8</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="shares" contextRef="i8d6665b2a485470da5f751271274fa6f_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTQ5NzU1ODIwMTE3_0ad5ca71-46b6-4037-aece-0609c7e9d3a8">239,475</ix:nonFraction> performance restricted stock units outstanding at the year ended December&#160;31, 2022. For the three months ended March&#160;31, 2023, the Company granted <ix:nonFraction unitRef="shares" contextRef="id72ab97139f6499186284a9e549e2dcd_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMzQ2OA_56e20ed4-ca0f-4a9f-b87f-cfbc8616d5e5">no</ix:nonFraction> performance restricted stock units to its employees related to the achievement of certain clinical development and/or financing milestones, released <ix:nonFraction unitRef="shares" contextRef="i1b8ca7e990664a5b82b28aaeab2809ac_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTQ5NzU1ODIwMTMy_3b635efd-f921-4657-a47d-329086ebfa66">9,616</ix:nonFraction> performance restricted stock units due to the achievement of certain milestones, and had <ix:nonFraction unitRef="shares" contextRef="id72ab97139f6499186284a9e549e2dcd_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMzYxOA_c2b2eed7-9cd6-4125-a7d2-3aede977bd0c">no</ix:nonFraction> performance restricted stock units forfeited. As of March&#160;31, 2023, the Company had <ix:nonFraction unitRef="shares" contextRef="i7f5dc11878354eceb96d35803df03196_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMzY5Mw_ea66caa3-40e5-49e0-b1ff-5a42b410536c">229,859</ix:nonFraction> performance restricted stock units outstanding.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management&#8217;s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">16</span></div></div></div></div><hr style="page-break-after:always"/><div style="background-color:#ffffff"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, for performance-based restricted stock units that were outstanding, the achievement of milestones was considered probable for <ix:nonFraction unitRef="shares" contextRef="iaedbd1575db640bfa3b1a3840d2f60c1_I20230331" decimals="INF" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTQ5NzU1ODIwNzg5_138e66c4-35b0-4dcf-addf-e66b56fe5df5">17,859</ix:nonFraction> shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, two milestones for outstanding performance restricted stock units were achieved. For the three months ended March&#160;31, 2023, the Company recognized stock-based compensation expense related to these milestones of $<ix:nonFraction unitRef="usd" contextRef="i1b8ca7e990664a5b82b28aaeab2809ac_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTQ5NzU1ODIyMTcx_85ec38f1-ed36-4714-b8d0-52ce563b7133">29</ix:nonFraction>. The milestones that had not been met were considered not probable, and therefore <ix:nonFraction unitRef="usd" contextRef="id72ab97139f6499186284a9e549e2dcd_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNDIzNQ_81363952-6463-49d5-928d-dff15ef4c593">no</ix:nonFraction> expense had been recognized related to these awards in the three months ended March&#160;31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Employee stock purchase plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each <ix:nonNumeric contextRef="i92885a5fac644e64800d5f746f26e823_D20230101-20230331" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTIzNQ_25eb95c1-435d-46cb-8aaf-a89c63b950f1">six-month</ix:nonNumeric> offering period at a price equal to <ix:nonFraction unitRef="number" contextRef="i92885a5fac644e64800d5f746f26e823_D20230101-20230331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNDUwMA_1d65bd94-010f-4704-ad72-194a794586c2">85</ix:nonFraction>% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i34860dd43a7c4f3385bb39b1b3cce7d7_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTAyNw_94784f66-3d9d-4bd8-8adc-706882f2b3dd">10</ix:nonFraction>% of an employee&#8217;s eligible compensation for each payroll period, up to $<ix:nonFraction unitRef="usd" contextRef="i92885a5fac644e64800d5f746f26e823_D20230101-20230331" decimals="-3" name="bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTEwMA_430482d0-5a3c-4056-97df-365b21a4c565">25</ix:nonFraction> each calendar year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, there were <ix:nonFraction unitRef="shares" contextRef="i92885a5fac644e64800d5f746f26e823_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTE3Mg_9b108d94-c965-42b9-b677-b5362f842945">33,202</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i655a42e7d5614f70874d9d99b077d0ca_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTE3OQ_9e6cd46e-c569-4f41-91de-5447f04795cd">31,341</ix:nonFraction> shares, respectively, issued under the 2020 ESPP.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RleHRyZWdpb246ODMyMGRjNmE0YzJjNDM2OWE3YzlkMDNlNjYwMGI2MjJfODY0_591903d9-a264-43ca-8d46-04c05364c039" continuedAt="i85cbbf5793ef477d9bbf0291b8ae622b" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i85cbbf5793ef477d9bbf0291b8ae622b" continuedAt="i3dcb2aec22f24dd88762e79b7657fc32"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RleHRyZWdpb246ODMyMGRjNmE0YzJjNDM2OWE3YzlkMDNlNjYwMGI2MjJfODY2_a9f0955b-d3a9-438d-8c08-ccc99fa38bb6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.419%"><tr><td style="width:1.0%"></td><td style="width:72.914%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfMi01LTEtMS0yODMyOA_0cc95593-7411-48f7-a03c-d2c5e8633e1b">20,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfMi03LTEtMS0yODMyOA_47d60543-38bb-450e-a346-97a56f83b185">25,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfMy01LTEtMS0yODMyOA_00e6016d-1b93-4db8-8e5b-0e8e03832b1c"><ix:nonFraction unitRef="shares" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfMy01LTEtMS0yODMyOA_1f18f60e-968f-415e-9c23-49fe5d52ca66">36,483,878</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfMy03LTEtMS0yODMyOA_089b293a-9e1f-4c00-9748-907a52a44d79"><ix:nonFraction unitRef="shares" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfMy03LTEtMS0yODMyOA_b4711e14-9f5f-449e-9dd3-80fc8864c90f">36,271,291</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfNC01LTEtMS0yODMyOA_c76ada61-93cd-48b9-9274-ec981324d05f"><ix:nonFraction unitRef="usdPerShare" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfNC01LTEtMS0yODMyOA_ff0dda40-ed71-4c4f-9664-1b102ec349f9">0.57</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfNC03LTEtMS0yODMyOA_3e579a8a-563b-4513-ac49-707a2712b723"><ix:nonFraction unitRef="usdPerShare" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfNC03LTEtMS0yODMyOA_421273cf-9942-4f82-8a47-9fa7506bcfca">0.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RleHRyZWdpb246ODMyMGRjNmE0YzJjNDM2OWE3YzlkMDNlNjYwMGI2MjJfODY3_3c4dbe34-039a-4376-a1f1-dd937581402b" continuedAt="ib54979fec4c046fca3eb0291b1075f0d" escape="true">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">17</span></div></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><ix:continuation id="i3dcb2aec22f24dd88762e79b7657fc32"><ix:continuation id="ib54979fec4c046fca3eb0291b1075f0d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2e956203346c4f019b41b2e8a5ca63b5_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfMi0xLTEtMS0yODMyOA_8c14845f-04b2-4404-b164-b8ca44cf7bcd">7,710,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i480b155b6e9e4eb7bb0b1e836d5e7afb_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfMi0zLTEtMS0yODMyOA_b7ab5593-7c73-41dd-a4e9-c6c75e8cbb48">5,918,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i54c6774cffa04e968e001d62f8b99a07_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfMy0xLTEtMS0yODMyOA_aeefae0a-8bc0-4e90-ba64-fe4ebac109db">86,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib89eee0073ef4f748054dcd1018afcb4_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfMy0zLTEtMS0yODMyOA_6258ee96-92c7-4a89-9cd2-81bd4d4c37a4">45,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares issuable under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iaf82d51205674d83a503b0e61adba697_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNC0xLTEtMS0yODMyOA_1a9f8b07-dcaf-47e9-ad74-cfbf5011f531">102,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id425a5500c184a08bd09e08bff211884_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNC0zLTEtMS0yODMyOA_dc5b4ab4-05a9-4a1b-bd4a-56b577395c3d">27,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested performance restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i812984cbee954504a8f1cb1007753038_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNS0xLTEtMS0zMDQ0OA_8f83455b-3b73-4852-98a8-46efcdbc7e66">229,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if98a5e733c4c466b9290ddc071d57eb2_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNS0zLTEtMS0zMDQ0OA_9dfd3f7f-0e5c-4e40-a118-fa90bcdb03a1">19,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3c4704e3cd5b4f9ca3f745afab97bcbc_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNS0xLTEtMS0yODMyOA_17126467-8d28-4be1-9240-5b9cc9beb409">10,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iec9bf005920e479db53ec4495d3c9605_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNS0zLTEtMS0yODMyOA_3b967b90-45b7-4318-9dfa-6008cd01800b">10,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNi0xLTEtMS0yODMyOA_4bda412c-fa9b-456c-8b7b-eac08fadb14a">8,139,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNi0zLTEtMS0yODMyOA_f045dbf5-5490-4e1a-9293-019974ce61d3">6,021,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="ic06fdbc868994781830cfb9f962306b5_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMjU4Ng_d22a7a36-ea0b-4dbb-a727-d845ef03e7a0" continuedAt="i71d3040949fe4506bc5bf0830f51cc63" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i71d3040949fe4506bc5bf0830f51cc63" continuedAt="i0cb36f9c78134b5b81fe616f07ee01ec"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has historically entered into lease arrangements for its facilities. As of March&#160;31, 2023, the Company had <ix:nonFraction unitRef="contract" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="0" name="bdtx:LesseeOperatingLeaseNumberOfContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMTIy_3161bbf3-17a5-4e5c-8cc8-b1929ef5ecb1">two</ix:nonFraction> operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company&#8217;s leases generally do not include termination or purchase options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a <ix:nonNumeric contextRef="i09dbac4b37d84e3eb2e7dad646327861_I20200731" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMjU4OQ_0012e67d-fff7-44f6-adc5-c1c15bd9b3d3">seven-year</ix:nonNumeric> agreement with an option to extend for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfNTMw_02522d54-356b-489e-ae5f-0345b2c059f0">five</span> additional years to lease two floors totaling approximately <ix:nonFraction unitRef="sqft" contextRef="i09dbac4b37d84e3eb2e7dad646327861_I20200731" decimals="0" name="bdtx:LesseeOperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfNTkz_59152f73-64a6-4960-a3d5-89170db5ea35">25,578</ix:nonFraction> square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $<ix:nonFraction unitRef="usd" contextRef="i09dbac4b37d84e3eb2e7dad646327861_I20200731" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMTAwNQ_2ab1dd25-64c7-48ce-998d-c2c0842ffe3e">1,168</ix:nonFraction> letter of credit as security for the lease. Additionally, on December 12, 2022, the Company entered into a sublease for one floor of its Cambridge, Massachusetts office space. The sublease terminates on August 31, 2028, which is also the date on which the Company's lease terminates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2020, the Company entered into an <ix:nonNumeric contextRef="id28a5be0a35d4bc881d156351fc61d4e_I20201231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMjU4Mw_7f8926c6-ce67-431d-8c93-089c6d522557">eleven-year</ix:nonNumeric> agreement to lease approximately <ix:nonFraction unitRef="sqft" contextRef="id28a5be0a35d4bc881d156351fc61d4e_I20201231" decimals="0" name="bdtx:LesseeOperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMTU4NQ_9cf531bc-31ee-4692-9e9c-3707a1a67c22">18,120</ix:nonFraction> square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMTY5OA_c306ce76-7222-412d-9933-d5323bf1972b">five</span> additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMjU4NA_4b9e7c33-44e2-4fcc-bf4b-449dd7cc0f7c" continuedAt="i6b72807337784a25b3e243c72a9d26fe" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating lease for the three months ended March&#160;31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.400%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended March 31,</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfMy01LTEtMS0yODMyOA_d76206ed-150a-4c5f-99f9-34b31aa9984c">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfMy03LTEtMS0yODMyOA_8b4952f3-e865-416f-899e-dc84dc682b79">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNC01LTEtMS0yODMyOA_2e50dee5-110b-4764-8696-36de3143594c">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNC03LTEtMS0yODMyOA_16549314-427c-4f05-87e0-2eda98477a08">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNS01LTEtMS0yODMyOA_b84b58a3-6738-4801-8961-7fd2828134e6">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNS03LTEtMS0yODMyOA_f36e2015-1621-4822-a7a3-37509ed787da">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNi01LTEtMS0zMTIxMg_bdbedb15-a264-4e7b-822e-4ee36aa77486">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNi03LTEtMS0zMTIxMg_95d93856-a3e3-4b04-9564-e44f60b07cbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNi01LTEtMS0yODMyOA_33897730-2c2a-4640-b578-7bc05939dcc6">1,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNi03LTEtMS0yODMyOA_c98084e8-c9be-4111-8ad3-b11c149e6274">1,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><ix:continuation id="i0cb36f9c78134b5b81fe616f07ee01ec"><div style="margin-top:12pt"><ix:continuation id="i6b72807337784a25b3e243c72a9d26fe"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjEwMTcxYmRhMGJlYjQyMTZiYjc0YzAxZWRjYTI4NjdiL3RhYmxlcmFuZ2U6MTAxNzFiZGEwYmViNDIxNmJiNzRjMDFlZGNhMjg2N2JfMi0xLTEtMS0yODMyOA_a0b33987-94a3-40fe-8e39-b1cbd8d5c815">1,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjEwMTcxYmRhMGJlYjQyMTZiYjc0YzAxZWRjYTI4NjdiL3RhYmxlcmFuZ2U6MTAxNzFiZGEwYmViNDIxNmJiNzRjMDFlZGNhMjg2N2JfMi0zLTEtMS0yODMyOA_c09cc6c2-c9b8-4883-ad45-c37b5b7c6396">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjEwMTcxYmRhMGJlYjQyMTZiYjc0YzAxZWRjYTI4NjdiL3RhYmxlcmFuZ2U6MTAxNzFiZGEwYmViNDIxNmJiNzRjMDFlZGNhMjg2N2JfMy0xLTEtMS0yODMyOA_2dd34741-1039-4c10-88ed-fd9ad5e7507a">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjEwMTcxYmRhMGJlYjQyMTZiYjc0YzAxZWRjYTI4NjdiL3RhYmxlcmFuZ2U6MTAxNzFiZGEwYmViNDIxNmJiNzRjMDFlZGNhMjg2N2JfMy0zLTEtMS0yODMyOA_90d58fcc-f09b-49a6-ae2e-24ca764ffcab">8.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjEwMTcxYmRhMGJlYjQyMTZiYjc0YzAxZWRjYTI4NjdiL3RhYmxlcmFuZ2U6MTAxNzFiZGEwYmViNDIxNmJiNzRjMDFlZGNhMjg2N2JfNC0xLTEtMS0yODMyOA_fd5329d3-96fb-48fe-bcd6-5f1772d750c5">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjEwMTcxYmRhMGJlYjQyMTZiYjc0YzAxZWRjYTI4NjdiL3RhYmxlcmFuZ2U6MTAxNzFiZGEwYmViNDIxNmJiNzRjMDFlZGNhMjg2N2JfNC0zLTEtMS0yODMyOA_9db53614-bd56-405a-925d-1c51838eb0ba">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The variable lease costs for the three months ended March&#160;31, 2023 and 2022 include common area maintenance and other operating charges. As the Company&#8217;s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMjU4NQ_389c313d-1ccf-4f71-9009-5d6dc95d0f86" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company&#8217;s operating leases as of March&#160;31, 2023 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">As of March 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 (excluding the three months ended March&#160;31, 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfMS0xLTEtMS0yODMyOA_20d94d97-3ebd-44cb-b066-168d9f39cfe7">3,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfMi0xLTEtMS0yODMyOA_2122d4db-db63-4939-bb09-c0827558d7bd">4,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfMy0xLTEtMS0yODMyOA_0c1fb1da-4fe6-410a-801f-69c55d0f690c">4,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfNC0xLTEtMS0yODMyOA_b2d33c02-4420-45af-a287-052afb0d5c16">4,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfNS0xLTEtMS0yODMyOA_3cc50e7f-5436-4f33-b03d-69b315eb1525">4,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="bdtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfNi0xLTEtMS0yODMyOA_4a472716-c7a4-4820-a356-45d1ee71565a">12,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfNy0xLTEtMS0yODMyOA_1669d0ca-e807-4fb8-9633-52d3c284c4dc">33,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfOC0xLTEtMS0yODMyOA_b093bbbe-c9b3-4cd2-b005-cd1f9d21433f">6,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfOS0xLTEtMS0yODMyOA_c9141eaf-3a31-44f6-bc9f-9e0e803b265f">27,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="ic06fdbc868994781830cfb9f962306b5_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81OC9mcmFnOmM5Njk3ZjYxMTJiMDRjYWViOWU5YmYzYWMyY2FiNzQ2L3RleHRyZWdpb246Yzk2OTdmNjExMmIwNGNhZWI5ZTliZjNhYzJjYWI3NDZfMjU3OA_6b958832-d8eb-4a1d-b756-4e8c0d3dc5ce" continuedAt="i5bef62d178714214b609488f9c55d606" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i5bef62d178714214b609488f9c55d606" continuedAt="ib1aea089fb1441628df742336eba9df1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">License agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of March&#160;31, 2023, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnification agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of March&#160;31, 2023 or December&#160;31, 2022. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><ix:continuation id="ib1aea089fb1441628df742336eba9df1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Legal proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></div></ix:continuation><div id="ic06fdbc868994781830cfb9f962306b5_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV82MS9mcmFnOjk4N2ZhYjJiYTY4MzRiMDA5ZjJiYmMzYmNkNzAzYjkyL3RleHRyZWdpb246OTg3ZmFiMmJhNjgzNGIwMDlmMmJiYzNiY2Q3MDNiOTJfNjE2_11a64fe8-3085-40d6-a737-f5e2bbfcbffa" continuedAt="i4e98e70d4e53484b9b5a399f060190ca" escape="true">BENEFIT PLANS</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:continuation id="i4e98e70d4e53484b9b5a399f060190ca">The Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the 401(k) Plan). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to <ix:nonFraction unitRef="number" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="0" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV82MS9mcmFnOjk4N2ZhYjJiYTY4MzRiMDA5ZjJiYmMzYmNkNzAzYjkyL3RleHRyZWdpb246OTg3ZmFiMmJhNjgzNGIwMDlmMmJiYzNiY2Q3MDNiOTJfMjI3_b12ccdec-68d3-4d66-8f45-996a53b3077f">100</ix:nonFraction>% of a participant&#8217;s eligible contributions of up to <ix:nonFraction unitRef="number" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV82MS9mcmFnOjk4N2ZhYjJiYTY4MzRiMDA5ZjJiYmMzYmNkNzAzYjkyL3RleHRyZWdpb246OTg3ZmFiMmJhNjgzNGIwMDlmMmJiYzNiY2Q3MDNiOTJfMjgx_e811e76b-5bc3-4e32-9af1-3cbcd8fc2441">6</ix:nonFraction>% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the Code). All matching contributions are fully vested when made. During the three months ended March&#160;31, 2023 and 2022, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331" decimals="-3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV82MS9mcmFnOjk4N2ZhYjJiYTY4MzRiMDA5ZjJiYmMzYmNkNzAzYjkyL3RleHRyZWdpb246OTg3ZmFiMmJhNjgzNGIwMDlmMmJiYzNiY2Q3MDNiOTJfNTY0_79aa049f-6814-4b7b-b17b-2200a56de22e">376</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331" decimals="-3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV82MS9mcmFnOjk4N2ZhYjJiYTY4MzRiMDA5ZjJiYmMzYmNkNzAzYjkyL3RleHRyZWdpb246OTg3ZmFiMmJhNjgzNGIwMDlmMmJiYzNiY2Q3MDNiOTJfNTcz_59c9f497-835b-4522-8e75-c5d5564f5366">558</ix:nonFraction>, respectively, to the 401(k) Plan.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">20</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes thereto for the year ended December 31, 2022, as well as Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on March 9, 2023. This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth in our Annual Report on Form 10-K and in other SEC filings.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a clinical-stage precision oncology medicine company focused on pioneering the discovery and development of novel MasterKey therapies. We target families of oncogenic mutations in patients with genetically defined cancers. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Our proprietary technology platform, which we refer to as our Mutation-Allostery-Pharmacology (MAP) drug discovery engine, is designed to allow us to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Our goal is to identify families of mutations that can be inhibited with MasterKey therapies, thereby providing precision oncology to greater numbers of patients with genetically defined tumors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have designed our product candidates to be potent, brain penetrant and selective MasterKey inhibitors of oncogenic mutational families which occur across a range of tumor types. Our lead product candidate, BDTX-1535, is designed to selectively and irreversibly inhibit a family of oncogenic mutations in the ErbB-1 epidermal growth factor receptor (EGFR) which are resistant to current generation tyrosine kinase inhibitors (TKIs), while sparing wild type EGFR (EGFR WT) activity. We are currently evaluating BDTX-1535 in the dose escalation portion of a Phase 1 clinical trial in non-small cell lung cancer (NSCLC) patients with EGFR resistance mutations, with or without brain metastases and in patients with glioblastoma multiforme (GBM). We expect to provide an update on the dose escalation portion of the BDTX-1535 Phase 1 clinical trial in the second half of 2023. Our second product candidate, BDTX-4933, is designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers promoted by upstream oncogenic alterations, such as RAS mutations, which has the potential to avoid paradoxical activation. We expect to initiate a Phase 1 clinical trial for BDTX-4933 in select indications for patients harboring all-class BRAF or RAS mutations in the second quarter of 2023. We are also leveraging our MAP drug discovery engine to identify other families of oncogenic mutations in validated oncogenes, which have the potential to expand the reach of MasterKey therapies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In order to focus on progressing our pipeline through important upcoming milestones for BDTX-1535 and BDTX-4933, as well as on our discovery efforts, in April 2022, we announced the discontinuation of the development of BDTX-189, our EGFR/HER2 Exon 20 targeted therapy. In December 2022, we announced the spinout of certain early discovery stage antibody programs enabled by the MAP drug discovery engine into Launchpad Therapeutics, Inc. (Launchpad), a new company formed to exploit the MAP drug discovery engine for the discovery, development and commercialization of large molecule therapeutics.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since our inception in 2014, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights while conducting research and development activities for our programs. We do not have any products approved for sale and have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product. We have not yet successfully completed any pivotal clinical trials, obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To date, we have funded our operations with proceeds from the sale of preferred stock and common stock. Since inception, we have incurred significant operating losses. Our net losses were $20.9 million and $25.5 million for the three months ended March&#160;31, 2023 and 2022, respectively. As of March&#160;31, 2023, we had an accumulated deficit of $355.9 million. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">advance clinical studies for BDTX-1535 and BDTX-4933 and continue preclinical studies for our other product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">continue to identify additional product candidates from our proprietary MAP drug discovery engine; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtain, maintain, expand and protect our intellectual property portfolio; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">attract and retain key clinical, scientific, management and commercial personnel; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">seek marketing approvals for our product candidates that successfully complete clinical trials, if any; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">acquire or in-license additional product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates, delay our pursuit of potential in-licenses or acquisitions, and reduce headcount and general and administrative costs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, we continue to actively monitor macroeconomic conditions and market volatility resulting from global economic developments, political unrest, high inflation, the recent failure of certain banks and financial institutions, and health crises, such as the COVID-19 pandemic. While we believe such factors have had no significant impact on our business or financial results during the periods presented, future developments and potential impacts on our business are uncertain and cannot be predicted with confidence.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash, cash equivalents and investments of approximately $103.4 million, which we believe will fund our operating expenses and capital expenditure requirements into the third quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;&#8212;Liquidity and capital resources.&#8221; To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">22</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Components of our results of operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expenses incurred under agreements with contract research organizations, or CROs, that are primarily engaged in the oversight and conduct of our drug discovery efforts and preclinical studies, clinical trials and contract manufacturing organizations, or CMOs, that are primarily engaged to provide preclinical and clinical drug substance and product for our research and development programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">other costs related to acquiring and manufacturing materials in connection with our drug discovery efforts and preclinical studies and clinical trial materials, including manufacturing validation batches, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">payments made in cash or equity securities under third-party licensing, acquisition and option agreements; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">costs related to compliance with regulatory requirements; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">allocated facilities-related costs, depreciation and other expenses, which include rent and utilities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Any nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are expensed as the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our direct external research and development expenses consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses also include fees incurred under license, acquisition and option agreements. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years as we continue our clinical trials for BDTX-1535 and BDTX-4933, as well as conduct other preclinical and clinical development, including submitting regulatory filings for other product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect our discovery research efforts and our related personnel costs will increase and, as a result, we expect our research and development expenses, including costs associated with stock-based compensation, will increase above current year levels. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. The successful development and commercialization of our product candidates is highly uncertain. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establishing an appropriate safety and efficacy profile with IND-enabling studies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">successful patient enrollment in and the initiation and completion of clinical trials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the U.S. Food and Drug Administration (FDA) and non-U.S. regulators; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">significant and changing government regulation; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and benefits, travel and stock-based compensation expense for personnel in executive, business development, finance, human resources, legal, information technology, pre-commercial and support personnel functions. General and administrative expenses also include direct and allocated facility-related costs as well as insurance costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. </span></div><div style="margin-top:12pt;padding-left:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates and prepare for potential commercialization activities. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate. </span></div><div style="margin-top:12pt;padding-left:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of interest income earned on our cash equivalents and investment balances, sublease income and realized, unrealized foreign currency transaction gains and losses, and gain (loss) on sale of IP related to equity method investment.</span></div><div style="margin-top:12pt;padding-left:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Equity in (losses) of unconsolidated entity</span></div><div style="margin-top:12pt;padding-left:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Equity in (losses) of unconsolidated entity consists of our share of equity method investee losses on the basis of our equity ownership percentage and IPR&amp;D charges resulting from basis differences.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">25</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Results of operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">three months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ended March&#160;31, 2023 and 2022</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March&#160;31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,561&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4,118)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(21,561)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(25,679)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other (expense) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(20,875)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(25,507)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,632&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses were $14.8 million for the three months ended March&#160;31, 2023, compared to $17.8 million for the three months ended March&#160;31, 2022. The following table summarizes our research and development expenses for the three months ended March&#160;31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BDTX-1535 research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BDTX-4933 research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BDTX-189 research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other research programs and platform development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Personnel expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Allocated facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,753&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,786&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3,033)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The decrease of $3.0 million for the three months ended March&#160;31, 2023 was primarily due to a net increase of $4.0 million related to the progression of our clinical trials for BDTX-1535 and BDTX-4933 offset by decreased spend relating to other research programs and platform development of $2.7 million due to reduced spending on early discovery projects, compared to the three months ended March&#160;31, 2022. In addition, BDTX-189 expenses decreased $2.5 million due to reduced clinical trial activities stemming from the discontinuation of the development of BDTX-189 to focus on upcoming milestones for our pipeline programs, BDTX-1535 and BDTX-4933. Personnel expenses decreased $1.8 million as a result of the realignment of our workforce in April 2022 to focus on upcoming milestones for our pipeline programs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses were $6.8 million for the three months ended March&#160;31, 2023 compared to $7.9 million for the three months ended March&#160;31, 2022. This was primarily a result of a decrease in personnel-related costs, legal and other professional fees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense) </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income was $0.7 million for the three months ended March&#160;31, 2023, compared to $0.2 million for the three months ended March&#160;31, 2022. The increase was primarily attributable to amortization of premium on investments decreasing at a higher rate in 2023 compared to 2022, sublease income in 2023 and interest income decreasing due to market conditions.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Sources of liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from sales of any product candidates for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of preferred stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 3, 2020, we completed an IPO of 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, for aggregate gross proceeds of $231.3&#160;million. We received $212.1&#160;million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. Through March&#160;31, 2023, we had received net cash proceeds of $200.6 million from previous sales of our preferred stock and as of March&#160;31, 2023, we had cash, cash equivalents and investments of $103.4&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 14, 2022, we filed a shelf registration statement on Form S-3 (the Shelf Registration Statement) with the SEC, which covers the offering, issuance and sale of our common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum price of $500 million. We simultaneously entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">SM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the Sales Agreement) with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by us of up to $150 million of our common stock, or the Shares, from time to time through Jefferies as our sales agent (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Jefferies may sell the Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act. We may sell the Shares in amounts and at times to be determined by us from time to time subject to the terms and conditions of the Sales Agreement, but we have no obligation to sell any Shares under the Sales Agreement. We or Jefferies may suspend or terminate the offering of Shares upon notice to the other party and subject to other conditions. As of March&#160;31, 2023, no sales have been made pursuant to the ATM Program.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cash flows</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.839%"><tr><td style="width:1.0%"></td><td style="width:71.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(20,031)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(28,600)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash provided by investing activities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24,806&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,826&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(11,718)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we used cash in operating activities of $20.0&#160;million, primarily resulting from our net loss of $20.9&#160;million, partially offset by the non-cash charge related to stock compensation expense of $2.7&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we used cash in operating activities of $28.6&#160;million, primarily resulting from our net loss of $25.5&#160;million, partially offset by the non-cash charge related to stock compensation expense of $3.4&#160;million and an increase in prepaid expenses and other current assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in accounts payable and accrued expenses in all periods were generally due to growth in our business, the advancement of our product candidates, and the timing of vendor invoicing and payments. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we had cash provided by investing activities of $24.8&#160;million primarily from the sales and maturities of investments. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we had cash provided by investing activities of $16.7&#160;million primarily from the sales and maturities of investments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we had cash provided by financing activities of $0.1&#160;million, consisting of proceeds from the participation in the employee stock purchase plan. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we had cash provided by financing activities of $0.2&#160;million consisting of proceeds from exercise of stock options and participation in the employee stock purchase plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Funding requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. In addition, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. The timing and amount of our operating expenditures will depend largely on our ability to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">advance BDTX-1535 and BDTX-4933 through clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">advance preclinical development of our early stage programs, including our FGFR program;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">manufacture, or have manufactured on our behalf, our preclinical and clinical drug material and develop processes for late state and commercial manufacturing;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">hire additional clinical, quality control and scientific personnel; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">obtain, maintain, expand and protect our intellectual property portfolio.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash, cash equivalents and investments of $103.4 million, which we believe will fund our operating expenses and capital expenditure requirements into the third quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will require additional capital as we seek regulatory approval of our product candidates and if we choose to pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to further reduce or terminate our operations. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs, timing and ability to manufacture our product candidates to supply our clinical and preclinical development efforts and our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">subject to receipt of regulatory approval, the costs of commercialization activities for our product candidates, to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the ability to receive additional non-dilutive funding;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the extent to which we acquire or in-license other product candidates and technologies; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the costs of operating as a public company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time, if ever, as we can generate substantial product revenue from product sales, we expect to finance our operations through a combination of public or private equity offerings, debt financings, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties or through other sources of financing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. However, the trading prices for our common stock and for other biopharmaceutical companies have been highly volatile. As a result, we may face difficulties raising capital through sales of our common stock, and such sales may be on unfavorable terms. Similarly, adverse macroeconomic conditions and market volatility resulting from global economic developments, political unrest, high inflation, global health crises, such as the COVID-19 pandemic, or other factors could materially and adversely affect our ability to consummate an equity or debt financing on favorable terms or at all. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of private or public equity or convertible debt securities, the ownership interest of our stockholders may be materially diluted, and the terms of such securities could include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. In addition, debt financing may involve significant cash payment obligations and specific financial ratios that may restrict our ability to operate our business would result in fixed payment obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, obtain capital through arrangements with collaborators on terms unfavorable to us or pursue merger or acquisition strategies, all of which could adversely affect the holdings or the rights of our stockholders.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contractual obligations and commitments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following summarizes our contractual obligations as of March&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less than 1 Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1 to 3 Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3 to 5 Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">More than 5 Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property leases - commenced</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,272&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,896&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,601&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Property leases &#8211; commenced</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The amounts reported for property leases represent future minimum lease payments under non-cancelable operating leases in effect as of March&#160;31, 2023. The minimum lease payments do not include common area maintenance charges or real estate taxes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Other contractual obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The contractual obligations table does not include any potential future milestone payments or royalty payments we may be required to make under our existing license agreements due to the uncertainty of the occurrence of the events requiring payment under those agreements.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Critical accounting policies and significant judgments and use of estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our critical accounting policies are described under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212; Critical Accounting Policies and Use of Estimates&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on March 9, 2023. During the three months ended March&#160;31, 2023, there were no material changes to our critical accounting policies from those previously disclosed.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Emerging growth company and smaller reporting company status </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Jumpstart Our Business Startups Act of 2012 (the JOBS Act) permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to not &#8220;opt out&#8221; of this provision and, as a result, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualify as an emerging growth company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company&#8221; meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosure About Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">31</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March&#160;31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">32</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="ic06fdbc868994781830cfb9f962306b5_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information required with respect to this item can be found under &#8220;Legal Proceedings&#8221; in Note 11 to our condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q and is incorporated by reference into this Item 1. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business, the resolution of which we do not anticipate would have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are updating and supplementing our risk factors previously disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 9, 2023 to add the following new risk factor:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Conditions in the banking system and financial markets, including the failure of banks and financial institutions, could have an adverse effect on our operations and financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, the Federal Deposit Insurance Corporation took control and was appointed receiver of Silicon Valley Bank, or SVB, after it was unable to continue its operations. This event exposed vulnerabilities in the banking sector, including legal uncertainties, significant volatility and contagion risk, and caused market prices of regional bank stocks to plummet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report on Form 10-Q, we do not hold material cash deposits at SVB and have not experienced any adverse impact to our liquidity or to our current and projected business operations, financial condition, or results of operations; however, we are unable to predict the extent or nature of the impacts of evolving circumstances in the financial services industry at this time. If, for example, other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents and investments may be threatened. While it is not possible at this time to predict the extent of the impact that high market volatility and instability of the banking sector could have on economic activity and our business in particular, the failure of other banks and financial institutions and the measures taken by governments, businesses and other organizations in response to these events could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There have been no other material changes to the risk factors previously disclosed in Part I, Item 1A (Risk Factors) of our Annual Report on Form 10-K for the year ended December 31, 2022. Please refer to the complete Part I, Item 1A of our Annual Report for additional risks and uncertainties we are facing that may have a material adverse effect on our business prospects, financial condition and results of operations. In addition to the risks described in our Annual Report on Form 10-K, you should carefully consider the other information set forth in this Form 10-Q and the information in our other filings with the SEC, as they could materially affect our business, financial condition or future results of operations.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Equity Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds from IPO of Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 3, 2020, we completed the IPO of our common stock pursuant to which we issued and sold 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, at a public offering price of $19.00 per share.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The offer and sale of all of the shares of our common stock in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333-235789), which was declared effective by the SEC on January 29, 2020. J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company, LLC and Canaccord Genuity LLC acted as joint book-running managers of the offering and as representatives of the underwriters.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We received aggregate gross proceeds from our IPO of $231.3 million, or aggregate net proceeds of $212.1 million after deducting underwriting discounts and commissions and other offering costs. None of the underwriting discounts and commissions or offering expenses were incurred or paid, directly or indirectly, to any of our directors or officers or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus, filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on January 30, 2020.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">None.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic06fdbc868994781830cfb9f962306b5_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div id="ic06fdbc868994781830cfb9f962306b5_118"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">No.</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit311_q12023.htm">Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit312_q12023.htm">Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1*+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit321_q12023.htm">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Labels Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">35</span></div></div></div><div id="ic06fdbc868994781830cfb9f962306b5_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline" href="#ic06fdbc868994781830cfb9f962306b5_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.033%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date: May 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">/s/ David M. Epstein</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">David M. Epstein</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">President and Chief Executive Officer</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.033%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Black Diamond Therapeutics, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date: May 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">/s/ Fang Ni</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Fang Ni</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Chief Business Officer and Chief Financial Officer</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(Principal Financial Officer)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">36</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311_q12023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i85e3baf778c9415499c7b24f13bd2de3_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a) OR 15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, David M. Epstein, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2023 of Black Diamond Therapeutics, Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; David M. Epstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">David M. Epstein</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">President, Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and Director</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312_q12023.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if36b8de67dc345ea98afcfd682f96650_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a) OR 15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Fang Ni, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.75pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2023 of Black Diamond Therapeutics, Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:52.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Fang Ni</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fang Ni</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Business Officer and Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321_q12023.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib578143593454166902586814baee483_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, David M. Epstein, the Principal Executive Officer, and Fang Ni, the Principal Financial Officer, of Black Diamond Therapeutics, Inc. (the &#8220;Company&#8221;), hereby certify, that, to their knowledge&#58; </font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:5.18pt">the Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the &#8220;Report&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.18pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:47.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; David M. Epstein</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">David M. Epstein</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">President, Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and Director</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:47.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Fang Ni</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fang Ni</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Business Officer and Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>bdtx-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:73ec13c2-272f-4624-b8c8-b5925ba5540a,g:c0252310-7c05-47ef-aa9c-a55e1f9856cd-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bdtx="http://www.blackdiamondtherapeutics.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.blackdiamondtherapeutics.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdtx-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdtx-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdtx-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdtx-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.blackdiamondtherapeutics.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityUnaudited" roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESSANDBASISOFPRESENTATION" roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION">
        <link:definition>0000007 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000009 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTS" roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS">
        <link:definition>0000010 - Disclosure - INVESTMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>0000011 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYMETHODINVESTMENT" roleURI="http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT">
        <link:definition>0000012 - Disclosure - EQUITY METHOD INVESTMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES">
        <link:definition>0000013 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>0000014 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE">
        <link:definition>0000015 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASES">
        <link:definition>0000016 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BENEFITPLANS" roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS">
        <link:definition>0000018 - Disclosure - BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>0000020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSTables" roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables">
        <link:definition>0000021 - Disclosure - INVESTMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>0000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables">
        <link:definition>0000023 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>0000024 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables">
        <link:definition>0000025 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESTables">
        <link:definition>0000026 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails">
        <link:definition>0000027 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>0000028 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSScheduleofMarketableSecuritiesDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails">
        <link:definition>0000029 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSAdditionalInformationDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails">
        <link:definition>0000030 - Disclosure - INVESTMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails">
        <link:definition>0000031 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYMETHODINVESTMENTDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails">
        <link:definition>0000032 - Disclosure - EQUITY METHOD INVESTMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>0000033 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>0000034 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails">
        <link:definition>0000035 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails">
        <link:definition>0000036 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails">
        <link:definition>0000037 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREComputationofNetLossperShareDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails">
        <link:definition>0000038 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails">
        <link:definition>0000039 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails">
        <link:definition>0000040 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails">
        <link:definition>0000041 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofFutureMinimumLeasePaymentsDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails">
        <link:definition>0000042 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1">
        <link:definition>0000042 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BENEFITPLANSDetails" roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails">
        <link:definition>0000043 - Disclosure - BENEFIT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bdtx_AccruedContractResearchServiceFeesCurrent" abstract="false" name="AccruedContractResearchServiceFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_PerformanceRestrictedStockUnitsMember" abstract="true" name="PerformanceRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_OpenMarketSaleMember" abstract="true" name="OpenMarketSaleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_LesseeOperatingLeaseArea" abstract="false" name="LesseeOperatingLeaseArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_RentExpense" abstract="false" name="RentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_A2020EmployeeStockPurchasePlanMember" abstract="true" name="A2020EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_LesseeOperatingLeaseNumberOfContracts" abstract="false" name="LesseeOperatingLeaseNumberOfContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_ShelfRegistrationStatementMember" abstract="true" name="ShelfRegistrationStatementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bdtx_LaunchpadTherapeuticsIncMember" abstract="true" name="LaunchpadTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_LeaseOtherInformationAbstract" abstract="true" name="LeaseOtherInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bdtx_OperatingLeasePrincipalOfficeTwoMember" abstract="true" name="OperatingLeasePrincipalOfficeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" abstract="true" name="OperatingLeaseOfficeAndLaboratorySpaceNYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange" abstract="false" name="EquityMethodInvestmentSharesReceivedInNoncashExchange" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bdtx_SaleOfStockAuthorizedConsideration" abstract="false" name="SaleOfStockAuthorizedConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bdtx_OtherAwardTypeMember" abstract="true" name="OtherAwardTypeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bdtx_A2020StockOptionPlanMember" abstract="true" name="A2020StockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>bdtx-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:73ec13c2-272f-4624-b8c8-b5925ba5540a,g:c0252310-7c05-47ef-aa9c-a55e1f9856cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="bdtx-20230331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bd287494-ed6b-47a3-9684-2dd4ab6b3d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_929190d1-d199-4507-beda-225acf800084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bd287494-ed6b-47a3-9684-2dd4ab6b3d39" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_929190d1-d199-4507-beda-225acf800084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_73b15e4d-f8b6-4d49-a651-bfc5ba926a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bd287494-ed6b-47a3-9684-2dd4ab6b3d39" xlink:to="loc_us-gaap_CommonStockValue_73b15e4d-f8b6-4d49-a651-bfc5ba926a11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_03d3a046-0669-4f1e-97c5-7e4697d9a815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bd287494-ed6b-47a3-9684-2dd4ab6b3d39" xlink:to="loc_us-gaap_AdditionalPaidInCapital_03d3a046-0669-4f1e-97c5-7e4697d9a815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f2e95883-75e2-44d3-968f-cc63a9c0024f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bd287494-ed6b-47a3-9684-2dd4ab6b3d39" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f2e95883-75e2-44d3-968f-cc63a9c0024f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_25d4b528-9461-4690-ae7b-a6189656ae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bd287494-ed6b-47a3-9684-2dd4ab6b3d39" xlink:to="loc_us-gaap_PreferredStockValue_25d4b528-9461-4690-ae7b-a6189656ae8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f120a913-a2f2-4586-861c-9a59d654ee6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b50865d8-a40e-4116-84cd-8d589f2613eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f120a913-a2f2-4586-861c-9a59d654ee6c" xlink:to="loc_us-gaap_StockholdersEquity_b50865d8-a40e-4116-84cd-8d589f2613eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4ab6305f-f6fc-42e7-af16-028d2fe44c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f120a913-a2f2-4586-861c-9a59d654ee6c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4ab6305f-f6fc-42e7-af16-028d2fe44c2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1891c587-f186-4779-864a-c715bde0ea34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f120a913-a2f2-4586-861c-9a59d654ee6c" xlink:to="loc_us-gaap_Liabilities_1891c587-f186-4779-864a-c715bde0ea34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4ecf3755-9dfc-4766-9553-a28fceb95f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25562275-51da-40ed-af6b-ace33e68b552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4ecf3755-9dfc-4766-9553-a28fceb95f3d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25562275-51da-40ed-af6b-ace33e68b552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0cc9450a-1a40-4e0f-9b4f-da4b6fc09b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4ecf3755-9dfc-4766-9553-a28fceb95f3d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0cc9450a-1a40-4e0f-9b4f-da4b6fc09b19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_68a21b17-22bc-4171-ac87-e703a2d3dbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4ecf3755-9dfc-4766-9553-a28fceb95f3d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_68a21b17-22bc-4171-ac87-e703a2d3dbf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bb51f469-eab9-4972-b18e-2434ca2eb7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a4db5e06-15ea-4ff6-b93b-9b1efcb93a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb51f469-eab9-4972-b18e-2434ca2eb7db" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a4db5e06-15ea-4ff6-b93b-9b1efcb93a5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1c7c0c80-b75d-4a19-95e2-05a3e629aa18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb51f469-eab9-4972-b18e-2434ca2eb7db" xlink:to="loc_us-gaap_AccountsPayableCurrent_1c7c0c80-b75d-4a19-95e2-05a3e629aa18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cffb8e97-44b3-476a-8a51-0cbe97bac908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e7791e07-6015-469b-bb8b-d4beb4d4dc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cffb8e97-44b3-476a-8a51-0cbe97bac908" xlink:to="loc_us-gaap_AssetsCurrent_e7791e07-6015-469b-bb8b-d4beb4d4dc00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_26d738b2-80ec-4ffd-81db-0142bc106832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cffb8e97-44b3-476a-8a51-0cbe97bac908" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_26d738b2-80ec-4ffd-81db-0142bc106832" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ef47bfeb-c6ca-4fd2-81b3-7904941ad635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cffb8e97-44b3-476a-8a51-0cbe97bac908" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ef47bfeb-c6ca-4fd2-81b3-7904941ad635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_19e288b8-6043-4d0a-875b-d192c7bde74c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cffb8e97-44b3-476a-8a51-0cbe97bac908" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_19e288b8-6043-4d0a-875b-d192c7bde74c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8db1fb3a-3fd4-46e4-aef2-b658528dcdea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2af4d213-7a90-4654-9f0c-d8fa819b8b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8db1fb3a-3fd4-46e4-aef2-b658528dcdea" xlink:to="loc_us-gaap_LiabilitiesCurrent_2af4d213-7a90-4654-9f0c-d8fa819b8b13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1f33760f-bb18-4eea-9de1-8e5c848a1377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8db1fb3a-3fd4-46e4-aef2-b658528dcdea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1f33760f-bb18-4eea-9de1-8e5c848a1377" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="bdtx-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b1d5e53-7f53-40cf-a76a-1db9cce53d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2d10cfce-8f72-4fa6-97d9-a881e3fb2e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b1d5e53-7f53-40cf-a76a-1db9cce53d67" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2d10cfce-8f72-4fa6-97d9-a881e3fb2e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_8f8cf327-1214-496b-9871-10ec763b759b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b1d5e53-7f53-40cf-a76a-1db9cce53d67" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_8f8cf327-1214-496b-9871-10ec763b759b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c9527fe3-ff04-4f1d-a6e9-b717c19acf41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3d989704-2492-4524-86ee-99c66219e04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c9527fe3-ff04-4f1d-a6e9-b717c19acf41" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3d989704-2492-4524-86ee-99c66219e04d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fdb7eacf-4a8d-4501-b765-3dd716de7a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c9527fe3-ff04-4f1d-a6e9-b717c19acf41" xlink:to="loc_us-gaap_OperatingIncomeLoss_fdb7eacf-4a8d-4501-b765-3dd716de7a3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0523b0a4-79dc-4d40-a046-5fde6e0c4a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_084672e8-47d9-4e72-b1cc-b80b9ec7e4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0523b0a4-79dc-4d40-a046-5fde6e0c4a59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_084672e8-47d9-4e72-b1cc-b80b9ec7e4e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5663d65d-f5fb-4a97-b041-c9bf9d39ed4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0523b0a4-79dc-4d40-a046-5fde6e0c4a59" xlink:to="loc_us-gaap_NetIncomeLoss_5663d65d-f5fb-4a97-b041-c9bf9d39ed4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b80bb072-1820-4252-bf52-ed7f27d15968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2f8af8bd-3076-4e37-b43d-84ba2bd88002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b80bb072-1820-4252-bf52-ed7f27d15968" xlink:to="loc_us-gaap_OperatingExpenses_2f8af8bd-3076-4e37-b43d-84ba2bd88002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_840b753b-6fca-4565-a455-35a71d24e0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c55d4e67-fb5e-43a3-a8cb-f325b01e1f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_840b753b-6fca-4565-a455-35a71d24e0a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c55d4e67-fb5e-43a3-a8cb-f325b01e1f73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9c59156e-4392-4cba-8b08-88ad419e66ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_840b753b-6fca-4565-a455-35a71d24e0a1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9c59156e-4392-4cba-8b08-88ad419e66ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="bdtx-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39196899-2c48-42ea-aa6e-f7c6d8b4a3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a89c946-b01e-4c02-aa76-66f28225514e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39196899-2c48-42ea-aa6e-f7c6d8b4a3c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a89c946-b01e-4c02-aa76-66f28225514e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10806e55-486e-48e8-8a82-2aca1477015b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39196899-2c48-42ea-aa6e-f7c6d8b4a3c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10806e55-486e-48e8-8a82-2aca1477015b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa92f95e-653a-4038-91d7-fa8efef34850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39196899-2c48-42ea-aa6e-f7c6d8b4a3c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fa92f95e-653a-4038-91d7-fa8efef34850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a49e2e3f-0683-434f-88f5-86ff123af814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5616160a-00dd-4795-9aa9-225729c7caa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a49e2e3f-0683-434f-88f5-86ff123af814" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5616160a-00dd-4795-9aa9-225729c7caa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e3a7b78-d2fd-44a6-967b-0fd147d49a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a49e2e3f-0683-434f-88f5-86ff123af814" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e3a7b78-d2fd-44a6-967b-0fd147d49a4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f1cc8350-c1b0-4477-9ba5-c142fc5485f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a49e2e3f-0683-434f-88f5-86ff123af814" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f1cc8350-c1b0-4477-9ba5-c142fc5485f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18616776-1ae7-478a-b38e-98fbfc4e18a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2a23d00b-6acf-49f7-b2a9-9bb127c9ed2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18616776-1ae7-478a-b38e-98fbfc4e18a0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2a23d00b-6acf-49f7-b2a9-9bb127c9ed2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be2885ac-d1e9-4103-aa6c-531101288129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0b3cd189-e441-47ff-8f82-12034a15f9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be2885ac-d1e9-4103-aa6c-531101288129" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0b3cd189-e441-47ff-8f82-12034a15f9af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_91f00cfb-d410-4bc5-99e7-77f5a7739d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be2885ac-d1e9-4103-aa6c-531101288129" xlink:to="loc_us-gaap_Depreciation_91f00cfb-d410-4bc5-99e7-77f5a7739d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ab6fc86b-698a-4f44-ad8b-a3dce9e82117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be2885ac-d1e9-4103-aa6c-531101288129" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ab6fc86b-698a-4f44-ad8b-a3dce9e82117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_571fba95-7393-4eb5-995d-353ff579704d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be2885ac-d1e9-4103-aa6c-531101288129" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_571fba95-7393-4eb5-995d-353ff579704d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_63c4587e-9336-48a8-aa63-0f59c9bedf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be2885ac-d1e9-4103-aa6c-531101288129" xlink:to="loc_us-gaap_NetIncomeLoss_63c4587e-9336-48a8-aa63-0f59c9bedf13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1ecd6de2-964d-48f5-9e29-6873f26cedb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be2885ac-d1e9-4103-aa6c-531101288129" xlink:to="loc_us-gaap_ShareBasedCompensation_1ecd6de2-964d-48f5-9e29-6873f26cedb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_33032995-c500-4cba-b54f-21496f9c9bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be2885ac-d1e9-4103-aa6c-531101288129" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_33032995-c500-4cba-b54f-21496f9c9bc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_RentExpense_48e576c5-3d92-483c-a6b1-e7e09ab79962" xlink:href="bdtx-20230331.xsd#bdtx_RentExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be2885ac-d1e9-4103-aa6c-531101288129" xlink:to="loc_bdtx_RentExpense_48e576c5-3d92-483c-a6b1-e7e09ab79962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_425536bc-39ec-4de5-aaef-6ccaae3a6913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be2885ac-d1e9-4103-aa6c-531101288129" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_425536bc-39ec-4de5-aaef-6ccaae3a6913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_75a0f2d4-026c-4b1e-90c8-30e65ddbb5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be2885ac-d1e9-4103-aa6c-531101288129" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_75a0f2d4-026c-4b1e-90c8-30e65ddbb5fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_a7be6d7e-fcf2-4cb1-8cbc-1392f92724cc" xlink:href="bdtx-20230331.xsd#bdtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be2885ac-d1e9-4103-aa6c-531101288129" xlink:to="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_a7be6d7e-fcf2-4cb1-8cbc-1392f92724cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb55917d-899b-48e9-b6fd-cd253f703a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_97770c2a-48c0-484d-83d1-d86b017025ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb55917d-899b-48e9-b6fd-cd253f703a27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_97770c2a-48c0-484d-83d1-d86b017025ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9c7892f6-369f-46dd-8bcb-04383067d615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb55917d-899b-48e9-b6fd-cd253f703a27" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9c7892f6-369f-46dd-8bcb-04383067d615" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_99415dfe-b59e-4f9d-b5e6-6c5748a413cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_10916274-37ae-41d8-9eaa-767cfe078e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_99415dfe-b59e-4f9d-b5e6-6c5748a413cc" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_10916274-37ae-41d8-9eaa-767cfe078e97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c9b17d10-8ae6-4204-99f5-6feb8f506207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_99415dfe-b59e-4f9d-b5e6-6c5748a413cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c9b17d10-8ae6-4204-99f5-6feb8f506207" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#INVESTMENTSScheduleofMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1cfead08-52f2-4de0-9ac4-6b0ff6d3c6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1aef99b6-8ca0-4251-89a0-e466aa625560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1cfead08-52f2-4de0-9ac4-6b0ff6d3c6b8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1aef99b6-8ca0-4251-89a0-e466aa625560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_20351eb0-3de9-4bd5-b6a1-dbb8a29aaeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1cfead08-52f2-4de0-9ac4-6b0ff6d3c6b8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_20351eb0-3de9-4bd5-b6a1-dbb8a29aaeb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c3dd805a-59f1-4c37-bc93-04174b7e3128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1cfead08-52f2-4de0-9ac4-6b0ff6d3c6b8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c3dd805a-59f1-4c37-bc93-04174b7e3128" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_09243dff-0d58-46b2-8877-70ff3db8147d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_61765317-f34b-4658-bca2-6e062763af38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_09243dff-0d58-46b2-8877-70ff3db8147d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_61765317-f34b-4658-bca2-6e062763af38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e7f5318f-1229-4b5a-bc44-0fab7c65ebc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_09243dff-0d58-46b2-8877-70ff3db8147d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e7f5318f-1229-4b5a-bc44-0fab7c65ebc8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4db1381c-14d3-49f1-8a4e-8520af0f3233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_288ec12b-f2df-4928-9fdf-42aeadc0b4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4db1381c-14d3-49f1-8a4e-8520af0f3233" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_288ec12b-f2df-4928-9fdf-42aeadc0b4cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6a6ddff0-b73c-4331-97a3-f43ab34192ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4db1381c-14d3-49f1-8a4e-8520af0f3233" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6a6ddff0-b73c-4331-97a3-f43ab34192ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_AccruedContractResearchServiceFeesCurrent_bb740f59-851d-4e2a-a32c-3cf73435b6dd" xlink:href="bdtx-20230331.xsd#bdtx_AccruedContractResearchServiceFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4db1381c-14d3-49f1-8a4e-8520af0f3233" xlink:to="loc_bdtx_AccruedContractResearchServiceFeesCurrent_bb740f59-851d-4e2a-a32c-3cf73435b6dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3e63f188-455d-490d-9f94-969d2c5c5813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4db1381c-14d3-49f1-8a4e-8520af0f3233" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3e63f188-455d-490d-9f94-969d2c5c5813" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_7adf54e3-42dd-4f9b-adca-3fc41b6ad8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_87d9a276-1a89-4b42-9c86-eea27f8d14bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7adf54e3-42dd-4f9b-adca-3fc41b6ad8dd" xlink:to="loc_us-gaap_OperatingLeaseCost_87d9a276-1a89-4b42-9c86-eea27f8d14bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_cf52eea6-8913-4bdc-9193-53d286da6dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7adf54e3-42dd-4f9b-adca-3fc41b6ad8dd" xlink:to="loc_us-gaap_ShortTermLeaseCost_cf52eea6-8913-4bdc-9193-53d286da6dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_71aa6fef-f0f4-4f3f-a35a-659b11568061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7adf54e3-42dd-4f9b-adca-3fc41b6ad8dd" xlink:to="loc_us-gaap_VariableLeaseCost_71aa6fef-f0f4-4f3f-a35a-659b11568061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_61d91496-3a7d-4f5b-b291-0a5ffe091497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7adf54e3-42dd-4f9b-adca-3fc41b6ad8dd" xlink:to="loc_us-gaap_SubleaseIncome_61d91496-3a7d-4f5b-b291-0a5ffe091497" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe7d4074-e0ae-4797-b69f-f40050b2242a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d14ada60-7e1b-4ac2-9b24-c8dd64c707d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe7d4074-e0ae-4797-b69f-f40050b2242a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d14ada60-7e1b-4ac2-9b24-c8dd64c707d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f45e3073-9bdd-4c46-8050-9c5ed51d4e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe7d4074-e0ae-4797-b69f-f40050b2242a" xlink:to="loc_us-gaap_OperatingLeaseLiability_f45e3073-9bdd-4c46-8050-9c5ed51d4e1f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="bdtx-20230331.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37f5e456-d35e-44f3-a5fb-529883497a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_de2064fa-c7f1-4154-ba5f-beb84ecd995d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37f5e456-d35e-44f3-a5fb-529883497a98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_de2064fa-c7f1-4154-ba5f-beb84ecd995d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_64d619e1-7d45-4cb0-b2df-3a164a698f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37f5e456-d35e-44f3-a5fb-529883497a98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_64d619e1-7d45-4cb0-b2df-3a164a698f4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ac0c4206-70d6-477f-80a0-e82db83b4226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37f5e456-d35e-44f3-a5fb-529883497a98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ac0c4206-70d6-477f-80a0-e82db83b4226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_0729868b-7ee4-4a2c-a43c-c42f3de1ec84" xlink:href="bdtx-20230331.xsd#bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37f5e456-d35e-44f3-a5fb-529883497a98" xlink:to="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_0729868b-7ee4-4a2c-a43c-c42f3de1ec84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4d8997e3-0933-4dc9-a4b7-92904a9b0268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37f5e456-d35e-44f3-a5fb-529883497a98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4d8997e3-0933-4dc9-a4b7-92904a9b0268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_93d439ad-e743-429e-8540-d642ef9d589a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37f5e456-d35e-44f3-a5fb-529883497a98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_93d439ad-e743-429e-8540-d642ef9d589a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>bdtx-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:73ec13c2-272f-4624-b8c8-b5925ba5540a,g:c0252310-7c05-47ef-aa9c-a55e1f9856cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="bdtx-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended" id="i96732c2cd1a14923bd36d923e7049596_CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6a91fb8f-51be-4d71-a3c1-482fe85aa59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a91fb8f-51be-4d71-a3c1-482fe85aa59e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_17835585-4e10-447b-9022-78ba143d802b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_17835585-4e10-447b-9022-78ba143d802b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2137cee7-0711-47c0-9d8f-1b4db9173e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockholdersEquity_2137cee7-0711-47c0-9d8f-1b4db9173e75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14d42650-f36d-4d99-aa5f-287f746ea0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14d42650-f36d-4d99-aa5f-287f746ea0c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f5b0b0ed-72d4-4ce4-b8d7-bdce4a80572d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f5b0b0ed-72d4-4ce4-b8d7-bdce4a80572d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2f8e2c11-bdfd-451d-b5c8-2604ab8ef329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2f8e2c11-bdfd-451d-b5c8-2604ab8ef329" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_eceaa45c-18fd-4696-8841-e546c6fc8440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_eceaa45c-18fd-4696-8841-e546c6fc8440" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_913d0151-7dfb-40fb-b635-653ac2e5cfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_913d0151-7dfb-40fb-b635-653ac2e5cfaa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4308e849-f7e3-49b4-9d1c-1dc64799e9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4308e849-f7e3-49b4-9d1c-1dc64799e9ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ccf241be-05ed-4ba9-97fd-55be5d303be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ccf241be-05ed-4ba9-97fd-55be5d303be2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1ea4b69e-4898-4de0-bc37-3216d561f62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1ea4b69e-4898-4de0-bc37-3216d561f62b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_27fbab02-901d-42bc-aa85-d920a779d323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_27fbab02-901d-42bc-aa85-d920a779d323" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_003187c2-9208-43b0-9133-ab0b4bc99834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_NetIncomeLoss_003187c2-9208-43b0-9133-ab0b4bc99834" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a14f4a44-f46e-408f-811d-2edf0ea1cb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5c3f3027-5edd-4c60-93e8-d9da5ab544f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e56a4cd9-930b-4cc9-96cb-7b7638bb1b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6a91fb8f-51be-4d71-a3c1-482fe85aa59e" xlink:to="loc_us-gaap_StatementTable_e56a4cd9-930b-4cc9-96cb-7b7638bb1b7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_92853f90-a79a-4ab5-9ba0-c4d3fb038a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e56a4cd9-930b-4cc9-96cb-7b7638bb1b7d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_92853f90-a79a-4ab5-9ba0-c4d3fb038a6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_92853f90-a79a-4ab5-9ba0-c4d3fb038a6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_92853f90-a79a-4ab5-9ba0-c4d3fb038a6c" xlink:to="loc_us-gaap_EquityComponentDomain_92853f90-a79a-4ab5-9ba0-c4d3fb038a6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_680aff93-0cb5-45e6-b6b3-4654fb2b967c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_92853f90-a79a-4ab5-9ba0-c4d3fb038a6c" xlink:to="loc_us-gaap_EquityComponentDomain_680aff93-0cb5-45e6-b6b3-4654fb2b967c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_703d121e-3e34-498f-a918-5cd28abd3cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_680aff93-0cb5-45e6-b6b3-4654fb2b967c" xlink:to="loc_us-gaap_CommonStockMember_703d121e-3e34-498f-a918-5cd28abd3cae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_07779337-eb66-4f10-a6b5-c47a925e1e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_680aff93-0cb5-45e6-b6b3-4654fb2b967c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_07779337-eb66-4f10-a6b5-c47a925e1e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_17b46fc0-1f58-49a2-af0d-ea22b7d5e1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_680aff93-0cb5-45e6-b6b3-4654fb2b967c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_17b46fc0-1f58-49a2-af0d-ea22b7d5e1dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_82aa60e0-6949-4a5d-9a8f-13681b145727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_680aff93-0cb5-45e6-b6b3-4654fb2b967c" xlink:to="loc_us-gaap_RetainedEarningsMember_82aa60e0-6949-4a5d-9a8f-13681b145727" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="extended" id="i7d6f5710123c410f8062a3f88e29b538_NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_e8232af1-d762-4da7-bd87-0cbffbaf9a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_SaleOfStockAuthorizedConsideration_8d0a4747-9256-4bd0-b348-577815c18354" xlink:href="bdtx-20230331.xsd#bdtx_SaleOfStockAuthorizedConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e8232af1-d762-4da7-bd87-0cbffbaf9a13" xlink:to="loc_bdtx_SaleOfStockAuthorizedConsideration_8d0a4747-9256-4bd0-b348-577815c18354" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bb88e558-dfb0-492a-924a-321e7ab2c377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e8232af1-d762-4da7-bd87-0cbffbaf9a13" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bb88e558-dfb0-492a-924a-321e7ab2c377" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f1518ddd-75d4-422a-95cd-ff2dbba2aee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bb88e558-dfb0-492a-924a-321e7ab2c377" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f1518ddd-75d4-422a-95cd-ff2dbba2aee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f1518ddd-75d4-422a-95cd-ff2dbba2aee7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f1518ddd-75d4-422a-95cd-ff2dbba2aee7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f1518ddd-75d4-422a-95cd-ff2dbba2aee7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85d31b02-9d9f-4694-8d81-9de4762aa39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f1518ddd-75d4-422a-95cd-ff2dbba2aee7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85d31b02-9d9f-4694-8d81-9de4762aa39c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OpenMarketSaleMember_abd62ed1-3a34-472e-a49c-41fd6c3952b3" xlink:href="bdtx-20230331.xsd#bdtx_OpenMarketSaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85d31b02-9d9f-4694-8d81-9de4762aa39c" xlink:to="loc_bdtx_OpenMarketSaleMember_abd62ed1-3a34-472e-a49c-41fd6c3952b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShelfRegistrationStatementMember_5cfc31e0-a3c1-4343-af14-2cd3c2f7b485" xlink:href="bdtx-20230331.xsd#bdtx_ShelfRegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85d31b02-9d9f-4694-8d81-9de4762aa39c" xlink:to="loc_bdtx_ShelfRegistrationStatementMember_5cfc31e0-a3c1-4343-af14-2cd3c2f7b485" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended" id="ia85205941f0449b581b73bfe98439225_FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dcf14d3-f204-4c06-b7c4-3166e1a900f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_978efb81-7e0d-485a-8b3d-93c7b42c159e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dcf14d3-f204-4c06-b7c4-3166e1a900f3" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_978efb81-7e0d-485a-8b3d-93c7b42c159e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a3f59674-8471-448c-8a54-d2b8357a16bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_978efb81-7e0d-485a-8b3d-93c7b42c159e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a3f59674-8471-448c-8a54-d2b8357a16bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_719395bd-7ac8-4147-b590-9f997fd4f7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_978efb81-7e0d-485a-8b3d-93c7b42c159e" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_719395bd-7ac8-4147-b590-9f997fd4f7b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_44114d5b-2383-4d94-86c6-80e630ad165b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_978efb81-7e0d-485a-8b3d-93c7b42c159e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_44114d5b-2383-4d94-86c6-80e630ad165b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d35cc97-3389-4504-892f-87172c3eeb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dcf14d3-f204-4c06-b7c4-3166e1a900f3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d35cc97-3389-4504-892f-87172c3eeb5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ac4f7c3d-f2f4-451b-adb1-868649d44c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d35cc97-3389-4504-892f-87172c3eeb5e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ac4f7c3d-f2f4-451b-adb1-868649d44c07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ac4f7c3d-f2f4-451b-adb1-868649d44c07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ac4f7c3d-f2f4-451b-adb1-868649d44c07" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ac4f7c3d-f2f4-451b-adb1-868649d44c07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_582baf1d-9896-4ab6-8d3a-8e3db34a2cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ac4f7c3d-f2f4-451b-adb1-868649d44c07" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_582baf1d-9896-4ab6-8d3a-8e3db34a2cb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_54234d05-edb8-4697-9deb-eea5313aa62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_582baf1d-9896-4ab6-8d3a-8e3db34a2cb3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_54234d05-edb8-4697-9deb-eea5313aa62d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e16d70b0-848b-46ba-9efe-170b3c892c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d35cc97-3389-4504-892f-87172c3eeb5e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e16d70b0-848b-46ba-9efe-170b3c892c7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e16d70b0-848b-46ba-9efe-170b3c892c7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e16d70b0-848b-46ba-9efe-170b3c892c7e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e16d70b0-848b-46ba-9efe-170b3c892c7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eacf4430-c9dd-4998-9004-478b6181f860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e16d70b0-848b-46ba-9efe-170b3c892c7e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eacf4430-c9dd-4998-9004-478b6181f860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0aa80e1a-ab93-45bf-b570-f389600b11f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eacf4430-c9dd-4998-9004-478b6181f860" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0aa80e1a-ab93-45bf-b570-f389600b11f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5300c058-eccc-40c0-93f4-aeb87e055171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eacf4430-c9dd-4998-9004-478b6181f860" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5300c058-eccc-40c0-93f4-aeb87e055171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9bdaac17-b4a9-48e8-b413-35de4aaacf61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eacf4430-c9dd-4998-9004-478b6181f860" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9bdaac17-b4a9-48e8-b413-35de4aaacf61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bde21c81-5d8b-4d3c-8048-a8dc8f543174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d35cc97-3389-4504-892f-87172c3eeb5e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bde21c81-5d8b-4d3c-8048-a8dc8f543174" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bde21c81-5d8b-4d3c-8048-a8dc8f543174_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bde21c81-5d8b-4d3c-8048-a8dc8f543174" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bde21c81-5d8b-4d3c-8048-a8dc8f543174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e322519b-e767-4e07-a127-b71b3343f397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bde21c81-5d8b-4d3c-8048-a8dc8f543174" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e322519b-e767-4e07-a127-b71b3343f397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5de69cfc-3a41-4a25-b712-3e9c79740533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e322519b-e767-4e07-a127-b71b3343f397" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5de69cfc-3a41-4a25-b712-3e9c79740533" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_65edf229-5a7e-437d-9c53-9add4bf41bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e322519b-e767-4e07-a127-b71b3343f397" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_65edf229-5a7e-437d-9c53-9add4bf41bd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_02cdfc5c-6d31-40ee-b563-01974981ed3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e322519b-e767-4e07-a127-b71b3343f397" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_02cdfc5c-6d31-40ee-b563-01974981ed3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e6429e8d-44ce-40c8-b8af-048601035cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e322519b-e767-4e07-a127-b71b3343f397" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e6429e8d-44ce-40c8-b8af-048601035cb2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#INVESTMENTSScheduleofMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="extended" id="i4f6d7cec9a7c4bffa68910626e6cb23e_INVESTMENTSScheduleofMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0439e9aa-6ffa-49eb-bd0d-c589cf38baf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7e166b88-1469-41ba-8290-84f8c22419f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0439e9aa-6ffa-49eb-bd0d-c589cf38baf3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7e166b88-1469-41ba-8290-84f8c22419f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3b080381-7cea-4439-b9b4-d33f2fe78b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0439e9aa-6ffa-49eb-bd0d-c589cf38baf3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3b080381-7cea-4439-b9b4-d33f2fe78b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b17c0ff6-135a-4b3e-87d8-0bbaaa4ee628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0439e9aa-6ffa-49eb-bd0d-c589cf38baf3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b17c0ff6-135a-4b3e-87d8-0bbaaa4ee628" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_052e40db-a897-4c2a-9019-2c42150ede8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0439e9aa-6ffa-49eb-bd0d-c589cf38baf3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_052e40db-a897-4c2a-9019-2c42150ede8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6074b93f-f5f2-4eae-afe8-d5b2c9e2032e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0439e9aa-6ffa-49eb-bd0d-c589cf38baf3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6074b93f-f5f2-4eae-afe8-d5b2c9e2032e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d2d4d047-1fe7-466d-b4c9-a8a33890876c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6074b93f-f5f2-4eae-afe8-d5b2c9e2032e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d2d4d047-1fe7-466d-b4c9-a8a33890876c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d2d4d047-1fe7-466d-b4c9-a8a33890876c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d2d4d047-1fe7-466d-b4c9-a8a33890876c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d2d4d047-1fe7-466d-b4c9-a8a33890876c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97752eb5-3591-41e0-9c3a-99b2eec34c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d2d4d047-1fe7-466d-b4c9-a8a33890876c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97752eb5-3591-41e0-9c3a-99b2eec34c84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_01a04f1f-f7e0-42fc-8c24-2a60512c7c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97752eb5-3591-41e0-9c3a-99b2eec34c84" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_01a04f1f-f7e0-42fc-8c24-2a60512c7c0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_5a894b32-9716-4c1f-8ce0-40731fdb6329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97752eb5-3591-41e0-9c3a-99b2eec34c84" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_5a894b32-9716-4c1f-8ce0-40731fdb6329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_869de67d-dcc6-436c-96d5-a5ac2b7ae7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97752eb5-3591-41e0-9c3a-99b2eec34c84" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_869de67d-dcc6-436c-96d5-a5ac2b7ae7e4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended" id="i0a0539d438284771ac79a052ff9a5afe_PROPERTYANDEQUIPMENTDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f840c3b1-d381-43a3-8e97-638e6617cd70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_aa7995fb-71f5-4593-a42e-ca9d90df3a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f840c3b1-d381-43a3-8e97-638e6617cd70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_aa7995fb-71f5-4593-a42e-ca9d90df3a2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8da45c93-295d-45a7-ba97-9493ec36c780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f840c3b1-d381-43a3-8e97-638e6617cd70" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8da45c93-295d-45a7-ba97-9493ec36c780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_39a0cd56-7802-4cb0-81ce-027d5431df35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f840c3b1-d381-43a3-8e97-638e6617cd70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_39a0cd56-7802-4cb0-81ce-027d5431df35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_021195f9-bb24-4ce7-bf26-c0bec085bc23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f840c3b1-d381-43a3-8e97-638e6617cd70" xlink:to="loc_us-gaap_Depreciation_021195f9-bb24-4ce7-bf26-c0bec085bc23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a13c4719-cf39-452b-835e-bef98eeb06d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f840c3b1-d381-43a3-8e97-638e6617cd70" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a13c4719-cf39-452b-835e-bef98eeb06d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd67295-8dd3-49b0-881d-1c027d2d522d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a13c4719-cf39-452b-835e-bef98eeb06d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd67295-8dd3-49b0-881d-1c027d2d522d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0cd67295-8dd3-49b0-881d-1c027d2d522d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd67295-8dd3-49b0-881d-1c027d2d522d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0cd67295-8dd3-49b0-881d-1c027d2d522d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8b32fa3-1be6-48f8-b4d6-db01cb7a4b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd67295-8dd3-49b0-881d-1c027d2d522d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8b32fa3-1be6-48f8-b4d6-db01cb7a4b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_83d45c4d-730d-4775-a2a3-a2e2c0fa5cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8b32fa3-1be6-48f8-b4d6-db01cb7a4b59" xlink:to="loc_us-gaap_EquipmentMember_83d45c4d-730d-4775-a2a3-a2e2c0fa5cf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f504f4de-80cb-4871-9a89-5dd7c39be333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8b32fa3-1be6-48f8-b4d6-db01cb7a4b59" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f504f4de-80cb-4871-9a89-5dd7c39be333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_fff7ee17-b99a-4241-840f-6523ccf383d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8b32fa3-1be6-48f8-b4d6-db01cb7a4b59" xlink:to="loc_us-gaap_OfficeEquipmentMember_fff7ee17-b99a-4241-840f-6523ccf383d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6284b0fd-54e2-4f7e-9ca5-510fa29faba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8b32fa3-1be6-48f8-b4d6-db01cb7a4b59" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6284b0fd-54e2-4f7e-9ca5-510fa29faba2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#EQUITYMETHODINVESTMENTDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" xlink:type="extended" id="id36c033f3b9e4ab998f957b125bf5107_EQUITYMETHODINVESTMENTDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange_cc42f3b1-9d64-4138-9083-95a5cf0261bf" xlink:href="bdtx-20230331.xsd#bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange_cc42f3b1-9d64-4138-9083-95a5cf0261bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d5178882-e547-42dd-bb0c-f16cc8565f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d5178882-e547-42dd-bb0c-f16cc8565f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_54d3b25f-afd5-40eb-89b3-3eb71641c249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_us-gaap_EquityMethodInvestments_54d3b25f-afd5-40eb-89b3-3eb71641c249" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_4601c0b8-3f60-41c7-9750-dde685335134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_4601c0b8-3f60-41c7-9750-dde685335134" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_04d1f8f2-8a04-4c9f-add5-5fba31f19171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_04d1f8f2-8a04-4c9f-add5-5fba31f19171" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_313f42ef-98ee-41ba-814e-6507d7b8e596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_313f42ef-98ee-41ba-814e-6507d7b8e596" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_db7ed5d7-ccde-4566-8a2c-fcce5fde9b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_db7ed5d7-ccde-4566-8a2c-fcce5fde9b06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fdc16b3-3b0f-4ffc-9f7c-6f05e6cc3de2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_db7ed5d7-ccde-4566-8a2c-fcce5fde9b06" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fdc16b3-3b0f-4ffc-9f7c-6f05e6cc3de2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7fdc16b3-3b0f-4ffc-9f7c-6f05e6cc3de2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fdc16b3-3b0f-4ffc-9f7c-6f05e6cc3de2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7fdc16b3-3b0f-4ffc-9f7c-6f05e6cc3de2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_39837529-52bc-4d2b-ae8a-14bf8e61b29d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fdc16b3-3b0f-4ffc-9f7c-6f05e6cc3de2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_39837529-52bc-4d2b-ae8a-14bf8e61b29d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LaunchpadTherapeuticsIncMember_5cfeb9b6-cbcb-4e7c-b630-d08aaa12b4c2" xlink:href="bdtx-20230331.xsd#bdtx_LaunchpadTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_39837529-52bc-4d2b-ae8a-14bf8e61b29d" xlink:to="loc_bdtx_LaunchpadTherapeuticsIncMember_5cfeb9b6-cbcb-4e7c-b630-d08aaa12b4c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i4170d095cac34a6bb5c49e4f04450a9c_STOCKBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_dac6b0a0-0db1-46f4-804d-de62da048949" xlink:href="bdtx-20230331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_dac6b0a0-0db1-46f4-804d-de62da048949" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d39af87f-1552-419b-aaf7-733d00609949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d39af87f-1552-419b-aaf7-733d00609949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_edca93a2-59f4-4d60-a917-8db4b5fbd369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_edca93a2-59f4-4d60-a917-8db4b5fbd369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3e89e371-2c34-45b0-b74d-d52fcbe15398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3e89e371-2c34-45b0-b74d-d52fcbe15398" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5e8cf239-25df-41ed-9174-75fe6ce6bb91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5e8cf239-25df-41ed-9174-75fe6ce6bb91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_28f74393-dc70-4569-a8da-b844951d3a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_28f74393-dc70-4569-a8da-b844951d3a69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dad6de68-10df-4881-b117-4aa7a329d240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dad6de68-10df-4881-b117-4aa7a329d240" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5633b1f9-55e0-4d28-b08b-e9212b916998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5633b1f9-55e0-4d28-b08b-e9212b916998" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b71b1f8-6398-422c-839e-914e7bb8c5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b71b1f8-6398-422c-839e-914e7bb8c5a0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cd0554d0-f8d1-46bb-bd4f-a067677bd25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cd0554d0-f8d1-46bb-bd4f-a067677bd25a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee87c3bf-f482-4622-951c-505178e9d5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee87c3bf-f482-4622-951c-505178e9d5f9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1c1c00a6-2775-47e3-85fb-0ef972a8e29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1c1c00a6-2775-47e3-85fb-0ef972a8e29d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_17115d0f-f2a6-487b-94e4-f2f87fe7f073" xlink:href="bdtx-20230331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_17115d0f-f2a6-487b-94e4-f2f87fe7f073" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6a2aeb93-9373-441d-8cec-eb757dea443a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6a2aeb93-9373-441d-8cec-eb757dea443a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cfd9c79b-4072-416c-8320-4e233915be95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cfd9c79b-4072-416c-8320-4e233915be95" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_e8ec8e72-c854-4ed3-b3cc-2f6462dcda5e" xlink:href="bdtx-20230331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_e8ec8e72-c854-4ed3-b3cc-2f6462dcda5e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7a0c542-2519-4956-8f95-c1019e682292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7a0c542-2519-4956-8f95-c1019e682292" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_26157ada-416a-4f60-82a4-b1a984ff0d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7a0c542-2519-4956-8f95-c1019e682292" xlink:to="loc_us-gaap_AwardTypeAxis_26157ada-416a-4f60-82a4-b1a984ff0d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26157ada-416a-4f60-82a4-b1a984ff0d43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_26157ada-416a-4f60-82a4-b1a984ff0d43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26157ada-416a-4f60-82a4-b1a984ff0d43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_26157ada-416a-4f60-82a4-b1a984ff0d43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_66518fda-4770-4c40-892a-119d08160e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:to="loc_us-gaap_EmployeeStockOptionMember_66518fda-4770-4c40-892a-119d08160e6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5f2c5385-0f65-4906-8622-0483867cc7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5f2c5385-0f65-4906-8622-0483867cc7e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_PerformanceRestrictedStockUnitsMember_c7f2ee10-7b59-470e-b845-d4b6c71694f5" xlink:href="bdtx-20230331.xsd#bdtx_PerformanceRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:to="loc_bdtx_PerformanceRestrictedStockUnitsMember_c7f2ee10-7b59-470e-b845-d4b6c71694f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9c7f2b76-52f5-4463-a9c9-68c07eba3b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:to="loc_us-gaap_EmployeeStockMember_9c7f2b76-52f5-4463-a9c9-68c07eba3b7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a79015fa-9908-4c8d-9389-5c039e1c13bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:to="loc_us-gaap_PerformanceSharesMember_a79015fa-9908-4c8d-9389-5c039e1c13bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0aa4cb42-8be0-49c8-8c44-501aae9dc761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7a0c542-2519-4956-8f95-c1019e682292" xlink:to="loc_us-gaap_PlanNameAxis_0aa4cb42-8be0-49c8-8c44-501aae9dc761" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0aa4cb42-8be0-49c8-8c44-501aae9dc761_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0aa4cb42-8be0-49c8-8c44-501aae9dc761" xlink:to="loc_us-gaap_PlanNameDomain_0aa4cb42-8be0-49c8-8c44-501aae9dc761_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b02c8d2e-07f3-45af-b924-5048e9888ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0aa4cb42-8be0-49c8-8c44-501aae9dc761" xlink:to="loc_us-gaap_PlanNameDomain_b02c8d2e-07f3-45af-b924-5048e9888ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020StockOptionPlanMember_1ceab142-20c7-4e1c-86ab-a1e923c25a4f" xlink:href="bdtx-20230331.xsd#bdtx_A2020StockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b02c8d2e-07f3-45af-b924-5048e9888ead" xlink:to="loc_bdtx_A2020StockOptionPlanMember_1ceab142-20c7-4e1c-86ab-a1e923c25a4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020EmployeeStockPurchasePlanMember_f27ff347-9e37-457a-853a-14360d31227c" xlink:href="bdtx-20230331.xsd#bdtx_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b02c8d2e-07f3-45af-b924-5048e9888ead" xlink:to="loc_bdtx_A2020EmployeeStockPurchasePlanMember_f27ff347-9e37-457a-853a-14360d31227c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="extended" id="i7e9589067aec4962a663440e228c8fb3_STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b6ee330e-2962-4555-bba3-e7d91bf0630d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_24630b88-2d22-4586-bbe5-c55c4739bf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b6ee330e-2962-4555-bba3-e7d91bf0630d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_24630b88-2d22-4586-bbe5-c55c4739bf3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0065444c-8173-4178-b90c-eea5735abb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b6ee330e-2962-4555-bba3-e7d91bf0630d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0065444c-8173-4178-b90c-eea5735abb1b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4e0a51ef-bd1a-487f-85e3-1b37ef28ced4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0065444c-8173-4178-b90c-eea5735abb1b" xlink:to="loc_us-gaap_AwardTypeAxis_4e0a51ef-bd1a-487f-85e3-1b37ef28ced4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e0a51ef-bd1a-487f-85e3-1b37ef28ced4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4e0a51ef-bd1a-487f-85e3-1b37ef28ced4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e0a51ef-bd1a-487f-85e3-1b37ef28ced4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db3dbf66-31b9-4a45-9055-538ef6cd5c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4e0a51ef-bd1a-487f-85e3-1b37ef28ced4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db3dbf66-31b9-4a45-9055-538ef6cd5c6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f91eabe9-f55c-4428-ab57-0418881dc973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db3dbf66-31b9-4a45-9055-538ef6cd5c6e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f91eabe9-f55c-4428-ab57-0418881dc973" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0402723b-ab79-4526-9f08-f299c5f007e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db3dbf66-31b9-4a45-9055-538ef6cd5c6e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0402723b-ab79-4526-9f08-f299c5f007e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OtherAwardTypeMember_9aaa192b-9aad-4306-8a52-15d913e0fa27" xlink:href="bdtx-20230331.xsd#bdtx_OtherAwardTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db3dbf66-31b9-4a45-9055-538ef6cd5c6e" xlink:to="loc_bdtx_OtherAwardTypeMember_9aaa192b-9aad-4306-8a52-15d913e0fa27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_85f7ad8f-7f54-4afd-bbf4-9958ab717a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0065444c-8173-4178-b90c-eea5735abb1b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_85f7ad8f-7f54-4afd-bbf4-9958ab717a10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_85f7ad8f-7f54-4afd-bbf4-9958ab717a10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_85f7ad8f-7f54-4afd-bbf4-9958ab717a10" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_85f7ad8f-7f54-4afd-bbf4-9958ab717a10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_936b9323-02bd-4435-a57a-a922bf5100a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_85f7ad8f-7f54-4afd-bbf4-9958ab717a10" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_936b9323-02bd-4435-a57a-a922bf5100a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dd20d669-7e5a-445b-909a-1d0d99ee23a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_936b9323-02bd-4435-a57a-a922bf5100a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dd20d669-7e5a-445b-909a-1d0d99ee23a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9cdebb4a-2c93-4998-9a9b-0891a6111e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_936b9323-02bd-4435-a57a-a922bf5100a4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9cdebb4a-2c93-4998-9a9b-0891a6111e83" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" xlink:type="extended" id="i9af7060b2c884825b24f65f096e9cc42_STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36f697c5-1867-4e24-bf66-c23e53cd1556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9826ef26-1ada-44b7-bcaa-8223a0280433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36f697c5-1867-4e24-bf66-c23e53cd1556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9826ef26-1ada-44b7-bcaa-8223a0280433" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1e37bac-593a-444c-9995-065ed02d89cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9826ef26-1ada-44b7-bcaa-8223a0280433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1e37bac-593a-444c-9995-065ed02d89cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_98fcd1b9-5781-4fbc-9bf7-44556edf1b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9826ef26-1ada-44b7-bcaa-8223a0280433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_98fcd1b9-5781-4fbc-9bf7-44556edf1b44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_87a7f2ed-8b55-417e-b3b4-f20b7698e044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9826ef26-1ada-44b7-bcaa-8223a0280433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_87a7f2ed-8b55-417e-b3b4-f20b7698e044" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a0edb7f-e6a7-412e-ae17-0529dad49bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_750e350b-1b9a-491f-bbc7-a9e8ef39472e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36f697c5-1867-4e24-bf66-c23e53cd1556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_750e350b-1b9a-491f-bbc7-a9e8ef39472e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40af3c59-0896-4829-aa09-fd9317c04b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_750e350b-1b9a-491f-bbc7-a9e8ef39472e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40af3c59-0896-4829-aa09-fd9317c04b02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1e609feb-56d9-44e2-840b-a8f26d5a975f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_750e350b-1b9a-491f-bbc7-a9e8ef39472e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1e609feb-56d9-44e2-840b-a8f26d5a975f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_adae1d37-880d-4888-bc96-36590cfad53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_750e350b-1b9a-491f-bbc7-a9e8ef39472e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_adae1d37-880d-4888-bc96-36590cfad53a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1964a1b7-22d1-47d7-a1db-cb0bc607cb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable_2f499f83-a4ba-4970-8c44-184f4e79cc45" xlink:href="bdtx-20230331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36f697c5-1867-4e24-bf66-c23e53cd1556" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable_2f499f83-a4ba-4970-8c44-184f4e79cc45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fc30d8a-9a9d-4caa-aea4-ff72687a10cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36f697c5-1867-4e24-bf66-c23e53cd1556" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fc30d8a-9a9d-4caa-aea4-ff72687a10cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_46dc8010-113d-47f3-9f98-51cd6e5f8e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fc30d8a-9a9d-4caa-aea4-ff72687a10cc" xlink:to="loc_us-gaap_AwardTypeAxis_46dc8010-113d-47f3-9f98-51cd6e5f8e06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46dc8010-113d-47f3-9f98-51cd6e5f8e06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_46dc8010-113d-47f3-9f98-51cd6e5f8e06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46dc8010-113d-47f3-9f98-51cd6e5f8e06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_446992ec-60e7-4dc6-b95f-234c9342bde3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_46dc8010-113d-47f3-9f98-51cd6e5f8e06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_446992ec-60e7-4dc6-b95f-234c9342bde3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_98ed4b50-1314-41fc-b159-ee02a3d8c178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_446992ec-60e7-4dc6-b95f-234c9342bde3" xlink:to="loc_us-gaap_RestrictedStockMember_98ed4b50-1314-41fc-b159-ee02a3d8c178" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6692e07f-563e-434c-a2ac-37616346b754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_446992ec-60e7-4dc6-b95f-234c9342bde3" xlink:to="loc_us-gaap_PerformanceSharesMember_6692e07f-563e-434c-a2ac-37616346b754" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="extended" id="i484aaa0d184a48deb94431600fddb6a7_NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91088c77-c322-451e-b7e4-46edc0925c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7c17b02f-04b3-4489-9e8b-b1cea7b57e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91088c77-c322-451e-b7e4-46edc0925c7f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7c17b02f-04b3-4489-9e8b-b1cea7b57e48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4e42c78-9fd4-4056-95c3-2e66fef05d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91088c77-c322-451e-b7e4-46edc0925c7f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4e42c78-9fd4-4056-95c3-2e66fef05d87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_910e469a-b6bf-4bdc-8115-9ea737e07349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4e42c78-9fd4-4056-95c3-2e66fef05d87" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_910e469a-b6bf-4bdc-8115-9ea737e07349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_910e469a-b6bf-4bdc-8115-9ea737e07349_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_910e469a-b6bf-4bdc-8115-9ea737e07349" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_910e469a-b6bf-4bdc-8115-9ea737e07349_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_910e469a-b6bf-4bdc-8115-9ea737e07349" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4d21fade-afa5-42c9-a29a-b9479eb49237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4d21fade-afa5-42c9-a29a-b9479eb49237" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_034e0bbc-1c9b-4ba8-beb5-bf42334e3ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:to="loc_us-gaap_RestrictedStockMember_034e0bbc-1c9b-4ba8-beb5-bf42334e3ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_cc1fafd9-2631-453f-924f-ad59f4d5557c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:to="loc_us-gaap_EmployeeStockMember_cc1fafd9-2631-453f-924f-ad59f4d5557c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_67237f7d-b708-4520-a073-7bb24ff0258b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:to="loc_us-gaap_PerformanceSharesMember_67237f7d-b708-4520-a073-7bb24ff0258b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_7722a036-59f7-41c1-b138-f88f3655dd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:to="loc_us-gaap_WarrantMember_7722a036-59f7-41c1-b138-f88f3655dd0b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="extended" id="i30c80bd8737c435baae282701c7b3185_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseNumberOfContracts_4615d47f-5aac-47ac-905f-83c34dba5abe" xlink:href="bdtx-20230331.xsd#bdtx_LesseeOperatingLeaseNumberOfContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:to="loc_bdtx_LesseeOperatingLeaseNumberOfContracts_4615d47f-5aac-47ac-905f-83c34dba5abe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_341ae10b-8ca0-41bd-8146-2f62f6a18a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_341ae10b-8ca0-41bd-8146-2f62f6a18a01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_300dd005-fbd8-4e79-9af8-8062588aabd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_300dd005-fbd8-4e79-9af8-8062588aabd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseArea_94edc9b8-56e5-4c55-889b-139481aede4e" xlink:href="bdtx-20230331.xsd#bdtx_LesseeOperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:to="loc_bdtx_LesseeOperatingLeaseArea_94edc9b8-56e5-4c55-889b-139481aede4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_d2bd8e56-b448-4a5c-8ae0-b2492f26eacc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_d2bd8e56-b448-4a5c-8ae0-b2492f26eacc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_253b10bc-81e0-4430-816d-c6c1dca07798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_253b10bc-81e0-4430-816d-c6c1dca07798" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_47c89335-d433-4d1c-b6b5-68e5d65b9326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_253b10bc-81e0-4430-816d-c6c1dca07798" xlink:to="loc_us-gaap_LeaseContractualTermAxis_47c89335-d433-4d1c-b6b5-68e5d65b9326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_47c89335-d433-4d1c-b6b5-68e5d65b9326_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_47c89335-d433-4d1c-b6b5-68e5d65b9326" xlink:to="loc_us-gaap_LeaseContractualTermDomain_47c89335-d433-4d1c-b6b5-68e5d65b9326_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_0181b797-9d8f-498f-b60c-fef7142f4aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_47c89335-d433-4d1c-b6b5-68e5d65b9326" xlink:to="loc_us-gaap_LeaseContractualTermDomain_0181b797-9d8f-498f-b60c-fef7142f4aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember_8524df44-e660-4122-ab55-db8d33cb4e3b" xlink:href="bdtx-20230331.xsd#bdtx_OperatingLeasePrincipalOfficeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_0181b797-9d8f-498f-b60c-fef7142f4aa7" xlink:to="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember_8524df44-e660-4122-ab55-db8d33cb4e3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_eb17eacc-5bf1-4c33-8723-176a843c1ab4" xlink:href="bdtx-20230331.xsd#bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_0181b797-9d8f-498f-b60c-fef7142f4aa7" xlink:to="loc_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_eb17eacc-5bf1-4c33-8723-176a843c1ab4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>bdtx-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:73ec13c2-272f-4624-b8c8-b5925ba5540a,g:c0252310-7c05-47ef-aa9c-a55e1f9856cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3f38efce-a379-4e95-a34a-2beda441fba7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ec7fe9f-2b32-4349-bfeb-f03d1baa56f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6146560-cfc0-465c-918e-207d2ee3118e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_32f952a4-936b-4cf8-8ec4-f65776a4fde6_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_5afe8795-7bb8-48fe-be27-cc810979530c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_17088e1a-f038-44fb-a7f3-e2b15e796283_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e0a5373b-75cc-4c1f-9969-280e49ac88be_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fb31d134-7240-4794-87c6-2a9b4a09fba8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_11e2bd0d-f83c-442a-9dda-ba11fb2dd4f9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6d01961a-e31a-4419-bd81-5d2bc6de0469_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_OpenMarketSaleMember_ffaed8da-2feb-472d-8fe6-46606a5c82dc_terseLabel_en-US" xlink:label="lab_bdtx_OpenMarketSaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale</link:label>
    <link:label id="lab_bdtx_OpenMarketSaleMember_label_en-US" xlink:label="lab_bdtx_OpenMarketSaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale [Member]</link:label>
    <link:label id="lab_bdtx_OpenMarketSaleMember_documentation_en-US" xlink:label="lab_bdtx_OpenMarketSaleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OpenMarketSaleMember" xlink:href="bdtx-20230331.xsd#bdtx_OpenMarketSaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_OpenMarketSaleMember" xlink:to="lab_bdtx_OpenMarketSaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_323785e8-f0f7-4517-915d-f7cbb94b114d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_d2c6d53f-a9ab-4c54-ac1f-c439ec4b784e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73763138-9d45-4a30-9953-65437e445f93_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d5e68b5d-b447-427b-9cf8-60339b0bb66a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8fca3690-30a9-4eec-be47-a819c3a8db20_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_5f3152fc-ecaa-4bbe-ae82-23b61c03036b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_9e8d7fbf-ce2f-4f77-83c0-d576e11ae498_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4b530999-ab2a-49df-b433-27fd0ded2ea7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_SaleOfStockAuthorizedConsideration_a3731d4d-66a9-4a7f-b417-e1b2df951df0_terseLabel_en-US" xlink:label="lab_bdtx_SaleOfStockAuthorizedConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, authorized consideration</link:label>
    <link:label id="lab_bdtx_SaleOfStockAuthorizedConsideration_label_en-US" xlink:label="lab_bdtx_SaleOfStockAuthorizedConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Authorized Consideration</link:label>
    <link:label id="lab_bdtx_SaleOfStockAuthorizedConsideration_documentation_en-US" xlink:label="lab_bdtx_SaleOfStockAuthorizedConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Authorized Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_SaleOfStockAuthorizedConsideration" xlink:href="bdtx-20230331.xsd#bdtx_SaleOfStockAuthorizedConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_SaleOfStockAuthorizedConsideration" xlink:to="lab_bdtx_SaleOfStockAuthorizedConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_1051c8d1-2ffb-44f5-97b0-c2cb9976c510_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of fair value assets</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_000653c8-c916-46e3-b44d-bcb497e3d4ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ba70249e-75a7-40ca-b8f9-2642f1c197f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.0001 par value; 500,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 36,511,947 shares issued and outstanding at March&#160;31, 2023 and 36,434,297 shares issued and outstanding at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3ac69ebc-4096-4354-9cba-9a27aa0ec0bb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_27c9c276-3d18-4b52-ac52-2413beffc596_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a12183bd-1f6e-4c4d-a9b0-8d46f3e15260_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LesseeOperatingLeaseArea_44b20537-9a6a-4a8f-88a2-0e93a291604c_terseLabel_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area leased (square feet)</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseArea_label_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseArea_documentation_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseArea" xlink:href="bdtx-20230331.xsd#bdtx_LesseeOperatingLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LesseeOperatingLeaseArea" xlink:to="lab_bdtx_LesseeOperatingLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_38675119-91ba-4bb4-a44c-27990463f3f4_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c3e04a7e-7bf3-4bda-8403-2eb499f546a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5bff1328-a1e6-4cf6-87e4-d395f492ebee_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_dcc81b22-9795-4664-82a6-9b58d3bb239b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_db13fe29-61e0-4c72-ad17-76e7c1901e8e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_36b1711f-6b68-4988-aa9c-c074a2991c82_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0d08ff95-a1a9-4174-b4c9-9527ef527cfe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_4bcb1ea2-ae0e-4c6d-96a8-a5580d239c7c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c4e95dba-de92-46cb-90ce-b8807d0d82e0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ae0a1f0-6285-401d-bb2b-82cb6363e19b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72e175e3-eb96-49a3-8911-d059419c2e7a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44db2cea-29c9-4150-87e0-a39f4b1ec727_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f70ebdb7-aa17-4408-9f3d-a4f12e218749_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_566b328c-7af4-4a8a-b06f-05bdb185b2d2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b715e5af-941d-45b6-9f46-64753f02ed43_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_afe944a4-acd4-4616-92df-5b05447a9bf7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested or expected to vest, remaining life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_edabd41b-df67-4aed-bb6c-4dc4981b3a4c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets_57ddfff4-6a11-4b62-aec0-5837c131a1a5_terseLabel_en-US" xlink:label="lab_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of equipment included in prepaid expenses and other current assets</link:label>
    <link:label id="lab_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Equipment Included in Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Equipment Included in Prepaid Expenses and Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:href="bdtx-20230331.xsd#bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_917343b8-7091-4357-963a-2cbf3b5e7bc9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2ce6d127-3634-43a7-bc3d-419e65f19204_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8ffee52e-f78b-4edd-82ee-f27f874e1b53_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_fcb27893-87ca-4564-9bb2-1fc84a6d13a5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_409fdbb1-f0ef-41a9-be29-f733b5ccfba9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b389fecd-e37f-4a5f-aa8f-d4619cea0f0d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_895c9729-3d87-411e-a303-1f8cc1350d91_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution, percent of each participant's salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe138e13-5f99-4cba-9a46-e16bc8f65359_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6d4489b4-9b16-4fe6-8388-b10b380e9cea_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b56254d3-a2b5-4890-8089-168b912f0806_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e4348f9c-e201-4165-8c63-6a77ffc8bca8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_90b58acb-bfaf-441a-a144-69cc68e1797c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9689babe-e41d-47f1-acd5-9cd1331ac97a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_1063ba0b-a6f6-4c79-a2fd-049d72bd01fc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4a48102c-d55c-4922-a459-9a3e0944c7f1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a05b064c-af9e-4251-a3fc-f150d71a7a79_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock related to ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e608c2bd-e726-463d-9fb1-6d85fd64759c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_1d0de99c-8670-44eb-ac82-5e0475beee9b_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f835d291-720e-43c5-9335-906d2bc688c4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bb7c04a9-33f6-49be-8d4a-19bf88a1696e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock options and ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_05ce9cae-2344-46a0-a5e2-7102887e6296_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_58b1e755-c64e-422c-b427-ab444eb7bc9e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e90bdae0-7367-4da5-beff-90d8bcd07b00_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_62f3679a-137f-4752-baf0-5f3b4b5e9d9f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e2e538a1-21ee-4b41-8052-d83c7650535c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_abc29d6f-4429-4813-98cc-b94307a13bd7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Life and Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_63fe43c1-c921-40ff-b4af-c5de143933f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_fd6ebd40-6e5f-4252-98b6-d2cce9d871f6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_RentExpense_d4e550b7-7997-4965-855a-2642a76aa2e0_terseLabel_en-US" xlink:label="lab_bdtx_RentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash rent expense</link:label>
    <link:label id="lab_bdtx_RentExpense_label_en-US" xlink:label="lab_bdtx_RentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Expense</link:label>
    <link:label id="lab_bdtx_RentExpense_documentation_en-US" xlink:label="lab_bdtx_RentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_RentExpense" xlink:href="bdtx-20230331.xsd#bdtx_RentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_RentExpense" xlink:to="lab_bdtx_RentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_724ae86f-d426-423e-a6d9-bf2c8e906195_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ce56e90-398f-4c84-b619-5525d663f662_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_A2020StockOptionPlanMember_cfb822b4-a4e6-4f7e-808c-ac557d6a4e2d_terseLabel_en-US" xlink:label="lab_bdtx_A2020StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Option Plan</link:label>
    <link:label id="lab_bdtx_A2020StockOptionPlanMember_label_en-US" xlink:label="lab_bdtx_A2020StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Option Plan [Member]</link:label>
    <link:label id="lab_bdtx_A2020StockOptionPlanMember_documentation_en-US" xlink:label="lab_bdtx_A2020StockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Option Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020StockOptionPlanMember" xlink:href="bdtx-20230331.xsd#bdtx_A2020StockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_A2020StockOptionPlanMember" xlink:to="lab_bdtx_A2020StockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2478b14e-96b6-4d13-a647-4c11b6fc7949_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percent of fair market value of common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_98800422-45b6-45e6-9851-6481f9c7c1f4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_39c29e52-b948-490b-9597-107dcf942dca_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_02dc13d9-ec6b-45d2-83ff-4974fdb9ccd1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cb9e60d9-f5e1-4d3c-bfb5-9dda53fbe475_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (excluding the three months ended March&#160;31, 2023)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8fa49c95-e2ab-4f4b-905a-47463feab12b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ae2871a9-e8fd-461e-b730-9bc362c7fa64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_2b1aad55-cb53-4589-bcee-9c1d390e9b87_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4bdc0ce7-b806-4a9a-923f-8be6a4814dd2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock related to ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_b34a8094-c8f4-4ec7-bb84-6f50a638fc3b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_600f9556-e68f-4aa5-ae0a-b9c4452ce42e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, remaining life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6a1567f6-bac4-4395-8f41-2125aff2ab98_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1108330c-d065-4b3f-9438-3297f05e5f06_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_d88c6f0f-6081-4f99-b581-93fa58d5f393_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3619112c-1568-4cf6-8ff0-ced6842d9bb0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_2a47d2f7-7e11-401e-8fab-ae25a57fbdc3_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LaunchpadTherapeuticsIncMember_52995357-5eb2-4555-a1f5-8c1571959dec_terseLabel_en-US" xlink:label="lab_bdtx_LaunchpadTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Launchpad Therapeutics, Inc.</link:label>
    <link:label id="lab_bdtx_LaunchpadTherapeuticsIncMember_label_en-US" xlink:label="lab_bdtx_LaunchpadTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Launchpad Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_bdtx_LaunchpadTherapeuticsIncMember_documentation_en-US" xlink:label="lab_bdtx_LaunchpadTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Launchpad Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LaunchpadTherapeuticsIncMember" xlink:href="bdtx-20230331.xsd#bdtx_LaunchpadTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LaunchpadTherapeuticsIncMember" xlink:to="lab_bdtx_LaunchpadTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_18cdb18c-6572-4210-9afa-06b813017e10_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d3ac1dec-4653-495c-96a0-80cdbe4ba9ac_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_da369500-550a-4569-9bc0-42b4aa534c1a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_ShelfRegistrationStatementMember_93070e3c-83c4-40d2-ab3a-22cb6b230326_terseLabel_en-US" xlink:label="lab_bdtx_ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement</link:label>
    <link:label id="lab_bdtx_ShelfRegistrationStatementMember_label_en-US" xlink:label="lab_bdtx_ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement [Member]</link:label>
    <link:label id="lab_bdtx_ShelfRegistrationStatementMember_documentation_en-US" xlink:label="lab_bdtx_ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShelfRegistrationStatementMember" xlink:href="bdtx-20230331.xsd#bdtx_ShelfRegistrationStatementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_ShelfRegistrationStatementMember" xlink:to="lab_bdtx_ShelfRegistrationStatementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e0534e35-6eb9-4b5e-8c39-62a0c8521bc9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation and unaudited interim financial information</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4613343c-2ed7-41e3-843a-e24723c27298_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b7d87c81-75b6-440a-b073-eccd4145ca02_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8556c6ed-eabf-4cd5-9bc7-bc08b3b4de0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_af5c73aa-316e-4e20-8d00-ff6213bd2a71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a65a0f9b-955d-4fde-bddf-08d2819c218b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_36dd85b1-2bda-4075-be7c-33028aa019b5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_b5f001ba-ba81-420f-93b6-2e09764ac155_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_738f5dab-c3c1-4920-80af-05fe193d078c_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_765e8de6-c62b-4838-90e1-ce705aa25bea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_10159408-a1ef-40e2-9f27-08a98ab6d771_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0ca6c798-c8cf-4a7b-9d9e-a442f8f12200_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_db93afe8-973d-4028-85c9-ff3dd7254452_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d812760e-e2bb-4b4a-a62b-f4af07872fc4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dc22bdab-b88b-4a8d-b059-c4f58f2ada41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ca30877d-59f3-4486-a62f-a83ecb91286c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7b557f89-e39f-4765-a68d-55e2ef9fd28f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b96ebdac-1f77-403c-a354-05d4ba846027_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_dcdfeb0e-c308-45a8-b708-96f356fa4ed9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_bb8aa0d3-6161-4e2d-8341-e2e43ae801ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_50f0f602-bf84-40d2-bf85-cb9dab803030_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_3b69dd45-6253-48aa-9ba7-d4c7fd392e67_terseLabel_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase of authorized shares, percent of common stock outstanding</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_label_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_documentation_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:href="bdtx-20230331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:to="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_470aabc5-bf9b-405c-89bb-9180d9f54979_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b45cb14-d70b-48bf-94f5-dfa51a994fc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_87030307-e5a7-442f-951e-f24dd658fdaa_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_459522b8-c63e-490f-9307-f1699bfd82b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6a916c9b-2f23-4f1d-affd-a7da413a2bed_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_fc0156e2-fa9f-4afe-8547-c0ce395271be_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_b0b15b6c-934b-462c-9934-2670a1aacce3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_23105f44-6258-43d9-9b95-31d4cc1cabb9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b45d173-4b9a-498c-bd01-867aa0c430f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_137b656e-b6b5-4cde-ae72-1ab16ae5d1df_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4d5e1523-f9e4-41b8-b110-883f839f462a_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_146ea5a3-d5ec-4ee7-969b-3883152315f6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_14f310c8-5314-4ffb-8af5-f093d83a52e5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f2aa0edd-7d98-487a-bbf4-505263deb872_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_307b2ca1-52c1-4712-acd6-32f6535b1439_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9d66b041-8f25-4376-a3b0-cf309a463bab_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_303fe332-e595-41d8-ad33-fc142575c77e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ad382d93-32b7-404c-a8b6-e182c2117136_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_554db751-31b3-4993-9b48-252909040311_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3b9e6e07-a859-47e1-83f4-7f8557b093c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_02f5cf32-faf2-42fc-80ac-ab979189649b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under share-based compensation plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_d64323d6-2db1-4278-ae65-5816a2fdb822_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b3437457-5f6a-4064-bc6e-b6e87d3e7c0d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted common stock, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_011450d8-3a53-48c8-bec5-a89e3fb3a731_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted common stock, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_f1dc84d6-ee9b-4c09-876f-2408372ce99a_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2ffb58ac-4610-4d16-8b27-3d390f3f5593_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_659b6407-c43f-4460-88f2-5f5a92abca76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c957130d-93d9-4b71-9225-f57e712491aa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f4b9cb1f-bf80-432f-bfe5-4dede9bf9192_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_a830d3c9-f231-4d65-8275-cfdaabc484a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5f3e2c78-2003-4b2e-8e3a-aba4cb4163df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_2ac9a21b-79cc-4323-865a-741e6621df60_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_51e9bf8c-2f39-4b0d-abc2-85accf9b74b2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ad5c3475-d4e7-4541-ab38-93b11e32cc53_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c26092e0-5dc5-457e-86cd-e191ad904a3a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_c1b21b3a-a77e-4034-a0ea-d33aae9f78f7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d76c8982-45b9-4aef-b8e4-99b17939cea2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_69cfb1a8-3d44-4179-97bc-95ca79207263_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_154039bc-8307-47b3-9652-c9b68d17805e_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b2ae413e-94aa-4a7b-8d85-de4958e03198_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6b2f74ff-e411-456b-898a-9dac5b2e4aec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_20a1077a-6429-4a73-99a2-45f6e926208a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_3d65478e-debf-4946-b99d-c9fd41afdf9a_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested performance restricted stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5494b303-25fd-42f2-a0bb-4f0506726303_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6ca69c09-9a2f-4dd6-81b2-5d17041b3b2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_18bdb441-e358-4068-a85b-1d6ba05eb515_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e1d404d4-e300-4bfb-ac27-1efa6197b86d_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d5c4d34d-6dbb-4f3c-8ad1-0d5ad7385d68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_77e3e773-2049-422c-8939-e30da8fa3558_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_10c3d988-72dd-4a6a-a470-a5cd434e8b70_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a64bf1c4-6718-43a3-846c-b81e1e83f93a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_056a304f-f85b-4181-bbf7-abc21e99e13e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_c0572dab-5984-4e6a-8c3e-8631bd339c6b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1c3059d2-c4cc-4811-aa69-1f0277aae98d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_86d6e62a-f0bb-44a5-bd89-b18042faffbe_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_ab513227-49b2-4edb-ad22-caa926208503_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0c334c4e-55c8-4e32-9889-5e0583a155f4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d45ced3c-0f7d-4da9-a62b-8706ebc340b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested or expected to vest, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f51f47f0-2112-40c1-af45-8772f9956c64_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_c43880d1-bbfc-4048-ab39-b325ce0097c1_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of IP</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_50802475-00dc-4d6a-8b09-afd1cefb671e_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f8d7ac45-b203-4aca-958c-0ac8ac1df70e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a6a236d8-9ac1-4b90-8ce6-2e3b98964c13_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53709758-af50-43be-bd2a-be84602d9d0f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_25eee732-9be4-4131-9cb4-5620fca1c30d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, recognition period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c95d9580-43ef-4a03-8470-42632540e115_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, remaining life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_a0326041-4a5a-4d17-9ae8-f29fd7e43e21_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_da20f209-31ea-408a-b860-801e400b7c2d_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_81040503-3ac0-41d5-b1db-93978182f131_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_39463d88-38c5-4381-abb0-16351042ee7e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9af6cd31-bf53-4ca4-9c76-07ed2616156e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_703bd6e1-ddc7-483f-b588-4982b88dd30a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8a163a16-046e-401c-91c5-fafc3e9c9566_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c424f5f9-9e28-49df-8eb4-6a2434634c7f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a97ea3a7-c6b2-4f9a-9009-3663a9fbeadf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; no shares issued or outstanding at March&#160;31, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_d8b2c0eb-8526-4b02-ada7-7e2cb6dbc214_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_3f40b82b-c151-4ecd-b4b6-87c503597fcc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7d02bd6f-0105-4f37-bd0c-b9cd2a580eba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ccdd010e-0104-461f-871c-75775a46cfc7_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_c616a991-c076-4a1a-ab6c-d02b318463c3_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f9a81f1b-eb39-404b-ae89-74e72224e633_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_7da1b2d1-c8f6-48d3-9cfa-cde8adc9d146_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_733198f4-7271-467e-ba10-43a70fef05ae_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_85b6f964-52ac-4c06-a2d0-380fbcf43e2a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution, matching contribution percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LesseeOperatingLeaseNumberOfContracts_71f5099d-6502-44f9-b181-e2d62b4c3fce_terseLabel_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseNumberOfContracts_label_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseNumberOfContracts_documentation_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:href="bdtx-20230331.xsd#bdtx_LesseeOperatingLeaseNumberOfContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:to="lab_bdtx_LesseeOperatingLeaseNumberOfContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_49c362ee-a40a-479d-8d19-37a9b24e709c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_145904c0-2ccf-4179-950e-14ccd60c8521_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_92620457-d2bb-4396-81fe-482b063b1f41_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_422daed6-c8cf-4cd9-a4a5-29cfa2883b83_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_06a7dc84-b149-4001-a038-87548d802f54_terseLabel_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award purchase period (in months)</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="bdtx-20230331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8f473a0f-ed70-4ebd-bb1e-eec40805ec45_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_595eafc1-c497-465e-bcf2-1a3a792c0af5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9c358976-e5a8-4c74-ab0f-d74362346949_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_abdd16a6-f3b3-4a07-b75d-831a7dee8565_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ffa22ee9-0b96-4c7b-9042-40e6d3f98207_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_094c351d-1903-4bb8-94b9-b28ac44d393f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_49f8adb9-ba2e-4bed-9ef2-6cb1bdc1d5db_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_1ac01afc-18eb-4e82-b2ff-0048a724c4bb_terseLabel_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:label id="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="bdtx-20230331.xsd#bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_68e006dd-85ba-4508-a795-ef501c5e4a74_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_e71d6d1d-77fd-4f6e-855a-76a297623b9c_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_249c83dc-a04c-4a49-ac16-830578a5aea5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_375f35e1-aa33-481c-a88e-ee7c039a2580_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9cd9746b-6570-476e-8e6d-b5296d777837_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3b063f5b-2c31-4b3a-9aa8-14bb24adb25b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_a9af1f56-0ff4-4592-884c-03ebcd7b0a70_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1785c4df-0d6a-43d7-a193-35fb0cb351ef_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_AccruedContractResearchServiceFeesCurrent_5a996acb-4ee1-4ec1-87ec-6e39e6b5d83f_terseLabel_en-US" xlink:label="lab_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracted research services</link:label>
    <link:label id="lab_bdtx_AccruedContractResearchServiceFeesCurrent_label_en-US" xlink:label="lab_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Research Service Fees, Current</link:label>
    <link:label id="lab_bdtx_AccruedContractResearchServiceFeesCurrent_documentation_en-US" xlink:label="lab_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Research Service Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:href="bdtx-20230331.xsd#bdtx_AccruedContractResearchServiceFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:to="lab_bdtx_AccruedContractResearchServiceFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_15f8e51c-8075-4121-ad00-64183134f6e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b5a13f8d-7899-4338-9f92-a2ba1dadb66f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_62da97f9-14cd-417a-9e1d-85dae96e2270_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9380a1bd-4e31-4a16-9985-7ad35ca986da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested or expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_99bfcfda-e201-49d2-85fa-923c480d7242_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_3822d3bf-c0c9-480b-867d-8f35aa7ba927_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1ff5c0b7-041e-4c22-9eae-9b4c27c5af4c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_889cc324-86b5-4816-a1c5-178c4e8f2adb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_A2020EmployeeStockPurchasePlanMember_3a430f72-4bb2-4749-8a55-59672bc9c897_terseLabel_en-US" xlink:label="lab_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 ESPP</link:label>
    <link:label id="lab_bdtx_A2020EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_bdtx_A2020EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:href="bdtx-20230331.xsd#bdtx_A2020EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:to="lab_bdtx_A2020EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_93d41749-34c7-47f0-9fb1-60d3f0290b6f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_353524fa-aab5-4f90-9c1e-721d5b7eb98f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_cd421987-1cd9-4c99-af83-e86c12909523_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_488a06e2-285e-4f67-b4d7-891fa81c3a2c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_12500284-d821-41f8-bc63-100a8f3a7884_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f80a9e38-9aba-44dc-b500-7ddd70ab23a0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_LeaseOtherInformationAbstract_78132c62-8b86-4f5d-ad2e-3e206252f49d_terseLabel_en-US" xlink:label="lab_bdtx_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Lease Information</link:label>
    <link:label id="lab_bdtx_LeaseOtherInformationAbstract_label_en-US" xlink:label="lab_bdtx_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Other Information [Abstract]</link:label>
    <link:label id="lab_bdtx_LeaseOtherInformationAbstract_documentation_en-US" xlink:label="lab_bdtx_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Other Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseOtherInformationAbstract" xlink:href="bdtx-20230331.xsd#bdtx_LeaseOtherInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_LeaseOtherInformationAbstract" xlink:to="lab_bdtx_LeaseOtherInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_32de05b6-18b1-4d62-baf6-6627beee7434_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6c01503a-05cb-4275-9b34-96a5d2540383_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b4580714-104f-4402-beed-e64a5472c5e9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_PerformanceRestrictedStockUnitsMember_d0196c00-7b66-4d6b-8dd9-ec3230efd0ae_terseLabel_en-US" xlink:label="lab_bdtx_PerformanceRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Restricted Stock Units</link:label>
    <link:label id="lab_bdtx_PerformanceRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bdtx_PerformanceRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bdtx_PerformanceRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bdtx_PerformanceRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_PerformanceRestrictedStockUnitsMember" xlink:href="bdtx-20230331.xsd#bdtx_PerformanceRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_PerformanceRestrictedStockUnitsMember" xlink:to="lab_bdtx_PerformanceRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e69c11cb-71a5-4612-a463-c39c8b40fabf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_OtherAwardTypeMember_af957460-7a73-4128-bf77-53573d5420f5_terseLabel_en-US" xlink:label="lab_bdtx_OtherAwardTypeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan and Other</link:label>
    <link:label id="lab_bdtx_OtherAwardTypeMember_label_en-US" xlink:label="lab_bdtx_OtherAwardTypeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Award Type [Member]</link:label>
    <link:label id="lab_bdtx_OtherAwardTypeMember_documentation_en-US" xlink:label="lab_bdtx_OtherAwardTypeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Award Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OtherAwardTypeMember" xlink:href="bdtx-20230331.xsd#bdtx_OtherAwardTypeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_OtherAwardTypeMember" xlink:to="lab_bdtx_OtherAwardTypeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_fe161c21-807c-4276-9c07-3626f3425707_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9aa75719-2356-44dd-91bf-8a2246ff7457_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of units vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0b9b837c-18a3-48f0-8d95-69aec4793406_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c3d0eb31-1308-4b04-9977-419d5b76e21b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e3740740-7e80-44d0-a9ac-e7271ed86dbf_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_531aef8d-8fa2-41dc-af6a-c646cfaee108_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_30b569b4-bfc9-4a63-b8ee-9be7e047ccc4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e6132fe7-3312-43a1-aa80-5f3473583488_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_f301e2b2-c075-46f9-82c9-cb0a3dc30e3e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_9c8ca104-4d8b-4656-abe3-cf510bfc3a56_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e6f70a60-0ed6-462f-8381-98211ef21bc1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3363571-da3c-4b5f-8f3a-a92b5029e6af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_bf087cbe-6877-4212-afda-61fb2fee2fe3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7235bea3-daa3-462a-badd-479cdfa52349_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in current assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_30ffa407-b807-463d-a963-bddb2066e9b6_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_700cf7a6-f0b2-47cd-b0fb-9985356d8405_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_6cd99f99-6614-4683-af03-cbb2e5178413_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ee6f7eda-d8e2-404b-9bd0-015144b8e846_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1eeb2e09-4224-436e-83d8-c802fd14e351_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c63c1c1f-acb2-40c1-a7dc-036dd4aeb013_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_707e0850-1d3a-42ef-80b8-70e7f045e8fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_874590cf-8475-41ca-8590-c59b936a3470_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_7fe8f7bc-2c05-4ae0-a4b9-a6ca99e85fe2_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_a865aa9d-a12c-4481-83ea-b4d5e27921ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3e610e83-9d8c-43f1-b6b4-d3138bd6dee3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee subscription rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6fb8b171-8d88-4bc4-bf6e-7768a06a7074_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_5b969507-cdca-4e0a-8e74-857b0c66ac70_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Cost and Other Operating Lease Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_ba74cf21-96e0-48ab-9cec-8fea1ac63a73_terseLabel_en-US" xlink:label="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_label_en-US" xlink:label="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three</link:label>
    <link:label id="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_documentation_en-US" xlink:label="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:href="bdtx-20230331.xsd#bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:to="lab_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ce3e5e01-af5a-4467-8417-9497bb732ff7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c21ca754-5f09-477a-ab2f-9cdd3b90df2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_df98be2d-1e83-4e1a-9290-57b1a785db24_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term, optional extension (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_ae66296c-23e1-4ed6-89a2-08985ee4df61_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_9b4b2387-2cb3-40dd-b7e7-47ddf44c4098_terseLabel_en-US" xlink:label="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:label id="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="bdtx-20230331.xsd#bdtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_53267ff4-85ad-4e27-be79-58cf4514cdbd_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f9396039-b4f4-4715-b120-51f8d67b7a59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrender of shares for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_614244f6-b5ff-4fa0-9778-212eaee43457_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d333f8be-ec7c-4879-8593-90f241d5c078_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_65abf91d-882b-48d2-9139-7134ff8ce115_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_1fb979c9-8afb-44fd-acec-e66ca217c520_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset acquired other than through business combination, written-off</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3bdecbe6-7cc6-41e5-a39d-257e87f6fcb6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_c9d1d810-7012-4f16-aa86-0a29806a433c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_93cdaae0-6a85-4175-af80-9251541029d2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_37b67746-3e07-4eeb-8126-c9036606b87d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a758d47e-aea1-4637-890c-8e6d468d73a4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2fd1dbae-7098-40a6-bb9d-27aff2e333f4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cc361cc8-fd16-438a-9755-ed31827b4d3a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_93caad8c-c281-4152-a3a9-f3ed3165f7f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_26e438b1-fe40-484f-a280-3d285477c020_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant&#160;date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_e867b967-07eb-4ec8-a8a6-31183d6d1d35_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ac5e6c21-7610-422b-8670-2a7b9e37ec38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f460b80d-2735-4df4-a71a-a903908cff17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_8bacc9f5-1a50-47a2-8df8-7764c74b4ee3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b2be3e9a-28ef-4096-949c-fbf68ca854f4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a5b5491-9683-481f-9323-25d1cb2d992b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7bd933e6-254c-4423-b0d8-4377a5a51d46_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_9cf03ff6-b8cf-4d0d-b8c1-f34e8cfd3571_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional and consulting fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_37ee7d70-59c7-4a13-9c91-4bf5d2f00e11_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_180153da-9fbc-4851-b5d4-c61f0f95e9d5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ef27a4b7-4e57-49bd-93b2-11c93f148587_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f799a9a4-253d-4111-9774-b73909fccc89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_625fac09-6c2f-4dc6-b16b-7ce5fbe08104_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_269f66e9-bfd5-472c-89f6-2f1570feeff5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_264af998-847f-4996-96a7-464f92674aa0_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable_1f9d4096-8822-451d-a6cb-b51f0bac3da5_terseLabel_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Achievement of Milestones Probable</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable_label_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Achievement of Milestones Probable</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable_documentation_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Achievement of Milestones Probable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable" xlink:href="bdtx-20230331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable" xlink:to="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_14a7d4c9-3d8c-4087-a384-b42a8ff87617_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2eb37633-b87f-4b4b-a7c9-1f20dd8894c1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_a54a6751-1196-4042-92ca-9d94b08cdcc3_terseLabel_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee subscription amount</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_label_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:label id="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_documentation_en-US" xlink:label="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:href="bdtx-20230331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:to="lab_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7d2392b6-1e76-4996-8797-f9975230c02a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6bf4e0ad-03e2-498c-9800-f0de36a3cd89_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9163692b-c7d9-4aab-baa4-eec63b1e7ebe_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8df2488a-2cac-46c8-9d3b-748a09100ad0_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d79d4223-fdad-49d4-8012-f4285015cd26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange_a98d5bb4-8aee-41d5-9799-a50da2173d23_terseLabel_en-US" xlink:label="lab_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares received from equity method investment (in shares)</link:label>
    <link:label id="lab_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange_label_en-US" xlink:label="lab_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Shares Received in Noncash Exchange</link:label>
    <link:label id="lab_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange_documentation_en-US" xlink:label="lab_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Shares Received in Noncash Exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange" xlink:href="bdtx-20230331.xsd#bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange" xlink:to="lab_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember_142026f3-1242-49b9-ad0c-8c336f780ed1_terseLabel_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal office, lease two</link:label>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember_label_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Principal Office, Two [Member]</link:label>
    <link:label id="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember_documentation_en-US" xlink:label="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Principal Office, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:href="bdtx-20230331.xsd#bdtx_OperatingLeasePrincipalOfficeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:to="lab_bdtx_OperatingLeasePrincipalOfficeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_afbe99d4-81d1-4052-816e-fe21ad76aa3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested or expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_60744648-15c1-4bd0-bbc1-854ce8ae2fc7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recognized from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_f6f30c52-e583-4396-a4da-8e05e2fa2967_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY METHOD INVESTMENT</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dc594df3-fe5c-47a0-b3aa-7711589e66dd_terseLabel_en-US" xlink:label="lab_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligation</link:label>
    <link:label id="lab_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label id="lab_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_documentation_en-US" xlink:label="lab_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="bdtx-20230331.xsd#bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_50a5594c-a837-4cbf-b865-20842a324018_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_223a6c01-b0c8-4a88-8012-e5d5948b12d0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6c4b0b11-1de1-4565-8744-68c9276c1711_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_acda787b-6441-4067-a6a5-5aa02ab6acbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6fe64cc2-7859-4bba-a2bd-931d9b12c6f5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8ca64fda-3987-49db-8baa-dcae510d5226_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_5c727e22-42f4-4316-8191-1c16a32a43ef_terseLabel_en-US" xlink:label="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Office and Laboratory Space, NY</link:label>
    <link:label id="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_label_en-US" xlink:label="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Office and Laboratory Space, NY [Member]</link:label>
    <link:label id="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_documentation_en-US" xlink:label="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Office and Laboratory Space, NY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" xlink:href="bdtx-20230331.xsd#bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" xlink:to="lab_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ed456159-52aa-4d08-aa79-ffd54e1fc01a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ea9ebc39-0ccb-47d3-8ad9-edce94d12d3f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_da968bcf-f853-4535-a368-6690f280d445_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3c6d195f-f75b-43fa-9183-966c258c4502_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6994ec26-3d1a-4817-84da-a28dcb70b11e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_60ba7b1c-be3f-497a-ad17-f3c5f7718a48_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>bdtx-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:73ec13c2-272f-4624-b8c8-b5925ba5540a,g:c0252310-7c05-47ef-aa9c-a55e1f9856cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="bdtx-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f67ee97b-abad-4a21-b9ce-fd74dc0f8708" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_DocumentType_f67ee97b-abad-4a21-b9ce-fd74dc0f8708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c4691035-0f44-4486-a6c4-c4885881d709" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_DocumentQuarterlyReport_c4691035-0f44-4486-a6c4-c4885881d709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8faa2332-fbb6-4996-b17d-a4f6020557e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_DocumentPeriodEndDate_8faa2332-fbb6-4996-b17d-a4f6020557e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_731182cf-e746-4311-8e03-24f0e8acba9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_DocumentTransitionReport_731182cf-e746-4311-8e03-24f0e8acba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7b0b5a16-4ba9-4225-99f0-66ed442acb3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityFileNumber_7b0b5a16-4ba9-4225-99f0-66ed442acb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_acdecadf-193c-4d98-8572-28f010adf031" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityRegistrantName_acdecadf-193c-4d98-8572-28f010adf031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6cac68f9-626c-455e-b2c3-470509a23bdd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6cac68f9-626c-455e-b2c3-470509a23bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b429a12f-9b3d-4670-96cc-25ebb7f0ffec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityTaxIdentificationNumber_b429a12f-9b3d-4670-96cc-25ebb7f0ffec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cb949b59-bc3b-414c-b14c-b5279619aa25" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityAddressAddressLine1_cb949b59-bc3b-414c-b14c-b5279619aa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2ca1763c-8cfc-423d-b17c-0a13cce4549e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityAddressCityOrTown_2ca1763c-8cfc-423d-b17c-0a13cce4549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_98ae082b-e31f-4b75-9eca-d7edf521ad85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityAddressStateOrProvince_98ae082b-e31f-4b75-9eca-d7edf521ad85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f6093d14-3b4d-4c25-beb3-f9bb8c6aee67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityAddressPostalZipCode_f6093d14-3b4d-4c25-beb3-f9bb8c6aee67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8ec88104-0bb2-4a47-894a-990cef617517" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_CityAreaCode_8ec88104-0bb2-4a47-894a-990cef617517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0c0231d5-c482-4891-9e63-7d0bbd9f58e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_LocalPhoneNumber_0c0231d5-c482-4891-9e63-7d0bbd9f58e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_da8cf7b1-9731-4503-9cda-d97a27e030bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_Security12bTitle_da8cf7b1-9731-4503-9cda-d97a27e030bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b1a18ff5-9efb-430c-94b4-a5ddf892fd50" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_TradingSymbol_b1a18ff5-9efb-430c-94b4-a5ddf892fd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_98596d52-5e3e-465f-8c67-4c2fb667d820" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_SecurityExchangeName_98596d52-5e3e-465f-8c67-4c2fb667d820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_be2baa63-ac06-49e0-b656-905d5a0c7132" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityCurrentReportingStatus_be2baa63-ac06-49e0-b656-905d5a0c7132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8b5a7b8b-1f92-4955-bf2d-73b2cdeceaa4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityInteractiveDataCurrent_8b5a7b8b-1f92-4955-bf2d-73b2cdeceaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9aeba895-6b38-4c8b-9fc7-24eef718ecc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityFilerCategory_9aeba895-6b38-4c8b-9fc7-24eef718ecc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3bbcd5c6-10f1-48de-9d16-e1d08f6d67fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntitySmallBusiness_3bbcd5c6-10f1-48de-9d16-e1d08f6d67fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_30b80e0e-5f22-481d-96c6-d44a0328f3ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityEmergingGrowthCompany_30b80e0e-5f22-481d-96c6-d44a0328f3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_9c1937aa-4a1f-4f17-b13b-a394a7677d18" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityExTransitionPeriod_9c1937aa-4a1f-4f17-b13b-a394a7677d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_bbc38347-c6d6-4267-9039-467121f7cfaf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityShellCompany_bbc38347-c6d6-4267-9039-467121f7cfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_94ac5cdf-3707-408d-b6c7-992b6f656091" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_94ac5cdf-3707-408d-b6c7-992b6f656091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ab979ead-9145-41d7-994f-5eed8b99b684" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_AmendmentFlag_ab979ead-9145-41d7-994f-5eed8b99b684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6697e9c0-5c8d-4da5-89d5-aeea72beb433" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6697e9c0-5c8d-4da5-89d5-aeea72beb433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_bddb1084-e64d-4765-9472-14a6be00a0c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_DocumentFiscalYearFocus_bddb1084-e64d-4765-9472-14a6be00a0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bfb50c7b-2a3c-4795-8b88-f8fe59270987" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_EntityCentralIndexKey_bfb50c7b-2a3c-4795-8b88-f8fe59270987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_142cc93a-d6e4-4dfa-802e-8ac9c3adee4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e049d8ac-77ca-48b7-bcb6-8332cb0f4e1b" xlink:to="loc_dei_CurrentFiscalYearEndDate_142cc93a-d6e4-4dfa-802e-8ac9c3adee4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="bdtx-20230331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e4974a9e-34db-4d74-b3a9-14a91c098aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cf2a5317-f621-4d23-8e13-1da3dedf3731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e4974a9e-34db-4d74-b3a9-14a91c098aa1" xlink:to="loc_us-gaap_AssetsAbstract_cf2a5317-f621-4d23-8e13-1da3dedf3731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c604139b-1cbd-452a-a5c0-dca12f30fff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cf2a5317-f621-4d23-8e13-1da3dedf3731" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c604139b-1cbd-452a-a5c0-dca12f30fff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a1a08c9a-ce96-4a0c-a311-da8b02df2642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c604139b-1cbd-452a-a5c0-dca12f30fff8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a1a08c9a-ce96-4a0c-a311-da8b02df2642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_55f7bda4-5447-409f-abf4-1c757964f2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c604139b-1cbd-452a-a5c0-dca12f30fff8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_55f7bda4-5447-409f-abf4-1c757964f2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ee77bbfa-35a6-45e7-a2c9-0ce99e71f5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c604139b-1cbd-452a-a5c0-dca12f30fff8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ee77bbfa-35a6-45e7-a2c9-0ce99e71f5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_35fff13a-33f5-43b0-8259-553a7f3d11c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c604139b-1cbd-452a-a5c0-dca12f30fff8" xlink:to="loc_us-gaap_AssetsCurrent_35fff13a-33f5-43b0-8259-553a7f3d11c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_52f8af4e-54f9-4391-9620-8942cc64e26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cf2a5317-f621-4d23-8e13-1da3dedf3731" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_52f8af4e-54f9-4391-9620-8942cc64e26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2f96e808-be41-4b84-9720-b24bccc37bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cf2a5317-f621-4d23-8e13-1da3dedf3731" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2f96e808-be41-4b84-9720-b24bccc37bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2b660829-6903-48d2-a0f0-0079ce126ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cf2a5317-f621-4d23-8e13-1da3dedf3731" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2b660829-6903-48d2-a0f0-0079ce126ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_79f01fd5-938f-4b66-9522-521e68c0ce84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cf2a5317-f621-4d23-8e13-1da3dedf3731" xlink:to="loc_us-gaap_Assets_79f01fd5-938f-4b66-9522-521e68c0ce84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b44fa47-2444-4d83-a6c7-da18ec99d661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e4974a9e-34db-4d74-b3a9-14a91c098aa1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b44fa47-2444-4d83-a6c7-da18ec99d661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_17a5b9fc-b660-44a5-bc3f-e0914561b8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b44fa47-2444-4d83-a6c7-da18ec99d661" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_17a5b9fc-b660-44a5-bc3f-e0914561b8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6b8e24c3-87f3-46b3-83df-5fa061339278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17a5b9fc-b660-44a5-bc3f-e0914561b8ae" xlink:to="loc_us-gaap_AccountsPayableCurrent_6b8e24c3-87f3-46b3-83df-5fa061339278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a8cb0804-4fac-4d92-b76a-03761d6b87df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17a5b9fc-b660-44a5-bc3f-e0914561b8ae" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a8cb0804-4fac-4d92-b76a-03761d6b87df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5d4c8fa8-462b-42dc-857d-5fb2ff2b0d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17a5b9fc-b660-44a5-bc3f-e0914561b8ae" xlink:to="loc_us-gaap_LiabilitiesCurrent_5d4c8fa8-462b-42dc-857d-5fb2ff2b0d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2a3b9158-396e-4d48-9a28-746d2694f169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b44fa47-2444-4d83-a6c7-da18ec99d661" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2a3b9158-396e-4d48-9a28-746d2694f169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dbd7f6a6-184a-41e1-8ab2-6665f2a18a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b44fa47-2444-4d83-a6c7-da18ec99d661" xlink:to="loc_us-gaap_Liabilities_dbd7f6a6-184a-41e1-8ab2-6665f2a18a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c32b3c23-4e6a-49cc-bbed-19959f10883d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b44fa47-2444-4d83-a6c7-da18ec99d661" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c32b3c23-4e6a-49cc-bbed-19959f10883d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_84580459-c099-42b2-8a5e-5db013c95120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b44fa47-2444-4d83-a6c7-da18ec99d661" xlink:to="loc_us-gaap_StockholdersEquityAbstract_84580459-c099-42b2-8a5e-5db013c95120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1c3d35d5-2755-4b15-a0a9-582de3ff41ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84580459-c099-42b2-8a5e-5db013c95120" xlink:to="loc_us-gaap_PreferredStockValue_1c3d35d5-2755-4b15-a0a9-582de3ff41ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ceee45db-8384-4253-83fc-72a0011b7b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84580459-c099-42b2-8a5e-5db013c95120" xlink:to="loc_us-gaap_CommonStockValue_ceee45db-8384-4253-83fc-72a0011b7b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bd7bd7de-aead-4302-9010-268bd18a39c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84580459-c099-42b2-8a5e-5db013c95120" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bd7bd7de-aead-4302-9010-268bd18a39c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_09693b67-56ac-4a5e-a75d-8c5907380b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84580459-c099-42b2-8a5e-5db013c95120" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_09693b67-56ac-4a5e-a75d-8c5907380b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bab837e3-9c8e-46d1-b654-c873133f618d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84580459-c099-42b2-8a5e-5db013c95120" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bab837e3-9c8e-46d1-b654-c873133f618d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_71222a71-bf74-4dba-a47a-18682e1ffa23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_84580459-c099-42b2-8a5e-5db013c95120" xlink:to="loc_us-gaap_StockholdersEquity_71222a71-bf74-4dba-a47a-18682e1ffa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_84234d35-c8b0-42c3-a8f4-5f9a1fb40a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0b44fa47-2444-4d83-a6c7-da18ec99d661" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_84234d35-c8b0-42c3-a8f4-5f9a1fb40a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="bdtx-20230331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8ac45e1b-aebe-48f6-9d36-e1768fcc4c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9488d40e-f168-4edc-b5b6-93006a4524fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8ac45e1b-aebe-48f6-9d36-e1768fcc4c5b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9488d40e-f168-4edc-b5b6-93006a4524fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7c30007a-d4a7-4743-9619-79cfb7542099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8ac45e1b-aebe-48f6-9d36-e1768fcc4c5b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7c30007a-d4a7-4743-9619-79cfb7542099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_07962150-f518-40a6-90e7-e046600d1502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8ac45e1b-aebe-48f6-9d36-e1768fcc4c5b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_07962150-f518-40a6-90e7-e046600d1502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ffb6c6d7-3a80-49b7-b6e7-31a0dfd38594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8ac45e1b-aebe-48f6-9d36-e1768fcc4c5b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ffb6c6d7-3a80-49b7-b6e7-31a0dfd38594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_262180bd-2ddf-4326-9218-1b572c9472aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8ac45e1b-aebe-48f6-9d36-e1768fcc4c5b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_262180bd-2ddf-4326-9218-1b572c9472aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0479ee49-f821-4766-accc-493496539473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8ac45e1b-aebe-48f6-9d36-e1768fcc4c5b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0479ee49-f821-4766-accc-493496539473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_58e3a2b6-0569-4bbe-ac9a-ea12c655f6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8ac45e1b-aebe-48f6-9d36-e1768fcc4c5b" xlink:to="loc_us-gaap_CommonStockSharesIssued_58e3a2b6-0569-4bbe-ac9a-ea12c655f6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e98c78fe-c2a0-45fe-a987-db668676bbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8ac45e1b-aebe-48f6-9d36-e1768fcc4c5b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e98c78fe-c2a0-45fe-a987-db668676bbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="bdtx-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e7584e8a-2c97-45f2-8345-492919ce2f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_55b21ce5-0a89-470c-8bf8-d196b6ee0630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e7584e8a-2c97-45f2-8345-492919ce2f97" xlink:to="loc_us-gaap_OperatingExpensesAbstract_55b21ce5-0a89-470c-8bf8-d196b6ee0630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c89e1ae1-be6f-4ae1-9e78-901c7f463eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_55b21ce5-0a89-470c-8bf8-d196b6ee0630" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c89e1ae1-be6f-4ae1-9e78-901c7f463eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f0bbd9dc-a96a-4596-bd17-ce26206d3b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_55b21ce5-0a89-470c-8bf8-d196b6ee0630" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f0bbd9dc-a96a-4596-bd17-ce26206d3b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4010aaaa-0cfe-44e4-ad10-f248954a2b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_55b21ce5-0a89-470c-8bf8-d196b6ee0630" xlink:to="loc_us-gaap_OperatingExpenses_4010aaaa-0cfe-44e4-ad10-f248954a2b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_335e1dcd-87fc-4158-a048-5e7defb82e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e7584e8a-2c97-45f2-8345-492919ce2f97" xlink:to="loc_us-gaap_OperatingIncomeLoss_335e1dcd-87fc-4158-a048-5e7defb82e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_144fe55d-1f72-46cc-8a99-13afb631bd32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e7584e8a-2c97-45f2-8345-492919ce2f97" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_144fe55d-1f72-46cc-8a99-13afb631bd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_925bb155-06a7-4401-aa17-8aba9a62650b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_144fe55d-1f72-46cc-8a99-13afb631bd32" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_925bb155-06a7-4401-aa17-8aba9a62650b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_adefb35e-a32b-4a0d-8cf5-2a7c025bdfe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_144fe55d-1f72-46cc-8a99-13afb631bd32" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_adefb35e-a32b-4a0d-8cf5-2a7c025bdfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0962aef5-75ec-4316-aa86-e375f2a49b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_144fe55d-1f72-46cc-8a99-13afb631bd32" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0962aef5-75ec-4316-aa86-e375f2a49b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8864c1b5-f863-4992-be4d-b9f11dbcdf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e7584e8a-2c97-45f2-8345-492919ce2f97" xlink:to="loc_us-gaap_NetIncomeLoss_8864c1b5-f863-4992-be4d-b9f11dbcdf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bdd482bf-5137-4e97-9678-6e5564d8c702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e7584e8a-2c97-45f2-8345-492919ce2f97" xlink:to="loc_us-gaap_EarningsPerShareBasic_bdd482bf-5137-4e97-9678-6e5564d8c702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_08a14336-efa8-4f9a-975b-4c961e8ded38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e7584e8a-2c97-45f2-8345-492919ce2f97" xlink:to="loc_us-gaap_EarningsPerShareDiluted_08a14336-efa8-4f9a-975b-4c961e8ded38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c1fa02dd-26de-46fa-99b5-b3b2d0ed393d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e7584e8a-2c97-45f2-8345-492919ce2f97" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c1fa02dd-26de-46fa-99b5-b3b2d0ed393d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7abb48d7-6d83-40c3-bfca-46839db46928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e7584e8a-2c97-45f2-8345-492919ce2f97" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7abb48d7-6d83-40c3-bfca-46839db46928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_90eb7285-d4dc-47b8-85e3-b369bb9bc253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e7584e8a-2c97-45f2-8345-492919ce2f97" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_90eb7285-d4dc-47b8-85e3-b369bb9bc253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c0bcf454-596d-4375-94a8-1e398ad4d4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_90eb7285-d4dc-47b8-85e3-b369bb9bc253" xlink:to="loc_us-gaap_NetIncomeLoss_c0bcf454-596d-4375-94a8-1e398ad4d4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_62ac6c28-2dd9-42b2-b2f4-25ccccf26e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_90eb7285-d4dc-47b8-85e3-b369bb9bc253" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_62ac6c28-2dd9-42b2-b2f4-25ccccf26e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_20b7a997-375a-4c60-80c0-4279ded5f26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_62ac6c28-2dd9-42b2-b2f4-25ccccf26e9e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_20b7a997-375a-4c60-80c0-4279ded5f26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bd843375-5a81-4a9a-a931-e061c3241ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_90eb7285-d4dc-47b8-85e3-b369bb9bc253" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_bd843375-5a81-4a9a-a931-e061c3241ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="bdtx-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_edfd28fb-e872-4741-8b55-505e764eefd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18786848-c6ff-4d64-a0a0-1a167eaff66e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_edfd28fb-e872-4741-8b55-505e764eefd0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18786848-c6ff-4d64-a0a0-1a167eaff66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be886d69-9d6b-4961-845e-5ecfa01bbd00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18786848-c6ff-4d64-a0a0-1a167eaff66e" xlink:to="loc_us-gaap_NetIncomeLoss_be886d69-9d6b-4961-845e-5ecfa01bbd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0f99022e-e557-47f0-ab7f-435f73218250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18786848-c6ff-4d64-a0a0-1a167eaff66e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0f99022e-e557-47f0-ab7f-435f73218250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0e6b8e2f-6cf9-4902-a318-2d5a5d9a959f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0f99022e-e557-47f0-ab7f-435f73218250" xlink:to="loc_us-gaap_ShareBasedCompensation_0e6b8e2f-6cf9-4902-a318-2d5a5d9a959f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_dda9e48d-a2dd-49fd-bddf-5bbfffd98f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0f99022e-e557-47f0-ab7f-435f73218250" xlink:to="loc_us-gaap_Depreciation_dda9e48d-a2dd-49fd-bddf-5bbfffd98f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_391a427a-8ee9-4796-b7db-bf8e8cc90199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0f99022e-e557-47f0-ab7f-435f73218250" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_391a427a-8ee9-4796-b7db-bf8e8cc90199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_RentExpense_c040ae46-a3c7-4215-8cd6-165bc631536b" xlink:href="bdtx-20230331.xsd#bdtx_RentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0f99022e-e557-47f0-ab7f-435f73218250" xlink:to="loc_bdtx_RentExpense_c040ae46-a3c7-4215-8cd6-165bc631536b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e8d73044-d93f-4a01-ae36-d6ddacc394f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0f99022e-e557-47f0-ab7f-435f73218250" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e8d73044-d93f-4a01-ae36-d6ddacc394f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a705b9bf-3984-4301-8d0a-1fdb0adba77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0f99022e-e557-47f0-ab7f-435f73218250" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a705b9bf-3984-4301-8d0a-1fdb0adba77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b148dab3-addc-4392-a49a-a5cb510e305b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a705b9bf-3984-4301-8d0a-1fdb0adba77d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b148dab3-addc-4392-a49a-a5cb510e305b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7d4a0496-c088-45a3-b731-ad43b513a997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a705b9bf-3984-4301-8d0a-1fdb0adba77d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7d4a0496-c088-45a3-b731-ad43b513a997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_fd7590b9-00c6-4bc4-9fc3-820f580ef7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a705b9bf-3984-4301-8d0a-1fdb0adba77d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_fd7590b9-00c6-4bc4-9fc3-820f580ef7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_21438e2e-139b-4796-827c-6a17e02c2a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a705b9bf-3984-4301-8d0a-1fdb0adba77d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_21438e2e-139b-4796-827c-6a17e02c2a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_59e1a5bf-2961-4cfd-9398-5c6453448bb8" xlink:href="bdtx-20230331.xsd#bdtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a705b9bf-3984-4301-8d0a-1fdb0adba77d" xlink:to="loc_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities_59e1a5bf-2961-4cfd-9398-5c6453448bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97445df8-949a-4359-b074-60d58e188e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_18786848-c6ff-4d64-a0a0-1a167eaff66e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_97445df8-949a-4359-b074-60d58e188e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3e19588a-4fc6-4cbe-a73e-cf3fef6f58f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_edfd28fb-e872-4741-8b55-505e764eefd0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3e19588a-4fc6-4cbe-a73e-cf3fef6f58f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_56c4f93f-cbb0-4e60-baf7-5b460074ccf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3e19588a-4fc6-4cbe-a73e-cf3fef6f58f0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_56c4f93f-cbb0-4e60-baf7-5b460074ccf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_53037c53-7e7f-451c-8670-4eaf1a783996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3e19588a-4fc6-4cbe-a73e-cf3fef6f58f0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_53037c53-7e7f-451c-8670-4eaf1a783996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_f6c517e9-53e9-4dfa-9e87-c83ba030936b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3e19588a-4fc6-4cbe-a73e-cf3fef6f58f0" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_f6c517e9-53e9-4dfa-9e87-c83ba030936b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_303ebfbb-f5cf-4cb0-984e-333ff661c328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3e19588a-4fc6-4cbe-a73e-cf3fef6f58f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_303ebfbb-f5cf-4cb0-984e-333ff661c328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_311a1d49-714d-4c7b-bda4-f08e4f47b2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_edfd28fb-e872-4741-8b55-505e764eefd0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_311a1d49-714d-4c7b-bda4-f08e4f47b2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_89f4f06a-73f1-411a-b26d-6e68e716d49d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_311a1d49-714d-4c7b-bda4-f08e4f47b2c7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_89f4f06a-73f1-411a-b26d-6e68e716d49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc47f73c-10f0-4aee-aba0-11d6a822fa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_311a1d49-714d-4c7b-bda4-f08e4f47b2c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc47f73c-10f0-4aee-aba0-11d6a822fa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a9e0e601-fff4-4dc0-8656-2b14f7634e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_edfd28fb-e872-4741-8b55-505e764eefd0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a9e0e601-fff4-4dc0-8656-2b14f7634e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a27c5931-1390-4864-bcfb-76c2df377d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_edfd28fb-e872-4741-8b55-505e764eefd0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a27c5931-1390-4864-bcfb-76c2df377d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a320578-39ea-4319-a0c1-0f97fff83731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_edfd28fb-e872-4741-8b55-505e764eefd0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a320578-39ea-4319-a0c1-0f97fff83731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ada96030-d857-44a2-b838-d1140ea19d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_edfd28fb-e872-4741-8b55-505e764eefd0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ada96030-d857-44a2-b838-d1140ea19d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_847d940c-fa66-441a-b56c-b6e97fcef9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ada96030-d857-44a2-b838-d1140ea19d02" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_847d940c-fa66-441a-b56c-b6e97fcef9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_b3f1bd20-940b-4205-acfd-2ac389e36f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ada96030-d857-44a2-b838-d1140ea19d02" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_b3f1bd20-940b-4205-acfd-2ac389e36f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08408345-3be2-4374-ae44-3f896f5cc263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ada96030-d857-44a2-b838-d1140ea19d02" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08408345-3be2-4374-ae44-3f896f5cc263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0c46d51e-0d5a-412b-b2d4-a92a0d8ec63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_edfd28fb-e872-4741-8b55-505e764eefd0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0c46d51e-0d5a-412b-b2d4-a92a0d8ec63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets_5d07c98e-e63b-4285-ae98-c48616007b47" xlink:href="bdtx-20230331.xsd#bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0c46d51e-0d5a-412b-b2d4-a92a0d8ec63f" xlink:to="loc_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets_5d07c98e-e63b-4285-ae98-c48616007b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_849eb7cb-f7a9-4f1f-92ba-272872b33793" xlink:href="bdtx-20230331.xsd#bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0c46d51e-0d5a-412b-b2d4-a92a0d8ec63f" xlink:to="loc_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_849eb7cb-f7a9-4f1f-92ba-272872b33793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="bdtx-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_722c287e-337e-480b-83d9-f3eabd5fcf54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e56a4cd9-930b-4cc9-96cb-7b7638bb1b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_722c287e-337e-480b-83d9-f3eabd5fcf54" xlink:to="loc_us-gaap_StatementTable_e56a4cd9-930b-4cc9-96cb-7b7638bb1b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_92853f90-a79a-4ab5-9ba0-c4d3fb038a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e56a4cd9-930b-4cc9-96cb-7b7638bb1b7d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_92853f90-a79a-4ab5-9ba0-c4d3fb038a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_680aff93-0cb5-45e6-b6b3-4654fb2b967c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_92853f90-a79a-4ab5-9ba0-c4d3fb038a6c" xlink:to="loc_us-gaap_EquityComponentDomain_680aff93-0cb5-45e6-b6b3-4654fb2b967c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_703d121e-3e34-498f-a918-5cd28abd3cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_680aff93-0cb5-45e6-b6b3-4654fb2b967c" xlink:to="loc_us-gaap_CommonStockMember_703d121e-3e34-498f-a918-5cd28abd3cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_07779337-eb66-4f10-a6b5-c47a925e1e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_680aff93-0cb5-45e6-b6b3-4654fb2b967c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_07779337-eb66-4f10-a6b5-c47a925e1e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_17b46fc0-1f58-49a2-af0d-ea22b7d5e1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_680aff93-0cb5-45e6-b6b3-4654fb2b967c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_17b46fc0-1f58-49a2-af0d-ea22b7d5e1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_82aa60e0-6949-4a5d-9a8f-13681b145727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_680aff93-0cb5-45e6-b6b3-4654fb2b967c" xlink:to="loc_us-gaap_RetainedEarningsMember_82aa60e0-6949-4a5d-9a8f-13681b145727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6a91fb8f-51be-4d71-a3c1-482fe85aa59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e56a4cd9-930b-4cc9-96cb-7b7638bb1b7d" xlink:to="loc_us-gaap_StatementLineItems_6a91fb8f-51be-4d71-a3c1-482fe85aa59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a91fb8f-51be-4d71-a3c1-482fe85aa59e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_17835585-4e10-447b-9022-78ba143d802b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_17835585-4e10-447b-9022-78ba143d802b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2137cee7-0711-47c0-9d8f-1b4db9173e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockholdersEquity_2137cee7-0711-47c0-9d8f-1b4db9173e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14d42650-f36d-4d99-aa5f-287f746ea0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14d42650-f36d-4d99-aa5f-287f746ea0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f5b0b0ed-72d4-4ce4-b8d7-bdce4a80572d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f5b0b0ed-72d4-4ce4-b8d7-bdce4a80572d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2f8e2c11-bdfd-451d-b5c8-2604ab8ef329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2f8e2c11-bdfd-451d-b5c8-2604ab8ef329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_eceaa45c-18fd-4696-8841-e546c6fc8440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_eceaa45c-18fd-4696-8841-e546c6fc8440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_913d0151-7dfb-40fb-b635-653ac2e5cfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_913d0151-7dfb-40fb-b635-653ac2e5cfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4308e849-f7e3-49b4-9d1c-1dc64799e9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4308e849-f7e3-49b4-9d1c-1dc64799e9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ccf241be-05ed-4ba9-97fd-55be5d303be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ccf241be-05ed-4ba9-97fd-55be5d303be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1ea4b69e-4898-4de0-bc37-3216d561f62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1ea4b69e-4898-4de0-bc37-3216d561f62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_27fbab02-901d-42bc-aa85-d920a779d323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_27fbab02-901d-42bc-aa85-d920a779d323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_003187c2-9208-43b0-9133-ab0b4bc99834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_NetIncomeLoss_003187c2-9208-43b0-9133-ab0b4bc99834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a14f4a44-f46e-408f-811d-2edf0ea1cb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a14f4a44-f46e-408f-811d-2edf0ea1cb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5c3f3027-5edd-4c60-93e8-d9da5ab544f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9da2a8ab-ff2c-4975-b9d1-cac2c7873475" xlink:to="loc_us-gaap_StockholdersEquity_5c3f3027-5edd-4c60-93e8-d9da5ab544f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" xlink:type="simple" xlink:href="bdtx-20230331.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a2d0aaed-3840-44b8-9ec6-ca00c0c59002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_928333c7-18fe-4bac-b838-38fcdb8ace34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a2d0aaed-3840-44b8-9ec6-ca00c0c59002" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_928333c7-18fe-4bac-b838-38fcdb8ace34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bdtx-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ba49a977-79cc-4f11-8e19-0b8512daf68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_37d970f2-d3a8-4376-8d7c-7f9390fcab65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba49a977-79cc-4f11-8e19-0b8512daf68a" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_37d970f2-d3a8-4376-8d7c-7f9390fcab65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="bdtx-20230331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1c74caa9-a01c-4a76-b77f-9fa3df8250c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_80660dc2-270d-491e-8634-03a3e47b4557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1c74caa9-a01c-4a76-b77f-9fa3df8250c9" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_80660dc2-270d-491e-8634-03a3e47b4557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" xlink:type="simple" xlink:href="bdtx-20230331.xsd#INVESTMENTS"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_db5a14ee-3c30-47c0-9db0-8632c72c8a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_41b411f0-2c5f-4085-b98e-16e3701fae3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_db5a14ee-3c30-47c0-9db0-8632c72c8a15" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_41b411f0-2c5f-4085-b98e-16e3701fae3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="bdtx-20230331.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5b36aa55-288a-4fd6-b2af-76cfcc13bf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d487f4f0-c4cf-4f2a-95d6-ca7a54d88ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5b36aa55-288a-4fd6-b2af-76cfcc13bf32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d487f4f0-c4cf-4f2a-95d6-ca7a54d88ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT" xlink:type="simple" xlink:href="bdtx-20230331.xsd#EQUITYMETHODINVESTMENT"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_21684ec3-af19-4642-8c51-44e6cb8404d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_bc74ae85-1b0f-40b9-b311-878bc3924baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_21684ec3-af19-4642-8c51-44e6cb8404d9" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_bc74ae85-1b0f-40b9-b311-878bc3924baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bdtx-20230331.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_207e1a98-34f0-417f-bafd-3389fdc43735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_f47bdcfb-9d3f-4874-80f8-df0940ce6e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_207e1a98-34f0-417f-bafd-3389fdc43735" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_f47bdcfb-9d3f-4874-80f8-df0940ce6e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="bdtx-20230331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5021c885-0253-41ef-bffd-ae301b502352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_61f4efe4-c017-403e-8c9c-bbc279bef1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5021c885-0253-41ef-bffd-ae301b502352" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_61f4efe4-c017-403e-8c9c-bbc279bef1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="bdtx-20230331.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6cdbd19c-bb53-4c69-9f93-7769beea1836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_02316f5b-7a08-44d9-b17d-b8babd0a8188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6cdbd19c-bb53-4c69-9f93-7769beea1836" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_02316f5b-7a08-44d9-b17d-b8babd0a8188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASES" xlink:type="simple" xlink:href="bdtx-20230331.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_042cbdda-1a88-42c5-a8b0-61dae482175c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_6d23eca1-2587-40a0-8f11-920afb5d9149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_042cbdda-1a88-42c5-a8b0-61dae482175c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_6d23eca1-2587-40a0-8f11-920afb5d9149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bdtx-20230331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cf0b73fd-654e-41d5-aa69-7b088130cc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3183fb67-f2ff-4c0a-a8c5-bc50c33e4fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cf0b73fd-654e-41d5-aa69-7b088130cc93" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3183fb67-f2ff-4c0a-a8c5-bc50c33e4fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" xlink:type="simple" xlink:href="bdtx-20230331.xsd#BENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0c18f9ed-9acf-4f86-8b9e-836484970ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_18d4761a-91af-45d3-aada-a537f0e3f696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0c18f9ed-9acf-4f86-8b9e-836484970ab5" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_18d4761a-91af-45d3-aada-a537f0e3f696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bdtx-20230331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9e6f0f71-8e90-4226-a6b5-6c5b6411ef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_90d81007-9d16-4214-8a99-25cdfa03813a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f0f71-8e90-4226-a6b5-6c5b6411ef3f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_90d81007-9d16-4214-8a99-25cdfa03813a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0d81ffdb-9f87-4dca-a883-e4e297332ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f0f71-8e90-4226-a6b5-6c5b6411ef3f" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_0d81ffdb-9f87-4dca-a883-e4e297332ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a690d378-48bf-4143-bee7-e820082bd9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f0f71-8e90-4226-a6b5-6c5b6411ef3f" xlink:to="loc_us-gaap_UseOfEstimates_a690d378-48bf-4143-bee7-e820082bd9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="bdtx-20230331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ce3aecde-5088-4a38-93c0-6bba9a9ffb76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0857c80f-c5a9-4338-8f40-7442cf409c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ce3aecde-5088-4a38-93c0-6bba9a9ffb76" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0857c80f-c5a9-4338-8f40-7442cf409c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" xlink:type="simple" xlink:href="bdtx-20230331.xsd#INVESTMENTSTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a723fb15-1f92-4ec9-bb5b-727307b629ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_171b9526-2f6b-4a43-9e70-bd3109ea3c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a723fb15-1f92-4ec9-bb5b-727307b629ec" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_171b9526-2f6b-4a43-9e70-bd3109ea3c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="bdtx-20230331.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c594c788-e025-4aa0-8b6f-511d0cb83e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_eb974490-4ff5-4964-a831-e5afcb7bdfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c594c788-e025-4aa0-8b6f-511d0cb83e65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_eb974490-4ff5-4964-a831-e5afcb7bdfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bdtx-20230331.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_73bec383-cb74-4f63-8e0b-bbd419084fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_eadc7618-46ad-4dd1-9577-3db37f2a44b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_73bec383-cb74-4f63-8e0b-bbd419084fd0" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_eadc7618-46ad-4dd1-9577-3db37f2a44b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bdtx-20230331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38bdd012-f398-45e1-945f-30c3a2310555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ce32187f-fcd2-4b9a-b8b5-195f54c5a697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38bdd012-f398-45e1-945f-30c3a2310555" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ce32187f-fcd2-4b9a-b8b5-195f54c5a697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d91fb2be-47d3-41fb-8089-c6a172b752c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38bdd012-f398-45e1-945f-30c3a2310555" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d91fb2be-47d3-41fb-8089-c6a172b752c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_3ce9699f-42c4-461b-b0a3-3e7260f8ddd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38bdd012-f398-45e1-945f-30c3a2310555" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_3ce9699f-42c4-461b-b0a3-3e7260f8ddd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="bdtx-20230331.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_faab253e-c895-4463-a236-aad9f222e44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e78a3dd5-97a3-4a81-9dd2-5b2277331aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_faab253e-c895-4463-a236-aad9f222e44b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e78a3dd5-97a3-4a81-9dd2-5b2277331aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6b1aa425-3309-4ca5-9370-83312fc086d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_faab253e-c895-4463-a236-aad9f222e44b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6b1aa425-3309-4ca5-9370-83312fc086d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESTables" xlink:type="simple" xlink:href="bdtx-20230331.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_784040e7-8eff-458f-b0fa-8ddaa543c0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_ffd2caca-d751-478c-98fd-78017730869c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_784040e7-8eff-458f-b0fa-8ddaa543c0c4" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_ffd2caca-d751-478c-98fd-78017730869c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_51c022cf-4b19-430a-9ded-003af393adb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_784040e7-8eff-458f-b0fa-8ddaa543c0c4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_51c022cf-4b19-430a-9ded-003af393adb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b01aed27-629d-4dd7-bf0a-3444c25cd769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bb88e558-dfb0-492a-924a-321e7ab2c377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b01aed27-629d-4dd7-bf0a-3444c25cd769" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bb88e558-dfb0-492a-924a-321e7ab2c377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f1518ddd-75d4-422a-95cd-ff2dbba2aee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bb88e558-dfb0-492a-924a-321e7ab2c377" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f1518ddd-75d4-422a-95cd-ff2dbba2aee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85d31b02-9d9f-4694-8d81-9de4762aa39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f1518ddd-75d4-422a-95cd-ff2dbba2aee7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85d31b02-9d9f-4694-8d81-9de4762aa39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OpenMarketSaleMember_abd62ed1-3a34-472e-a49c-41fd6c3952b3" xlink:href="bdtx-20230331.xsd#bdtx_OpenMarketSaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85d31b02-9d9f-4694-8d81-9de4762aa39c" xlink:to="loc_bdtx_OpenMarketSaleMember_abd62ed1-3a34-472e-a49c-41fd6c3952b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShelfRegistrationStatementMember_5cfc31e0-a3c1-4343-af14-2cd3c2f7b485" xlink:href="bdtx-20230331.xsd#bdtx_ShelfRegistrationStatementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85d31b02-9d9f-4694-8d81-9de4762aa39c" xlink:to="loc_bdtx_ShelfRegistrationStatementMember_5cfc31e0-a3c1-4343-af14-2cd3c2f7b485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_e8232af1-d762-4da7-bd87-0cbffbaf9a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bb88e558-dfb0-492a-924a-321e7ab2c377" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_e8232af1-d762-4da7-bd87-0cbffbaf9a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_SaleOfStockAuthorizedConsideration_8d0a4747-9256-4bd0-b348-577815c18354" xlink:href="bdtx-20230331.xsd#bdtx_SaleOfStockAuthorizedConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e8232af1-d762-4da7-bd87-0cbffbaf9a13" xlink:to="loc_bdtx_SaleOfStockAuthorizedConsideration_8d0a4747-9256-4bd0-b348-577815c18354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_70782394-5f4f-455c-a730-f09e22200055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d35cc97-3389-4504-892f-87172c3eeb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_70782394-5f4f-455c-a730-f09e22200055" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d35cc97-3389-4504-892f-87172c3eeb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ac4f7c3d-f2f4-451b-adb1-868649d44c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d35cc97-3389-4504-892f-87172c3eeb5e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ac4f7c3d-f2f4-451b-adb1-868649d44c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_582baf1d-9896-4ab6-8d3a-8e3db34a2cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ac4f7c3d-f2f4-451b-adb1-868649d44c07" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_582baf1d-9896-4ab6-8d3a-8e3db34a2cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_54234d05-edb8-4697-9deb-eea5313aa62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_582baf1d-9896-4ab6-8d3a-8e3db34a2cb3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_54234d05-edb8-4697-9deb-eea5313aa62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e16d70b0-848b-46ba-9efe-170b3c892c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d35cc97-3389-4504-892f-87172c3eeb5e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e16d70b0-848b-46ba-9efe-170b3c892c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eacf4430-c9dd-4998-9004-478b6181f860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e16d70b0-848b-46ba-9efe-170b3c892c7e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eacf4430-c9dd-4998-9004-478b6181f860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0aa80e1a-ab93-45bf-b570-f389600b11f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eacf4430-c9dd-4998-9004-478b6181f860" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0aa80e1a-ab93-45bf-b570-f389600b11f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5300c058-eccc-40c0-93f4-aeb87e055171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eacf4430-c9dd-4998-9004-478b6181f860" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5300c058-eccc-40c0-93f4-aeb87e055171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9bdaac17-b4a9-48e8-b413-35de4aaacf61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eacf4430-c9dd-4998-9004-478b6181f860" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9bdaac17-b4a9-48e8-b413-35de4aaacf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bde21c81-5d8b-4d3c-8048-a8dc8f543174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d35cc97-3389-4504-892f-87172c3eeb5e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bde21c81-5d8b-4d3c-8048-a8dc8f543174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e322519b-e767-4e07-a127-b71b3343f397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bde21c81-5d8b-4d3c-8048-a8dc8f543174" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e322519b-e767-4e07-a127-b71b3343f397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5de69cfc-3a41-4a25-b712-3e9c79740533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e322519b-e767-4e07-a127-b71b3343f397" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5de69cfc-3a41-4a25-b712-3e9c79740533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_65edf229-5a7e-437d-9c53-9add4bf41bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e322519b-e767-4e07-a127-b71b3343f397" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_65edf229-5a7e-437d-9c53-9add4bf41bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_02cdfc5c-6d31-40ee-b563-01974981ed3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e322519b-e767-4e07-a127-b71b3343f397" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_02cdfc5c-6d31-40ee-b563-01974981ed3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e6429e8d-44ce-40c8-b8af-048601035cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e322519b-e767-4e07-a127-b71b3343f397" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e6429e8d-44ce-40c8-b8af-048601035cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dcf14d3-f204-4c06-b7c4-3166e1a900f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6d35cc97-3389-4504-892f-87172c3eeb5e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dcf14d3-f204-4c06-b7c4-3166e1a900f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_978efb81-7e0d-485a-8b3d-93c7b42c159e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dcf14d3-f204-4c06-b7c4-3166e1a900f3" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_978efb81-7e0d-485a-8b3d-93c7b42c159e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a3f59674-8471-448c-8a54-d2b8357a16bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_978efb81-7e0d-485a-8b3d-93c7b42c159e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a3f59674-8471-448c-8a54-d2b8357a16bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_719395bd-7ac8-4147-b590-9f997fd4f7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_978efb81-7e0d-485a-8b3d-93c7b42c159e" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_719395bd-7ac8-4147-b590-9f997fd4f7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_44114d5b-2383-4d94-86c6-80e630ad165b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_978efb81-7e0d-485a-8b3d-93c7b42c159e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_44114d5b-2383-4d94-86c6-80e630ad165b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#INVESTMENTSScheduleofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1a16204f-3d2f-4aa4-b7ac-ae24be7bd1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6074b93f-f5f2-4eae-afe8-d5b2c9e2032e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1a16204f-3d2f-4aa4-b7ac-ae24be7bd1ae" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6074b93f-f5f2-4eae-afe8-d5b2c9e2032e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d2d4d047-1fe7-466d-b4c9-a8a33890876c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6074b93f-f5f2-4eae-afe8-d5b2c9e2032e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d2d4d047-1fe7-466d-b4c9-a8a33890876c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97752eb5-3591-41e0-9c3a-99b2eec34c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d2d4d047-1fe7-466d-b4c9-a8a33890876c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97752eb5-3591-41e0-9c3a-99b2eec34c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_01a04f1f-f7e0-42fc-8c24-2a60512c7c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97752eb5-3591-41e0-9c3a-99b2eec34c84" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_01a04f1f-f7e0-42fc-8c24-2a60512c7c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_5a894b32-9716-4c1f-8ce0-40731fdb6329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97752eb5-3591-41e0-9c3a-99b2eec34c84" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_5a894b32-9716-4c1f-8ce0-40731fdb6329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_869de67d-dcc6-436c-96d5-a5ac2b7ae7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97752eb5-3591-41e0-9c3a-99b2eec34c84" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_869de67d-dcc6-436c-96d5-a5ac2b7ae7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0439e9aa-6ffa-49eb-bd0d-c589cf38baf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_6074b93f-f5f2-4eae-afe8-d5b2c9e2032e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0439e9aa-6ffa-49eb-bd0d-c589cf38baf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7e166b88-1469-41ba-8290-84f8c22419f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0439e9aa-6ffa-49eb-bd0d-c589cf38baf3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7e166b88-1469-41ba-8290-84f8c22419f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3b080381-7cea-4439-b9b4-d33f2fe78b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0439e9aa-6ffa-49eb-bd0d-c589cf38baf3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3b080381-7cea-4439-b9b4-d33f2fe78b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b17c0ff6-135a-4b3e-87d8-0bbaaa4ee628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0439e9aa-6ffa-49eb-bd0d-c589cf38baf3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b17c0ff6-135a-4b3e-87d8-0bbaaa4ee628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_052e40db-a897-4c2a-9019-2c42150ede8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0439e9aa-6ffa-49eb-bd0d-c589cf38baf3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_052e40db-a897-4c2a-9019-2c42150ede8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#INVESTMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f240cf80-49c0-47d4-bef9-7afbd39270e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_750f0ced-7958-4063-aaa4-45bd1fc8abdb" xlink:href="bdtx-20230331.xsd#bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f240cf80-49c0-47d4-bef9-7afbd39270e6" xlink:to="loc_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_750f0ced-7958-4063-aaa4-45bd1fc8abdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_6f9a0083-b9ec-41c7-976e-8388568cfeee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f240cf80-49c0-47d4-bef9-7afbd39270e6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_6f9a0083-b9ec-41c7-976e-8388568cfeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#PROPERTYANDEQUIPMENTDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_00658cb0-0d72-42cc-bc35-4e3d82c53a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a13c4719-cf39-452b-835e-bef98eeb06d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_00658cb0-0d72-42cc-bc35-4e3d82c53a7d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a13c4719-cf39-452b-835e-bef98eeb06d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd67295-8dd3-49b0-881d-1c027d2d522d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a13c4719-cf39-452b-835e-bef98eeb06d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd67295-8dd3-49b0-881d-1c027d2d522d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8b32fa3-1be6-48f8-b4d6-db01cb7a4b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cd67295-8dd3-49b0-881d-1c027d2d522d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8b32fa3-1be6-48f8-b4d6-db01cb7a4b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_83d45c4d-730d-4775-a2a3-a2e2c0fa5cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8b32fa3-1be6-48f8-b4d6-db01cb7a4b59" xlink:to="loc_us-gaap_EquipmentMember_83d45c4d-730d-4775-a2a3-a2e2c0fa5cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f504f4de-80cb-4871-9a89-5dd7c39be333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8b32fa3-1be6-48f8-b4d6-db01cb7a4b59" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f504f4de-80cb-4871-9a89-5dd7c39be333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_fff7ee17-b99a-4241-840f-6523ccf383d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8b32fa3-1be6-48f8-b4d6-db01cb7a4b59" xlink:to="loc_us-gaap_OfficeEquipmentMember_fff7ee17-b99a-4241-840f-6523ccf383d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6284b0fd-54e2-4f7e-9ca5-510fa29faba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8b32fa3-1be6-48f8-b4d6-db01cb7a4b59" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6284b0fd-54e2-4f7e-9ca5-510fa29faba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f840c3b1-d381-43a3-8e97-638e6617cd70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a13c4719-cf39-452b-835e-bef98eeb06d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f840c3b1-d381-43a3-8e97-638e6617cd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_aa7995fb-71f5-4593-a42e-ca9d90df3a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f840c3b1-d381-43a3-8e97-638e6617cd70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_aa7995fb-71f5-4593-a42e-ca9d90df3a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8da45c93-295d-45a7-ba97-9493ec36c780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f840c3b1-d381-43a3-8e97-638e6617cd70" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8da45c93-295d-45a7-ba97-9493ec36c780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_39a0cd56-7802-4cb0-81ce-027d5431df35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f840c3b1-d381-43a3-8e97-638e6617cd70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_39a0cd56-7802-4cb0-81ce-027d5431df35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_021195f9-bb24-4ce7-bf26-c0bec085bc23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f840c3b1-d381-43a3-8e97-638e6617cd70" xlink:to="loc_us-gaap_Depreciation_021195f9-bb24-4ce7-bf26-c0bec085bc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#EQUITYMETHODINVESTMENTDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e4971a65-87d9-47fd-9122-d7d7ecaa1db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_db7ed5d7-ccde-4566-8a2c-fcce5fde9b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e4971a65-87d9-47fd-9122-d7d7ecaa1db7" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_db7ed5d7-ccde-4566-8a2c-fcce5fde9b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fdc16b3-3b0f-4ffc-9f7c-6f05e6cc3de2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_db7ed5d7-ccde-4566-8a2c-fcce5fde9b06" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fdc16b3-3b0f-4ffc-9f7c-6f05e6cc3de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_39837529-52bc-4d2b-ae8a-14bf8e61b29d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7fdc16b3-3b0f-4ffc-9f7c-6f05e6cc3de2" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_39837529-52bc-4d2b-ae8a-14bf8e61b29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LaunchpadTherapeuticsIncMember_5cfeb9b6-cbcb-4e7c-b630-d08aaa12b4c2" xlink:href="bdtx-20230331.xsd#bdtx_LaunchpadTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_39837529-52bc-4d2b-ae8a-14bf8e61b29d" xlink:to="loc_bdtx_LaunchpadTherapeuticsIncMember_5cfeb9b6-cbcb-4e7c-b630-d08aaa12b4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_db7ed5d7-ccde-4566-8a2c-fcce5fde9b06" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange_cc42f3b1-9d64-4138-9083-95a5cf0261bf" xlink:href="bdtx-20230331.xsd#bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange_cc42f3b1-9d64-4138-9083-95a5cf0261bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d5178882-e547-42dd-bb0c-f16cc8565f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d5178882-e547-42dd-bb0c-f16cc8565f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_54d3b25f-afd5-40eb-89b3-3eb71641c249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_us-gaap_EquityMethodInvestments_54d3b25f-afd5-40eb-89b3-3eb71641c249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_4601c0b8-3f60-41c7-9750-dde685335134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_4601c0b8-3f60-41c7-9750-dde685335134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_04d1f8f2-8a04-4c9f-add5-5fba31f19171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_04d1f8f2-8a04-4c9f-add5-5fba31f19171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_313f42ef-98ee-41ba-814e-6507d7b8e596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_fa82d0ce-33ab-4343-83a9-c7726fbc44d6" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_313f42ef-98ee-41ba-814e-6507d7b8e596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2b7e2e4d-c798-4d02-92d4-260056ece8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_AccruedContractResearchServiceFeesCurrent_4f627040-82fd-4acc-b6ba-6252f20cd046" xlink:href="bdtx-20230331.xsd#bdtx_AccruedContractResearchServiceFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2b7e2e4d-c798-4d02-92d4-260056ece8cb" xlink:to="loc_bdtx_AccruedContractResearchServiceFeesCurrent_4f627040-82fd-4acc-b6ba-6252f20cd046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_02188681-64b6-4ea4-8847-785baef69f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2b7e2e4d-c798-4d02-92d4-260056ece8cb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_02188681-64b6-4ea4-8847-785baef69f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_dcef2b72-0f66-4426-9cf8-7fc88937e526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2b7e2e4d-c798-4d02-92d4-260056ece8cb" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_dcef2b72-0f66-4426-9cf8-7fc88937e526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2b7554f2-d62d-4339-9d55-71f722a84328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2b7e2e4d-c798-4d02-92d4-260056ece8cb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2b7554f2-d62d-4339-9d55-71f722a84328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ed923f00-5fc5-4cac-b485-d6b21a8d0545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2b7e2e4d-c798-4d02-92d4-260056ece8cb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ed923f00-5fc5-4cac-b485-d6b21a8d0545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_16dfa774-fcf6-4178-a89d-a93637a16776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2b7e2e4d-c798-4d02-92d4-260056ece8cb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_16dfa774-fcf6-4178-a89d-a93637a16776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9de97793-ff5d-4a3a-8691-073e09e5f2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7a0c542-2519-4956-8f95-c1019e682292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9de97793-ff5d-4a3a-8691-073e09e5f2b4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7a0c542-2519-4956-8f95-c1019e682292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_26157ada-416a-4f60-82a4-b1a984ff0d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7a0c542-2519-4956-8f95-c1019e682292" xlink:to="loc_us-gaap_AwardTypeAxis_26157ada-416a-4f60-82a4-b1a984ff0d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_26157ada-416a-4f60-82a4-b1a984ff0d43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_66518fda-4770-4c40-892a-119d08160e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:to="loc_us-gaap_EmployeeStockOptionMember_66518fda-4770-4c40-892a-119d08160e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5f2c5385-0f65-4906-8622-0483867cc7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5f2c5385-0f65-4906-8622-0483867cc7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_PerformanceRestrictedStockUnitsMember_c7f2ee10-7b59-470e-b845-d4b6c71694f5" xlink:href="bdtx-20230331.xsd#bdtx_PerformanceRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:to="loc_bdtx_PerformanceRestrictedStockUnitsMember_c7f2ee10-7b59-470e-b845-d4b6c71694f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9c7f2b76-52f5-4463-a9c9-68c07eba3b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:to="loc_us-gaap_EmployeeStockMember_9c7f2b76-52f5-4463-a9c9-68c07eba3b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a79015fa-9908-4c8d-9389-5c039e1c13bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee0f68cd-6a6b-4f44-846d-ec8c5065de27" xlink:to="loc_us-gaap_PerformanceSharesMember_a79015fa-9908-4c8d-9389-5c039e1c13bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0aa4cb42-8be0-49c8-8c44-501aae9dc761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7a0c542-2519-4956-8f95-c1019e682292" xlink:to="loc_us-gaap_PlanNameAxis_0aa4cb42-8be0-49c8-8c44-501aae9dc761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b02c8d2e-07f3-45af-b924-5048e9888ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0aa4cb42-8be0-49c8-8c44-501aae9dc761" xlink:to="loc_us-gaap_PlanNameDomain_b02c8d2e-07f3-45af-b924-5048e9888ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020StockOptionPlanMember_1ceab142-20c7-4e1c-86ab-a1e923c25a4f" xlink:href="bdtx-20230331.xsd#bdtx_A2020StockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b02c8d2e-07f3-45af-b924-5048e9888ead" xlink:to="loc_bdtx_A2020StockOptionPlanMember_1ceab142-20c7-4e1c-86ab-a1e923c25a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_A2020EmployeeStockPurchasePlanMember_f27ff347-9e37-457a-853a-14360d31227c" xlink:href="bdtx-20230331.xsd#bdtx_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b02c8d2e-07f3-45af-b924-5048e9888ead" xlink:to="loc_bdtx_A2020EmployeeStockPurchasePlanMember_f27ff347-9e37-457a-853a-14360d31227c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7a0c542-2519-4956-8f95-c1019e682292" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_dac6b0a0-0db1-46f4-804d-de62da048949" xlink:href="bdtx-20230331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding_dac6b0a0-0db1-46f4-804d-de62da048949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d39af87f-1552-419b-aaf7-733d00609949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d39af87f-1552-419b-aaf7-733d00609949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_edca93a2-59f4-4d60-a917-8db4b5fbd369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_edca93a2-59f4-4d60-a917-8db4b5fbd369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3e89e371-2c34-45b0-b74d-d52fcbe15398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3e89e371-2c34-45b0-b74d-d52fcbe15398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5e8cf239-25df-41ed-9174-75fe6ce6bb91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5e8cf239-25df-41ed-9174-75fe6ce6bb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_28f74393-dc70-4569-a8da-b844951d3a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_28f74393-dc70-4569-a8da-b844951d3a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dad6de68-10df-4881-b117-4aa7a329d240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_dad6de68-10df-4881-b117-4aa7a329d240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5633b1f9-55e0-4d28-b08b-e9212b916998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5633b1f9-55e0-4d28-b08b-e9212b916998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b71b1f8-6398-422c-839e-914e7bb8c5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9b71b1f8-6398-422c-839e-914e7bb8c5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cd0554d0-f8d1-46bb-bd4f-a067677bd25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cd0554d0-f8d1-46bb-bd4f-a067677bd25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee87c3bf-f482-4622-951c-505178e9d5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee87c3bf-f482-4622-951c-505178e9d5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1c1c00a6-2775-47e3-85fb-0ef972a8e29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1c1c00a6-2775-47e3-85fb-0ef972a8e29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_17115d0f-f2a6-487b-94e4-f2f87fe7f073" xlink:href="bdtx-20230331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_17115d0f-f2a6-487b-94e4-f2f87fe7f073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6a2aeb93-9373-441d-8cec-eb757dea443a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_6a2aeb93-9373-441d-8cec-eb757dea443a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cfd9c79b-4072-416c-8320-4e233915be95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_cfd9c79b-4072-416c-8320-4e233915be95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_e8ec8e72-c854-4ed3-b3cc-2f6462dcda5e" xlink:href="bdtx-20230331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bf414ec3-a71b-42d4-bacf-28b6c9c65d20" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_e8ec8e72-c854-4ed3-b3cc-2f6462dcda5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46cff317-17d6-44cc-a3db-f2898c3f8b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0065444c-8173-4178-b90c-eea5735abb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46cff317-17d6-44cc-a3db-f2898c3f8b3d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0065444c-8173-4178-b90c-eea5735abb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4e0a51ef-bd1a-487f-85e3-1b37ef28ced4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0065444c-8173-4178-b90c-eea5735abb1b" xlink:to="loc_us-gaap_AwardTypeAxis_4e0a51ef-bd1a-487f-85e3-1b37ef28ced4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db3dbf66-31b9-4a45-9055-538ef6cd5c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4e0a51ef-bd1a-487f-85e3-1b37ef28ced4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db3dbf66-31b9-4a45-9055-538ef6cd5c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f91eabe9-f55c-4428-ab57-0418881dc973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db3dbf66-31b9-4a45-9055-538ef6cd5c6e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f91eabe9-f55c-4428-ab57-0418881dc973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0402723b-ab79-4526-9f08-f299c5f007e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db3dbf66-31b9-4a45-9055-538ef6cd5c6e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0402723b-ab79-4526-9f08-f299c5f007e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OtherAwardTypeMember_9aaa192b-9aad-4306-8a52-15d913e0fa27" xlink:href="bdtx-20230331.xsd#bdtx_OtherAwardTypeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_db3dbf66-31b9-4a45-9055-538ef6cd5c6e" xlink:to="loc_bdtx_OtherAwardTypeMember_9aaa192b-9aad-4306-8a52-15d913e0fa27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_85f7ad8f-7f54-4afd-bbf4-9958ab717a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0065444c-8173-4178-b90c-eea5735abb1b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_85f7ad8f-7f54-4afd-bbf4-9958ab717a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_936b9323-02bd-4435-a57a-a922bf5100a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_85f7ad8f-7f54-4afd-bbf4-9958ab717a10" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_936b9323-02bd-4435-a57a-a922bf5100a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dd20d669-7e5a-445b-909a-1d0d99ee23a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_936b9323-02bd-4435-a57a-a922bf5100a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dd20d669-7e5a-445b-909a-1d0d99ee23a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9cdebb4a-2c93-4998-9a9b-0891a6111e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_936b9323-02bd-4435-a57a-a922bf5100a4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9cdebb4a-2c93-4998-9a9b-0891a6111e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b6ee330e-2962-4555-bba3-e7d91bf0630d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0065444c-8173-4178-b90c-eea5735abb1b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b6ee330e-2962-4555-bba3-e7d91bf0630d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_24630b88-2d22-4586-bbe5-c55c4739bf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b6ee330e-2962-4555-bba3-e7d91bf0630d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_24630b88-2d22-4586-bbe5-c55c4739bf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c204ae59-31f9-4221-a4b4-1f4448d359dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_18a6724e-33e2-4fd9-a48a-4aba1d254198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c204ae59-31f9-4221-a4b4-1f4448d359dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_18a6724e-33e2-4fd9-a48a-4aba1d254198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_719e65a1-e7d0-4824-b611-6cb8740e3406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_18a6724e-33e2-4fd9-a48a-4aba1d254198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_719e65a1-e7d0-4824-b611-6cb8740e3406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_28087bde-c84f-4142-ab8f-b4d4b9e7654d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_18a6724e-33e2-4fd9-a48a-4aba1d254198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_28087bde-c84f-4142-ab8f-b4d4b9e7654d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d313c7ee-b462-43fe-a259-aa259babb57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_18a6724e-33e2-4fd9-a48a-4aba1d254198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d313c7ee-b462-43fe-a259-aa259babb57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f3634f90-cf32-4a3e-9e4a-7bddadd94f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_18a6724e-33e2-4fd9-a48a-4aba1d254198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f3634f90-cf32-4a3e-9e4a-7bddadd94f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_41579e8f-53ed-439b-8604-791e52611e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_18a6724e-33e2-4fd9-a48a-4aba1d254198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_41579e8f-53ed-439b-8604-791e52611e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_27433aa9-9a89-4f64-93e1-517fa95989a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c204ae59-31f9-4221-a4b4-1f4448d359dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_27433aa9-9a89-4f64-93e1-517fa95989a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4b6805b6-f29b-4dff-b362-b9e8920fbe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c204ae59-31f9-4221-a4b4-1f4448d359dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4b6805b6-f29b-4dff-b362-b9e8920fbe2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a5d429d2-0030-4b0b-acd4-4af4f4f6f063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c204ae59-31f9-4221-a4b4-1f4448d359dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a5d429d2-0030-4b0b-acd4-4af4f4f6f063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_062ecb2b-cb77-4f5b-b92e-566bf35b42ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a5d429d2-0030-4b0b-acd4-4af4f4f6f063" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_062ecb2b-cb77-4f5b-b92e-566bf35b42ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4b57c62e-7921-416a-980c-fbb0ba73ef53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a5d429d2-0030-4b0b-acd4-4af4f4f6f063" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4b57c62e-7921-416a-980c-fbb0ba73ef53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0d2e16d8-0855-41fc-b9b8-cd8f86eec860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a5d429d2-0030-4b0b-acd4-4af4f4f6f063" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0d2e16d8-0855-41fc-b9b8-cd8f86eec860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_af92f0d5-56ed-4956-a22a-7cb11d8af6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a5d429d2-0030-4b0b-acd4-4af4f4f6f063" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_af92f0d5-56ed-4956-a22a-7cb11d8af6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a91cec2d-f245-429f-bc4e-a2b29f63e2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a5d429d2-0030-4b0b-acd4-4af4f4f6f063" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a91cec2d-f245-429f-bc4e-a2b29f63e2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_791ed25b-04c6-4b05-8330-62c7dc70c1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c204ae59-31f9-4221-a4b4-1f4448d359dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_791ed25b-04c6-4b05-8330-62c7dc70c1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_dfe5cb57-fdfd-492e-b973-11963fd5e6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c204ae59-31f9-4221-a4b4-1f4448d359dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_dfe5cb57-fdfd-492e-b973-11963fd5e6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_385d9d78-e3d4-4abb-a7dc-1aae906d11d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c204ae59-31f9-4221-a4b4-1f4448d359dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_385d9d78-e3d4-4abb-a7dc-1aae906d11d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_017e16bb-3d66-47da-a3d2-3d67be68fd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_385d9d78-e3d4-4abb-a7dc-1aae906d11d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_017e16bb-3d66-47da-a3d2-3d67be68fd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bd77e3de-0253-4cc5-99b5-84c79d21c1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_385d9d78-e3d4-4abb-a7dc-1aae906d11d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bd77e3de-0253-4cc5-99b5-84c79d21c1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_082e1ad7-52b5-4b11-b337-7ef36eb0a48e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_385d9d78-e3d4-4abb-a7dc-1aae906d11d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_082e1ad7-52b5-4b11-b337-7ef36eb0a48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e74cc9b7-146c-40f8-b4c1-cd15cef57628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_385d9d78-e3d4-4abb-a7dc-1aae906d11d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e74cc9b7-146c-40f8-b4c1-cd15cef57628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_05dc8c90-47d5-4b6f-8c2b-c88133d53d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_385d9d78-e3d4-4abb-a7dc-1aae906d11d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_05dc8c90-47d5-4b6f-8c2b-c88133d53d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8b0ed374-8d49-45dc-aee4-a34482e4006d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_385d9d78-e3d4-4abb-a7dc-1aae906d11d0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8b0ed374-8d49-45dc-aee4-a34482e4006d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a815c29-c2bc-4b00-8c7f-0ce46f13534b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fc30d8a-9a9d-4caa-aea4-ff72687a10cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a815c29-c2bc-4b00-8c7f-0ce46f13534b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fc30d8a-9a9d-4caa-aea4-ff72687a10cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_46dc8010-113d-47f3-9f98-51cd6e5f8e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fc30d8a-9a9d-4caa-aea4-ff72687a10cc" xlink:to="loc_us-gaap_AwardTypeAxis_46dc8010-113d-47f3-9f98-51cd6e5f8e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_446992ec-60e7-4dc6-b95f-234c9342bde3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_46dc8010-113d-47f3-9f98-51cd6e5f8e06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_446992ec-60e7-4dc6-b95f-234c9342bde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_98ed4b50-1314-41fc-b159-ee02a3d8c178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_446992ec-60e7-4dc6-b95f-234c9342bde3" xlink:to="loc_us-gaap_RestrictedStockMember_98ed4b50-1314-41fc-b159-ee02a3d8c178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6692e07f-563e-434c-a2ac-37616346b754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_446992ec-60e7-4dc6-b95f-234c9342bde3" xlink:to="loc_us-gaap_PerformanceSharesMember_6692e07f-563e-434c-a2ac-37616346b754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36f697c5-1867-4e24-bf66-c23e53cd1556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fc30d8a-9a9d-4caa-aea4-ff72687a10cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36f697c5-1867-4e24-bf66-c23e53cd1556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9826ef26-1ada-44b7-bcaa-8223a0280433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36f697c5-1867-4e24-bf66-c23e53cd1556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9826ef26-1ada-44b7-bcaa-8223a0280433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1e37bac-593a-444c-9995-065ed02d89cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9826ef26-1ada-44b7-bcaa-8223a0280433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f1e37bac-593a-444c-9995-065ed02d89cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_98fcd1b9-5781-4fbc-9bf7-44556edf1b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9826ef26-1ada-44b7-bcaa-8223a0280433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_98fcd1b9-5781-4fbc-9bf7-44556edf1b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_87a7f2ed-8b55-417e-b3b4-f20b7698e044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9826ef26-1ada-44b7-bcaa-8223a0280433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_87a7f2ed-8b55-417e-b3b4-f20b7698e044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a0edb7f-e6a7-412e-ae17-0529dad49bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9826ef26-1ada-44b7-bcaa-8223a0280433" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a0edb7f-e6a7-412e-ae17-0529dad49bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_750e350b-1b9a-491f-bbc7-a9e8ef39472e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36f697c5-1867-4e24-bf66-c23e53cd1556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_750e350b-1b9a-491f-bbc7-a9e8ef39472e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40af3c59-0896-4829-aa09-fd9317c04b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_750e350b-1b9a-491f-bbc7-a9e8ef39472e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40af3c59-0896-4829-aa09-fd9317c04b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1e609feb-56d9-44e2-840b-a8f26d5a975f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_750e350b-1b9a-491f-bbc7-a9e8ef39472e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1e609feb-56d9-44e2-840b-a8f26d5a975f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_adae1d37-880d-4888-bc96-36590cfad53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_750e350b-1b9a-491f-bbc7-a9e8ef39472e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_adae1d37-880d-4888-bc96-36590cfad53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1964a1b7-22d1-47d7-a1db-cb0bc607cb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_750e350b-1b9a-491f-bbc7-a9e8ef39472e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1964a1b7-22d1-47d7-a1db-cb0bc607cb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable_2f499f83-a4ba-4970-8c44-184f4e79cc45" xlink:href="bdtx-20230331.xsd#bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36f697c5-1867-4e24-bf66-c23e53cd1556" xlink:to="loc_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable_2f499f83-a4ba-4970-8c44-184f4e79cc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#NETLOSSPERSHAREComputationofNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_320be111-a769-4ecd-97de-a3143877305a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_63c000aa-bae3-4852-ae28-355a8c7c903f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_320be111-a769-4ecd-97de-a3143877305a" xlink:to="loc_us-gaap_NetIncomeLoss_63c000aa-bae3-4852-ae28-355a8c7c903f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a88ff9bd-5c5e-415c-bf72-a3ecc66b4078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_320be111-a769-4ecd-97de-a3143877305a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a88ff9bd-5c5e-415c-bf72-a3ecc66b4078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5976f22e-e543-4ea3-8ed7-476f606332f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_320be111-a769-4ecd-97de-a3143877305a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5976f22e-e543-4ea3-8ed7-476f606332f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_08c5c595-05f8-4403-ba5d-0cf7c38ed90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_320be111-a769-4ecd-97de-a3143877305a" xlink:to="loc_us-gaap_EarningsPerShareBasic_08c5c595-05f8-4403-ba5d-0cf7c38ed90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d8a85fef-87e6-4c10-9363-759abf447360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_320be111-a769-4ecd-97de-a3143877305a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d8a85fef-87e6-4c10-9363-759abf447360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_66d703b1-38ac-4ba2-b0fd-f359cc7a1875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4e42c78-9fd4-4056-95c3-2e66fef05d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_66d703b1-38ac-4ba2-b0fd-f359cc7a1875" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4e42c78-9fd4-4056-95c3-2e66fef05d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_910e469a-b6bf-4bdc-8115-9ea737e07349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4e42c78-9fd4-4056-95c3-2e66fef05d87" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_910e469a-b6bf-4bdc-8115-9ea737e07349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_910e469a-b6bf-4bdc-8115-9ea737e07349" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4d21fade-afa5-42c9-a29a-b9479eb49237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4d21fade-afa5-42c9-a29a-b9479eb49237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_034e0bbc-1c9b-4ba8-beb5-bf42334e3ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:to="loc_us-gaap_RestrictedStockMember_034e0bbc-1c9b-4ba8-beb5-bf42334e3ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_cc1fafd9-2631-453f-924f-ad59f4d5557c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:to="loc_us-gaap_EmployeeStockMember_cc1fafd9-2631-453f-924f-ad59f4d5557c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_67237f7d-b708-4520-a073-7bb24ff0258b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:to="loc_us-gaap_PerformanceSharesMember_67237f7d-b708-4520-a073-7bb24ff0258b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_7722a036-59f7-41c1-b138-f88f3655dd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_607f9af3-b7db-489d-b54b-e7534f4d4bfa" xlink:to="loc_us-gaap_WarrantMember_7722a036-59f7-41c1-b138-f88f3655dd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91088c77-c322-451e-b7e4-46edc0925c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4e42c78-9fd4-4056-95c3-2e66fef05d87" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91088c77-c322-451e-b7e4-46edc0925c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7c17b02f-04b3-4489-9e8b-b1cea7b57e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91088c77-c322-451e-b7e4-46edc0925c7f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7c17b02f-04b3-4489-9e8b-b1cea7b57e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_437a28e7-8c1d-41d1-bbd5-53127ad13793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_253b10bc-81e0-4430-816d-c6c1dca07798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_437a28e7-8c1d-41d1-bbd5-53127ad13793" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_253b10bc-81e0-4430-816d-c6c1dca07798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_47c89335-d433-4d1c-b6b5-68e5d65b9326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_253b10bc-81e0-4430-816d-c6c1dca07798" xlink:to="loc_us-gaap_LeaseContractualTermAxis_47c89335-d433-4d1c-b6b5-68e5d65b9326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_0181b797-9d8f-498f-b60c-fef7142f4aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_47c89335-d433-4d1c-b6b5-68e5d65b9326" xlink:to="loc_us-gaap_LeaseContractualTermDomain_0181b797-9d8f-498f-b60c-fef7142f4aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember_8524df44-e660-4122-ab55-db8d33cb4e3b" xlink:href="bdtx-20230331.xsd#bdtx_OperatingLeasePrincipalOfficeTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_0181b797-9d8f-498f-b60c-fef7142f4aa7" xlink:to="loc_bdtx_OperatingLeasePrincipalOfficeTwoMember_8524df44-e660-4122-ab55-db8d33cb4e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_eb17eacc-5bf1-4c33-8723-176a843c1ab4" xlink:href="bdtx-20230331.xsd#bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_0181b797-9d8f-498f-b60c-fef7142f4aa7" xlink:to="loc_bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember_eb17eacc-5bf1-4c33-8723-176a843c1ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_253b10bc-81e0-4430-816d-c6c1dca07798" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseNumberOfContracts_4615d47f-5aac-47ac-905f-83c34dba5abe" xlink:href="bdtx-20230331.xsd#bdtx_LesseeOperatingLeaseNumberOfContracts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:to="loc_bdtx_LesseeOperatingLeaseNumberOfContracts_4615d47f-5aac-47ac-905f-83c34dba5abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_341ae10b-8ca0-41bd-8146-2f62f6a18a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_341ae10b-8ca0-41bd-8146-2f62f6a18a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_300dd005-fbd8-4e79-9af8-8062588aabd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_300dd005-fbd8-4e79-9af8-8062588aabd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseArea_94edc9b8-56e5-4c55-889b-139481aede4e" xlink:href="bdtx-20230331.xsd#bdtx_LesseeOperatingLeaseArea"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:to="loc_bdtx_LesseeOperatingLeaseArea_94edc9b8-56e5-4c55-889b-139481aede4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_d2bd8e56-b448-4a5c-8ae0-b2492f26eacc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_11ce6c31-c312-4143-a024-92905ad16f55" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_d2bd8e56-b448-4a5c-8ae0-b2492f26eacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0f5c10a9-7c01-45e7-bda5-438b45f97f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_16329814-a8c3-43f3-ae73-c1560ae3a0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f5c10a9-7c01-45e7-bda5-438b45f97f7e" xlink:to="loc_us-gaap_LeaseCostAbstract_16329814-a8c3-43f3-ae73-c1560ae3a0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0663a81f-94aa-4951-ab59-8552eae36a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_16329814-a8c3-43f3-ae73-c1560ae3a0dd" xlink:to="loc_us-gaap_OperatingLeaseCost_0663a81f-94aa-4951-ab59-8552eae36a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_6a13f37d-626b-4a41-a567-97c170f7d61e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_16329814-a8c3-43f3-ae73-c1560ae3a0dd" xlink:to="loc_us-gaap_ShortTermLeaseCost_6a13f37d-626b-4a41-a567-97c170f7d61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ab969668-be39-4b30-8a47-c66e023882e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_16329814-a8c3-43f3-ae73-c1560ae3a0dd" xlink:to="loc_us-gaap_VariableLeaseCost_ab969668-be39-4b30-8a47-c66e023882e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_27dda1c4-8edc-4164-a9f6-ec90d48a8c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_16329814-a8c3-43f3-ae73-c1560ae3a0dd" xlink:to="loc_us-gaap_SubleaseIncome_27dda1c4-8edc-4164-a9f6-ec90d48a8c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_763bc3b1-4df6-4c53-9143-cee7b522e1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_16329814-a8c3-43f3-ae73-c1560ae3a0dd" xlink:to="loc_us-gaap_LeaseCost_763bc3b1-4df6-4c53-9143-cee7b522e1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LeaseOtherInformationAbstract_b25b1f9a-fb61-4ab1-ab14-6efedce0b000" xlink:href="bdtx-20230331.xsd#bdtx_LeaseOtherInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f5c10a9-7c01-45e7-bda5-438b45f97f7e" xlink:to="loc_bdtx_LeaseOtherInformationAbstract_b25b1f9a-fb61-4ab1-ab14-6efedce0b000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_0ab4e1c2-9e99-4989-93f7-5bafbd55e1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bdtx_LeaseOtherInformationAbstract_b25b1f9a-fb61-4ab1-ab14-6efedce0b000" xlink:to="loc_us-gaap_OperatingLeasePayments_0ab4e1c2-9e99-4989-93f7-5bafbd55e1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7977add9-9b21-4e07-943d-ef0d3ca3efce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bdtx_LeaseOtherInformationAbstract_b25b1f9a-fb61-4ab1-ab14-6efedce0b000" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7977add9-9b21-4e07-943d-ef0d3ca3efce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1281366f-9c9d-40a6-b074-dd19e8223823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bdtx_LeaseOtherInformationAbstract_b25b1f9a-fb61-4ab1-ab14-6efedce0b000" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1281366f-9c9d-40a6-b074-dd19e8223823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_19ce4252-df0c-41f8-9e78-cc875efc94a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b6c7c6c5-49a7-44b9-a1f0-a6b5370d0f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19ce4252-df0c-41f8-9e78-cc875efc94a7" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b6c7c6c5-49a7-44b9-a1f0-a6b5370d0f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ddec9bb7-0839-49ea-afbc-7e1f95a0c828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b6c7c6c5-49a7-44b9-a1f0-a6b5370d0f63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ddec9bb7-0839-49ea-afbc-7e1f95a0c828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_74a99e70-acc5-406c-b4f9-3970c44f78d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b6c7c6c5-49a7-44b9-a1f0-a6b5370d0f63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_74a99e70-acc5-406c-b4f9-3970c44f78d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cd9e7f0c-b9ca-4285-ae98-9218d5e73ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b6c7c6c5-49a7-44b9-a1f0-a6b5370d0f63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cd9e7f0c-b9ca-4285-ae98-9218d5e73ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f197ef57-7f3e-408b-b9fa-77d4c9c65eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b6c7c6c5-49a7-44b9-a1f0-a6b5370d0f63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f197ef57-7f3e-408b-b9fa-77d4c9c65eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d2623ce9-9802-4099-a552-646c3e8f8b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b6c7c6c5-49a7-44b9-a1f0-a6b5370d0f63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d2623ce9-9802-4099-a552-646c3e8f8b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_5cba4ac6-bff4-45b6-93c4-8b0beffa818f" xlink:href="bdtx-20230331.xsd#bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b6c7c6c5-49a7-44b9-a1f0-a6b5370d0f63" xlink:to="loc_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_5cba4ac6-bff4-45b6-93c4-8b0beffa818f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_76e67cf2-a8fd-4402-a011-6d2c71649749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b6c7c6c5-49a7-44b9-a1f0-a6b5370d0f63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_76e67cf2-a8fd-4402-a011-6d2c71649749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_72d8ea65-2259-461d-8fd0-64c050f0c4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b6c7c6c5-49a7-44b9-a1f0-a6b5370d0f63" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_72d8ea65-2259-461d-8fd0-64c050f0c4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_41c9d6fe-4384-4edc-bebe-56cf5a982c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b6c7c6c5-49a7-44b9-a1f0-a6b5370d0f63" xlink:to="loc_us-gaap_OperatingLeaseLiability_41c9d6fe-4384-4edc-bebe-56cf5a982c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="bdtx-20230331.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" xlink:type="simple" xlink:href="bdtx-20230331.xsd#BENEFITPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d75459b0-f15a-4f18-a660-d8c00c3c2c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_ed4d4b77-d8b5-45da-8c1b-da2fe06d24b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d75459b0-f15a-4f18-a660-d8c00c3c2c71" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_ed4d4b77-d8b5-45da-8c1b-da2fe06d24b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_22ee2d45-9e0e-455e-a229-81c072c6564f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d75459b0-f15a-4f18-a660-d8c00c3c2c71" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_22ee2d45-9e0e-455e-a229-81c072c6564f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_071ab075-7c76-494c-bfa5-b4f4ce4863a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d75459b0-f15a-4f18-a660-d8c00c3c2c71" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_071ab075-7c76-494c-bfa5-b4f4ce4863a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172134656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BLACK DIAMOND THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-4254660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Main Street, 14th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">252-0848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BDTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,512,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001701541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172414592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 39,141<span></span>
</td>
<td class="nump">$ 34,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">64,225<span></span>
</td>
<td class="nump">88,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,611<span></span>
</td>
<td class="nump">4,899<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">107,977<span></span>
</td>
<td class="nump">127,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,333<span></span>
</td>
<td class="nump">2,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">24,104<span></span>
</td>
<td class="nump">24,794<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">135,582<span></span>
</td>
<td class="nump">156,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,046<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,801<span></span>
</td>
<td class="nump">13,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,847<span></span>
</td>
<td class="nump">15,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">24,545<span></span>
</td>
<td class="nump">25,299<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">37,392<span></span>
</td>
<td class="nump">40,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; no shares issued or outstanding at March&#160;31, 2023 and December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.0001 par value; 500,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 36,511,947 shares issued and outstanding at March&#160;31, 2023 and 36,434,297 shares issued and outstanding at December&#160;31, 2022</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">455,225<span></span>
</td>
<td class="nump">452,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,176)<span></span>
</td>
<td class="num">(1,824)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(355,864)<span></span>
</td>
<td class="num">(334,989)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">98,190<span></span>
</td>
<td class="nump">115,695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 135,582<span></span>
</td>
<td class="nump">$ 156,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159171896848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">36,511,947<span></span>
</td>
<td class="nump">36,434,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">36,511,947<span></span>
</td>
<td class="nump">36,434,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172412784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 14,753<span></span>
</td>
<td class="nump">$ 17,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,808<span></span>
</td>
<td class="nump">7,893<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">21,561<span></span>
</td>
<td class="nump">25,679<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(21,561)<span></span>
</td>
<td class="num">(25,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="nump">64<span></span>
</td>
<td class="num">(234)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,875)<span></span>
</td>
<td class="num">$ (25,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">36,483,878<span></span>
</td>
<td class="nump">36,271,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">36,483,878<span></span>
</td>
<td class="nump">36,271,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,875)<span></span>
</td>
<td class="num">$ (25,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on investments, net</a></td>
<td class="nump">648<span></span>
</td>
<td class="num">(1,361)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (20,227)<span></span>
</td>
<td class="num">$ (26,868)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159171830288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,875)<span></span>
</td>
<td class="num">$ (25,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,671<span></span>
</td>
<td class="nump">3,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of premium on investments</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_RentExpense', window );">Noncash rent expense</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of property and equipment</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in current assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">383<span></span>
</td>
<td class="num">(2,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="num">(2,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(3,583)<span></span>
</td>
<td class="num">(1,958)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Non-current operating lease liabilities</a></td>
<td class="num">(754)<span></span>
</td>
<td class="num">(687)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,031)<span></span>
</td>
<td class="num">(28,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">24,806<span></span>
</td>
<td class="nump">37,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,504)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">24,806<span></span>
</td>
<td class="nump">16,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of common stock options and ESPP</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">4,826<span></span>
</td>
<td class="num">(11,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">35,483<span></span>
</td>
<td class="nump">67,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">40,309<span></span>
</td>
<td class="nump">55,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">39,141<span></span>
</td>
<td class="nump">54,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">40,309<span></span>
</td>
<td class="nump">55,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets', window );">Sale of equipment included in prepaid expenses and other current assets</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_RentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_RentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Equipment Included in Prepaid Expenses and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159166907120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,234,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 195,900<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 440,129<span></span>
</td>
<td class="num">$ (414)<span></span>
</td>
<td class="num">$ (243,820)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to ESPP</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(1,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,507)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,287,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 172,560<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">443,657<span></span>
</td>
<td class="num">(1,775)<span></span>
</td>
<td class="num">(269,327)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">36,434,297<span></span>
</td>
<td class="nump">36,434,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 115,695<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">452,503<span></span>
</td>
<td class="num">(1,824)<span></span>
</td>
<td class="num">(334,989)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Surrender of shares for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to ESPP</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,875)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">36,511,947<span></span>
</td>
<td class="nump">36,511,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 98,190<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 455,225<span></span>
</td>
<td class="num">$ (1,176)<span></span>
</td>
<td class="num">$ (355,864)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172131472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">NATURE OF BUSINESS AND BASIS OF PRESENTATION</a></td>
<td class="text">NATURE OF BUSINESS AND BASIS OF PRESENTATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the Company) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development of its mutation, allostery, and pharmacology drug discovery engine. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 14, 2022, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement), with the Securities and Exchange Commission (the SEC), which covers the offering, issuance and sale of the Company&#8217;s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum offering price of $500&#160;million. The Company simultaneously entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. As of March&#160;31, 2023, no sales have been made pursuant to the ATM Program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred stock and common stock. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of May&#160;9, 2023, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, or reduce headcount and general and administrative costs, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159175263200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company continues to monitor the impact of global economic developments, political unrest, high inflation, the recent failure of certain banks and financial institutions, and health crises, such as the COVID-19 pandemic, on all aspects of its business, and has considered the impact of these factors on estimates within its financial statements. The extent to which future developments may impact the Company&#8217;s business, results of operations or financial condition are uncertain and cannot be predicted with confidence and there may be changes to estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of these factors and is not aware of any specific related event or circumstance that would require it to update its estimates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159254373376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at March 31, 2023 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">64,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">79,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at December 31, 2022 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,278&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">88,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120,770&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no transfers in or out of Level 3 categories in the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159175151968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">INVESTMENTS</a></td>
<td class="text">INVESTMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(538)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">65,401&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,176)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">64,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">90,316&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,824)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">88,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for corporate bonds with a fair value of $1,983 that had maturities of one to three years. As of March&#160;31, 2023, all marketable securities held by the Company were in a loss position. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds, and commercial paper with a fair value of $13,687 that had maturities of one to three years. As of December&#160;31, 2022, all marketable securities held by the Company were in a loss position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company reviewed its investment portfolio to assess the unrealized losses on its available-for-sale investments.  The Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company also determined no portion of the unrealized losses relate to a credit loss.  There have been no impairments of the Company&#8217;s assets measured and carried at fair value during the three months ended March&#160;31, 2023 and the year ended December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159254373376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computer and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(845)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,333&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March&#160;31, 2023 and 2022 was $122 and $125, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159174984112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY METHOD INVESTMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">EQUITY METHOD INVESTMENT</a></td>
<td class="text">EQUITY METHOD INVESTMENT<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2022, the Company received 9,000,000 shares of common stock in a newly formed antibody-focused precision oncology company, Launchpad Therapeutics, Inc. (Launchpad), in exchange for contributing early discovery-stage antibody programs and granting Launchpad a license to use its MAP drug discovery engine to discover, develop and commercialize large molecule therapeutics. As of the transaction date and as of March&#160;31, 2023, the Company has a 39.1% voting interest in Launchpad and one seat on Launchpad&#8217;s Board of Directors which provide the Company with significant influence over Launchpad. The remaining voting interest in Launchpad is held by Versant Ventures and New Enterprise Associates (NEA), who are shareholders of the Company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company accounted for the transaction under the equity method and recorded the carrying value of the Company&#8217;s investment in Launchpad common shares of $2,250 in equity method investments in the consolidated balance sheets. The contributed in process research and development (IPR&amp;D) had zero basis on the Company&#8217;s books prior to the transaction, therefore the Company recognized a gain on sale of IPR&amp;D of $2,232 in the consolidated statements of operations and comprehensive loss. The Company also recognized a loss from investments in equity method investee of $1,540 in the consolidated statement of operations and comprehensive loss, associated with the Company&#8217;s proportionate share of Launchpad&#8217;s losses. The assets contributed by the Company were principally IPR&amp;D and were not deemed a business by Launchpad, therefore the Company determined its remaining basis difference of $710 was substantially related to IPR&amp;D and immediately expensed it. As of December&#160;31, 2022, the carrying value of the investment in Launchpad was reduced to zero. Since the Company has no obligation to provide financing support to Launchpad, the Company is not required to record further losses exceeding the carrying value of the investment. The Company also determined that its investment in Launchpad is not material or significant to its operations or financial position. As of March&#160;31, 2023, the carrying value of the investment in Launchpad was zero.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159176747792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_5102cdaa-2077-4a92-ad76-9ae9e3ad93f1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_fd6e36e0-6ca5-4d7c-bac0-99a6f8cd4f37">Current portion of operating lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,801&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172118576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.419%"><tr><td style="width:1.0%"/><td style="width:72.914%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(20,875)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(25,507)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,483,878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,271,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.57)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.70)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,710,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,918,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">86,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares issuable under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">102,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested performance restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">229,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,139,542&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,021,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159175263200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has historically entered into lease arrangements for its facilities. As of March&#160;31, 2023, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company&#8217;s leases generally do not include termination or purchase options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a seven-year agreement with an option to extend for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfNTMw_02522d54-356b-489e-ae5f-0345b2c059f0">five</span> additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease. Additionally, on December 12, 2022, the Company entered into a sublease for one floor of its Cambridge, Massachusetts office space. The sublease terminates on August 31, 2028, which is also the date on which the Company's lease terminates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMTY5OA_c306ce76-7222-412d-9933-d5323bf1972b">five</span> additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating lease for the three months ended March&#160;31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended March 31,</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,192&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,335&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The variable lease costs for the three months ended March&#160;31, 2023 and 2022 include common area maintenance and other operating charges. As the Company&#8217;s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company&#8217;s operating leases as of March&#160;31, 2023 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.320%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">As of March 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 (excluding the three months ended March&#160;31, 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(6,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,453&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159176747792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">License agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of March&#160;31, 2023, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnification agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of March&#160;31, 2023 or December&#160;31, 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Legal proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159174984112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">BENEFIT PLANS</a></td>
<td class="text">BENEFIT PLANSThe Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the 401(k) Plan). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant&#8217;s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the Code). All matching contributions are fully vested when made. During the three months ended March&#160;31, 2023 and 2022, the Company contributed $376 and $558, respectively, to the 401(k) Plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159166536848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Principles of consolidation and unaudited interim financial information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the Company) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development of its mutation, allostery, and pharmacology drug discovery engine. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">Use of estimates The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159174984112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at March 31, 2023 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">64,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">79,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at December 31, 2022 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,278&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">88,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120,770&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159254491792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(538)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">65,401&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,176)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">64,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">90,316&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,824)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">88,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159175263200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computer and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(845)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,333&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159175600144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_5102cdaa-2077-4a92-ad76-9ae9e3ad93f1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_fd6e36e0-6ca5-4d7c-bac0-99a6f8cd4f37">Current portion of operating lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,801&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172396112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.325%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three Months Ended<br/>March 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan and Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.325%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>March 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,722&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,671&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company&#8217;s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:46.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exercise</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,359,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,659,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(240,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(68,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,710,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options vested or expected to vest at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,710,285&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,828,178&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text">The following table summarizes time-based restricted stock activity since January 1, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number&#160;of</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">average</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">grant&#160;date</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">fair value</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">101,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(13,959)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">86,290&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.57&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159175007232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Net Loss per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.419%"><tr><td style="width:1.0%"/><td style="width:72.914%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(20,875)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(25,507)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,483,878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,271,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.57)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.70)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share</a></td>
<td class="text">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,710,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,918,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">86,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares issuable under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">102,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested performance restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">229,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,139,542&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,021,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159175336624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Cost and Other Operating Lease Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating lease for the three months ended March&#160;31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.400%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended March 31,</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,192&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,335&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company&#8217;s operating leases as of March&#160;31, 2023 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.320%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">As of March 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 (excluding the three months ended March&#160;31, 2023)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(6,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,453&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172384256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Nov. 14, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdtx_OpenMarketSaleMember', window );">Open Market Sale</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_SaleOfStockAuthorizedConsideration', window );">Sale of stock, authorized consideration</a></td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdtx_ShelfRegistrationStatementMember', window );">Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_SaleOfStockAuthorizedConsideration', window );">Sale of stock, authorized consideration</a></td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_SaleOfStockAuthorizedConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Authorized Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_SaleOfStockAuthorizedConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bdtx_OpenMarketSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bdtx_OpenMarketSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bdtx_ShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bdtx_ShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159170473024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 79,812<span></span>
</td>
<td class="nump">$ 120,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">15,587<span></span>
</td>
<td class="nump">32,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">36,242<span></span>
</td>
<td class="nump">45,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">27,983<span></span>
</td>
<td class="nump">39,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">15,587<span></span>
</td>
<td class="nump">32,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">15,587<span></span>
</td>
<td class="nump">32,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">64,225<span></span>
</td>
<td class="nump">88,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">36,242<span></span>
</td>
<td class="nump">45,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">27,983<span></span>
</td>
<td class="nump">39,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159171506240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENTS - Schedule of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 65,401<span></span>
</td>
<td class="nump">$ 90,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,176)<span></span>
</td>
<td class="num">(1,824)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">64,225<span></span>
</td>
<td class="nump">88,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">36,780<span></span>
</td>
<td class="nump">46,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(538)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">36,242<span></span>
</td>
<td class="nump">45,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">28,621<span></span>
</td>
<td class="nump">40,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(638)<span></span>
</td>
<td class="num">(1,023)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 27,983<span></span>
</td>
<td class="nump">$ 39,102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159175600016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENTS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree', window );">Fair value</a></td>
<td class="nump">$ 1,983,000<span></span>
</td>
<td class="nump">$ 13,687,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded', window );">Impairment of fair value assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159166543664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 3,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(750)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total Property and Equipment, net</a></td>
<td class="nump">2,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Computer and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 2,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,512<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159169977488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY METHOD INVESTMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain on sale of IP</a></td>
<td class="nump">$ 2,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development asset acquired other than through business combination, written-off</a></td>
<td class="nump">$ 710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bdtx_LaunchpadTherapeuticsIncMember', window );">Launchpad Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange', window );">Common shares received from equity method investment (in shares)</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss recognized from equity method investment</a></td>
<td class="nump">$ 1,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Shares Received in Noncash Exchange</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bdtx_LaunchpadTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bdtx_LaunchpadTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172037152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_AccruedContractResearchServiceFeesCurrent', window );">Contracted research services</a></td>
<td class="nump">$ 4,186<span></span>
</td>
<td class="nump">$ 4,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">1,826<span></span>
</td>
<td class="nump">4,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional and consulting fees</a></td>
<td class="nump">$ 881<span></span>
</td>
<td class="nump">$ 1,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Total accrued expenses and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">$ 2,908<span></span>
</td>
<td class="nump">$ 2,841<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 9,801<span></span>
</td>
<td class="nump">$ 13,384<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_AccruedContractResearchServiceFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Contract Research Service Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_AccruedContractResearchServiceFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159170259312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,671<span></span>
</td>
<td class="nump">$ 3,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdtx_A2020StockOptionPlanMember', window );">2020 Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding', window );">Increase of authorized shares, percent of common stock outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">1,457,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdtx_A2020EmployeeStockPurchasePlanMember', window );">2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding', window );">Increase of authorized shares, percent of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">326,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,455<span></span>
</td>
<td class="nump">3,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2020 Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued under share-based compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdtx_PerformanceRestrictedStockUnitsMember', window );">Performance Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Units outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares issuable under employee stock purchase plan | 2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued under share-based compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,202<span></span>
</td>
<td class="nump">31,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Award purchase period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Maximum percent of fair market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount', window );">Maximum employee subscription amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Unvested performance restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Units outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdtx_A2020StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdtx_A2020StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdtx_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdtx_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdtx_PerformanceRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdtx_PerformanceRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172059984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,671<span></span>
</td>
<td class="nump">$ 3,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,722<span></span>
</td>
<td class="nump">1,847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,455<span></span>
</td>
<td class="nump">3,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdtx_OtherAwardTypeMember', window );">Employee Stock Purchase Plan and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdtx_OtherAwardTypeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdtx_OtherAwardTypeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159171915200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">5,359,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,659,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled or forfeited (in shares)</a></td>
<td class="num">(240,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(68,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">7,710,285<span></span>
</td>
<td class="nump">5,359,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested or expected to vest (in shares)</a></td>
<td class="nump">7,710,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">2,828,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 12.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">2.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">11.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">28.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">9.02<span></span>
</td>
<td class="nump">$ 12.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested or expected to vest (in dollars per share)</a></td>
<td class="nump">9.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 14.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Life and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, remaining life (in years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested or expected to vest, remaining life (in years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, remaining life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, intrinsic value</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested or expected to vest, intrinsic value</a></td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, intrinsic value</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172032336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted common stock, beginning balance (in shares)</a></td>
<td class="nump">101,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(13,959)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled or forfeited (in shares)</a></td>
<td class="num">(1,148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted common stock, ending balance (in shares)</a></td>
<td class="nump">86,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant&#160;date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted common stock, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">14.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled or forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">2.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted common stock, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Unvested performance restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted common stock, beginning balance (in shares)</a></td>
<td class="nump">239,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(9,616)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant&#160;date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Achievement of Milestones Probable</a></td>
<td class="nump">17,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Achievement of Milestones Probable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172384128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Computation of Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,875)<span></span>
</td>
<td class="num">$ (25,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">36,483,878<span></span>
</td>
<td class="nump">36,271,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">36,483,878<span></span>
</td>
<td class="nump">36,271,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159171540640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">8,139,542<span></span>
</td>
<td class="nump">6,021,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">7,710,285<span></span>
</td>
<td class="nump">5,918,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">86,290<span></span>
</td>
<td class="nump">45,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares issuable under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">102,351<span></span>
</td>
<td class="nump">27,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Unvested performance restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">229,859<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">10,757<span></span>
</td>
<td class="nump">10,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172414128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>contract</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseNumberOfContracts', window );">Number of leases | contract</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeTwoMember', window );">Principal office, lease two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term, optional extension (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseArea', window );">Area leased (square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember', window );">Operating Lease, Office and Laboratory Space, NY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term, optional extension (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseArea', window );">Area leased (square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LesseeOperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LesseeOperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LesseeOperatingLeaseNumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LesseeOperatingLeaseNumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeasePrincipalOfficeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159171537712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,054<span></span>
</td>
<td class="nump">$ 1,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(135)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_LeaseOtherInformationAbstract', window );"><strong>Other Operating Lease Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liability</a></td>
<td class="nump">$ 1,051<span></span>
</td>
<td class="nump">$ 702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LeaseOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Other Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LeaseOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159167507632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023 (excluding the three months ended March&#160;31, 2023)</a></td>
<td class="nump">$ 3,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">4,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">4,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">4,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">4,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">12,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">33,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(6,148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 27,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140159172076416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BENEFIT PLANS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer contribution, matching contribution percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer contribution, percent of each participant's salary</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution amount</a></td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">$ 558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>bdtx-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bdtx="http://www.blackdiamondtherapeutics.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bdtx-20230331.xsd" xlink:type="simple"/>
    <context id="i249d943305564527a84d83a0112cc5dc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i66226731c0624aabac4ffa6c672102e6_I20230501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="if76381c49969430b8ee1ce9004b721ee_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i17eafc42a82d4f13904b976d1891eb47_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i934d06c2cd304821941d941437f4ef83_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i18236f10c6bb43fba2c9c3fbf41ce4ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9928ba02038f4ae78a1c4a0dd70f34fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5805f6a69cd441a69d534bb81c0e06da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68d16179c5a14c7ebdbc734b0382415d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i456bfd3daab443ea80542d825dc5fe07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08b218a8d5294a0cbed694379ad58ce2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3e95a40d0c894120a1db7291d5cee4e2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i94cc5dde32e24698bf33abd440aee5b4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic1e742d729ce432ca0f35a2494585ade_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i28226edd859e4dab945d64e22ffcaebf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9ef21fb740fd4df29d87c63818a8be4f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i550bd7cfc5394510a5c782d6d944408a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i58ce2b6758eb48fa96ddd6fc6e0b2a03_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7dad2752f6d24f69beb01b7d41d018ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i44fbc51eccac4780a51aa2110725c195_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3aa33c9766164861a9a2941ebecacdc5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d19e2d7bf5648c0a1412530bc5a4c83_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3528e294eb84233bd324a45f9d5729f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0092b7cc057941c08850f1ad6c56a4d3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9a14724cbb314a469c727f2b58faa85e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i43d5ebddb1f54d71b47373c1b912f7e9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1759f611756a4cffabc3f4c4fb8a6561_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4440f7aa29164195bfa74c860ee07235_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id112bbe0621046fca2f448c03c6b6480_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4c4a9410dd2e40eb9adaf67022861157_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i759d4ddb3ad64fd38d5531cb44817594_D20221114-20221114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdtx:ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-14</startDate>
            <endDate>2022-11-14</endDate>
        </period>
    </context>
    <context id="i5f823a64b85d4ac7bd10d06b5df686fb_D20221114-20221114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdtx:OpenMarketSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-14</startDate>
            <endDate>2022-11-14</endDate>
        </period>
    </context>
    <context id="ibb328d7ce3ad4166b5b61eefd59f420a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ice5277e7080f4af5bb25a652a809641e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6687f45413a4419bb690fef99015b01f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0274173257c24f579ec10811eeb0c81a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7b0e3b7df6074918b33a2cdc71901202_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i08fef76a1c7c437c9d1b3eda6db89dd3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i55653debaf274b11b4ac7a51ce4696e4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7a33cd0b3c4a4b16a14fe04651a86c84_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0a75e0a6cc5a43a49aa062ef1bece4c0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i84693306474940138214ef4e5288008e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0023816158b34fbdbb78091138c96439_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i92484769461f4b74b3d02cb2e1f9e9a2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7d84216f3a25460d9a88c52522dd8d6f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i206b8d6455b84e2f9f3f3b9a6c71a580_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3da457e1122144b4b86fe4e412be3000_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie1de270b96e64e8d86b7cbcec1f81067_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4b518c619fde4699bb430693ce9bb402_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0954e4764df9420ca7f966a581b88ab5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3bdbcb5dab7449a919d62bf333c2769_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifff94a18639d4cc9ace4b7980f18491b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea5548dbdcc84e34b38db41da417d969_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie47787450b694b2ea0d0a633fb578e87_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i143f2d561c544650ae4cec160b40d837_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i559c92eb9a82422882d92a40b4732e87_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c4d688c720846d2a8ca1d0ef6ad503a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55878f702cbe4a6785d7165f6bc9ba1b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf6167cc94b8412da93063def658ef27_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76c3bea13eeb4df78dbeccc4af6e9ef1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i694eac40ab4244e99565a2f9e0787907_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2134d67ef3194c7486e8e79dbdced6a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i885123a2113040f3b1921f9e90183ed4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70fe665f9b0b4d5f97f1dd8448e2e411_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i38fd7a41430b45bb87c13424399f3a46_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie9f1757297d34af5b00fef34b103aa0a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75b0d8ea13e94b30a9276dd91f107156_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i939ee62047f64d468543c94f23dee9b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9351ba53ff254b0f88999f498b0319e9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia8f2c21f696d4b7da626acb69831ccb0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4e1463d111734f7ba01a42c102369654_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04d9627eeb7e470e8198fa77f00eba51_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5395e8eff10344b5ac2d2b3de662edb3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i700858d5fb2842d8aa731adad03358f0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if5f6c4be62384e909f6b4e404ead2edc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i93b69b82ac6a4bb9a460d33085d57f68_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i521fe07ef68d4b4a935d05639717ad02_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2982e6cbd8454350b0195b786784f14a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a98c5b77af845f1970750ebfc01cbf6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4c3fa369595f4fd88697523852da9e92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i758366b058d642888997dc00f48056d1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic51c923c2ba142dca072c9813d731cae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13adc33a304f4c00a11e5a74299bae27_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bdtx:LaunchpadTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd3f10ee0c2541fd9d0fc8361fe6a9e4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bdtx:LaunchpadTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if35bb4b182804be19ee91c94ba0ca241_I20221201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bdtx:LaunchpadTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-01</instant>
        </period>
    </context>
    <context id="i865dd29de11f4df59827ccfa2b07a604_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bdtx:LaunchpadTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i53da331621624cf18bde372f78562fe5_I20200114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-14</instant>
        </period>
    </context>
    <context id="iae929b9e760640749d3650b763b62da4_D20230101-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ibeabbd2a73b145ea98866ff29f77c989_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="iac7a453a75f14538a02a138efbfaf7a5_I20200114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-14</instant>
        </period>
    </context>
    <context id="i4476e554da044810af3f1a45eaa2a804_D20230101-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i549acd543c9a4b5aa7c94abf409f84da_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3f33b8615f184762bdde93307f038957_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie89b78b326fe4b0a997b225ea39acef4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2ab72299068b42fdbaa9a32deddc9c0d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icd05de7566d7485c87c6e0a63d1068f1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:OtherAwardTypeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idf76fbfd9fad48fbafde9bd4d08feef3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:OtherAwardTypeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i531627ec9aa54ef1ba96e5c5b9e70e77_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2a68a37a9356497ebf39ad08f89e5202_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i40eacd0ad8714a8b8f4aa9d78df3b014_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie179c4253b6c47ac8c91e9c01f937de2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0b7e706f65f045e882a5da0982835947_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4e69e52e4e6d406fb3c05c1f565e0fc4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ba383758bc7459cbba65c787855cd79_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1bbb31a5e28c45da9f270f4b2a17dc96_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id1dd1836d0a04ec5916ed35f6b8154f9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8d6665b2a485470da5f751271274fa6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id72ab97139f6499186284a9e549e2dcd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1b8ca7e990664a5b82b28aaeab2809ac_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7f5dc11878354eceb96d35803df03196_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdtx:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaedbd1575db640bfa3b1a3840d2f60c1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i92885a5fac644e64800d5f746f26e823_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i34860dd43a7c4f3385bb39b1b3cce7d7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i655a42e7d5614f70874d9d99b077d0ca_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdtx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2e956203346c4f019b41b2e8a5ca63b5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i480b155b6e9e4eb7bb0b1e836d5e7afb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i54c6774cffa04e968e001d62f8b99a07_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib89eee0073ef4f748054dcd1018afcb4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf82d51205674d83a503b0e61adba697_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id425a5500c184a08bd09e08bff211884_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i812984cbee954504a8f1cb1007753038_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if98a5e733c4c466b9290ddc071d57eb2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3c4704e3cd5b4f9ca3f745afab97bcbc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iec9bf005920e479db53ec4495d3c9605_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i09dbac4b37d84e3eb2e7dad646327861_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bdtx:OperatingLeasePrincipalOfficeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="id28a5be0a35d4bc881d156351fc61d4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001701541</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">bdtx:OperatingLeaseOfficeAndLaboratorySpaceNYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="contract">
        <measure>bdtx:contract</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80L2ZyYWc6NWM4OWRjOTQ1YjM4NGI1MWI2MDQ4NTJiYWFhNmVhNzkvdGFibGU6ZDUyZGQ0OTcyM2I5NGYzMDk4ODM4MDE3YWI4MmMzNzMvdGFibGVyYW5nZTpkNTJkZDQ5NzIzYjk0ZjMwOTg4MzgwMTdhYjgyYzM3M18yLTEtMS0xLTI4MzI4_dcae7fe2-1a28-4f51-bef1-12f033ef0509">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80L2ZyYWc6NWM4OWRjOTQ1YjM4NGI1MWI2MDQ4NTJiYWFhNmVhNzkvdGFibGU6ZDUyZGQ0OTcyM2I5NGYzMDk4ODM4MDE3YWI4MmMzNzMvdGFibGVyYW5nZTpkNTJkZDQ5NzIzYjk0ZjMwOTg4MzgwMTdhYjgyYzM3M18zLTEtMS0xLTI4MzI4_fb1317ae-7e7f-4634-90ff-f377080ea7ce">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80L2ZyYWc6NWM4OWRjOTQ1YjM4NGI1MWI2MDQ4NTJiYWFhNmVhNzkvdGFibGU6ZDUyZGQ0OTcyM2I5NGYzMDk4ODM4MDE3YWI4MmMzNzMvdGFibGVyYW5nZTpkNTJkZDQ5NzIzYjk0ZjMwOTg4MzgwMTdhYjgyYzM3M180LTEtMS0xLTI4MzI4_948289de-1409-408d-a855-1a20bf67770d">2023</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80L2ZyYWc6NWM4OWRjOTQ1YjM4NGI1MWI2MDQ4NTJiYWFhNmVhNzkvdGFibGU6ZDUyZGQ0OTcyM2I5NGYzMDk4ODM4MDE3YWI4MmMzNzMvdGFibGVyYW5nZTpkNTJkZDQ5NzIzYjk0ZjMwOTg4MzgwMTdhYjgyYzM3M181LTEtMS0xLTI4MzI4_bd19ea92-5a76-477a-a5de-13c9cb493f7d">0001701541</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80L2ZyYWc6NWM4OWRjOTQ1YjM4NGI1MWI2MDQ4NTJiYWFhNmVhNzkvdGFibGU6ZDUyZGQ0OTcyM2I5NGYzMDk4ODM4MDE3YWI4MmMzNzMvdGFibGVyYW5nZTpkNTJkZDQ5NzIzYjk0ZjMwOTg4MzgwMTdhYjgyYzM3M182LTEtMS0xLTI4MzI4_3757cd07-c175-4a78-b1a2-cc237b135885">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_5102cdaa-2077-4a92-ad76-9ae9e3ad93f1">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_fd6e36e0-6ca5-4d7c-bac0-99a6f8cd4f37">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i09dbac4b37d84e3eb2e7dad646327861_I20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfNTMw_02522d54-356b-489e-ae5f-0345b2c059f0">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="id28a5be0a35d4bc881d156351fc61d4e_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMTY5OA_c306ce76-7222-412d-9933-d5323bf1972b">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:DocumentType
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18xMjY_33a4d7c0-2487-4268-a914-065efa49d5e1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NjY4MmI4OTk3MzI4NDM5NGJlNGFiMmJiODU2MGQ0NmYvdGFibGVyYW5nZTo2NjgyYjg5OTczMjg0Mzk0YmU0YWIyYmI4NTYwZDQ2Zl8wLTAtMS0xLTI4MzI4_acedc0cd-ce1a-41c8-a2e1-f9f3cec829cf">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18yNDE_ff9b8032-1538-447b-9596-891736548edb">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6MjI1ZGE2NjA3Mjk4NGM3OGI0NDMwYzJjYTE3YmEyNWYvdGFibGVyYW5nZToyMjVkYTY2MDcyOTg0Yzc4YjQ0MzBjMmNhMTdiYTI1Zl8wLTAtMS0xLTI4MzI4_89d16f49-ab5b-4a2b-9a3b-024701049a52">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18zMDk_1e7edf8f-8ec3-47d1-8046-ca15cc8c32aa">001-38501</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18zNTY_ec7ad3b4-e244-4ad4-97f5-decb0a3ba89d">BLACK DIAMOND THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8wLTAtMS0xLTI4MzI4_b8f23498-4914-413e-9878-8c0eab394bbf">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8wLTEtMS0xLTI4MzI4_ec8207c1-9d3f-4003-afdf-ecf8f6b2edfe">81-4254660</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8yLTAtMS0xLTI4MzI4L3RleHRyZWdpb246NjQ5MzVlZTYzMmMxNDk3YThhZGRmOThiNDRmMDgzZDJfNQ_62ac466c-a214-4f80-931f-eaeb5c9ba9e5">One Main Street, 14th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8yLTAtMS0xLTI4MzI4L3RleHRyZWdpb246NjQ5MzVlZTYzMmMxNDk3YThhZGRmOThiNDRmMDgzZDJfOQ_f2d250fd-86bf-4d88-90de-e67d60821ebb">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8yLTAtMS0xLTI4MzI4L3RleHRyZWdpb246NjQ5MzVlZTYzMmMxNDk3YThhZGRmOThiNDRmMDgzZDJfMTM_5fcf9a54-0908-4652-a465-7f3ccb325f8f">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8yLTEtMS0xLTI4MzI4L3RleHRyZWdpb246ZmM5NTM5YjVlZmEyNDJmMWJkZDliZmVjODBmMjdkZGJfNQ_08d89c60-a1b5-48f1-8a46-2722e2ca7cf0">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8zLTAtMS0xLTI4MzI4L3RleHRyZWdpb246MDE4YWI2MDYyYmZiNDQ4NzlkYWM4N2EzMmNmN2QxMDlfNQ_12dd326b-42cd-4ae8-a024-e6e2fe125334">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6ZjM0ZmViNmE5NmFjNDhlZWJkYzg3MTkzOWM3ZWZmMzEvdGFibGVyYW5nZTpmMzRmZWI2YTk2YWM0OGVlYmRjODcxOTM5YzdlZmYzMV8zLTAtMS0xLTI4MzI4L3RleHRyZWdpb246MDE4YWI2MDYyYmZiNDQ4NzlkYWM4N2EzMmNmN2QxMDlfOA_b28f64b4-6b3f-4011-8aa9-2a14fd5f3562">252-0848</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NWE0ZmYyNTE1NWE1NGQzNTg5ZmUxZDgyZmNhZGVmZjYvdGFibGVyYW5nZTo1YTRmZjI1MTU1YTU0ZDM1ODlmZTFkODJmY2FkZWZmNl8xLTAtMS0xLTI4MzI4_676932de-e657-4f28-8d86-8a6ab96dab72">Common stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NWE0ZmYyNTE1NWE1NGQzNTg5ZmUxZDgyZmNhZGVmZjYvdGFibGVyYW5nZTo1YTRmZjI1MTU1YTU0ZDM1ODlmZTFkODJmY2FkZWZmNl8xLTEtMS0xLTI4MzI4_14c1826e-053f-46ca-a951-dc5a28be52f9">BDTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NWE0ZmYyNTE1NWE1NGQzNTg5ZmUxZDgyZmNhZGVmZjYvdGFibGVyYW5nZTo1YTRmZjI1MTU1YTU0ZDM1ODlmZTFkODJmY2FkZWZmNl8xLTItMS0xLTI4MzI4_9a1d8a00-059e-4d6a-bffb-f0827d61ace6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY185MDc_1dc39f0c-ac97-4a33-9158-1acaeec58531">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18xMjM0_d32475e4-d05f-4888-99b8-dfc02092aae1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NWQwOGNlNjRlYWU2NDJkZjkxZjU0ZGRlODQxYTFlMDMvdGFibGVyYW5nZTo1ZDA4Y2U2NGVhZTY0MmRmOTFmNTRkZGU4NDFhMWUwM18yLTAtMS0xLTI4MzI4_88ac8518-ed5a-4904-a7e1-eecbbe863631">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NWQwOGNlNjRlYWU2NDJkZjkxZjU0ZGRlODQxYTFlMDMvdGFibGVyYW5nZTo1ZDA4Y2U2NGVhZTY0MmRmOTFmNTRkZGU4NDFhMWUwM18yLTMtMS0xLTI4MzI4_3b17a3c1-9876-4a3c-a643-143c0521638a">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGFibGU6NWQwOGNlNjRlYWU2NDJkZjkxZjU0ZGRlODQxYTFlMDMvdGFibGVyYW5nZTo1ZDA4Y2U2NGVhZTY0MmRmOTFmNTRkZGU4NDFhMWUwM180LTMtMS0xLTI4MzI4_43db3659-834c-478e-8f7b-fa389dd70a31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18xODQ5_bfa634fc-5761-4c51-804e-780446d10d6f">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18xOTcz_63cdf7ef-7884-44cb-8b67-a86f407c03d8">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i66226731c0624aabac4ffa6c672102e6_I20230501"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xL2ZyYWc6NWNkMDk5ODc3MGVjNGNmNDhlZWIyZDdlNDhkMTdkMGMvdGV4dHJlZ2lvbjo1Y2QwOTk4NzcwZWM0Y2Y0OGVlYjJkN2U0OGQxN2QwY18yMDE0_d2e10d66-1b03-4385-b0a1-ce9b52543be0"
      unitRef="shares">36512572</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNC0xLTEtMS0yODMyOA_4b42d27d-34ae-42a9-89cd-aaf6b92eceb4"
      unitRef="usd">39141000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNC0zLTEtMS0yODMyOA_45c9e7a4-979f-42e5-a4d5-49bf43276df4"
      unitRef="usd">34315000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNS0xLTEtMS0yODMyOA_36d10e21-611e-43fc-bde6-7d69723cffe9"
      unitRef="usd">64225000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNS0zLTEtMS0yODMyOA_0ff55300-c0cd-425f-b18d-f6ad737f91fd"
      unitRef="usd">88492000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNi0xLTEtMS0yODMyOA_17a92ed0-27e0-46ce-afd1-f655f1d78d88"
      unitRef="usd">4611000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNi0zLTEtMS0yODMyOA_80ac6d49-d97d-4213-be6e-3d77d25ae43e"
      unitRef="usd">4899000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNy0xLTEtMS0yODMyOA_138253ee-5974-4e09-8569-366f1fcf39af"
      unitRef="usd">107977000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfNy0zLTEtMS0yODMyOA_58207be5-cffc-491f-b427-daeb80907798"
      unitRef="usd">127706000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfOC0xLTEtMS0yODMyOA_c94f4f54-0851-42dc-b39d-19c805743ad4"
      unitRef="usd">2333000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfOC0zLTEtMS0yODMyOA_25d2451d-3c7b-482f-9735-4dfc0f41a071"
      unitRef="usd">2587000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfOS0xLTEtMS0yODMyOA_43d5c31b-1724-41d5-9502-69dec207d887"
      unitRef="usd">1168000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfOS0zLTEtMS0yODMyOA_0c301850-7736-48a2-aa5a-56be8baba020"
      unitRef="usd">1168000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTAtMS0xLTEtMjgzMjg_bef4dc73-3ae2-4456-a664-4c30ac23ca9f"
      unitRef="usd">24104000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTAtMy0xLTEtMjgzMjg_743b4bbb-c52f-4ffa-99af-1630fae39367"
      unitRef="usd">24794000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTItMS0xLTEtMjgzMjg_7b1c5c34-4dfc-48b3-9f63-90e8bf6c38c0"
      unitRef="usd">135582000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTItMy0xLTEtMjgzMjg_3af1376e-b30a-401b-851e-4ea4d3b09dec"
      unitRef="usd">156255000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTUtMS0xLTEtMjgzMjg_e28c6c3a-d094-4e61-8f92-dd4a29f3781e"
      unitRef="usd">3046000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTUtMy0xLTEtMjgzMjg_5d28fc83-558b-4d1c-8e33-f95638165774"
      unitRef="usd">1877000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTctMS0xLTEtMjgzMjg_54facc15-787f-4218-8360-322d8f5cbb65"
      unitRef="usd">9801000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTctMy0xLTEtMjgzMjg_ef879022-8704-464e-92c1-0de07a623076"
      unitRef="usd">13384000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTgtMS0xLTEtMjgzMjg_e3c23c2c-06e4-4945-b214-bab771b3a3ee"
      unitRef="usd">12847000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTgtMy0xLTEtMjgzMjg_3e83744f-2b8b-484c-be6a-4324a45e4d2d"
      unitRef="usd">15261000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTktMS0xLTEtMjgzMjg_3136736c-b4ca-4a59-b70c-1f0aabd82f08"
      unitRef="usd">24545000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMTktMy0xLTEtMjgzMjg_2da48658-574f-4eea-b42e-a96f29e53203"
      unitRef="usd">25299000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjAtMS0xLTEtMjgzMjg_48fac619-3ada-4568-8322-0afd6463a9b5"
      unitRef="usd">37392000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjAtMy0xLTEtMjgzMjg_4633c475-42fb-411b-b506-775b8f88ea32"
      unitRef="usd">40560000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjEtMS0xLTEtMjgzMjg_e98e52e1-bb4b-499d-94e0-ab283c674332"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjEtMy0xLTEtMjgzMjg_305826f5-a298-4351-9d78-97a9ec19d47c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF8yMQ_3d80c300-76e3-49ff-b282-74bcb8b5ae13"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF8yMQ_fd298202-2c06-4634-b463-c16c58b8c918"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF8zNQ_5246d909-b43e-42d1-8b93-7dbcf758d93e"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF8zNQ_a57f59bb-1ffa-4618-9d05-386a59e05239"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF83MA_1af2c3e4-4a71-4972-b898-7821b4b29da5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF83MA_b2ff6bd9-6588-49be-af4d-5dfff729062f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF83MA_b4c35379-6a37-4b5f-bfb2-e80f1314d585"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjpjMGQxMzcxYjFmMWU0NDk4YmMzODI0M2FhYWMwYWNiZF83MA_d357dbb0-395c-46b4-8d3d-1f685e97e45a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMS0xLTEtMjgzMjg_3cbd3a53-8147-4589-93ff-826a68b9223f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjQtMy0xLTEtMjgzMjg_7b2902dc-8f15-49f9-b963-5c39bd637ab7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV8xOA_891035ff-045a-4cac-9a5b-6670ccfeaa43"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV8xOA_aaa899fd-1e54-42a4-aa1c-251721ceb271"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV8zMg_36aaa981-a150-461d-bd5f-79a30daca807"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV8zMg_e0655524-cd66-4905-8997-694af4d00b1e"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV82Nw_17c433ab-06af-4828-8294-95c17a5d9c58"
      unitRef="shares">36511947</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV82Nw_9f1887d9-a5f4-4ccc-815c-27cc696726fb"
      unitRef="shares">36511947</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV8xMTA_06fbd806-3b89-4e4f-947e-46dca713154e"
      unitRef="shares">36434297</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMC0xLTEtMjgzMjgvdGV4dHJlZ2lvbjo0NGRiYTZkMGUyY2E0NmU5OTgxNWYwZTQwZmQxMDExZV8xMTA_7b81b0ce-2932-41f2-b931-d0b8280dd611"
      unitRef="shares">36434297</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMS0xLTEtMjgzMjg_780b5be8-a73c-48f7-be3a-5cdab70d9c5a"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjUtMy0xLTEtMjgzMjg_8983b37f-e0a3-482e-8cc5-2eb0ce9c00f4"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjYtMS0xLTEtMjgzMjg_ca9fc1ae-6786-4db4-8e10-90877756049f"
      unitRef="usd">455225000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjYtMy0xLTEtMjgzMjg_446f6f0e-1179-4b4c-a644-a272088d3bb0"
      unitRef="usd">452503000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjctMS0xLTEtMjgzMjg_26d9a5e4-69b9-45d3-aedf-fffe73bb6301"
      unitRef="usd">-1176000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjctMy0xLTEtMjgzMjg_89bbd50f-2f40-4471-977f-80311139eccf"
      unitRef="usd">-1824000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjgtMS0xLTEtMjgzMjg_af2e28ad-be48-4292-a764-00ba0b635717"
      unitRef="usd">-355864000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjgtMy0xLTEtMjgzMjg_b702b26d-2a34-4989-9824-d6ee54364ebe"
      unitRef="usd">-334989000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjktMS0xLTEtMjgzMjg_b9d6ab3a-1298-46f3-b89e-c4753f94a2df"
      unitRef="usd">98190000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMjktMy0xLTEtMjgzMjg_bb3a6c97-56c5-4504-99ee-1651fd42be8a"
      unitRef="usd">115695000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMzAtMS0xLTEtMjgzMjg_a842bc5b-4cf4-4738-a65d-132478be889a"
      unitRef="usd">135582000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xNi9mcmFnOmZhZjQwYmJlYTA1YzRiM2M4ZDE5MzMzMTNmYTkzZTYxL3RhYmxlOmNhNTM4MWIwODAyNDRlYTk5MDVkOGFmMjE3Yjg2OGU5L3RhYmxlcmFuZ2U6Y2E1MzgxYjA4MDI0NGVhOTkwNWQ4YWYyMTdiODY4ZTlfMzAtMy0xLTEtMjgzMjg_6da0b855-1d7c-467c-9318-aa4202a52d2e"
      unitRef="usd">156255000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMy01LTEtMS0yODMyOA_aac5c777-cabb-4b60-822c-d9385105b235"
      unitRef="usd">14753000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMy03LTEtMS0yODMyOA_00d8f501-30c3-4ad6-abcc-e9fa5cec349d"
      unitRef="usd">17786000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfNC01LTEtMS0yODMyOA_30e29c0c-076c-46c2-8052-5b7f1c471014"
      unitRef="usd">6808000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfNC03LTEtMS0yODMyOA_39947f0d-98d4-42f4-b3e1-0e0ab43218f7"
      unitRef="usd">7893000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfNS01LTEtMS0yODMyOA_10540da1-288f-40c3-b9c0-8b10ac1d88a7"
      unitRef="usd">21561000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfNS03LTEtMS0yODMyOA_f9f52497-b47a-44fe-8184-3cd6ffb5c38d"
      unitRef="usd">25679000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfNi01LTEtMS0yODMyOA_73c8cf08-faac-44fb-a7fe-d35c68572ce0"
      unitRef="usd">-21561000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfNi03LTEtMS0yODMyOA_7c8bd6cc-cbc4-40d6-91fa-20729c5eb671"
      unitRef="usd">-25679000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfOS01LTEtMS0yODMyOA_3e20412c-894c-4184-a43a-81e4169191cc"
      unitRef="usd">622000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfOS03LTEtMS0yODMyOA_d1e88c6c-4588-491a-acf6-0b39a1b891db"
      unitRef="usd">406000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTAtNS0xLTEtMjgzMjg_1f664478-2672-42b7-af2e-405586df0691"
      unitRef="usd">64000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTAtNy0xLTEtMjgzMjg_07a11c6f-80d2-4794-89b9-322b90bc2bad"
      unitRef="usd">-234000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTEtNS0xLTEtMjgzMjg_ee53a4ab-3287-419f-a763-ea463a59968f"
      unitRef="usd">686000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTEtNy0xLTEtMjgzMjg_fe09fa7c-77b9-411d-aa88-6537ac3a0741"
      unitRef="usd">172000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTItNS0xLTEtMjgzMjg_619db430-cdf9-423f-b67a-9e4e8d43739c"
      unitRef="usd">-20875000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTItNy0xLTEtMjgzMjg_1af97a28-7010-4afa-98de-529110b0e973"
      unitRef="usd">-25507000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTMtNS0xLTEtMjgzMjg_1db7baa0-dde5-4435-8834-068a7d2c922f"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTMtNS0xLTEtMjgzMjg_c3667fa9-7f3b-48c6-a85d-ef28c0ad1930"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTMtNy0xLTEtMjgzMjg_05330ddd-6f54-40c1-8410-9cccc1dabf9d"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTMtNy0xLTEtMjgzMjg_8f963f13-fcc2-4d29-b632-dc8707c9d44d"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTQtNS0xLTEtMjgzMjg_140c5106-86be-416d-a53c-694c03aad9ec"
      unitRef="shares">36483878</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTQtNS0xLTEtMjgzMjg_5a2341d7-a90d-46c3-a11a-2aefce5b150b"
      unitRef="shares">36483878</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTQtNy0xLTEtMjgzMjg_d272ed3c-face-47a7-9cc0-a87690669ea9"
      unitRef="shares">36271291</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTQtNy0xLTEtMjgzMjg_f40aca61-65e9-4527-a7eb-26e51c421265"
      unitRef="shares">36271291</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTctNS0xLTEtMjgzMjg_0dc72721-0ed4-45ab-ad69-f7a207059c80"
      unitRef="usd">-20875000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTctNy0xLTEtMjgzMjg_32102d79-2698-4966-9e1b-7c51085b276c"
      unitRef="usd">-25507000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTktNS0xLTEtMjgzMjg_737bfecf-42f0-442c-bde2-19afe400991e"
      unitRef="usd">648000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMTktNy0xLTEtMjgzMjg_c64d582f-2297-4267-a413-9c4e0e1f0dbc"
      unitRef="usd">-1361000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMjAtNS0xLTEtMjgzMjg_2b46a7f8-8e01-4579-a9bf-993cef921f24"
      unitRef="usd">-20227000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8xOS9mcmFnOmEyMDAzMjRiNGNlYTRmZDE5MWFjMTg0OGJlYjgxYWQxL3RhYmxlOjM2ZDk4YjliN2E4YTQzMDA5ZThmYjdjNmQ4YTVhODU2L3RhYmxlcmFuZ2U6MzZkOThiOWI3YThhNDMwMDllOGZiN2M2ZDhhNWE4NTZfMjAtNy0xLTEtMjgzMjg_e43556eb-35de-4635-816c-2d17d6615e95"
      unitRef="usd">-26868000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMy0xLTEtMS0yODMyOA_b1fe9fb7-b946-424a-a1cf-2ff5c6e2d015"
      unitRef="usd">-20875000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMy0zLTEtMS0yODMyOA_f71427f1-5e02-44fc-97f8-41b3d2182841"
      unitRef="usd">-25507000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNS0xLTEtMS0yODMyOA_0ff6df5e-da06-4bab-9600-cf9f3d262979"
      unitRef="usd">2671000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNS0zLTEtMS0yODMyOA_679b9ac6-cf74-41fa-8a2a-20a90efa4b3d"
      unitRef="usd">3375000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNi0xLTEtMS0yODMyOA_2d58cd27-5eda-4fba-b91b-be600327e612"
      unitRef="usd">122000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNi0zLTEtMS0yODMyOA_64d39116-ee73-4a63-9da4-656758c3e860"
      unitRef="usd">125000</us-gaap:Depreciation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNy0xLTEtMS0yODMyOA_e1198b93-a8d7-4c95-8943-dcd17af04528"
      unitRef="usd">-109000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNy0zLTEtMS0yODMyOA_a72bb456-b274-4f0c-955a-c6bd42cb4a0b"
      unitRef="usd">-232000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <bdtx:RentExpense
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfOS0xLTEtMS0yODMyOA_b384aea4-0b87-40a4-988a-027fb5c62c92"
      unitRef="usd">690000</bdtx:RentExpense>
    <bdtx:RentExpense
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfOS0zLTEtMS0yODMyOA_340570e9-40d8-4cdc-9daf-0cf59bbb280b"
      unitRef="usd">686000</bdtx:RentExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTItMS0xLTEtMzAxMzk_c9cf4c6b-f2ed-4ccf-bdf6-092a47d3d61c"
      unitRef="usd">-37000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTItMy0xLTEtMzAxMzk_426e7716-7419-4495-95c3-f49b26c03626"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTMtMS0xLTEtMjgzMjg_be7ea442-d5e5-45bf-aedf-7b9b3c416d71"
      unitRef="usd">-383000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTMtMy0xLTEtMjgzMjg_a365aea0-c481-457b-b004-1299c2315d62"
      unitRef="usd">2648000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTQtMS0xLTEtMjgzMjg_c5b0a80e-c52a-4ce9-afea-d239a2ea9720"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTQtMy0xLTEtMjgzMjg_52e1797a-0ff1-46d8-892f-29be58ea51e9"
      unitRef="usd">-6000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTUtMS0xLTEtMjgzMjg_f8a345e3-7a88-44c4-9995-4ff4592761bd"
      unitRef="usd">1169000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTUtMy0xLTEtMjgzMjg_7be72bf9-4e4b-4a30-9abf-64bbaf881d16"
      unitRef="usd">-2224000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTYtMS0xLTEtMjgzMjg_2285770b-8c4c-492f-b25f-7bb39b86c32d"
      unitRef="usd">-3583000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTYtMy0xLTEtMjgzMjg_ce7116b3-f6d0-496f-91a6-c6c7068afa06"
      unitRef="usd">-1958000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <bdtx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTctMS0xLTEtMjgzMjg_68ba4115-f4c0-43ed-bf57-5dc2ef5e0e5d"
      unitRef="usd">-754000</bdtx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <bdtx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTctMy0xLTEtMjgzMjg_e40d2a79-2393-4aa5-b665-d784989292f8"
      unitRef="usd">-687000</bdtx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTgtMS0xLTEtMjgzMjg_1076eee5-0932-4e8d-a803-15dda6d0704c"
      unitRef="usd">-20031000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMTgtMy0xLTEtMjgzMjg_ddca5cb4-63f7-469d-a097-ed40ccb5827d"
      unitRef="usd">-28600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjEtMS0xLTEtMjgzMjg_cfc66b69-b0fd-44fe-8884-5fc8b74c261b"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjEtMy0xLTEtMjgzMjg_f3f56140-8eda-4c7c-bb66-a1e749b1cd67"
      unitRef="usd">7000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjItMS0xLTEtMjgzMjg_1e891ad0-a966-4889-b434-6cd7346f4e36"
      unitRef="usd">24806000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjItMy0xLTEtMjgzMjg_3f2bfd1d-adf4-40ce-ad4e-90d4c0cfd605"
      unitRef="usd">37240000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjMtMS0xLTEtMjgzMjg_af707127-1e41-4d58-b454-004717244880"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjMtMy0xLTEtMjgzMjg_a3047a90-2486-4eae-b5c8-7f7fb01b01bb"
      unitRef="usd">20504000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjQtMS0xLTEtMjgzMjg_035104b9-265b-4ef9-82fd-caadaeeb6216"
      unitRef="usd">24806000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjQtMy0xLTEtMjgzMjg_a5bcfc15-53c9-4842-9571-8817ea09cd60"
      unitRef="usd">16729000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjctMS0xLTEtMjgzMjg_a4fcc066-a894-4c9a-91e3-6eebf5b81f86"
      unitRef="usd">51000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMjctMy0xLTEtMjgzMjg_ef41d0aa-5d53-4f68-a4cb-a0e21669c29b"
      unitRef="usd">153000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzAtMS0xLTEtMjgzMjg_c9e575f5-7be5-496a-8869-5f6869b58895"
      unitRef="usd">51000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzAtMy0xLTEtMjgzMjg_4a36b67a-2157-4cec-b67c-88a60d02e9e2"
      unitRef="usd">153000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzEtMS0xLTEtMjgzMjg_d0ff5ae6-d812-4e23-a803-51a22fddaabb"
      unitRef="usd">4826000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzEtMy0xLTEtMjgzMjg_b3372ba7-89ba-4acc-a006-248aba0cbcf1"
      unitRef="usd">-11718000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzItMS0xLTEtMjgzMjg_dee0c3e4-3846-43fc-b71b-0f3ea5cbe30b"
      unitRef="usd">35483000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i18236f10c6bb43fba2c9c3fbf41ce4ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzItMy0xLTEtMjgzMjg_1bae7717-fa95-4501-bae1-5eaaff5b4420"
      unitRef="usd">67022000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzMtMS0xLTEtMjgzMjg_556f099d-5c30-4326-9558-173845f64b61"
      unitRef="usd">40309000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzMtMy0xLTEtMjgzMjg_1ee0eb54-d70c-4498-a7aa-140fa1689916"
      unitRef="usd">55304000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzUtMS0xLTEtMjgzMjg_f318e46f-c4b5-4217-a239-7b25b135cd50"
      unitRef="usd">39141000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzUtMy0xLTEtMjgzMjg_5add4f79-8835-4d22-8fae-9c84708fc483"
      unitRef="usd">54081000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzYtMS0xLTEtMjgzMjg_9d80d442-9982-45c3-9216-6da3e344dae1"
      unitRef="usd">1168000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzYtMy0xLTEtMjgzMjg_2fe692ea-9b62-4bd1-9adf-24a1025d8765"
      unitRef="usd">1223000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzctMS0xLTEtMjgzMjg_cdfcc680-3490-4b3e-b627-c51f122fc0ee"
      unitRef="usd">40309000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfMzctMy0xLTEtMjgzMjg_716d6289-8535-4694-93ab-6eb2a75145fe"
      unitRef="usd">55304000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <bdtx:SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNDMtMS0xLTEtMzAxNzA_34907199-cc59-4e4b-ad2c-c3be3430820f"
      unitRef="usd">95000</bdtx:SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets>
    <bdtx:SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNDMtMy0xLTEtMzAxNzA_52e84414-1f61-41a3-b17e-3b5f0d189409"
      unitRef="usd">0</bdtx:SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets>
    <bdtx:IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNDItMS0xLTEtMjgzMjg_375843df-79ce-4340-96e0-9337052d8983"
      unitRef="usd">0</bdtx:IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <bdtx:IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yMi9mcmFnOmY2MjM1OGIzNzIwMDRlMzBiNmNlOTdlMmQ1NTg4MzRmL3RhYmxlOmQ2MDYzNDUzMTE0MDQzMTI4YjZjMzU3YzBiNTM1OWE1L3RhYmxlcmFuZ2U6ZDYwNjM0NTMxMTQwNDMxMjhiNmMzNTdjMGI1MzU5YTVfNDItMy0xLTEtMjgzMjg_fe6062a1-17be-4cba-b2bc-798d97a0498b"
      unitRef="usd">115000</bdtx:IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9928ba02038f4ae78a1c4a0dd70f34fe_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMy0xLTEtMS0yODMyOA_db616723-c1d2-4243-ba02-49ed2eb9048e"
      unitRef="shares">36234624</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9928ba02038f4ae78a1c4a0dd70f34fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMy0zLTEtMS0yODMyOA_24e26e91-1911-4fdb-9b8e-590c1a51df88"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5805f6a69cd441a69d534bb81c0e06da_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMy01LTEtMS0yODMyOA_6a10c35b-9ba1-4665-aa6d-269ec2d3de81"
      unitRef="usd">440129000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i68d16179c5a14c7ebdbc734b0382415d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMy03LTEtMS0yODMyOA_e0c81dfc-0ba5-47d2-b3a3-b9cec6a9b497"
      unitRef="usd">-414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i456bfd3daab443ea80542d825dc5fe07_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMy05LTEtMS0yODMyOA_1c2f0e0c-952d-497c-8e13-df72ceb6ea01"
      unitRef="usd">-243820000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i18236f10c6bb43fba2c9c3fbf41ce4ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMy0xMS0xLTEtMjgzMjg_c01b1098-61c9-4c4e-86d5-47d1df219c45"
      unitRef="usd">195900000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i08b218a8d5294a0cbed694379ad58ce2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNC0xLTEtMS0yODMyOA_7ff9d1a6-7203-4c33-adbd-08c8162318c6"
      unitRef="shares">3565</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3e95a40d0c894120a1db7291d5cee4e2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNC01LTEtMS0yODMyOA_b0a0be93-3db4-4a32-a4cf-b596778acb2a"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNC0xMS0xLTEtMjgzMjg_a91b13b1-b7f7-45c9-8979-a58c6b1c5626"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i08b218a8d5294a0cbed694379ad58ce2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNS0xLTEtMS0yODMyOA_ed789315-cf89-40a0-a0f2-56920545bb8e"
      unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i08b218a8d5294a0cbed694379ad58ce2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNi0xLTEtMS0yODc3Nw_dc3de71d-f860-4bb8-ad57-c33d5afb48b3"
      unitRef="shares">31341</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3e95a40d0c894120a1db7291d5cee4e2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNi01LTEtMS0yODc3Nw_55dd451f-01f0-4f8c-b47e-fa97572a93c9"
      unitRef="usd">142000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNi0xMS0xLTEtMjg3Nzc_0f6e2367-e43a-4389-b260-39700bd581fe"
      unitRef="usd">142000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i08b218a8d5294a0cbed694379ad58ce2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNi0xLTEtMS0yODMyOA_ca4c724e-a6c3-43a4-9388-1695d7b53fb9"
      unitRef="shares">13038</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3e95a40d0c894120a1db7291d5cee4e2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNi01LTEtMS0yODMyOA_bf047aa1-60f2-476a-8a64-717072717e81"
      unitRef="usd">3375000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNi0xMS0xLTEtMjgzMjg_f39db605-77de-451d-86fe-9fdb01c3edac"
      unitRef="usd">3375000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i94cc5dde32e24698bf33abd440aee5b4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNy03LTEtMS0yODMyOA_e2681f61-cc96-4d65-bb1b-d863b2dcfe44"
      unitRef="usd">-1361000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfNy0xMS0xLTEtMjgzMjg_326e9944-edf3-4e11-9515-12ceab43708d"
      unitRef="usd">-1361000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ic1e742d729ce432ca0f35a2494585ade_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOC05LTEtMS0yODMyOA_79158554-d1f8-4362-8d32-2c0233566c31"
      unitRef="usd">-25507000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOC0xMS0xLTEtMjgzMjg_69c20bc0-274e-4ff4-b931-42682d759b72"
      unitRef="usd">-25507000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i28226edd859e4dab945d64e22ffcaebf_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOS0xLTEtMS0yODMyOA_ecd62544-a8de-42c4-85a1-fd1870377e0c"
      unitRef="shares">36287568</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i28226edd859e4dab945d64e22ffcaebf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOS0zLTEtMS0yODMyOA_f83bcf27-70c5-4acd-900f-245687f6f092"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ef21fb740fd4df29d87c63818a8be4f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOS01LTEtMS0yODMyOA_fb45e474-bf9d-47bf-a236-8a8b068a7c48"
      unitRef="usd">443657000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i550bd7cfc5394510a5c782d6d944408a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOS03LTEtMS0yODMyOA_3faca209-11ea-470a-a226-fd56d27a6c52"
      unitRef="usd">-1775000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58ce2b6758eb48fa96ddd6fc6e0b2a03_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOS05LTEtMS0yODMyOA_7f618d77-d003-4a5c-90d3-827a66737853"
      unitRef="usd">-269327000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfOS0xMS0xLTEtMjgzMjg_c8a2726c-d722-4272-8c75-a38525ac2fcf"
      unitRef="usd">172560000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7dad2752f6d24f69beb01b7d41d018ea_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjYtMS0xLTEtMjgzMjg_7139c44f-f0c0-4340-ab15-299014767b07"
      unitRef="shares">36434297</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7dad2752f6d24f69beb01b7d41d018ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjYtMy0xLTEtMjgzMjg_9d9e671f-84eb-46fe-b27b-858ae326ce0a"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i44fbc51eccac4780a51aa2110725c195_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjYtNS0xLTEtMjgzMjg_ee135480-fb04-4b78-968b-872847a57b3c"
      unitRef="usd">452503000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3aa33c9766164861a9a2941ebecacdc5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjYtNy0xLTEtMjgzMjg_0e0f2c67-3c12-4a66-8c7e-16a93a8461f1"
      unitRef="usd">-1824000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d19e2d7bf5648c0a1412530bc5a4c83_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjYtOS0xLTEtMjgzMjg_45b0f622-6d5f-4579-8456-e864bf186723"
      unitRef="usd">-334989000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjYtMTEtMS0xLTI4MzI4_8cdcc683-b23b-4d16-b3db-68797a0d46cb"
      unitRef="usd">115695000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="if3528e294eb84233bd324a45f9d5729f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjgtMS0xLTEtMjgzMjg_475d7ad1-57cb-4e71-aca9-d0dcc7bdf235"
      unitRef="shares">23575</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="if3528e294eb84233bd324a45f9d5729f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzEtMS0xLTEtMzEyNDc_693f4272-6a6a-48cb-9186-1403b97c80e0"
      unitRef="shares">3903</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if3528e294eb84233bd324a45f9d5729f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjktMS0xLTEtMjgzMjg_42648c00-0924-4ec6-867a-34b0bf1468d1"
      unitRef="shares">33202</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0092b7cc057941c08850f1ad6c56a4d3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjktNS0xLTEtMjgzMjg_44aab3c7-03ec-4d99-a8f5-7681e0957141"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMjktMTEtMS0xLTI4MzI4_99724132-caee-4c30-b4cd-67912fad6883"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if3528e294eb84233bd324a45f9d5729f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzAtMS0xLTEtMjgzMjg_a00ede78-f3c3-40b8-be88-6397c61c1ecf"
      unitRef="shares">24776</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0092b7cc057941c08850f1ad6c56a4d3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzAtNS0xLTEtMjgzMjg_8027ae7a-96d2-4746-9cc8-52599837f188"
      unitRef="usd">2671000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzAtMTEtMS0xLTI4MzI4_fff23e3e-d38a-40d9-94ab-74d7f6b1cbfc"
      unitRef="usd">2671000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i9a14724cbb314a469c727f2b58faa85e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzEtNy0xLTEtMjgzMjg_a5592a09-04e2-46f2-8a70-46ee7e5da32c"
      unitRef="usd">648000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzEtMTEtMS0xLTI4MzI4_0d165030-d1ed-4f04-8f7d-fdeca1d1a08b"
      unitRef="usd">648000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i43d5ebddb1f54d71b47373c1b912f7e9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzItOS0xLTEtMjgzMjg_e4d97407-4fbd-40e2-a282-c5b7edc63aad"
      unitRef="usd">-20875000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzItMTEtMS0xLTI4MzI4_e5de7be7-8645-49ee-9c4d-d5fc267a8dfa"
      unitRef="usd">-20875000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1759f611756a4cffabc3f4c4fb8a6561_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzMtMS0xLTEtMjgzMjg_1f86151c-8736-4961-9585-26a60f532fe5"
      unitRef="shares">36511947</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1759f611756a4cffabc3f4c4fb8a6561_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzMtMy0xLTEtMjgzMjg_3ca0d9ed-1457-4708-a5e1-cfda26344fa6"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4440f7aa29164195bfa74c860ee07235_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzMtNS0xLTEtMjgzMjg_5cd1e669-8c86-420d-a22a-d08f5bebc97b"
      unitRef="usd">455225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id112bbe0621046fca2f448c03c6b6480_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzMtNy0xLTEtMjgzMjg_80327be0-a386-401d-82b5-9438a6fcdb01"
      unitRef="usd">-1176000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c4a9410dd2e40eb9adaf67022861157_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzMtOS0xLTEtMjgzMjg_ce3e5137-cf2a-48a4-819c-61086c509d38"
      unitRef="usd">-355864000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8yNS9mcmFnOjU1NjIwYzFhOTU4NTQ1ZWQ5NWZkOTQxNjNmNWEyN2I5L3RhYmxlOmM3YmE1NWRiM2FkNjQ0OGY4NzUwMzEzYmQ1MmQ2ZGQ0L3RhYmxlcmFuZ2U6YzdiYTU1ZGIzYWQ2NDQ4Zjg3NTAzMTNiZDUyZDZkZDRfMzMtMTEtMS0xLTI4MzI4_d0db7a7b-f6ef-4f81-a0b5-37580125fc4f"
      unitRef="usd">98190000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zMS9mcmFnOjc2MGE2N2U0OTAxNjQwMDc4OGZhZDFmZjQ0ZDhiOGU1L3RleHRyZWdpb246NzYwYTY3ZTQ5MDE2NDAwNzg4ZmFkMWZmNDRkOGI4ZTVfNzA0NA_6cb709d6-4a00-442f-b641-48016514a9ab">NATURE OF BUSINESS AND BASIS OF PRESENTATION&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Black Diamond Therapeutics, Inc. (the Company) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development of its mutation, allostery, and pharmacology drug discovery engine. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;On November 14, 2022, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement), with the Securities and Exchange Commission (the SEC), which covers the offering, issuance and sale of the Company&#x2019;s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum offering price of $500&#160;million. The Company simultaneously entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. As of March&#160;31, 2023, no sales have been made pursuant to the ATM Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred stock and common stock. The Company expects to continue to generate operating losses for the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of May&#160;9, 2023, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, or reduce headcount and general and administrative costs, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zMS9mcmFnOjc2MGE2N2U0OTAxNjQwMDc4OGZhZDFmZjQ0ZDhiOGU1L3RleHRyZWdpb246NzYwYTY3ZTQ5MDE2NDAwNzg4ZmFkMWZmNDRkOGI4ZTVfNzA0NQ_958d29bc-5a10-4453-95a1-8ff098e354fb">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Black Diamond Therapeutics, Inc. (the Company) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development of its mutation, allostery, and pharmacology drug discovery engine. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited interim financial information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#x2019;s Annual Report. In the opinion of the Company&#x2019;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <bdtx:SaleOfStockAuthorizedConsideration
      contextRef="i759d4ddb3ad64fd38d5531cb44817594_D20221114-20221114"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zMS9mcmFnOjc2MGE2N2U0OTAxNjQwMDc4OGZhZDFmZjQ0ZDhiOGU1L3RleHRyZWdpb246NzYwYTY3ZTQ5MDE2NDAwNzg4ZmFkMWZmNDRkOGI4ZTVfMTY0OTI2NzQ1MjE4NA_e66eba25-f1af-4173-a434-e634c461c573"
      unitRef="usd">500000000</bdtx:SaleOfStockAuthorizedConsideration>
    <bdtx:SaleOfStockAuthorizedConsideration
      contextRef="i5f823a64b85d4ac7bd10d06b5df686fb_D20221114-20221114"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zMS9mcmFnOjc2MGE2N2U0OTAxNjQwMDc4OGZhZDFmZjQ0ZDhiOGU1L3RleHRyZWdpb246NzYwYTY3ZTQ5MDE2NDAwNzg4ZmFkMWZmNDRkOGI4ZTVfMjE4NQ_998365e7-a5af-4fa8-81a6-6c7784164024"
      unitRef="usd">150000000</bdtx:SaleOfStockAuthorizedConsideration>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNC9mcmFnOjJhNzU1OWY1NWRkZDRmNzBiM2ExYzJlYWE4MzFiOTAyL3RleHRyZWdpb246MmE3NTU5ZjU1ZGRkNGY3MGIzYTFjMmVhYTgzMWI5MDJfMzY3MQ_bbf90c69-0e79-4231-9346-9b104f590f5e">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited interim financial information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#x2019;s Annual Report. In the opinion of the Company&#x2019;s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company continues to monitor the impact of global economic developments, political unrest, high inflation, the recent failure of certain banks and financial institutions, and health crises, such as the COVID-19 pandemic, on all aspects of its business, and has considered the impact of these factors on estimates within its financial statements. The extent to which future developments may impact the Company&#x2019;s business, results of operations or financial condition are uncertain and cannot be predicted with confidence and there may be changes to estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of these factors and is not aware of any specific related event or circumstance that would require it to update its estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNC9mcmFnOjJhNzU1OWY1NWRkZDRmNzBiM2ExYzJlYWE4MzFiOTAyL3RleHRyZWdpb246MmE3NTU5ZjU1ZGRkNGY3MGIzYTFjMmVhYTgzMWI5MDJfMzY2NQ_b1b130ea-ec60-4b48-a554-dfe7adbf7faa">Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNC9mcmFnOjJhNzU1OWY1NWRkZDRmNzBiM2ExYzJlYWE4MzFiOTAyL3RleHRyZWdpb246MmE3NTU5ZjU1ZGRkNGY3MGIzYTFjMmVhYTgzMWI5MDJfMzY2OQ_79f59514-5b19-423f-911a-50e09a4a902a">Use of estimates The preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</us-gaap:UseOfEstimates>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RleHRyZWdpb246YTlhZTNhZDRjNTU0NDhmY2FhM2FlZjg4ZjViMTI3OWFfMTE5OQ_f6bef67d-c5c5-42fd-8dfe-7571975af16e">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Fair value measurements at March 31, 2023 using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;15,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;15,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;27,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;27,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;15,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;64,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;79,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Fair value measurements at December 31, 2022 using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;32,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;32,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;45,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;45,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;32,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;88,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;120,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;There were no transfers in or out of Level 3 categories in the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RleHRyZWdpb246YTlhZTNhZDRjNTU0NDhmY2FhM2FlZjg4ZjViMTI3OWFfMTIwMA_19982715-8b10-4000-a4c2-250d7b76446b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Fair value measurements at March 31, 2023 using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;15,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;15,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;27,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;27,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;15,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;64,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;79,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Fair value measurements at December 31, 2022 using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;32,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;32,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;45,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;45,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;32,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;88,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;120,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibb328d7ce3ad4166b5b61eefd59f420a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNC0xLTEtMS0yODMyOA_9195f23c-eded-40e7-a37e-7dee8932430d"
      unitRef="usd">15587000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ice5277e7080f4af5bb25a652a809641e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNC0zLTEtMS0yODMyOA_aa41793a-26a3-4de2-98aa-bb04e6ca108b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6687f45413a4419bb690fef99015b01f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNC01LTEtMS0yODMyOA_b18b7e63-7881-4a07-b92f-29576756c931"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0274173257c24f579ec10811eeb0c81a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNC03LTEtMS0yODMyOA_f10c3830-52d9-4783-98b0-2adf1b870f62"
      unitRef="usd">15587000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7b0e3b7df6074918b33a2cdc71901202_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNy0xLTEtMS0yODMyOA_31b4caed-f104-43cb-98e5-4a529d24016d"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i08fef76a1c7c437c9d1b3eda6db89dd3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNy0zLTEtMS0yODMyOA_c919322f-2164-4011-bf17-c3d61f831caa"
      unitRef="usd">36242000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i55653debaf274b11b4ac7a51ce4696e4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNy01LTEtMS0yODMyOA_f0bbc9e1-d0f0-428d-abc5-cb47789976b9"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7a33cd0b3c4a4b16a14fe04651a86c84_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfNy03LTEtMS0yODMyOA_5195c55e-3e92-4eec-a34e-79c62a25704c"
      unitRef="usd">36242000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0a75e0a6cc5a43a49aa062ef1bece4c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOC0xLTEtMS0yODMyOA_23d2d341-c5e1-4133-a659-900e72572fde"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i84693306474940138214ef4e5288008e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOC0zLTEtMS0yODMyOA_f814c2bb-26b9-4c51-aa9c-a9413c3666ca"
      unitRef="usd">27983000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0023816158b34fbdbb78091138c96439_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOC01LTEtMS0yODMyOA_c84103e9-1180-4e58-8365-f5c438dd5b99"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i92484769461f4b74b3d02cb2e1f9e9a2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOC03LTEtMS0yODMyOA_cb7f14d6-2204-4811-81e1-43f238c802a0"
      unitRef="usd">27983000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7d84216f3a25460d9a88c52522dd8d6f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOS0xLTEtMS0yODMyOA_44b3cc76-383d-4ec0-a577-a0170e3e3815"
      unitRef="usd">15587000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i206b8d6455b84e2f9f3f3b9a6c71a580_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOS0zLTEtMS0yODMyOA_1de0791b-d9b3-452a-859c-21268552f6aa"
      unitRef="usd">64225000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3da457e1122144b4b86fe4e412be3000_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOS01LTEtMS0yODMyOA_9ae67d0a-4799-4525-976c-8115d6203345"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie1de270b96e64e8d86b7cbcec1f81067_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmI3Y2Q2M2FjZTc4ZDQyM2ZiMWEzODk3OTU1NDQyMjlhL3RhYmxlcmFuZ2U6YjdjZDYzYWNlNzhkNDIzZmIxYTM4OTc5NTU0NDIyOWFfOS03LTEtMS0yODMyOA_10a81cff-76a4-4948-81bd-b16fbef12f78"
      unitRef="usd">79812000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4b518c619fde4699bb430693ce9bb402_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNC0xLTEtMS0yODMyOA_9c7fa682-dce9-4415-83e3-098824e60da8"
      unitRef="usd">32278000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0954e4764df9420ca7f966a581b88ab5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNC0zLTEtMS0yODMyOA_8152656d-49eb-451f-8c0f-5b3620752a65"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if3bdbcb5dab7449a919d62bf333c2769_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNC01LTEtMS0yODMyOA_ebb10b52-c811-4ae6-afe0-1b02a8701e5b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifff94a18639d4cc9ace4b7980f18491b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNC03LTEtMS0yODMyOA_8b8243fe-2714-4c03-a70e-c6fe81aae4e2"
      unitRef="usd">32278000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="iea5548dbdcc84e34b38db41da417d969_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNi0xLTEtMS0yODMyOA_d49c6298-3ba2-4b3e-8a6a-10422c14f0e3"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie47787450b694b2ea0d0a633fb578e87_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNi0zLTEtMS0yODMyOA_b8f4d2e5-b903-4857-bbad-892f83010ec7"
      unitRef="usd">3747000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i143f2d561c544650ae4cec160b40d837_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNi01LTEtMS0yODMyOA_f3ff6638-efec-4143-8632-2d4e71070734"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i559c92eb9a82422882d92a40b4732e87_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNi03LTEtMS0yODMyOA_50767c07-f470-4869-820f-ce657cf136b0"
      unitRef="usd">3747000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5c4d688c720846d2a8ca1d0ef6ad503a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNy0xLTEtMS0yODMyOA_f68d3942-b53a-4975-bb2a-2a6bf8560176"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i55878f702cbe4a6785d7165f6bc9ba1b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNy0zLTEtMS0yODMyOA_8b61f8ab-43d7-4374-b2c4-99e99404a328"
      unitRef="usd">45643000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="idf6167cc94b8412da93063def658ef27_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNy01LTEtMS0yODMyOA_68d3a191-7e95-40fa-8952-2a7f277123a4"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i76c3bea13eeb4df78dbeccc4af6e9ef1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfNy03LTEtMS0yODMyOA_3051bc79-9d15-4160-b97b-d8d82a8ed26a"
      unitRef="usd">45643000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i694eac40ab4244e99565a2f9e0787907_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOC0xLTEtMS0yODMyOA_d0536e1a-e5be-4c48-852a-744458ce5e0c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2134d67ef3194c7486e8e79dbdced6a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOC0zLTEtMS0yODMyOA_5f7baef7-a8bb-407f-9431-697d5b9e7f91"
      unitRef="usd">39102000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i885123a2113040f3b1921f9e90183ed4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOC01LTEtMS0yODMyOA_3877c651-83b2-4a37-af30-6d013cef769d"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i70fe665f9b0b4d5f97f1dd8448e2e411_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOC03LTEtMS0yODMyOA_3d51901c-f6fc-4c22-872c-8814b27b77fa"
      unitRef="usd">39102000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i38fd7a41430b45bb87c13424399f3a46_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOS0xLTEtMS0yODMyOA_7bf879a0-7010-4251-9831-495beb72564a"
      unitRef="usd">32278000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie9f1757297d34af5b00fef34b103aa0a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOS0zLTEtMS0yODMyOA_1266b53e-b60f-4db9-8a04-49998954ddb9"
      unitRef="usd">88492000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i75b0d8ea13e94b30a9276dd91f107156_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOS01LTEtMS0yODMyOA_0035ae77-e00e-4941-bcd9-a46f39e7e2ba"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i939ee62047f64d468543c94f23dee9b3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV8zNy9mcmFnOmE5YWUzYWQ0YzU1NDQ4ZmNhYTNhZWY4OGY1YjEyNzlhL3RhYmxlOmY3NzY4ZDQ0MDM5OTRkNzliMTAzZTVkMGNhNjY4YjRjL3RhYmxlcmFuZ2U6Zjc3NjhkNDQwMzk5NGQ3OWIxMDNlNWQwY2E2NjhiNGNfOS03LTEtMS0yODMyOA_2990d23d-4d4b-462c-b0b7-a866bb9ada88"
      unitRef="usd">120770000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RleHRyZWdpb246M2JjOGQxMmE1MjRlNDU2Zjg0YzVkNmQ5OWVlNmRkOWJfMTYxNw_8f4d7a17-0c97-4410-a567-d4ac512a099b">INVESTMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, investments were comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;28,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;27,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;65,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(1,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;64,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, investments were comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;46,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;45,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;40,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(1,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;90,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(1,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;88,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for corporate bonds with a fair value of $1,983 that had maturities of one to three years. As of March&#160;31, 2023, all marketable securities held by the Company were in a loss position. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds, and commercial paper with a fair value of $13,687 that had maturities of one to three years. As of December&#160;31, 2022, all marketable securities held by the Company were in a loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company reviewed its investment portfolio to assess the unrealized losses on its available-for-sale investments.  The Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company also determined no portion of the unrealized losses relate to a credit loss.  There have been no impairments of the Company&#x2019;s assets measured and carried at fair value during the three months ended March&#160;31, 2023 and the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RleHRyZWdpb246M2JjOGQxMmE1MjRlNDU2Zjg0YzVkNmQ5OWVlNmRkOWJfMTYxOA_48faf8d3-7855-4a90-b9a3-6f965e54ab33">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, investments were comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;28,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;27,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;65,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(1,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;64,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, investments were comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;46,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;45,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;U.S. Government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;40,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(1,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;39,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;90,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(1,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;88,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9351ba53ff254b0f88999f498b0319e9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMi0xLTEtMS0yODMyOA_a954ef97-015f-4e0e-90d6-a04b3278592f"
      unitRef="usd">36780000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9351ba53ff254b0f88999f498b0319e9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMi0zLTEtMS0yODMyOA_14caca5a-0580-43ba-9284-7c885d4bf589"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9351ba53ff254b0f88999f498b0319e9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMi01LTEtMS0yODMyOA_1612e321-9bbc-4383-8150-1351ee24b24f"
      unitRef="usd">538000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9351ba53ff254b0f88999f498b0319e9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMi03LTEtMS0yODMyOA_88fb8410-a65a-4f97-adb7-a648b2a8ba2e"
      unitRef="usd">36242000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia8f2c21f696d4b7da626acb69831ccb0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMy0xLTEtMS0yODMyOA_98e9e8b7-0100-4122-bdcf-06e563fd6b67"
      unitRef="usd">28621000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia8f2c21f696d4b7da626acb69831ccb0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMy0zLTEtMS0yODMyOA_cd250422-ced5-4618-92a7-da99bc470abb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia8f2c21f696d4b7da626acb69831ccb0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMy01LTEtMS0yODMyOA_ab5056d4-72ef-4fc8-aa55-20b9ba38a4dd"
      unitRef="usd">638000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8f2c21f696d4b7da626acb69831ccb0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfMy03LTEtMS0yODMyOA_7f38e395-c799-4882-a214-1c0b9958cbf4"
      unitRef="usd">27983000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfNC0xLTEtMS0yODMyOA_a119e1b9-4426-406a-8133-41838ac2aa7e"
      unitRef="usd">65401000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfNC0zLTEtMS0yODMyOA_23ccafc3-b2ac-446a-89e1-e8af03a80dd2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfNC01LTEtMS0yODMyOA_0f3fb17e-42c4-42d7-b94d-f0b9eedce0a2"
      unitRef="usd">1176000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOmZlMGE5MDQzYmQ0MzRjMjViMWEyNTZmNDc4OTc0MDNmL3RhYmxlcmFuZ2U6ZmUwYTkwNDNiZDQzNGMyNWIxYTI1NmY0Nzg5NzQwM2ZfNC03LTEtMS0yODMyOA_dc982aa1-2831-466d-a202-a4bb5922fa15"
      unitRef="usd">64225000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4e1463d111734f7ba01a42c102369654_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMS0xLTEtMS0yODMyOA_f60983e9-47e8-415a-a533-1bac871cfcd3"
      unitRef="usd">3748000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4e1463d111734f7ba01a42c102369654_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMS0zLTEtMS0yODMyOA_56322659-817e-4e81-8a91-07ee9ec14acb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4e1463d111734f7ba01a42c102369654_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMS01LTEtMS0yODMyOA_82a3b1b0-75ab-42af-86e9-72efcc1caa1b"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e1463d111734f7ba01a42c102369654_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMS03LTEtMS0yODMyOA_21063dcf-08d4-42d3-84a1-baf101dd1c79"
      unitRef="usd">3747000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i04d9627eeb7e470e8198fa77f00eba51_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMi0xLTEtMS0yODMyOA_f0575909-eb31-42d6-b821-1327c8693aab"
      unitRef="usd">46443000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i04d9627eeb7e470e8198fa77f00eba51_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMi0zLTEtMS0yODMyOA_040609d9-64f8-4a3c-ab20-5482f7c90f43"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i04d9627eeb7e470e8198fa77f00eba51_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMi01LTEtMS0yODMyOA_f69f8f6e-5bbd-4810-855f-7d7ff493baff"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i04d9627eeb7e470e8198fa77f00eba51_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMi03LTEtMS0yODMyOA_fe9e6615-b9eb-49e6-8dc9-04df58022f47"
      unitRef="usd">45643000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5395e8eff10344b5ac2d2b3de662edb3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMy0xLTEtMS0yODMyOA_a2685213-5b6c-4473-990f-9a66394ba88a"
      unitRef="usd">40125000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5395e8eff10344b5ac2d2b3de662edb3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMy0zLTEtMS0yODMyOA_c4218523-cd51-4847-bc6e-412f0eb12cb9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5395e8eff10344b5ac2d2b3de662edb3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMy01LTEtMS0yODMyOA_a938861c-872f-4d89-842f-2280de9a7a89"
      unitRef="usd">1023000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5395e8eff10344b5ac2d2b3de662edb3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfMy03LTEtMS0yODMyOA_4be00f81-5e50-404d-87ef-e1cc15744754"
      unitRef="usd">39102000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfNC0xLTEtMS0yODMyOA_7b61f4ba-42f6-470f-bc99-846336f88612"
      unitRef="usd">90316000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfNC0zLTEtMS0yODMyOA_e9e35d62-861f-4ed5-ade4-79a806ddb94f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfNC01LTEtMS0yODMyOA_490bcd97-4bf6-4bbf-8856-a80315dd783e"
      unitRef="usd">1824000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RhYmxlOjM3YzA3ZTVlN2NmZTQ3Yjc5MjQzMWVhZTFkYmJkZGY5L3RhYmxlcmFuZ2U6MzdjMDdlNWU3Y2ZlNDdiNzkyNDMxZWFlMWRiYmRkZjlfNC03LTEtMS0yODMyOA_21a7581c-ff6b-44e9-bbaf-89f4989c26be"
      unitRef="usd">88492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RleHRyZWdpb246M2JjOGQxMmE1MjRlNDU2Zjg0YzVkNmQ5OWVlNmRkOWJfMzQx_5916e45b-d1ee-4bcf-9d88-65b683412e98"
      unitRef="usd">1983000</bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree>
    <bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RleHRyZWdpb246M2JjOGQxMmE1MjRlNDU2Zjg0YzVkNmQ5OWVlNmRkOWJfNTY4_b3972022-0c63-4c75-bb1d-73fefd7c289a"
      unitRef="usd">13687000</bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RleHRyZWdpb246M2JjOGQxMmE1MjRlNDU2Zjg0YzVkNmQ5OWVlNmRkOWJfMTA5OTUxMTYzMDkzNg_0d6e3869-bcd4-447d-beeb-f25bdca4a572"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="i700858d5fb2842d8aa731adad03358f0_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80MC9mcmFnOjNiYzhkMTJhNTI0ZTQ1NmY4NGM1ZDZkOTllZTZkZDliL3RleHRyZWdpb246M2JjOGQxMmE1MjRlNDU2Zjg0YzVkNmQ5OWVlNmRkOWJfMTA5OTUxMTYzMDkzNg_697b67cd-035d-4aa2-b3a3-7b0ac8a1b915"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RleHRyZWdpb246YWVjMjk4YjQ5MDRkNGFiY2JhODNhNGVlNWU0MmVjNjJfMTcx_079d7360-dae8-4828-af1c-6ac2a8de42ee">PROPERTY AND EQUIPMENT&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total Property and Equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the three months ended March&#160;31, 2023 and 2022 was $122 and $125, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RleHRyZWdpb246YWVjMjk4YjQ5MDRkNGFiY2JhODNhNGVlNWU0MmVjNjJfMTcy_00c1578c-5f29-40f8-a692-a9e7215a05af">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total Property and Equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if5f6c4be62384e909f6b4e404ead2edc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfMS0xLTEtMS0yODMyOA_e7d475a8-43be-4613-a8d1-dbaf30005e93"
      unitRef="usd">611000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i93b69b82ac6a4bb9a460d33085d57f68_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfMS0zLTEtMS0yODMyOA_82fe5e45-da46-4604-b5b4-00ea0893d00d"
      unitRef="usd">770000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i521fe07ef68d4b4a935d05639717ad02_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfMi0xLTEtMS0yODMyOA_669e5e4b-81c4-496e-ace0-46822e27498f"
      unitRef="usd">17000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2982e6cbd8454350b0195b786784f14a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfMi0zLTEtMS0yODMyOA_b764fe87-cbf5-4265-b58d-9eb117549ba5"
      unitRef="usd">17000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7a98c5b77af845f1970750ebfc01cbf6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfMy0xLTEtMS0yODMyOA_8d05c33f-0ac6-4b32-9dd0-e1be64166a26"
      unitRef="usd">38000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4c3fa369595f4fd88697523852da9e92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfMy0zLTEtMS0yODMyOA_914d98b9-39ad-42f6-b2a9-a8c1097686a6"
      unitRef="usd">38000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i758366b058d642888997dc00f48056d1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfNC0xLTEtMS0yODMyOA_5959f065-564a-4d36-aa69-333eeddb3a8e"
      unitRef="usd">2512000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic51c923c2ba142dca072c9813d731cae_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfNC0zLTEtMS0yODMyOA_0c5c89da-606a-4ca5-87bb-7a28711f399a"
      unitRef="usd">2512000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfNi0xLTEtMS0yODMyOA_ebdd874c-0bae-4368-a9ec-8578efba22e4"
      unitRef="usd">3178000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfNi0zLTEtMS0yODMyOA_787827b9-db0e-4caf-b034-6095f09be1f6"
      unitRef="usd">3337000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfNy0xLTEtMS0yODMyOA_67b7206e-d3f8-4e0b-9b33-cc7ed375fd7a"
      unitRef="usd">845000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfNy0zLTEtMS0yODMyOA_f438125e-9d40-47ce-8b4e-3d05a5dbb7d4"
      unitRef="usd">750000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfOC0xLTEtMS0yODMyOA_7f94b373-c811-4f19-b0a3-5b548fcbc334"
      unitRef="usd">2333000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RhYmxlOjk2OWUxYjBlMWZmNjQ1MWJhODY5ZGM0OTRiMTE2NTBkL3RhYmxlcmFuZ2U6OTY5ZTFiMGUxZmY2NDUxYmE4NjlkYzQ5NGIxMTY1MGRfOC0zLTEtMS0yODMyOA_34a102d2-bf4c-4af4-a2a7-6e85223755b1"
      unitRef="usd">2587000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RleHRyZWdpb246YWVjMjk4YjQ5MDRkNGFiY2JhODNhNGVlNWU0MmVjNjJfMTQ4_92aeb3cb-ca22-43ec-b702-3ae42244f7c4"
      unitRef="usd">122000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80My9mcmFnOmFlYzI5OGI0OTA0ZDRhYmNiYTgzYTRlZTVlNDJlYzYyL3RleHRyZWdpb246YWVjMjk4YjQ5MDRkNGFiY2JhODNhNGVlNWU0MmVjNjJfMTU1_038794af-3d81-433b-917c-bfcd56e56dee"
      unitRef="usd">125000</us-gaap:Depreciation>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzE2NDkyNjc0NDM3Mzg_f5f434a3-9b1c-48aa-b6ed-aa9f9fd091da">EQUITY METHOD INVESTMENT&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company received 9,000,000 shares of common stock in a newly formed antibody-focused precision oncology company, Launchpad Therapeutics, Inc. (Launchpad), in exchange for contributing early discovery-stage antibody programs and granting Launchpad a license to use its MAP drug discovery engine to discover, develop and commercialize large molecule therapeutics. As of the transaction date and as of March&#160;31, 2023, the Company has a 39.1% voting interest in Launchpad and one seat on Launchpad&#x2019;s Board of Directors which provide the Company with significant influence over Launchpad. The remaining voting interest in Launchpad is held by Versant Ventures and New Enterprise Associates (NEA), who are shareholders of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company accounted for the transaction under the equity method and recorded the carrying value of the Company&#x2019;s investment in Launchpad common shares of $2,250 in equity method investments in the consolidated balance sheets. The contributed in process research and development (IPR&amp;amp;D) had zero basis on the Company&#x2019;s books prior to the transaction, therefore the Company recognized a gain on sale of IPR&amp;amp;D of $2,232 in the consolidated statements of operations and comprehensive loss. The Company also recognized a loss from investments in equity method investee of $1,540 in the consolidated statement of operations and comprehensive loss, associated with the Company&#x2019;s proportionate share of Launchpad&#x2019;s losses. The assets contributed by the Company were principally IPR&amp;amp;D and were not deemed a business by Launchpad, therefore the Company determined its remaining basis difference of $710 was substantially related to IPR&amp;amp;D and immediately expensed it. As of December&#160;31, 2022, the carrying value of the investment in Launchpad was reduced to zero. Since the Company has no obligation to provide financing support to Launchpad, the Company is not required to record further losses exceeding the carrying value of the investment. The Company also determined that its investment in Launchpad is not material or significant to its operations or financial position. As of March&#160;31, 2023, the carrying value of the investment in Launchpad was zero.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <bdtx:EquityMethodInvestmentSharesReceivedInNoncashExchange
      contextRef="i13adc33a304f4c00a11e5a74299bae27_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2Mjc4NDg_fee3cf8c-7d4d-43a2-a01d-77bc8c15abaf"
      unitRef="shares">9000000</bdtx:EquityMethodInvestmentSharesReceivedInNoncashExchange>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifd3f10ee0c2541fd9d0fc8361fe6a9e4_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2MjgyNDc_806f0bef-d47c-40fb-bf51-f3e485e85f43"
      unitRef="number">0.391</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="if35bb4b182804be19ee91c94ba0ca241_I20221201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2Mjg2OTg_9abde480-3cad-4469-8d4d-89543bb0a556"
      unitRef="usd">2250000</us-gaap:EquityMethodInvestments>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i700858d5fb2842d8aa731adad03358f0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2Mjg5MTM_f9bc06f3-7b94-4972-8b7e-8535448c58e2"
      unitRef="usd">2232000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i865dd29de11f4df59827ccfa2b07a604_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2MjkwNjc_3bbd30e2-0b95-4260-a15f-bd5e5a4ac3ad"
      unitRef="usd">-1540000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i700858d5fb2842d8aa731adad03358f0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2MjkzODU_0ac6e924-2eaa-448a-93d2-d7b9d4716171"
      unitRef="usd">710000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:EquityMethodInvestments
      contextRef="i13adc33a304f4c00a11e5a74299bae27_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzEwOTk1MTE2Mjk1Mjk_69b3c36d-b360-4607-b1a3-c497cf3be104"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ifd3f10ee0c2541fd9d0fc8361fe6a9e4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81MDgvZnJhZzo4NzkyN2I1ZGFmNTA0NTNhOTgyZDEzOTcyMDY1NWQ2ZS90ZXh0cmVnaW9uOjg3OTI3YjVkYWY1MDQ1M2E5ODJkMTM5NzIwNjU1ZDZlXzU0OTc1NTgxNDExNTU_6bedc3c9-742d-4301-8e03-9d510b69241b"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RleHRyZWdpb246MjI2N2Y1MzUxMTNlNDc4Yjg3ZGNmYTMwZWU4MTY4MjNfMTMx_6a53767e-9295-4be9-afcf-594a2606375f">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Contracted research services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Professional and consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_5102cdaa-2077-4a92-ad76-9ae9e3ad93f1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_fd6e36e0-6ca5-4d7c-bac0-99a6f8cd4f37"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;9,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;13,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RleHRyZWdpb246MjI2N2Y1MzUxMTNlNDc4Yjg3ZGNmYTMwZWU4MTY4MjNfMTMy_54867332-c4fc-44c6-8fd9-5b37b74aeb4d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Contracted research services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Professional and consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_5102cdaa-2077-4a92-ad76-9ae9e3ad93f1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0wLTEtMS0yODMyOA_fd6e36e0-6ca5-4d7c-bac0-99a6f8cd4f37"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;9,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;13,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <bdtx:AccruedContractResearchServiceFeesCurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfMS0xLTEtMS0yODMyOA_3734fccd-c380-48ed-95be-ff49cb4ff3cf"
      unitRef="usd">4186000</bdtx:AccruedContractResearchServiceFeesCurrent>
    <bdtx:AccruedContractResearchServiceFeesCurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfMS0zLTEtMS0yODMyOA_130cf368-683f-4e65-b58d-7dc0381582c7"
      unitRef="usd">4713000</bdtx:AccruedContractResearchServiceFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfMi0xLTEtMS0yODMyOA_deaf8bdd-6f89-47cc-893e-f62aa2f28300"
      unitRef="usd">1826000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfMi0zLTEtMS0yODMyOA_46d25be5-c158-488a-82c3-4ec67fb3b53e"
      unitRef="usd">4648000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfMy0xLTEtMS0yODMyOA_ad26e607-dbce-45bc-aa05-59de60d6d6e3"
      unitRef="usd">881000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfMy0zLTEtMS0yODMyOA_e510607f-e331-471d-a4e2-1116355cff32"
      unitRef="usd">1182000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0xLTEtMS0yODMyOA_743426c3-f800-4ef3-b2be-c1b89ca2690c"
      unitRef="usd">2908000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNC0zLTEtMS0yODMyOA_d250c297-261c-4cc8-a65f-dab46bf57b2d"
      unitRef="usd">2841000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNS0xLTEtMS0yODMyOA_33fc3ef3-8ce1-48cd-8761-e90910914aa3"
      unitRef="usd">9801000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80Ni9mcmFnOjIyNjdmNTM1MTEzZTQ3OGI4N2RjZmEzMGVlODE2ODIzL3RhYmxlOmEyMzBlOGU4YWZhYzRjYjhhYjVkMDZjY2ZkMDM4Y2RlL3RhYmxlcmFuZ2U6YTIzMGU4ZThhZmFjNGNiOGFiNWQwNmNjZmQwMzhjZGVfNS0zLTEtMS0yODMyOA_014fb88b-7395-4c18-998b-b3d9c65c54a0"
      unitRef="usd">13384000</us-gaap:AccruedLiabilitiesCurrent>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding
      contextRef="i53da331621624cf18bde372f78562fe5_I20200114"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfODQx_bf454383-3e8a-4d52-a992-5932dce48037"
      unitRef="number">0.04</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="iae929b9e760640749d3650b763b62da4_D20230101-20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfOTU0_e7ebfa28-5fad-4bfb-b463-6ac246f7642c"
      unitRef="shares">1457371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding
      contextRef="ibeabbd2a73b145ea98866ff29f77c989_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfOTk0_c3b0d9aa-cbb9-4152-9350-9819c1db4e65"
      unitRef="number">0.04</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding
      contextRef="iac7a453a75f14538a02a138efbfaf7a5_I20200114"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMTU2Ng_7e2a48b3-5203-4566-b6a2-140e81e133e9"
      unitRef="number">0.01</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i4476e554da044810af3f1a45eaa2a804_D20230101-20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMTc2OA_46140c0d-93c0-4cf1-aebf-7a6c8a155111"
      unitRef="shares">326364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTIzMQ_23af05fe-1926-4cb3-8671-3e46ff03079f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i549acd543c9a4b5aa7c94abf409f84da_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfMi01LTEtMS0yODMyOA_d467a327-773d-41eb-9319-8bc37d758545"
      unitRef="usd">2455000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f33b8615f184762bdde93307f038957_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfMi03LTEtMS0yODMyOA_b379e31c-d9e7-40b9-8ca0-b78a1e4b3dc6"
      unitRef="usd">3193000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie89b78b326fe4b0a997b225ea39acef4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfMy01LTEtMS0yODMyOA_30d3ba52-ee44-489f-932c-a5e251246819"
      unitRef="usd">112000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2ab72299068b42fdbaa9a32deddc9c0d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfMy03LTEtMS0yODMyOA_2979c4a8-53f6-476b-a505-5976a3394483"
      unitRef="usd">121000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icd05de7566d7485c87c6e0a63d1068f1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfNC01LTEtMS0yODMyOA_6ee85c50-d43d-4b62-a7bd-970e0e9fd24c"
      unitRef="usd">104000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idf76fbfd9fad48fbafde9bd4d08feef3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfNC03LTEtMS0yODMyOA_724a7f37-229a-427c-add9-117d49da133a"
      unitRef="usd">61000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfNS01LTEtMS0yODMyOA_e1cfc7c6-e26f-4d46-992e-aac317f177ee"
      unitRef="usd">2671000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjUzMDY2YzZmN2IxMjRlMjM4OTgxOWIyNzdjZjM5ZjBiL3RhYmxlcmFuZ2U6NTMwNjZjNmY3YjEyNGUyMzg5ODE5YjI3N2NmMzlmMGJfNS03LTEtMS0yODMyOA_968f0aca-b841-43c4-beae-47f8d434fbff"
      unitRef="usd">3375000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i531627ec9aa54ef1ba96e5c5b9e70e77_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMjA3OA_8bf2ed1d-aae8-4e38-83b5-aa121ad8484e"
      unitRef="shares">24776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a68a37a9356497ebf39ad08f89e5202_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOmM1NWI2YzVkZTBlMjQ4MDVhZjYwNTdkZmRiMGY4NmZjL3RhYmxlcmFuZ2U6YzU1YjZjNWRlMGUyNDgwNWFmNjA1N2RmZGIwZjg2ZmNfMi01LTEtMS0yODMyOA_f6fb55c0-ca64-4e4f-a9ef-1ab9511ab6b8"
      unitRef="usd">949000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i40eacd0ad8714a8b8f4aa9d78df3b014_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOmM1NWI2YzVkZTBlMjQ4MDVhZjYwNTdkZmRiMGY4NmZjL3RhYmxlcmFuZ2U6YzU1YjZjNWRlMGUyNDgwNWFmNjA1N2RmZGIwZjg2ZmNfMi03LTEtMS0yODMyOA_2c252159-2cb4-44f2-aaec-f80177334c7a"
      unitRef="usd">1528000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie179c4253b6c47ac8c91e9c01f937de2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOmM1NWI2YzVkZTBlMjQ4MDVhZjYwNTdkZmRiMGY4NmZjL3RhYmxlcmFuZ2U6YzU1YjZjNWRlMGUyNDgwNWFmNjA1N2RmZGIwZjg2ZmNfMy01LTEtMS0yODMyOA_b4632845-740e-49e6-88d6-4d0cfa754f5f"
      unitRef="usd">1722000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0b7e706f65f045e882a5da0982835947_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOmM1NWI2YzVkZTBlMjQ4MDVhZjYwNTdkZmRiMGY4NmZjL3RhYmxlcmFuZ2U6YzU1YjZjNWRlMGUyNDgwNWFmNjA1N2RmZGIwZjg2ZmNfMy03LTEtMS0yODMyOA_b03bd36d-74bb-426d-b574-f0eee244361b"
      unitRef="usd">1847000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOmM1NWI2YzVkZTBlMjQ4MDVhZjYwNTdkZmRiMGY4NmZjL3RhYmxlcmFuZ2U6YzU1YjZjNWRlMGUyNDgwNWFmNjA1N2RmZGIwZjg2ZmNfNC01LTEtMS0yODMyOA_f5de65a2-63ea-4650-ac04-a4ef3c2d6a1a"
      unitRef="usd">2671000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOmM1NWI2YzVkZTBlMjQ4MDVhZjYwNTdkZmRiMGY4NmZjL3RhYmxlcmFuZ2U6YzU1YjZjNWRlMGUyNDgwNWFmNjA1N2RmZGIwZjg2ZmNfNC03LTEtMS0yODMyOA_8a0bc05d-ee4e-44ef-9cb8-112f69ef3e6a"
      unitRef="usd">3375000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTIzMw_180daaaf-e8d3-48ed-827b-f2d9617cd610">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity under the Company&#x2019;s equity awards plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;(in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Outstanding December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5,359,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;12.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,659,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(240,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;11.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(68,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;28.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Outstanding March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;7,710,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;9.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options vested or expected to vest at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;7,710,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;9.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2,828,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;14.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfMS0xLTEtMS0yODMyOA_24e74873-c402-4369-8567-d78f4a488c48"
      unitRef="shares">5359400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfMS0zLTEtMS0yODMyOA_4596386a-06df-4831-afb8-e75a30a63267"
      unitRef="usdPerShare">12.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i700858d5fb2842d8aa731adad03358f0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfMS01LTEtMS0yODMyOA_a0d72043-080d-4374-8a07-ecc2396b230a">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i17eafc42a82d4f13904b976d1891eb47_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfMS03LTEtMS0yODMyOA_7b801648-c148-457a-b1c4-c63ea2f661f6"
      unitRef="usd">76000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfMi0xLTEtMS0yODMyOA_f047549c-e147-49ef-a14b-8a1982acfc5b"
      unitRef="shares">2659250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfMi0zLTEtMS0yODMyOA_4c619baf-d54a-412f-8322-51854de3cd88"
      unitRef="usdPerShare">2.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNC0xLTEtMS0yODMyOA_ff9ef850-6c37-4f4e-a85c-4ccdc0144c71"
      unitRef="shares">240241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNC0zLTEtMS0yODMyOA_29b3cf85-c7e6-4cf4-9f55-b539dd9e533e"
      unitRef="usdPerShare">11.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNS0xLTEtMS0zMDIzNw_fe563eb9-0bdc-4437-aa1b-a2767a126ebc"
      unitRef="shares">68124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNS0zLTEtMS0zMDIzNw_c1b846d2-57fd-4add-970f-8d9beb67b9d8"
      unitRef="usdPerShare">28.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNS0xLTEtMS0yODMyOA_51f46d59-eff0-4efc-8db8-28111a5ab86e"
      unitRef="shares">7710285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNS0zLTEtMS0yODMyOA_dca8efe5-69e5-410b-8c99-291469050674"
      unitRef="usdPerShare">9.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNS01LTEtMS0yODMyOA_a85a4e27-43b5-48d1-b2c0-11283d3e4b26">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNS03LTEtMS0yODMyOA_037f2f21-8a8e-42bc-bedb-ef0ce700a3af"
      unitRef="usd">116000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNi0xLTEtMS0yODMyOA_e5c6ca29-929b-4a7d-8069-171c4098333d"
      unitRef="shares">7710285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNi0zLTEtMS0yODMyOA_f7e69f15-394f-412d-a198-befc359ab5ee"
      unitRef="usdPerShare">9.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNi01LTEtMS0yODMyOA_585482b0-aade-4758-9afc-eb7ef60e5db9">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNi03LTEtMS0yODMyOA_ec66378c-b0b3-410c-9b8c-67f06c7722c9"
      unitRef="usd">116000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNy0xLTEtMS0yODMyOA_e1448766-1747-431c-892b-d6525e5dd2bc"
      unitRef="shares">2828178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNy0zLTEtMS0yODMyOA_4a66a8c4-6e13-4b31-9cf8-0d4ea668af3a"
      unitRef="usdPerShare">14.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNy01LTEtMS0yODMyOA_891b4a02-cf17-4836-a407-c90af8306773">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjBmNTAwY2UyZTQ5MDQ0ZGY4NTgzZDgwNmU4NWUwZjEzL3RhYmxlcmFuZ2U6MGY1MDBjZTJlNDkwNDRkZjg1ODNkODA2ZTg1ZTBmMTNfNy03LTEtMS0yODMyOA_ef59e1ba-c6e5-4146-b00c-48d1ac66e455"
      unitRef="usd">32000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMjY0MQ_3625dfe2-9c7a-4436-b6ac-c43b413ccb6e"
      unitRef="usd">17489000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i549acd543c9a4b5aa7c94abf409f84da_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMjcxNA_f6a15995-c020-4b25-b32a-f3dab5626db9">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTIzNA_cb4de927-770d-452d-bed3-4602e6a49093">The following table summarizes time-based restricted stock activity since January 1, 2023:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;grant&#160;date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Unvested restricted common stock as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;101,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(13,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;14.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(1,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Unvested restricted common stock as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;86,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4e69e52e4e6d406fb3c05c1f565e0fc4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfNS0xLTEtMS0yODMyOA_fbb73213-6044-48bd-af1e-bb556b2cf8cc"
      unitRef="shares">101397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4e69e52e4e6d406fb3c05c1f565e0fc4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfNS0zLTEtMS0yODMyOA_fb217307-e6fb-4682-8365-725b274d1172"
      unitRef="usdPerShare">5.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i4ba383758bc7459cbba65c787855cd79_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfNy0xLTEtMS0yODMyOA_b6d6c4f9-386d-482d-8fcf-ca3e8460ab53"
      unitRef="shares">13959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4ba383758bc7459cbba65c787855cd79_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfNy0zLTEtMS0yODMyOA_0446430b-0410-43ae-bc24-b7249f8298fe"
      unitRef="usdPerShare">14.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i4ba383758bc7459cbba65c787855cd79_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfOC0xLTEtMS0yODMyOA_05ed9b63-31fa-416a-866e-56dda4c5aeed"
      unitRef="shares">1148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i4ba383758bc7459cbba65c787855cd79_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfOC0zLTEtMS0yODMyOA_e2f8ae55-4f99-4c0b-85fc-2db5c8a27019"
      unitRef="usdPerShare">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1bbb31a5e28c45da9f270f4b2a17dc96_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfOS0xLTEtMS0yODMyOA_2e02df7b-99eb-4c16-8173-331587521c0e"
      unitRef="shares">86290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1bbb31a5e28c45da9f270f4b2a17dc96_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RhYmxlOjgzYzQ3Y2ViYTgxMDQ0OWY5NzdjZDEwMDc3M2EyYTY2L3RhYmxlcmFuZ2U6ODNjNDdjZWJhODEwNDQ5Zjk3N2NkMTAwNzczYTJhNjZfOS0zLTEtMS0yODMyOA_41e772b4-b7a9-4f25-a943-fb8df1674842"
      unitRef="usdPerShare">4.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ie89b78b326fe4b0a997b225ea39acef4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMzIwOA_4c313468-e3b5-4115-bfb2-5753680a0cb8"
      unitRef="usd">203000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="id1dd1836d0a04ec5916ed35f6b8154f9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMzM0MA_52cfda2d-518e-43a3-8bb8-cdde1d05cd7f"
      unitRef="usd">212000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie89b78b326fe4b0a997b225ea39acef4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMzQxMw_8dfc0846-2451-4df2-8ad8-b7c9f4f0cbe7">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8d6665b2a485470da5f751271274fa6f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTQ5NzU1ODIwMTE3_0ad5ca71-46b6-4037-aece-0609c7e9d3a8"
      unitRef="shares">239475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id72ab97139f6499186284a9e549e2dcd_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMzQ2OA_56e20ed4-ca0f-4a9f-b87f-cfbc8616d5e5"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1b8ca7e990664a5b82b28aaeab2809ac_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTQ5NzU1ODIwMTMy_3b635efd-f921-4657-a47d-329086ebfa66"
      unitRef="shares">9616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="id72ab97139f6499186284a9e549e2dcd_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMzYxOA_c2b2eed7-9cd6-4125-a7d2-3aede977bd0c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7f5dc11878354eceb96d35803df03196_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfMzY5Mw_ea66caa3-40e5-49e0-b1ff-5a42b410536c"
      unitRef="shares">229859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable
      contextRef="iaedbd1575db640bfa3b1a3840d2f60c1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTQ5NzU1ODIwNzg5_138e66c4-35b0-4dcf-addf-e66b56fe5df5"
      unitRef="shares">17859</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1b8ca7e990664a5b82b28aaeab2809ac_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTQ5NzU1ODIyMTcx_85ec38f1-ed36-4714-b8d0-52ce563b7133"
      unitRef="usd">29000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id72ab97139f6499186284a9e549e2dcd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNDIzNQ_81363952-6463-49d5-928d-dff15ef4c593"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="i92885a5fac644e64800d5f746f26e823_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTIzNQ_25eb95c1-435d-46cb-8aaf-a89c63b950f1">P6M</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i92885a5fac644e64800d5f746f26e823_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNDUwMA_1d65bd94-010f-4704-ad72-194a794586c2"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i34860dd43a7c4f3385bb39b1b3cce7d7_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTAyNw_94784f66-3d9d-4bd8-8adc-706882f2b3dd"
      unitRef="number">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount
      contextRef="i92885a5fac644e64800d5f746f26e823_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTEwMA_430482d0-5a3c-4056-97df-365b21a4c565"
      unitRef="usd">25000</bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i92885a5fac644e64800d5f746f26e823_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTE3Mg_9b108d94-c965-42b9-b677-b5362f842945"
      unitRef="shares">33202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i655a42e7d5614f70874d9d99b077d0ca_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV80OS9mcmFnOjUyOGE3NWE0ZGMxYTQ4ZTQ5NzJhMzVhOWQ5YmQ5ZWNhL3RleHRyZWdpb246NTI4YTc1YTRkYzFhNDhlNDk3MmEzNWE5ZDliZDllY2FfNTE3OQ_9e6cd46e-c569-4f41-91de-5447f04795cd"
      unitRef="shares">31341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RleHRyZWdpb246ODMyMGRjNmE0YzJjNDM2OWE3YzlkMDNlNjYwMGI2MjJfODY0_591903d9-a264-43ca-8d46-04c05364c039">NET LOSS PER SHARE&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.419%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(20,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(25,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,483,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,271,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(0.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;7,710,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5,918,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;86,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;45,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Shares issuable under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;102,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;27,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Unvested performance restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;229,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;19,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;10,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;10,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;8,139,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;6,021,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RleHRyZWdpb246ODMyMGRjNmE0YzJjNDM2OWE3YzlkMDNlNjYwMGI2MjJfODY2_a9f0955b-d3a9-438d-8c08-ccc99fa38bb6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.419%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(20,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(25,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Weighted average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,483,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;36,271,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(0.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(0.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfMi01LTEtMS0yODMyOA_0cc95593-7411-48f7-a03c-d2c5e8633e1b"
      unitRef="usd">-20875000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfMi03LTEtMS0yODMyOA_47d60543-38bb-450e-a346-97a56f83b185"
      unitRef="usd">-25507000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfMy01LTEtMS0yODMyOA_00e6016d-1b93-4db8-8e5b-0e8e03832b1c"
      unitRef="shares">36483878</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfMy01LTEtMS0yODMyOA_1f18f60e-968f-415e-9c23-49fe5d52ca66"
      unitRef="shares">36483878</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfMy03LTEtMS0yODMyOA_089b293a-9e1f-4c00-9748-907a52a44d79"
      unitRef="shares">36271291</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfMy03LTEtMS0yODMyOA_b4711e14-9f5f-449e-9dd3-80fc8864c90f"
      unitRef="shares">36271291</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfNC01LTEtMS0yODMyOA_c76ada61-93cd-48b9-9274-ec981324d05f"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfNC01LTEtMS0yODMyOA_ff0dda40-ed71-4c4f-9664-1b102ec349f9"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfNC03LTEtMS0yODMyOA_3e579a8a-563b-4513-ac49-707a2712b723"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOjY0OTY0YjJjYjg5MTQyNDRhOTIwN2JkMzI1YzBlNjZhL3RhYmxlcmFuZ2U6NjQ5NjRiMmNiODkxNDI0NGE5MjA3YmQzMjVjMGU2NmFfNC03LTEtMS0yODMyOA_421273cf-9942-4f82-8a47-9fa7506bcfca"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RleHRyZWdpb246ODMyMGRjNmE0YzJjNDM2OWE3YzlkMDNlNjYwMGI2MjJfODY3_3c4dbe34-039a-4376-a1f1-dd937581402b">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;7,710,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5,918,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;86,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;45,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Shares issuable under employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;102,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;27,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Unvested performance restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;229,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;19,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;10,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;10,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;8,139,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;6,021,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2e956203346c4f019b41b2e8a5ca63b5_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfMi0xLTEtMS0yODMyOA_8c14845f-04b2-4404-b164-b8ca44cf7bcd"
      unitRef="shares">7710285</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i480b155b6e9e4eb7bb0b1e836d5e7afb_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfMi0zLTEtMS0yODMyOA_b7ab5593-7c73-41dd-a4e9-c6c75e8cbb48"
      unitRef="shares">5918794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i54c6774cffa04e968e001d62f8b99a07_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfMy0xLTEtMS0yODMyOA_aeefae0a-8bc0-4e90-ba64-fe4ebac109db"
      unitRef="shares">86290</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib89eee0073ef4f748054dcd1018afcb4_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfMy0zLTEtMS0yODMyOA_6258ee96-92c7-4a89-9cd2-81bd4d4c37a4"
      unitRef="shares">45742</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaf82d51205674d83a503b0e61adba697_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNC0xLTEtMS0yODMyOA_1a9f8b07-dcaf-47e9-ad74-cfbf5011f531"
      unitRef="shares">102351</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id425a5500c184a08bd09e08bff211884_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNC0zLTEtMS0yODMyOA_dc5b4ab4-05a9-4a1b-bd4a-56b577395c3d"
      unitRef="shares">27572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i812984cbee954504a8f1cb1007753038_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNS0xLTEtMS0zMDQ0OA_8f83455b-3b73-4852-98a8-46efcdbc7e66"
      unitRef="shares">229859</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if98a5e733c4c466b9290ddc071d57eb2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNS0zLTEtMS0zMDQ0OA_9dfd3f7f-0e5c-4e40-a118-fa90bcdb03a1"
      unitRef="shares">19000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3c4704e3cd5b4f9ca3f745afab97bcbc_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNS0xLTEtMS0yODMyOA_17126467-8d28-4be1-9240-5b9cc9beb409"
      unitRef="shares">10757</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iec9bf005920e479db53ec4495d3c9605_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNS0zLTEtMS0yODMyOA_3b967b90-45b7-4318-9dfa-6008cd01800b"
      unitRef="shares">10757</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNi0xLTEtMS0yODMyOA_4bda412c-fa9b-456c-8b7b-eac08fadb14a"
      unitRef="shares">8139542</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81Mi9mcmFnOjgzMjBkYzZhNGMyYzQzNjlhN2M5ZDAzZTY2MDBiNjIyL3RhYmxlOmRjOTI1ZjBlMjFlYTQzYWI4M2FhOWU1ODk2NzMxNjM5L3RhYmxlcmFuZ2U6ZGM5MjVmMGUyMWVhNDNhYjgzYWE5ZTU4OTY3MzE2MzlfNi0zLTEtMS0yODMyOA_f045dbf5-5490-4e1a-9293-019974ce61d3"
      unitRef="shares">6021865</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMjU4Ng_d22a7a36-ea0b-4dbb-a727-d845ef03e7a0">LEASES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company has historically entered into lease arrangements for its facilities. As of March&#160;31, 2023, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company&#x2019;s leases generally do not include termination or purchase options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into a seven-year agreement with an option to extend for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfNTMw_02522d54-356b-489e-ae5f-0345b2c059f0"&gt;five&lt;/span&gt; additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease. Additionally, on December 12, 2022, the Company entered into a sublease for one floor of its Cambridge, Massachusetts office space. The sublease terminates on August 31, 2028, which is also the date on which the Company's lease terminates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMTY5OA_c306ce76-7222-412d-9933-d5323bf1972b"&gt;five&lt;/span&gt; additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating lease for the three months ended March&#160;31, 2023 and 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;Three Months Ended March 31,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Operating Lease Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The variable lease costs for the three months ended March&#160;31, 2023 and 2022 include common area maintenance and other operating charges. As the Company&#x2019;s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the Company&#x2019;s operating leases as of March&#160;31, 2023 were as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;As of March 31, 2023&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2023 (excluding the three months ended March&#160;31, 2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;12,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;33,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(6,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;27,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <bdtx:LesseeOperatingLeaseNumberOfContracts
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMTIy_3161bbf3-17a5-4e5c-8cc8-b1929ef5ecb1"
      unitRef="contract">2</bdtx:LesseeOperatingLeaseNumberOfContracts>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i09dbac4b37d84e3eb2e7dad646327861_I20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMjU4OQ_0012e67d-fff7-44f6-adc5-c1c15bd9b3d3">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <bdtx:LesseeOperatingLeaseArea
      contextRef="i09dbac4b37d84e3eb2e7dad646327861_I20200731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfNTkz_59152f73-64a6-4960-a3d5-89170db5ea35"
      unitRef="sqft">25578</bdtx:LesseeOperatingLeaseArea>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i09dbac4b37d84e3eb2e7dad646327861_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMTAwNQ_2ab1dd25-64c7-48ce-998d-c2c0842ffe3e"
      unitRef="usd">1168000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="id28a5be0a35d4bc881d156351fc61d4e_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMjU4Mw_7f8926c6-ce67-431d-8c93-089c6d522557">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <bdtx:LesseeOperatingLeaseArea
      contextRef="id28a5be0a35d4bc881d156351fc61d4e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMTU4NQ_9cf531bc-31ee-4692-9e9c-3707a1a67c22"
      unitRef="sqft">18120</bdtx:LesseeOperatingLeaseArea>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMjU4NA_4b9e7c33-44e2-4fcc-bf4b-449dd7cc0f7c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating lease for the three months ended March&#160;31, 2023 and 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;Three Months Ended March 31,&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Operating Lease Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfMy01LTEtMS0yODMyOA_d76206ed-150a-4c5f-99f9-34b31aa9984c"
      unitRef="usd">1054000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfMy03LTEtMS0yODMyOA_8b4952f3-e865-416f-899e-dc84dc682b79"
      unitRef="usd">1059000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNC01LTEtMS0yODMyOA_2e50dee5-110b-4764-8696-36de3143594c"
      unitRef="usd">17000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNC03LTEtMS0yODMyOA_16549314-427c-4f05-87e0-2eda98477a08"
      unitRef="usd">19000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNS01LTEtMS0yODMyOA_b84b58a3-6738-4801-8961-7fd2828134e6"
      unitRef="usd">256000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNS03LTEtMS0yODMyOA_f36e2015-1621-4822-a7a3-37509ed787da"
      unitRef="usd">257000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNi01LTEtMS0zMTIxMg_bdbedb15-a264-4e7b-822e-4ee36aa77486"
      unitRef="usd">135000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNi03LTEtMS0zMTIxMg_95d93856-a3e3-4b04-9564-e44f60b07cbd"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNi01LTEtMS0yODMyOA_33897730-2c2a-4640-b578-7bc05939dcc6"
      unitRef="usd">1192000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjU4NTk2ZDgxODQ2MTQyM2U4NjExNWQzNDU4N2IwM2JmL3RhYmxlcmFuZ2U6NTg1OTZkODE4NDYxNDIzZTg2MTE1ZDM0NTg3YjAzYmZfNi03LTEtMS0yODMyOA_c98084e8-c9be-4111-8ad3-b11c149e6274"
      unitRef="usd">1335000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjEwMTcxYmRhMGJlYjQyMTZiYjc0YzAxZWRjYTI4NjdiL3RhYmxlcmFuZ2U6MTAxNzFiZGEwYmViNDIxNmJiNzRjMDFlZGNhMjg2N2JfMi0xLTEtMS0yODMyOA_a0b33987-94a3-40fe-8e39-b1cbd8d5c815"
      unitRef="usd">1051000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjEwMTcxYmRhMGJlYjQyMTZiYjc0YzAxZWRjYTI4NjdiL3RhYmxlcmFuZ2U6MTAxNzFiZGEwYmViNDIxNmJiNzRjMDFlZGNhMjg2N2JfMi0zLTEtMS0yODMyOA_c09cc6c2-c9b8-4883-ad45-c37b5b7c6396"
      unitRef="usd">702000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjEwMTcxYmRhMGJlYjQyMTZiYjc0YzAxZWRjYTI4NjdiL3RhYmxlcmFuZ2U6MTAxNzFiZGEwYmViNDIxNmJiNzRjMDFlZGNhMjg2N2JfMy0xLTEtMS0yODMyOA_2dd34741-1039-4c10-88ed-fd9ad5e7507a">P7Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjEwMTcxYmRhMGJlYjQyMTZiYjc0YzAxZWRjYTI4NjdiL3RhYmxlcmFuZ2U6MTAxNzFiZGEwYmViNDIxNmJiNzRjMDFlZGNhMjg2N2JfMy0zLTEtMS0yODMyOA_90d58fcc-f09b-49a6-ae2e-24ca764ffcab">P8Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjEwMTcxYmRhMGJlYjQyMTZiYjc0YzAxZWRjYTI4NjdiL3RhYmxlcmFuZ2U6MTAxNzFiZGEwYmViNDIxNmJiNzRjMDFlZGNhMjg2N2JfNC0xLTEtMS0yODMyOA_fd5329d3-96fb-48fe-bcd6-5f1772d750c5"
      unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8a418bd9d4f446f08f3bc2947d3e53de_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOjEwMTcxYmRhMGJlYjQyMTZiYjc0YzAxZWRjYTI4NjdiL3RhYmxlcmFuZ2U6MTAxNzFiZGEwYmViNDIxNmJiNzRjMDFlZGNhMjg2N2JfNC0zLTEtMS0yODMyOA_9db53614-bd56-405a-925d-1c51838eb0ba"
      unitRef="number">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RleHRyZWdpb246NzZmYzU0Y2VjYjY5NGQ4NWJjYzFhNjkzN2RjM2ExZDlfMjU4NQ_389c313d-1ccf-4f71-9009-5d6dc95d0f86">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under the Company&#x2019;s operating leases as of March&#160;31, 2023 were as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;As of March 31, 2023&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2023 (excluding the three months ended March&#160;31, 2023)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;4,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;12,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;33,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;(6,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;27,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfMS0xLTEtMS0yODMyOA_20d94d97-3ebd-44cb-b066-168d9f39cfe7"
      unitRef="usd">3192000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfMi0xLTEtMS0yODMyOA_2122d4db-db63-4939-bb09-c0827558d7bd"
      unitRef="usd">4359000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfMy0xLTEtMS0yODMyOA_0c1fb1da-4fe6-410a-801f-69c55d0f690c"
      unitRef="usd">4477000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfNC0xLTEtMS0yODMyOA_b2d33c02-4420-45af-a287-052afb0d5c16"
      unitRef="usd">4599000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfNS0xLTEtMS0yODMyOA_3cc50e7f-5436-4f33-b03d-69b315eb1525"
      unitRef="usd">4724000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <bdtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfNi0xLTEtMS0yODMyOA_4a472716-c7a4-4820-a356-45d1ee71565a"
      unitRef="usd">12250000</bdtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfNy0xLTEtMS0yODMyOA_1669d0ca-e807-4fb8-9633-52d3c284c4dc"
      unitRef="usd">33601000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfOC0xLTEtMS0yODMyOA_b093bbbe-c9b3-4cd2-b005-cd1f9d21433f"
      unitRef="usd">6148000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="if76381c49969430b8ee1ce9004b721ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81NS9mcmFnOjc2ZmM1NGNlY2I2OTRkODViY2MxYTY5MzdkYzNhMWQ5L3RhYmxlOmZlMjVhMGFmODg5ZTQyZmU5NjBiZTNmZDEwN2M2ZjhjL3RhYmxlcmFuZ2U6ZmUyNWEwYWY4ODllNDJmZTk2MGJlM2ZkMTA3YzZmOGNfOS0xLTEtMS0yODMyOA_c9141eaf-3a31-44f6-bc9f-9e0e803b265f"
      unitRef="usd">27453000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV81OC9mcmFnOmM5Njk3ZjYxMTJiMDRjYWViOWU5YmYzYWMyY2FiNzQ2L3RleHRyZWdpb246Yzk2OTdmNjExMmIwNGNhZWI5ZTliZjNhYzJjYWI3NDZfMjU3OA_6b958832-d8eb-4a1d-b756-4e8c0d3dc5ce">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company enters into contracts in the normal course of business with contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;License agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of March&#160;31, 2023, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of March&#160;31, 2023 or December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV82MS9mcmFnOjk4N2ZhYjJiYTY4MzRiMDA5ZjJiYmMzYmNkNzAzYjkyL3RleHRyZWdpb246OTg3ZmFiMmJhNjgzNGIwMDlmMmJiYzNiY2Q3MDNiOTJfNjE2_11a64fe8-3085-40d6-a737-f5e2bbfcbffa">BENEFIT PLANSThe Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the 401(k) Plan). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant&#x2019;s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the Code). All matching contributions are fully vested when made. During the three months ended March&#160;31, 2023 and 2022, the Company contributed $376 and $558, respectively, to the 401(k) Plan.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV82MS9mcmFnOjk4N2ZhYjJiYTY4MzRiMDA5ZjJiYmMzYmNkNzAzYjkyL3RleHRyZWdpb246OTg3ZmFiMmJhNjgzNGIwMDlmMmJiYzNiY2Q3MDNiOTJfMjI3_b12ccdec-68d3-4d66-8f45-996a53b3077f"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV82MS9mcmFnOjk4N2ZhYjJiYTY4MzRiMDA5ZjJiYmMzYmNkNzAzYjkyL3RleHRyZWdpb246OTg3ZmFiMmJhNjgzNGIwMDlmMmJiYzNiY2Q3MDNiOTJfMjgx_e811e76b-5bc3-4e32-9af1-3cbcd8fc2441"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i249d943305564527a84d83a0112cc5dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV82MS9mcmFnOjk4N2ZhYjJiYTY4MzRiMDA5ZjJiYmMzYmNkNzAzYjkyL3RleHRyZWdpb246OTg3ZmFiMmJhNjgzNGIwMDlmMmJiYzNiY2Q3MDNiOTJfNTY0_79aa049f-6814-4b7b-b17b-2200a56de22e"
      unitRef="usd">376000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i934d06c2cd304821941d941437f4ef83_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwNmZkYmM4Njg5OTQ3ODE4MzBjZmI5Zjk2MjMwNmI1L3NlYzpjMDZmZGJjODY4OTk0NzgxODMwY2ZiOWY5NjIzMDZiNV82MS9mcmFnOjk4N2ZhYjJiYTY4MzRiMDA5ZjJiYmMzYmNkNzAzYjkyL3RleHRyZWdpb246OTg3ZmFiMmJhNjgzNGIwMDlmMmJiYzNiY2Q3MDNiOTJfNTcz_59c9f497-835b-4522-8e75-c5d5564f5366"
      unitRef="usd">558000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MQ9X0E W _:64YG%BNXZZRXS^ %!+ P04    " "U/:E6PHXL[YP$  !Q$@
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M J9.U.<;]4#Q;75$\,R5XD5UF3*:,*$-X/F:<W4<Z!>TITR+_P%02P,$%
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MF&#: 6S+0 3=@*<-X*D_>55.Z.7/=99X_#FU_CJ>!AUX#IDD=L,+@Y;$ B_
M7W6B*O<)K#+7>%1GJ'P&BHX ^;NB.^U2)R\%]OJ;=" [9((>Q >T&_H988O+
M#1&ZF*05-X[%0A#%MQIR3O&*YOUE9:_\3'7E7-J.70%;5T!O\!:<[##-7A96
M[0$FMX1W7./T!+3CEZ!N &VA(8S'24\06U8/O90Y^\V +%DY? 50Y%E$>YBV
M2%]FM+0;^GGW)DU9I=NX'7[&J]R9MGL51V4EC+MUQ2$UA!".>Q"V_!MZ>4LC
MY!7QAO\@'9SX(QL9BNQ5X! +IU'?*FB9,?13X]>#^+>-04X45YY$;K/?<!*-
MN\ =4G'2T_>$+4F&?I;\^IJNQHG:YD35L 6H2^U.N20.^HIGRY]A\J9VNF;-
M5[1CH9>8WUPWSZ3MV LM*8=^5EY4/-UBG3&*\?PD9Y.N57MLD6'/"H,M+4,_
M+2\X2PG)]E'2Y%QGM]I]5]Q$24,_T?- FWWA. GBC@$.,32!XYZU!ENBAE[V
M._;R*:CA23\[1%3N1$%/&84MBT(_BS;9K'J?!ZIVT6#U[$P,)W";()T^ML7"
M> *G/=A;'H5OVQZO:8G5+NQT/L.S[H_/I>W8"RU50S]5'V<+>2(\I<*TLVK#
M5>CN5N_!5)76^X8ZD>Z6BX73+S971]WJ[) )(]03RI;-H9_-G<O0%4\G;)NA
M;=BV3#_LEL/A"0Y7L&F9<D/:[S-2CSZ8]EQ;HYUM!KK./JA"UE<!;*H>)]#*
M(P>AA^$D[&E%8$OIT$_I.I$N+* &O5JQDM-4'^ZE1FI%-K0L=5#TAHEPRC*G
M13:)HVAL-5<.L7@2P)Z-)VRI'OKWRF^QB.C&T6N+O3<>!\C:03O$H@CUENB6
ML.'T9)F[J ]3[UI;+L!]:\C\9;%UW]V=6'?>5N'-A?!,VH[/2MNV ?G;AGE?
MQKTBQ,C1!DS#<;>*.,2B<9"$[A"CMEM _F[A_GA-.A':'8#:;25=@ XI"'OJ
M'&J[!.3O$LZ:3LAN!USIY!#SI!,Z.%/W=PW+:K?+S24%SD%&19HS47%#F&9+
MKHT\:("4-:_N*]!YS]W_C[X"M7T%\O<5R_VA6+-%T$R75UF]Z=O]E],79/<0
MT^ZQO4.FIRE';9>!_%V&N6T<LO50;5U?SLW82F(E9HPB3ZDY7P-KQJT].5OE
M=&,.7YTF1=8U0[>'=XB$8?=,>'1P)U<0OC%7E0*8TYCZ'JMYVUR'WIA+P,[[
MV_!R7E]JMFKJ.]8OF"L*%\JLM5(9?)PH7+R^MJP?)-N9F[\5DY(59K@E."-<
M"ZC?UXS)EP?]!\WE\>Q?4$L#!!0    ( +4]J5;N<_=JO08  .HP   8
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MHY^DZB+ U [5K6T!&C0"18NAT&0R>Q& F$4 *.74'&8TKT.MO[A6JKQ"!HU
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M>OMB_?:$LW7W(OA7QCDKN\,5342?VAJ(WY>,\5\G[;OE^W]OF/\/4$L#!!0
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M:JS<(J+N\%"1$A-/''?LUWK!!.>4]EGY!1PR%R#4PTF=<P4]^WCA[>LV=NP
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M9-EIS\6S\^H>:/IL9>+9 @=^CZS>@'6U+LE*-+#6/Z$]C@H:S K,JX)96E/
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M9?/01:,J$9,Q!T<H"E]"H;/^>]]@]=G$\3 QZ=$50.=S:.D9N3!9T+AHT1R
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MX^M1 F[_$ETC]W$+%Z.KY9%#2IXGX'OAT/MW+[S!<$%[_A]02P,$%     @
MM3VI5N041@\H!P  Y!$  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6RM
M6-MN&S<0_15" 8($4"1;=BY-; .R<JF )G$C.T51](':'4FLN>2&Y%KQW_<,
MN3<UL@&W?;&UNS/#,[<SLWNRM>[:;XB"^%YHXT\'FQ#*U^.QSS942#^R)1D\
M65E7R(!+MQ[[TI',HU*AQY.#@Q?C0BHS.#N)]R[<V8FM@E:&+ISP55%(=WM.
MVFY/!X>#YL87M=X$OC$^.RGEFA84KLH+AZMQ:R57!1FOK!&.5J>#Z>'K\V.6
MCP)?%6U][[=@3Y;67O/%/#\='# @TI0%MB#Q[X9FI#4; HQOM<U!>R0K]G\W
MUM]'W^'+4GJ:6?V;RL/F=/!J('):R4J'+W;[,]7^/&=[F=4^_A7;)'M\-!!9
MY8,M:F4@*)1)_^7W.@X]A5<'=RA,:H5)Q)T.BBC?RB#/3IS="L?2L,8_HJM1
M&^"4X:0L@L-3!;UPMKCZ^''ZY7?Q^;U8S#]\FK^?SZ:?+L5T-OM\]>ER_NF#
MN/C\RWPV?[<X&0><QUKCK+9]GFQ/[K!])#Y:$S9>O#,YY;OZ8^!LP4X:L.>3
M>PU^E&XDC@Z'8G(P.;K'WE'K_%&T=W2'O6F6V<H$9=;BPFJ5*?+BC^G2!X=B
M^7.?P\G>\7Y[W$"O?2DS.AV@0SRY&QJ</7YT^.+@S3UHCUNTQ_=9_X^I^K]L
MB\L-B975Z&:.F_)"-ATM[$IXM39JI3)I CJN#6_9A#=I4BZ4$0&6$*=2.AD[
M%.JXY4ED%@5C/*3PRT,UEP$7*V6DR934P@?< #6 C\2%4[A9:AB'@4Z!+3)6
M1E&4TMPRC@=8%AMY0V))9&J0"32;<SFD"9T:-CM.=DC69,A)K6_Y.96A<_C*
M*+Y:\#D1\;0@AWB))Q^FTXNG0AH6S7254Y2O[?LZ.F*6G$ERN+W=6#[&;@VL
M^FKI5:ZD0ZB'XES+[%J\5;* UQP+)TNJ@LJ\>#*31N;RZ5#,33:*QNZ17E!6
M.15N<;@K;<K64,A5("=(*]!2FT#XO%,#RD H:S WOO!Y:#+C9>1F9/'*R"I7
M*4[04$4O)\JDX=-D]"%)_$?4ZLCF NX1,O)CCH<QK1A?(@(:BK)ROF)7@HVF
M7,4)9@\<K2L=8;7G+-[-1F)&+F <[N!F^96UP=A (E<^T]97X AA6(0SV$*#
MYEY7[JM"KIV>,UV$K!.V4"'&Q]D"(-&QOU;2(<@X] LAGW!2>N[DDEPMN[Q%
M+66;_<Z.Q#0>CYK7M\.']ZSPB*_&(0@F]@CV!SI_528-ZN@0!W.O+F/A('H6
M<82D] /7R_7C1Z\FAR_?>#$UIH*-Y.H(!1^E;*E,1SH_*!7HCW4\<AAK6N9_
M81@G"$_80^5CST,]9; .$AK%\?V>_-,8$943Y\Y01MXS6:(V0)TKJ5SG7H,&
MA8&MPD<9OFYZ @E2-H^EX"'.==SFO D#>@GI@"$"PB*RS.5>HOW!YX>D,.6,
MZYMYH:M!1]\JQ77=!9 ;IY#7U /$L9(>8Z-,W1,V$OVV6F%5J_WG7.%LD%%#
M?I"G.O]:R:72*JC:U%TJ]+UD?[S(JYB43B[2=0KF2"QZ?'4W1FR+O$JV=?;
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M-&Q WS--"FT7O$$_Z:_^!E!+ P04    " "U/:E6949D9:8$   ,#   &0
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M9(=08>X80=#/"L]0*08B-[YO, >]25;<_KY#?^=CIUCFPN*95K_*PI7'@VP
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M=K( \W-KP^9%'+0?8I-_ 5!+ P04    " "U/:E6%GCX9=D"  !P!@  &0
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M4^S_X<!.\A]7_[Y-FS)B#OA,WJ'WM96F1$576BFL#0C.5EQPPVDUD_3&M2&
M+("BH)""S(+7ZQ[0<6>E.^]KS+!:$84=3.A2V>,AC!7I@JQ6GA'?&22=,.VZ
M]C*,@8Y8$:-3H5 P<R@M[*11EP*[20IS)0O4UF]8$VV5T?,F)5 @!:=I2( P
MC6"RSV,CE7,74DY&J9B+%4@^T:;X E'G*DCIFR8AW$MCR=]7H3.XZJ1!2&T8
M=^(T@6,7R3]P@0K5VGF=K>ZV-HTAM+.MG8X:%_D;WG@Q57W-:TV)% 0-SB\O
M/%"-OS4#(S?.4U;2D$.Y;DF_!%0V@-8+*<WKP&[0_F2&?P!02P,$%     @
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M?X#V5YIR=SOQ"OJWX?Q?4$L#!!0    ( +4]J5:\3=D-C04  #0-   9
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MPPH@-VV,D76Z[@8HD565*D%MW.XN2]YO@1=J7:D435HJHVLVUJ/7^^?7@:O
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M#>YI"PKIAYB"T8CQ&WH*AV+"?6@J3B'!"".2<H!1P)=6P.UB_0*8+%JRT^\
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M9R^N'M.N(<'NE8$Z0BGO]89#A!M-WF65VD*:0^=SGOVYL$F$Z%I9=J3!>MU
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M@-HYT/Y**;LSW 'M'X_I?U!+ P04    " "U/:E65D,8F"D#   B!P  &0
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MNP.:<:JYHC8O1J[<M7 N#5TRW3*C6STJ*T#["RG-]L4:V/U/&/T#4$L#!!0
M   ( +4]J5:KP>'?_@,  %,)   9    >&PO=V]R:W-H965T<R]S:&5E=#(T
M+GAM;)U676_J1A#]*R.WJH*T#;;!,:2 E*1<W4KW X7<YJ'JPV(/>!5[U]U=
MAZ2_OK-K<$ E]*HO]G[-F3.S9SR>;)5^,@6BA9>JE&8:%-;6U_V^R0JLN+E4
M-4K:62M=<4M3O>F;6B//O5%5]N,PO.I77,A@-O%K"SV;J,:60N)"@VFJBNO7
M6RS5=AI$P7[A7FP*ZQ;ZLTG--[A$^ZU>:)KU.Y1<5"B-4!(TKJ?!371]F[CS
M_L#O K?F8 PNDI523V[R6SX-0D<(2\RL0^#T>L8[+$L'1#3^VF$&G4MG>#C>
MHW_PL5,L*V[P3I6/(K?%-!@%D..:-Z6]5]N/N(O'$\Q4:?P3MKNS80!98ZRJ
M=L;$H!*R??.771Z^QR#>&<2>=^O(L_R56SZ;:+4%[4X3FAOX4+TUD1/27<K2
M:MH59&=G7^8/\.GK<@F+^3TL/][<S^'B@:]*-+U)WY(#=ZR?[<!N6[#X'; !
M?%;2%@;F,L?\V+Y/Q#IV\9[=;7P6\#/7ES"(&,1A/#B#-^BB'7B\P3MX<ZZE
MD!L#"]2P++A&^.-F9:PF<?QY*MX6;G@:SA7,M:EYAM. *L*@?L9@]M,/T57X
MRQFRPX[L\!SZ;$D%F#<E@EK#G:KJQG(O9)I^H6K]I(R!>A_'*?+GX1\*A+4J
MJ2HI(V#=G>]*4_R-!BQM9\=>2?TB RYSR$796,Q!$H]RS\/X?')KM5@U+9Y5
M#J,B<[]9J#)';1R6@W=!<?D*%T+27#6&H T#?,FPMGLX\G8 7JE&6M.[AH="
M(Q[)S6O$/6*?'D_K1[B(0S9*DYX?)BP)TQX\^E(E"_Z,FKX\1QR)76.-);^4
M%G8BYL$5&XX&!#IRPSB-6#R.WEQV9$_9$HGP,DE[[2 ->V=DDG0R2;Y;)C?2
M"N^+OG2PQ*S1P@H*:?Z2E8W+T5JKZO^)Z2R)TY7P<'#'N&=@CV17*XO$F9?'
M=\# HTB7,_?-S<%]P-O+/[P?4AL@SPI'7:@<4.:LC?&$?,^(EIJ;MVAA# A"
MS[CWCAEO#-**X^\KA=HBM9JFS*$@ =&#A$3L*(R?N]SC>DUMYS]D^K5VU(RK
MDKK164&!=FFP*GN"E*51R.)1 @D;1R.6CH?P33ZC<<PH051IF1NVIT>DQG$(
MPX2EP[B]2(K$F,:78D/.-6!5E^J5*+4FG=NZI!"B,&:#)((X94D:OWFBK/CN
M+S/\M]=&"KJ3.!ZS43*&:,S",(1'KC5W=_5N:!17FJ3[UXA%@S%+B/85"^.(
MC:X2.%4:_8-&5Z'>^'9N")F$T?:\;K7[8[AI&^7;\?9W@UK+1E#R2UR3*14C
M"5RW+;R=6%7[MKE2EIJP'Q;TUX/:':#]M2+M[B;.0?<?-?L'4$L#!!0    (
M +4]J5;+>7H=W@,  #<)   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;(U6;6_;-A#^*P=U*Q+ M=XLRTEL XZ7H@46)*BS]L.P#[1TMHB*HD92<;)?
MOR,EJT[F>/U@ZTC>/??<FZCI3JKOND T\"3*2L^\PICZTO=U5J!@>BAKK.AD
M(Y5@AI9JZ^M:(<N=D2C]* C&OF"\\N93MW>OYE/9F))7>*] -T(P]7R-I=S-
MO-#;;WSAV\+8#7\^K=D65VC^J.\5K?P>)><"*\UE!0HW,V\17EXG5M\I?.6X
MTP<RV$C64GZWB\_YS LL(2PQ,Q:!T>,1EUB6%HAH_-UA>KU+:W@H[]$_NM@I
MEC73N)3E-YZ;8N9-/,AQPYK2?)&[3]C%XPAFLM3N'W:M[CCP(&NTD:(S)@:"
M5^V3/75Y.#"8O&40=0:1X]TZ<BQ_8X;-ITKN0%EM0K.""]59$SE>V:*LC*)3
M3G9F_OO-8G6S@K,'MBY1GT]]0Z#VR,\Z@.L6('H#((9;69E"PTV58_[2WB<R
M/:-HS^@Z.@EXR]00XG  41#%)_#B/L+8X<5O18A4- U_+M;:*&J"OX[%V$*,
MCD/8P;C4-<MPYE'G:U2/Z,W?OPO'P=4)@J.>X.@4^GS5S@/(#3BNL)3: *MR
MN#,%*KBK43'#JVUW_+EJ9Y&:^E@HIYT]% @;6=(L6D!CJPX9%9#&5P/;SZ;E
M0KZA= XSXJ-I C.YK?@_F$-#I5:P6"UA,HH<4^F8\A_,@$A;4.=%.K"E%#6K
MGM^_FT1A>J5!]G&U;LC6Z9E"(8)HNPIM5P'U1%;T3>$\DA!=PH/3/>S U[I6
M[S"O=Z^\VN#@%P@'03+JGA>P*J0R'PPJ<:@5IA!>P%>FN$O;P4F4C.F7PJI9
MM[N\RJ1 . OCY!Q<Q-$5/$C#RM=NPXO(/>,X^?]ZOP[NQ3*")=,%U(SG+I=,
MR*:BPA&7LK&9X97+KR#41B&]68VM<\NGI)AXR<USEX.0GFD0P3?W6L/\ WLD
M5END-A!=65M#EZ1T.(;),/FO=LYU9ED 1820#&/XM?T_,3=)/S?)Z;FA"RIO
MJ! 4Q,?&4$AP2\Q$([K$W;-G&Z0^-B4GH8\/?.=#=#[:\.O.1S<3/]'G-&;:
M4GY5RAT2-IVTPZDO87%,R_V=X9.MJ!NMGYF7<ZIE[!J-5B,8#6)J<1(3$D=I
M:L4QB<F%VTU)3$F-WA1TRV^HOA!&@R@)7O1O'W<<#\9!2!G7Q)E7I([4V6?C
M03B:G+\P.6RQ*!V,DAB.=8%_<)D)5%MW96MP;=3>:_UN_U6P:"_#'^KM)P6E
M86O?:R5NR#08IE1UU5[3[<+(VEV-:VGHHG5B05\VJ*P"G6^D-/N%==!_*\W_
M!5!+ P04    " "U/:E614=BB8("  #=!@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6RUE5%OVC 0Q[_**:NF5JJ:$"!L78@$A:I(*T6D; _3'DQR
M$ LGSFP#W3[]; <BM@$/DWA);,?WO]_=V9=PR\5*9H@*WG)6R*Z3*57>NZY,
M,LR)O.,E%OK+@HN<*#T52U>6 DEJC7+F^IX7N#FAA1.%=FTBHI"O%:,%3@3(
M=9X3\;./C&^[3L/9+TSI,E-FP8W"DBPQ1C4K)T+/W%HEI3D6DO("!"ZZ3J]Q
MW^^8_7;#%XI;>3 &$\F<\Y69C-*NXQD@9)@HHT#T:X,/R)@1TA@_=II.[=(8
M'H[WZH\V=AW+G$A\X.PK3576=3XXD.*"K)F:\NT3[N)I&[V$,VF?L*WV!A\=
M2-92\7QGK ER6E1O\K;+PX&![Y\P\'<&ON6N'%G* 5$D"@7?@C"[M9H9V%"M
MM8:CA2E*K(3^2K6=BL:]U]ET""^/T)_%H_$PCJ$W'D"_%X]BLSJ9#N/A^+7W
M.GH9P_4 %:%,WL 5T *>*6,ZLS)TE28Q>FZR\]JOO/JGO/+-'31:M^![O@^S
M> #75S=_RK@ZD#H:OX[&M[JM$[HO^JS",Q$K?9ICPO 8V5D%<P?N94D2[#KZ
MD$L4&W2B]^\:@??I#%^SYFM:]>8)OG@]ES2E^O3?6C[@"X@53U;P[;/>"B.%
MN?Q^C+IY >I63=TZF]4]J32DMT#6*N."_L(4$EU]FJ(@YH8=PZZ$ RML^L,F
M:K2]T-T<H6G7-.WS-!FR!4QQ2:6J'.L4$ITX+-0QA+-J_YFYH&8-+E3OX +4
MG9JZ<ZEZ=_ZI=]O[N][N0;<RC5_?UR4M)#!<:"OOKJ,K)JIF6DT4+VT#FW.E
MVZ$=9OK_@\)LT-\7G*O]Q/3$^H\6_0902P,$%     @ M3VI5CW;H;*#!@
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M'F3)<O.XRD.294FT>;E0<JYT'F ^?TR2[-=!_@1,^<33Y']02P,$%     @
MM3VI5N7!I=$_!   "A4  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
MM5AM;YLZ%/XK%INF35H#-H20+HG4I7NIM$[5TO9^N+H?'.(TJ("9[22[]]=?
M0RBOQDU4^B7!<,[CYSF8<XX]V5/VR#>$"/ G"F,^-39").>FR?T-B3 ?T(3$
M\LF:L@@+.60/)D\8P:O,*0I-9%FN&>$@-F:3[-X-FTWH5H1!3&X8X-LHPNS?
MSR2D^ZD!C:<;OX*'C4AOF+-)@A_(@HB[Y(;)D5F@K(*(Q#R@,6!D/34NX/D<
M.:E#9G$?D#VO7(-4RI+2QW1PM9H:5LJ(A,07*026?SLR)V&8(DD>OW-0HY@S
M=:Q>/Z%_S<1+,4O,R9R&?P4KL9D:G@%69(VWH?A%]]])+FB8XODTY-DOV.>V
ME@'\+1<TRITE@RB(#__X3QZ(B@-T.AQ0[H".=;!S!SL3>F"6R;K$ L\FC.X!
M2ZTE6GJ1Q2;SEFJ".'V-"\'DTT#ZB=G5S_LOB]OK+S]O%^ ,+.0J66U# N@:
M7&/V2 1>RM&"^%L6B(!P\/Y2W@M"_D%:WRTNP?NW'\!;$,3@=D.W',<K/C&%
MY)6BFW[.X?.! ^K@(&<: !M^!,A"ML)]KG>_)'[ACNKNIHQ&$1)4A 1E>'8G
MWE)4)'\$%SNI. W$F?QLSCB6$?G[AW0"5X)$_!^5X,,,CGJ&]-,\YPGVR=20
MWQXG;$>,V;LWT+4^J>3W!%8+AET$P]:ASRXBRD3P'UF!.>5")?7@[V;^:=+8
MS=RA8\&)N:MJ:%N-+1NZA56-G%.0<[3D[F*9N<*,W3>9L91+[X PK$QL-:CI
M+&JTA@6MX;&T?E#.B9+7L#7K&80CM\%-9>4A1\W/+?BY6GY?<<# /0ZW1$7,
M;4WI.@@-&\3:5I[GC)&:V*@@-M(2F],H(LP/< @2G!"FHJ=%./7+Z@FL)M8K
MQ'JOGF:\/H/1$U@M&.,B&.,7IAFM_ZE2QZW5:X\<3[UXH5664NO%Z4@/<:J.
M'.V(W 4K#0%\>?;28YPL RK27(>.LHI#;5U\)LOIG4\6@%0+:M0AH:R]4%]\
MYY0EE&%!P))V=59:A)-U](16UUN6<^B\>DJ$VI;AY(#TA%8/2-E(0'TG\7Q:
MA.T.P79'7K/'49@YKN/8'2NT["2@OI4X*N6U>X46/9U)G5K92T!],W%<'ANU
M,\_0]IKT%%:>U<6P; "@MJ0^EZ$\Q9M%#FIR:YLY0[?SS98%&>HK\MU@,0#?
MZ(ZP6.[:!9![^M@/.J+8:W'N"ZV^^2NK.+)>?_O7:Y7O"ZT>D+(A0/J&X/DD
MA-KU&WDN:NX!%69RHUC96M0)5O;K^DI_3!)"[0K=3$):DSJULH(C?04_*@GE
M&+7TXK:2D,H*9@<F2HIET47Z3;0^"^7.U8T[&HT]NTFN;6:/);L&.;-R4)6>
M$EYC]B!?& C)6OI9@Y%4QPX';X>!H$EV=K6D0M HN]P0O"(L-9#/UY2*IT%Z
M'%8<?\[^!U!+ P04    " "U/:E6Y23ETY "  "%!@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6RM55U/VS 4_2M6-DT@,9PF;6$LC53:HO4!A"BP
MAVD/;G+36#AVL)T6_OUL)\T*"WG:2^*/>\X]YSJ^B79"/JD<0*.7@G$U\7*M
MRPN,59)#0=2I*(&;G4S(@F@SE1NL2@DD=:""X<#WQ[@@E'MQY-9N91R)2C/*
MX58B514%D:^7P,1NX@V\_<(=W>3:+N X*LD&5J ?REMI9KAE26D!7%'!D81L
MXDT'%[.1C7<!CQ1VZF",K).U$$]VLDPGGF\% 8-$6P9B7EN8 6.6R,AX;CB]
M-J4%'H[W[%?.N_&R)@IF@OVDJ<XGWKF'4LA(Q?2=V/V QH\3F BFW!/MZMC1
MF8>22FE1-&"CH*"\?I.7I@X' ,/3#0@:0/ >,/X $#: T!FME3E;<Z))'$FQ
M0])&&S8[<+5Q:..&<GN**RW-+C4X'2]O'A>K^^O%S?T*?473-*6VNH2A):\_
M$5OKHSEH0IDZ-B$/JSDZ^GP<86VR6PZ<-)DNZTS!!YE"="VXSA5:\!32#ORL
M'S\(>@BPL=UZ#_;>+X->QFLB3U$X.$&!'X1=@OKA<TA:>- C)VR/(G1\X4='
MP;>@M+DA6IV@.:PU(CQ%B^>*ZE>T@J22YFQ H5_3M=+2?/^_NPZASC'LSF%[
MPH4J20(3SUQZ!7(+7OSETV#L?^\JP'\B>U..85N.81][?$6H1%O"*NBR66/'
M#FL[U38>?#L/?=^/\/;004=<.#X_.PQ\HV[4JAOUJEL6I=%G#PN)#&6M5D24
M JVZ)(_^D?)>;%]$K1(?W/0"Y,8U0(4247%=7_IVM>VQ4]=:\-_PND&;KW]#
MN4(,,@/U3\],=EDWO7JB1>GZQEIHTX7<,#?_"9 VP.QG0NC]Q"9H_SSQ'U!+
M P04    " "U/:E6AJ9?,T$$  #;%P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,"YX;6RU6&MOXC@4_2M6=K2:D3H-3H  "T@MZ6@JM;-,'[-:K?:#FUQ*
M-$G,V ZT_W[M) 0"P3-9N5\@#]]S[CG.=6X\WE#VG2\!!'I)XI1/K*40JY%M
M\V )">'G= 6IO+.@+"%"GK)GFZ\8D# /2F+;Z73Z=D*BU)J.\VMS-AW33,11
M"G.&>)8DA+U>0DPW$PM;VPMWT?-2J OV=+PBSW /XG$U9_+,KE#"*(&41S1%
M#!83ZP*/?#Q4 ?F(;Q%L^-XQ4E*>*/VN3J[#B=51&4$,@5 01/ZM809QK)!D
M'C]*4*OB5('[QUOT3[EX*>:)<)C1^*\H%,N)-;!0" N2Q>*.;CY#*:BG\ (:
M\_P7;8JQ/3DXR+B@21DL,TBBM/@G+Z41>P$2ISG *0.<PX#NB0"W#'!_-:!;
M!G1S9PHIN0\^$60Z9G2#F!HMT=1!;F8>+>5'J9KW>\'DW4C&B>G\[L_YU=W#
MW^CBBX^NOCY>SV^OOCR@]SX($L7\ _J('N]]]/[=!_0.12EZ6-*,DS3D8UM(
M>@5B!R7594'EG*!RT2U-Q9*CJS2$L!YOR[2KW)UM[I>.%O"6L'/DXC/D=!RW
M(9_9KX<[#>&^/MR'X%1X38U;S82;X[FG9H+)8F;B]0S-8Y(*)$U&5S^R:"6K
M3*!_;N1P="T@X?\V65]@=YNQU>(QXBL2P,22JP,'M@9K^OMON-_YH\DWDV"^
M(;":I]W*TZX.O?(T-Q.V9C;Y5^#T<QRU5JZG+O8&8WN][XN6K*TO#8RNZU6,
M-;V]2F]/J_<&.!_)M33(DBPF D*Y!,I<@HBH1;9)=X'7V\OBXZ#;.]"M)6VK
MNX'1ZW6:=?<KW7VM[@<J2(QJLUV5SAE*H7'*^T>).'(&#J1K>=M*;V#L#4Y,
MN5=)][32_;T)1O B^P$.36J](VZLEJV:6._HD<3.P;/@:[/YG^4\J+0.](\W
M>:*,",I>]<6L16F[&)H$\PV!U=P;5NX-W_ %,S3IJ4DPWQ!8S5/<V?5/'4.O
MF!)HOP3[&!^4H)ZMK34-E)YW8JW%>RTCUDK^E+$T$AF#7/,B>E''S0VA%JCM
M4V,4S3>%5C?1V9GHO&$UEN"FC#6)YIM"JQN[:Z.QMJ-L4Y#N\3O1.ZQ'H[VP
MGK$N>-?C8GV3.Z/)*A/ <L%TL8@"^(ENDWWLS"B:;PJM[N6N?\:]MZQ*DXWR
MS"B:;PJM;NRN0<?Z#KU%51YWR>[AAYB>K+4U6L:ZX%U;CO5]^0T0#DL:ARA*
M5HRN0>EM?DD::JE+:TRB^:;0ZB;N^GT\>,MR-/H=8!3--X56-W;W*8"U77&;
M<AP>?10Z/7SXY:BG:VW.3S@+T?;>KF<"[#G?/>8HH%DJBDW$ZFJU0WV1[\L>
M7+_$HUFQS[R#*;:];PE[CE*.8EA(R,ZY)]<(5NPD%R>"KO*]U2<J!$WRPR60
M$)@:(.\O*!7;$T50[>=/_P-02P,$%     @ M3VI5EW>K)W6 P  2 \  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULO9=M;]LV$,>_RD$KB@1(HP<_
M)9EMH(G<U4#398G381CV@I'.%E&)5$G*;O?I=Y)LQ4H4M1Z$^H4L4KS_'7\B
M3[SQ1JK/.D(T\#6)A9Y8D3'IA6WK(,*$Z5.9HJ G2ZD29JBI5K9.%;*P,$IB
MVW.<H9TP+JSIN.B[4=.QS$S,!=XHT%F2,/7M$F.YF5BNM>NXY:O(Y!WV=)RR
M%=ZAN4]O%+7L2B7D"0K-I0"%RXGUUKWPW<*@&/&)XT;OW4,^E0<I/^>->3BQ
MG#PBC#$PN02COS5>81SG2A3'EZVH5?G,#??O=^KOBLG39!Z8QBL9_\E#$TVL
M,PM"7+(L-K=R\QZW$QKD>H&,=7&%S7:L8T&0:2.3K3%%D'!1_K.O6Q![!N[P
M!0-O:^ ]->B_8-#;&O1^U*"_->@79,JI%!Q\9MATK.0&5#Z:U/*; F9A3=/G
M(G_O=T;14TYV9CK[XWZ^^ NN9XOWO_LP__AI=K>XGGU<P)&/AO%8'\,;N+_S
MX>C5,;P"+F 1R4PS$>JQ;2B 7,8.MLXN2V?>"\Y<#ZZE,)&&F0@QK O8%'D5
MOK<+_])K5?0Q.(6>>P*>XWD- 5VUFU\S59GW&LS]'_#N-'JOS:97O8Q>H==[
M0>^.=G68Q0AR";,O&3??X!I-)$.8BS5J0_O-:/C[ YG!W&"B_VEZ!Z6/?K./
M/(]<Z)0%.+$H46A4:[2FKW]QA\ZO3?RZ%/,[$JNQ[5=L^VWJT]\H!P(E&LU*
MOO.;)G:EQK#0R%/F>NIY/7JUZWTFK8X.9=*16(W)H&(R:&5R2XI,!1'0=J9D
MN::O0)JO,6!:TR>'!;0&%88@380*3,0$793,5A$\9)K$M(9 )@]<L#R)G\!&
M<6-0O)'+91/=P3.Z(]=Y K<UXD/A=B16@SNLX Y;X7Y@F0BBE(64,5&Q%#/#
M WU"6SDX;8+3JG;HMNU2S.](K$9Q5%$<_824..J2;9=B?D=B-;9G%=NSUA5Z
M)9,DSX@1(VTZQ 5(1[ 0EDHF@"7KI&3-*]9PQ'<6QTVD2X^#O2U^[A2_)]N\
M-;)#(78D5H-X7D$\;X4X>P'4"<B-0*4CGD***J N.D<W(6O5/W1QEF+G>_R=
MT]ZY6Z?O=^2R!LQU'H^<SO]"UGB@=)Y],YXNI>\/\1N&>-[@<51](GMG9[<]
MQ4M=[!NY$OS?[^V<QMFYS^)R!_UG$VR-XM#-TI5:R<S>*ST25*NBA,M/!9DP
M9152]59EXMNB.+(?AY<U)AW&5UQHB'%)IL[IB+*(*LNVLF%D6A0R#])0653<
M1E3JHLH'T/.EE&;7R!U4Q?/T/U!+ P04    " "U/:E6=AL8T$X#  !@"0
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MN<-?(% V ,<W4IJ7CKUEFY^J]!]02P,$%     @ M3VI5A2].Q*N"   ME,
M !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULQ9Q=;]N\&8;_"N&]&%J@
MC:T/VW&7&$@L<NNVM$;3; ?##AB;B85:DE]*3IIA/W[41TQ15FBKN >?)+:L
MYR*EFWI(W:)X\9S('^E*B(S\C-9Q>ME;9=GF4[^?+E8BXNE9LA&Q^N4AD1'/
MU%?YV$\W4O!E$12M^^Y@,.I'/(Q[TXMBVUQ.+Y)MM@YC,9<DW481ER_78IT\
M7_:<WNN&;^'C*LLW]*<7&_XH;D5VMYE+]:V_HRS#2,1IF,1$BH?+WI7SB?E^
M'E#L\8]0/*>USR0_E/LD^9%_^;R\[ WR&HFU6&0Y@JM_3V(FUNN<I.KQ>P7M
M[<K, ^N?7^FL.'AU,/<\%;-D_<]PF:TN>^<]LA0/?+O.OB7/?Q'5 0USWB)9
MI\5?\ESN.Y[TR&*;9DE4!:L:1&%<_N<_JQ-1"W#\-P+<*L!M!+C#-P*\*L [
MM@2_"O"/#1A6 <-C T95P*@X]^7)*LYTP#,^O9#),Y'YWHJ6?RCD*J+5"0[C
MO&7=9E+]&JJX;'K[_>OL;Q^OKVYI0&9?;^;TR^W5]\]?OY"/Y N7DN>ZDW>!
MR'BX3M^KK7>W 7GWVWOR&PEC\GV5;%,>+].+?J8JDR/[BZK@65FP^T;!'KE)
MXFR5$AHOQ=*,[ZN#V!V)^WHDUZX5^%<>GY&!\X&X ]=KJX\]_(;+,^*]'1X<
M'^ZVA%-[>" 6UG!VQ+$[?A$^L)Q+;]<JO(+GO=4J5ER*C_D5NR2S)%)I+.5%
M(KA232)^%"JU9.3^A=3WF_.78O/5,Y=+\J^_*R3YG(DH_7?+\5R7Y?OMY>?I
M]%.ZX0MQV5/Y,A7R2?2F?_R#,QK\J4U9)"Q PB@2QD PHT7XNQ;AV^C3NUB*
M1?(8A_]14B_J36*1I-D'DFSR+VUYX-H*[BIU"1L5L+S7?)HZ8_]\<M%_JFN(
M+)(B80P$,S0<[C0<6C6\S9+%C^IJ-204/_//HDT\*[&K>,,]\=S1V&EHM[^3
MYXV'YDX462T&@AF:C'::C*R:Y F;%,*0K\4E1.9K'K<I8>5T50()"Y PBH0Q
M$,Q0=KQ3=GSB/G2,;!%(6("$422,@6!&BSC?M8ASZ[7^.5ZHF[]4D.2!\&VV
M2F31FZ9Y T@_D(V0BUQ\]:O*SI%J*6F1%]3]8)JI0788/[:U@K),9U!+F(.S
M@6\FS)FU9EWE1<(H$L8.G0Q#M\E.MXE5MR_;Z%[(0K7E,LRO8;ZN5*OK^$[=
M$)5;W[?I5)8QK(]<_.'8:_9_,VM=NBJ%A%$DC(%@AJ#.0-_U#@YWN_1V/F]3
MRA[;-;%":0&41J$TAJ*9FM:<#.?$'6Y5 53#0-("*(U":0Q%,QN&JQN&>X)^
MUUYHY\: I 50&H726$5K]M%.>Q_M:,O*L?H?H%ZZ*J3>37ONR!LUQU/VRG36
M"VHZ06D,13-EU;Z38S>>RGMCB[UDC^]\'2)I 91&H32&HIFZ:B_*&9ZZMX9Z
M5U!: *51*(VA:&;#T(:88W?$#CG-U:_%%M5UATF9TU\$EV^D=*AS=J#V;ED1
MXI&H?+SEG),E?VG+7 &T8A1*8RB:V0BT=^98C9A?LJKMR,XZC_?-:G_8\*&#
M:B]CN.!,O(9;#:T90]%,:;2)Y=A=+*-#)O\EQSO8=G!G@:"6%I1&H32&HIF"
M:_?+F9RZIT8Z2S,H+8#2*)3&4#1SOH4VT5R[B79;WER%:;I5DF_CI;K]2FN-
MP$C<FS>2@KV,KMI7M*&1M<?C42-M0PNE4!I#T4Q1M8OF6LV8Z3>19C)<9+E!
M4B3UK1IKM=YXV4&=E8.Z85 :A=(8BF8*K-TPUSUQ.G>ASAB4%D!I%$IC*)K9
M,+2!YMH--/B-E[V\SNW 7OO)$3=<T I1*(VA:*;XVF9S[38;XZ$D3WR]+5SR
M(N>3)]45-*=F5LI"/3=W?U*7._":73;42H/2&(IF:J>M--<^K\M^X;;J![7&
M*IHQZ'+<IGY0QPM*8RB:J9]VO%R[9_0K9H<=V5G!T=X5Z.PKV+*3VYB]0*'U
M8BB:*8QVH5R["S47LGAW(UX(4AL7EV;'W9OC8J@/!:4%4!J%TAB*9HJM?2WW
M_-3C8JC_!:4%4!J%TAB*9C8,[7^Y]NE??U;R9X>?'-LIG=7=GRXV:.9CJ#,%
MI3$4S7Q[13M3GMV98HE\$.$1HMDYG=]#V7>?FJ)!"Z10&D/13-&T\^39G:>B
M0ZW/NCDH'M2 JFC&*-:=G ^;[Y9 2Z50&D/13 6UM>39)UK]RD#6CNPLHKLW
M1MV[ J$.$)3&4#13O]I;?W8/I6;H\_NUJ"Q]$6W6R8L0E1^\V<K%*I]-ESOZ
MK\__WII*:R^PL[K8%_VP;_IA7_7[?[A!GG:#//_$8V$/ZB!!:0&41J$TAJ*9
M#4-;3=Z!5P@1C_SL9736?M]]\CR5E)IIOV4WQ_.;_@6T;@Q%,]72QI)G-Y;*
M2U$G;&W:EUYY^Z@*ZBP=J.&HJDGK90B='@6E,13-%%8;4Y[=F+KA/\-H&]6G
MKC_D!G[$Y0^1:1^_/I^]56NH5571&C.[SYMSIJ"%4BB-H6BFKMJ#\NQSJUYU
MU4.N[7VZD&$YKTKRK'T(#?65O-9WZ)IO:4/+I% :0]%,$;5?Y-G](KN(/$JV
M<>M#&3NVLXR3_8=J>U<BU$&"TAB*9JYVH1TDW^X@W<7ET\\\Q>Z> <BCY\;8
MZ5VUA-("*(U":0Q%,U77%I1_ZE<(?:AG!:4%4!J%TAB*9C8,[6SY=F?KKC8A
MXI M:4=UEMC=NV^9C)SFA$9HF11*8RB:*9TVM?Q#TYHZVLIV7F?]H)X5E$;]
M_9<=76_B-U?;8:A2305K2T_9YR;]BJUL1W86L66&TMZ:4U#7"$IC*%HI8+^V
MW& DY&.Q,&2JI%$#VW*]OMW6W>*35\62BXWM,^=34"XAJ3'EBI8W7#Z&<4K6
MXD$A!V=CU49EN4AD^25+-L6BAO=)EB51\7$E^%+(? ?U^T.29*]?\@)V2W5.
M_P=02P,$%     @ M3VI5B,D:0,4!   ,A0  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&ULQ5A=;Z-&%/TK([I:[4I)8,"?6=N2[;AMU&9CQ=GNPZH/
M$[@V*,"P,V,[Z:_OS$# V)C6$9)?;#[N/9Q[[@$N,]A2]LQ] (%>HC#F0\,7
M(KDV3>[Z$!%^11.(Y9DE91$1<I>M3)XP()Y.BD+3MJR.&9$@-D8#?6S.1@.Z
M%F$0PYPAOHXBPEXG$-+MT,#&VX&'8.4+=< <#1*R@@6(;\F<R3TS1_&""&(>
MT!@Q6 Z-,;Z>XKY*T!%_!;#E.]M(E?)$Z;/:N?6&AJ4800BN4!!$_FU@"F&H
MD"2/GQFHD5]3)>YNOZ'_JHN7Q3P1#E,:?@\\X0^-GH$\6))U*![H]G?("FHK
M/)>&7/^B;19K&<A=<T&C+%DRB((X_2<OF1 ["1*G.L'.$NS]A-:1!"=+<'2A
M*3-=U@T19#1@=(N8BI9H:D-KH[-E-4&LVK@03)X-9)X8+1[OIW]<3L:+V0V:
MWM_-9U\7X\?;^Z_H$BVD9;QU"(@NT4)0]_ER(O7RT)1&TD2<Z#9\N@%!@I!_
ME@G?%C?HTX?/Z ,*8O3HTS4GL<<'II \U=5,-^,T23G91S@YZ([&PN=H%GO@
ME?--65]>I/U6Y,2N!;PC[ HY^ +9ENU4\)G^_W2[AHZ3:^YH/.>8YCYA</FD
MQ9R35WE3"#1FC,0K4-L7:/:B!)9GI7YH2I) D##X![P+-([H6D;_^%-"HEL!
M$?^[2M_T^JWJZZLGPS5/B M#0][Z'-@&C-''7W#'^E(E3D-@):E:N52M.O11
MZKM4*G?7=Y!*5%5\BMC1B.HIMAG9G2X>F)O=H@Z#'*?;SH-*9-LYV78MV0=9
M/F&NK]OFP48^(Q/5T"J2M4BG=J@AL%+1G;SHSIG-W&E2JH; 2E)U<ZFZC9LY
M16SO^+3?ZN]Y^3 &M^U>M9=[.==>+=??( 9&0MTTXLD73\ %(^J56\6R%NO4
M%C4$5BJ[GY?=/[.;^TU*U1!822IL%:.#U;B?,\B26;OJK5IR=%54K]6MMC3>
MF77P?Q-&-%$DJ^>2VOQ3N],46KE:NZC6/K.7,P)-R=406EFN8BC#M8/,^]SL
M'/C4;K7;^VX^C')PWSGBYF(TPO6SD1PW! M<(?ER;>QU'(AJ6]<"G=RGAM#*
M91=#%FZ?V]:-#F=-H97E*L8S7#O2O,_6G</'+SYX1E<$V?B(J8L1"=?/2+,H
M">DK0/K%B>9K.4]+[F@>DE@W]%[XP"I)UP*?W+6&T,HR%-,7[IW;Y(W.;$VA
ME>4JIC9<.^F\S^3]@T] ;+7V37X8U-GWN+FS^A(!6^E%*2YYR#:D:Q3YT7SA
M:ZR7>_:.3]2"F%[5*6#2U;0[PE9!S%$(2PEI777E7<?2!:IT1]!$K_$\42%H
MI#=](!XP%2#/+RD5;SOJ ODRX>A?4$L#!!0    ( +4]J582%>^"\00  .H8
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;+69;5/J.!3'OTJF>V='
M9Y0VH2W%!680O;O.KE=']-[7L0V0L6W8)(!^^TT?;*&MH;+R1M*2<W)^)P_G
M3QQL&'\1"T(D>(W"6 R-A93+"],4_H)$6'38DL3JFQGC$9;JD<]-L>0$!ZE1
M%)K(LEPSPC0V1H/TW3T?#=A*AC0F]QR(511A_G9)0K89&M!X?_% YPN9O#!'
M@R6>DRF13\M[KI[,PDM (Q(+RF+ R6QHC.'%!#F)0=KC)R4;L=4&"<HS8R_)
MPTTP-*PD(A(27R8NL/I8DPD)P\23BN/?W*E1C)D8;K??O7]/X17,,Q9DPL)?
M-)"+H>$9(" SO KE ]O\17*@-$"?A2+]"S9Y7\L _DI(%N7&*H*(QMDG?LT3
ML66@0)L-4&Z VAIT<X-N"II%EF)=88E' \XV@">]E;>DD>8FM58T-$ZF<2JY
M^I8J.SF:/MY-_CZ_'$^OK\#D[O;^^L=T_'AS]P.<@ZE:,L$J)(#-P%0R_P7<
M+=/4CY/44_D&3JZ(Q#04IZKWT_0*G'P[!=^ "<0"<R( C<%33*4X4R]5^W'!
M5@+'@1B84D6>C&_Z>927693H@RB[X);%<B' =1R0H,%^HK>'2./ 5"DK\H;>
M\W:)M!YO,>^ +CP#R$+=IH#TYE?$+\R1)IQN,8W=U%_W W_9S#1F-C.TFPV3
M4^)"++%/AH8Z!@3A:V*,?O\-NM8?351?Y&R'T2X8;9WWT=U*"JG6#XWG9^"9
MS&D<JZ;:Q"&.?0).U!++%MYI4QHRWT[J.SG;UB.GZ_1MRQJ8ZVU";0P'$CH%
MH:,E_)/C6))@'XI30T&NTT=.%44[V($H;H'B:E$FR9R$BH5QH(K-C- 68&X-
M[!S9%K)A!4P[](%@O0*LIP6[?EU2OA^E5T=Q/8CL"HEVK -)O(+$:[^?2/K9
M=C-Y-;I>#UK(<RIX]7[53;<3>;^(O*^//#OMP)H(F2TQ\KI4ND"U)4O?[@/H
MMP30QG'@_$"KK,U6*T[R2KA/!7X.]\Y,[G'G</"0!WM>A4P_]*%H6[(#:@O6
MKU1?J0D;KPE7>A%<9XP$W'/JDT8T^)65[*N\[?*CDA_]WV(6L##$7( EX=F,
M-T]X-HZW->$0=:KGC#Z:0VE+=0*UPF"GL+7$RAQ"N+V0._TJUC'T""P%"=0K
MDJS(-5:YEI1VG1+"#JP>0_HX#N4L90G4ZY+MFM<2S&F8/J^#W"K8,30*+$4*
MU*N4?26P):Q;A^UW+%1E=?4[=9>AU"-0+TA:%L.6*+UV*,?0+; 4+G"/<OF@
M+K9D].KS8'=J(E,?PZ&,I<2!_<\5R >2W,HD*_0?.B- K5IP$TM.8T%]\!.'
MJ^:B^44*)L_),?00*O40:J>'V/:VY45>PB0OR3IX(VH5-,[]G@&\S!38(,JN
M"Y - OS6]+MZLL=5+W?5?W<%O097NXDHU1/2JI,6>_ZS>=&/]ZF\'$-8H5)8
MH3W"JGXV?#87^@'RB6U$/X;*0J7*0GJ5U;@]:'%&K#\Z(W*W[HX(J5;JADX]
MM[EVH5) H3U7.BW6<1N ^N5. \ Q-!0J-132:ZC&==F&S:GEO5LMQ_JA/XMF
M;MTF1X3/TTMV 7RVBF5VL5R\+2[RQ^GUM5EVS_X+<(NY^F4C0$AFRM3J]%2@
M/+M8SQXD6Z9WT\],2A:ES07! >%)!_7]C#'Y_I ,4/Q[8_0?4$L#!!0    (
M +4]J5: H<$J" 0   @/   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM
M;+57;6_B.!#^*U;N=-J56A(GO*4'2$"[NNK4@LJ^?#;$$*N.S=H.;*7[\3=.
MTH0[0K;ECB\0)YYYGAE[_'@&>ZF>=4RI03\2+O30B8W9WKBN7L4T(;HEMU3
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M_:X?>O4DPY)DV+CSOV4',3 C.ZI 6-!&$6'R/1L10]&:,(5VA*>TCE-X@7K
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MC4+_7Q1X06CAL_CS]&" 3M@5/C1XX:G"=T6VU:;)'=ES]=:^$15.8>ZHO2N
M;\%)WO[C1]X[F[!7 CN0.>IDCH;0D_UG4QC!Z0G!#4ID4/31LTU\;SR:N=N^
M$&O0M LZ(#CN"(X'"2YSQN65!%Z>8=C C/N+QT?\+"$GV$4=NVB0W0_,"5X5
M<(9;]&+A8!P=D;/%Q'9V<<<N'JY=O6IX$9JR$FS,XA>K7OGA^(C:RR#/3FS2
M$9L,$OO&)"[.U&SRLEG^-#AB9@D*>_0/R$T[<M/!G7_V/+6QG;[F@?!*8 ?J
M?6]_XWB#S5E@D:,*DPPIQ0B7K*92Z$^HJ-5)KZ\-52!4JJK4')1CD/I.:GI9
MJ,U "B*?K/>)9SL>_*..6J)B+[!WU._=HOZ@II_&+D!VA;>JK1M0#D=[J/VY
M9PZ8"Z7M"3 7EU;^PTO$32J*4=E<C!'*\)/M9EV<09JT2%&+--358%^!X.\J
MD!&1ZM8B]9E;CX86<-K?]M?>.#QNV+FPAK#;\T E\(VQA@(9"HU)Z&8[^WEK
M3-?1_)VVI<9;[6$:3ZLLP(90H3JZ5I#>=:S.!=[8Q&8@666<UHI)Y=O,8ZZL
M-7 =H-ZO&9// [U 9]:3_P%02P,$%     @ M3VI5J1?<ZSO @  & @  !D
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M><PSKH9.JG5Q[KHJ3B&GJB,*X+BS%#*G&J=RY:I" DTL*,]<W_-"-Z>,.]'
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M[8HTCJ-^?.Y;,DQ57DNN<1)&0TA(%:YE5USA!,^C BT703* @M3@GM(-@ZF
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MR7^2]5WKU5__2VC7N%9E<_1GW0^;^2=02P$"% ,4    " "U/:E6!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( +4]J59!(K$0[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +4]J5:97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MM3VI5G11<UKX!0  O!\  !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +4]J5:PDZ>B:P4  "(6   8
M          " @3P.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " "U/:E6HT/5WP<#  !Q"@  &               @('=$P  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ M3VI5L*.+.^<!   <1(
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M965T."YX;6Q02P$"% ,4    " "U/:E6I'NZY@$%  #U"P  &
M    @(%..@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
MM3VI5F5&9&6F!   # P  !D              ("!A3\  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " "U/:E6R*BIN_8"  !U!@  &0
M            @(%B1   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( +4]J5:JO'/-H@4  )0-   9              " @8]'  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ M3VI5A9X^&79 @
M< 8  !D              ("!:$T  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " "U/:E6B^@H:T<$   G"@  &0              @(%X
M4   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( +4]J5:\
M3=D-C04  #0-   9              " @?94  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ M3VI5DD<8 %$!@  YPX  !D
M     ("!NEH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +4]J5:T7F ^U0(  "<&   9              "
M@7=T  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ M3VI
M5@7K^#GH @  . 8  !D              ("!@W<  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " "U/:E6*WCL\^P$   S#   &0
M        @(&B>@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( +4]J5:KP>'?_@,  %,)   9              " @<5_  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ M3VI5LMY>AW> P  -PD
M !D              ("!^H,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " "U/:E614=BB8("  #=!@  &0              @($/B
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( +4]J58]VZ&R
M@P8  /TT   9              " @<B*  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ M3VI5N7!I=$_!   "A4  !D
M ("!@I$  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "U
M/:E6Y23ETY "  "%!@  &0              @('XE0  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( +4]J5:&IE\S000  -L7   9
M          " @;^8  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#
M%     @ M3VI5EW>K)W6 P  2 \  !D              ("!-YT  'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "U/:E6=AL8T$X#  !@
M"0  &0              @(%$H0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+ 0(4 Q0    ( +4]J584O3L2K@@  +93   9              " @<FD
M  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ M3VI5B,D
M:0,4!   ,A0  !D              ("!KJT  'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6Q02P$"% ,4    " "U/:E6$A7O@O$$  #J&   &0
M    @('YL0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M +4]J5: H<$J" 0   @/   9              " @2&W  !X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ M3VI5N6G//X. P  ]@@  !D
M             ("!8+L  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " "U/:E63Z8:"QH$  #9%   &0              @(&EO@  >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( +4]J5;XN[7T_@,
M '$4   9              " @?;"  !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ M3VI5C&D!=R) P  N L  !D              ("!
M*\<  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " "U/:E6
MI%]SK.\"   8"   &0              @('KR@  >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( +4]J5;\YGC\MP(  'X'   9
M      " @1'.  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ M3VI5@G#4SLL P  \!(   T              ( !_]   'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " "U/:E6EXJ[',     3 @  "P
M@ %6U   7W)E;',O+G)E;'-02P$"% ,4    " "U/:E6>5#FI/8#  !&'
M#P              @ $_U0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MM3VI5K[+,T&9 0  =1D  !H              ( !8MD  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ M3VI5B/5;@VH 0  N!D  !,
M             ( !,]L  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #(
,,@"5#0  #-T

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>127</ContextCount>
  <ElementCount>214</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION</Role>
      <ShortName>NATURE OF BUSINESS AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/INVESTMENTS</Role>
      <ShortName>INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - EQUITY METHOD INVESTMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT</Role>
      <ShortName>EQUITY METHOD INVESTMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS</Role>
      <ShortName>BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - INVESTMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables</Role>
      <ShortName>INVESTMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/INVESTMENTS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/LEASES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails</Role>
      <ShortName>NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails</Role>
      <ShortName>INVESTMENTS - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - INVESTMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails</Role>
      <ShortName>INVESTMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - EQUITY METHOD INVESTMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails</Role>
      <ShortName>EQUITY METHOD INVESTMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Computation of Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails</Role>
      <ShortName>LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>LEASES - Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bdtx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - BENEFIT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails</Role>
      <ShortName>BENEFIT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LesseeOperatingLeaseRenewalTerm -  bdtx-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="bdtx-20230331.htm">bdtx-20230331.htm</File>
    <File>bdtx-20230331.xsd</File>
    <File>bdtx-20230331_cal.xml</File>
    <File>bdtx-20230331_def.xml</File>
    <File>bdtx-20230331_lab.xml</File>
    <File>bdtx-20230331_pre.xml</File>
    <File>exhibit311_q12023.htm</File>
    <File>exhibit312_q12023.htm</File>
    <File>exhibit321_q12023.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="424">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bdtx-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 424,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 127,
   "dts": {
    "calculationLink": {
     "local": [
      "bdtx-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bdtx-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bdtx-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bdtx-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bdtx-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bdtx-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 335,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 4,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 9
   },
   "keyCustom": 15,
   "keyStandard": 199,
   "memberCustom": 9,
   "memberStandard": 24,
   "nsprefix": "bdtx",
   "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.blackdiamondtherapeutics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - INVESTMENTS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS",
     "shortName": "INVESTMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - PROPERTY AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - EQUITY METHOD INVESTMENT",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT",
     "shortName": "EQUITY METHOD INVESTMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - NET LOSS PER SHARE",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - BENEFIT PLANS",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS",
     "shortName": "BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - INVESTMENTS (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables",
     "shortName": "INVESTMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - NET LOSS PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i5f823a64b85d4ac7bd10d06b5df686fb_D20221114-20221114",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:SaleOfStockAuthorizedConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails",
     "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i5f823a64b85d4ac7bd10d06b5df686fb_D20221114-20221114",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:SaleOfStockAuthorizedConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "ie1de270b96e64e8d86b7cbcec1f81067_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "ie1de270b96e64e8d86b7cbcec1f81067_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails",
     "shortName": "INVESTMENTS - Schedule of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - INVESTMENTS - Additional Information (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails",
     "shortName": "INVESTMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i700858d5fb2842d8aa731adad03358f0_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - EQUITY METHOD INVESTMENT (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails",
     "shortName": "EQUITY METHOD INVESTMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i700858d5fb2842d8aa731adad03358f0_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:AccruedContractResearchServiceFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:AccruedContractResearchServiceFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i2a68a37a9356497ebf39ad08f89e5202_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i17eafc42a82d4f13904b976d1891eb47_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i4e69e52e4e6d406fb3c05c1f565e0fc4_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i4e69e52e4e6d406fb3c05c1f565e0fc4_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails",
     "shortName": "NET LOSS PER SHARE - Computation of Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails",
     "shortName": "NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:LesseeOperatingLeaseNumberOfContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - LEASES - Narrative (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "bdtx:LesseeOperatingLeaseNumberOfContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails",
     "shortName": "LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails",
     "shortName": "LEASES - Schedule of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "if76381c49969430b8ee1ce9004b721ee_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - BENEFIT PLANS (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails",
     "shortName": "BENEFIT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i9928ba02038f4ae78a1c4a0dd70f34fe_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i9928ba02038f4ae78a1c4a0dd70f34fe_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION",
     "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - FAIR VALUE MEASUREMENTS",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdtx-20230331.htm",
      "contextRef": "i249d943305564527a84d83a0112cc5dc_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "bdtx_A2020EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Employee Stock Purchase Plan",
        "label": "2020 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 ESPP"
       }
      }
     },
     "localname": "A2020EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_A2020StockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Option Plan",
        "label": "2020 Stock Option Plan [Member]",
        "terseLabel": "2020 Stock Option Plan"
       }
      }
     },
     "localname": "A2020StockOptionPlanMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_AccruedContractResearchServiceFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Contract Research Service Fees, Current",
        "label": "Accrued Contract Research Service Fees, Current",
        "terseLabel": "Contracted research services"
       }
      }
     },
     "localname": "AccruedContractResearchServiceFeesCurrent",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Shares Received in Noncash Exchange",
        "label": "Equity Method Investment, Shares Received in Noncash Exchange",
        "terseLabel": "Common shares received from equity method investment (in shares)"
       }
      }
     },
     "localname": "EquityMethodInvestmentSharesReceivedInNoncashExchange",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdtx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Operating Lease Liabilities",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "label": "Increase (Decrease) in Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligation"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_LaunchpadTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Launchpad Therapeutics, Inc.",
        "label": "Launchpad Therapeutics, Inc. [Member]",
        "terseLabel": "Launchpad Therapeutics, Inc."
       }
      }
     },
     "localname": "LaunchpadTherapeuticsIncMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_LeaseOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Other Information [Abstract]",
        "label": "Lease, Other Information [Abstract]",
        "terseLabel": "Other Operating Lease Information"
       }
      }
     },
     "localname": "LeaseOtherInformationAbstract",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdtx_LesseeOperatingLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area",
        "label": "Lessee, Operating Lease, Area",
        "terseLabel": "Area leased (square feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseArea",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_LesseeOperatingLeaseNumberOfContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Contracts",
        "label": "Lessee, Operating Lease, Number Of Contracts",
        "terseLabel": "Number of leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfContracts",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdtx_OpenMarketSaleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sale",
        "label": "Open Market Sale [Member]",
        "terseLabel": "Open Market Sale"
       }
      }
     },
     "localname": "OpenMarketSaleMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Office and Laboratory Space, NY",
        "label": "Operating Lease, Office and Laboratory Space, NY [Member]",
        "terseLabel": "Operating Lease, Office and Laboratory Space, NY"
       }
      }
     },
     "localname": "OperatingLeaseOfficeAndLaboratorySpaceNYMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_OperatingLeasePrincipalOfficeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Principal Office, Two",
        "label": "Operating Lease, Principal Office, Two [Member]",
        "terseLabel": "Principal office, lease two"
       }
      }
     },
     "localname": "OperatingLeasePrincipalOfficeTwoMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_OtherAwardTypeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Award Type",
        "label": "Other Award Type [Member]",
        "terseLabel": "Employee Stock Purchase Plan and Other"
       }
      }
     },
     "localname": "OtherAwardTypeMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_PerformanceRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Restricted Stock Units",
        "label": "Performance Restricted Stock Units [Member]",
        "terseLabel": "Performance Restricted Stock Units"
       }
      }
     },
     "localname": "PerformanceRestrictedStockUnitsMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdtx_RentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent Expense",
        "label": "Rent Expense",
        "terseLabel": "Noncash rent expense"
       }
      }
     },
     "localname": "RentExpense",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Equipment Included in Prepaid Expenses and Other Current Assets",
        "label": "Sale of Equipment Included in Prepaid Expenses and Other Current Assets",
        "terseLabel": "Sale of equipment included in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "SaleOfEquipmentIncludedInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_SaleOfStockAuthorizedConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Authorized Consideration",
        "label": "Sale of Stock, Authorized Consideration",
        "terseLabel": "Sale of stock, authorized consideration"
       }
      }
     },
     "localname": "SaleOfStockAuthorizedConsideration",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding",
        "terseLabel": "Increase of authorized shares, percent of common stock outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Achievement of Milestones Probable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Achievement of Milestones Probable",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Achievement of Milestones Probable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAchievementOfMilestonesProbable",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "terseLabel": "Maximum employee subscription amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "terseLabel": "Award purchase period (in months)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bdtx_ShelfRegistrationStatementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement",
        "label": "Shelf Registration Statement [Member]",
        "terseLabel": "Shelf Registration Statement"
       }
      }
     },
     "localname": "ShelfRegistrationStatementMember",
     "nsuri": "http://www.blackdiamondtherapeutics.com/20230331",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r346"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional and consulting fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r55",
      "r103"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r105",
      "r317",
      "r324",
      "r325"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r14",
      "r17",
      "r78",
      "r281",
      "r320",
      "r321",
      "r357",
      "r358",
      "r359",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r346"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r364",
      "r365",
      "r366",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r73",
      "r74",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r82",
      "r88",
      "r104",
      "r121",
      "r153",
      "r156",
      "r158",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r244",
      "r246",
      "r259",
      "r346",
      "r374",
      "r375",
      "r411"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r99",
      "r106",
      "r121",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r244",
      "r246",
      "r259",
      "r346",
      "r374",
      "r375",
      "r411"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r161",
      "r174"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r45",
      "r160",
      "r174",
      "r313"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r44",
      "r174"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation and unaudited interim financial information"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r36",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "NATURE OF BUSINESS AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r101",
      "r332"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents, end of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r29",
      "r34",
      "r35"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash, end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r29",
      "r80"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r376",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r12",
      "r84",
      "r92"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r58",
      "r181",
      "r182",
      "r327",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r364",
      "r365",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r346"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.0001 par value; 500,000,000 shares authorized at March\u00a031, 2023 and December\u00a031, 2022; 36,511,947 shares issued and outstanding at March\u00a031, 2023 and 36,434,297 shares issued and outstanding at December\u00a031, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "BENEFIT PLANS"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r18",
      "r110",
      "r112",
      "r116",
      "r314",
      "r318"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded",
        "terseLabel": "Impairment of fair value assets"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer contribution, percent of each participant's salary"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer contribution, matching contribution percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r32",
      "r53"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r206",
      "r234",
      "r235",
      "r237",
      "r241",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r117",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r135",
      "r137",
      "r139",
      "r140",
      "r141",
      "r145",
      "r250",
      "r251",
      "r315",
      "r319",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "verboseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r117",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r137",
      "r139",
      "r140",
      "r141",
      "r145",
      "r250",
      "r251",
      "r315",
      "r319",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, recognition period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares issuable under employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r59",
      "r97",
      "r113",
      "r114",
      "r115",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r147",
      "r168",
      "r196",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r249",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r281",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r49",
      "r154",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "EQUITY METHOD INVESTMENT"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r252",
      "r253",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r192",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r253",
      "r285",
      "r286",
      "r287",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r192",
      "r197",
      "r202",
      "r253",
      "r285",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r192",
      "r197",
      "r202",
      "r253",
      "r286",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r192",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r253",
      "r287",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r192",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r285",
      "r286",
      "r287",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r256",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r178",
      "r193",
      "r195",
      "r248",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r338",
      "r369",
      "r370",
      "r371",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "terseLabel": "Gain on sale of IP"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on sale of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r19",
      "r32",
      "r49",
      "r85",
      "r93",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Loss recognized from equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in current assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedTerseLabel": "Amortization of premium on investments"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r252"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments:"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r48",
      "r81",
      "r87",
      "r95",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r278",
      "r345"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Cost and Other Operating Lease Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023 (excluding the three months ended March\u00a031, 2023)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease term, optional extension (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r121",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r245",
      "r246",
      "r247",
      "r259",
      "r336",
      "r374",
      "r411",
      "r412"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r83",
      "r90",
      "r346",
      "r363",
      "r372",
      "r406"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r100",
      "r121",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r245",
      "r246",
      "r247",
      "r259",
      "r346",
      "r374",
      "r411",
      "r412"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r29",
      "r30",
      "r33"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r20",
      "r33",
      "r86",
      "r94",
      "r98",
      "r109",
      "r111",
      "r115",
      "r121",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r133",
      "r134",
      "r138",
      "r153",
      "r155",
      "r157",
      "r159",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r251",
      "r259",
      "r337",
      "r374"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Computer and office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r153",
      "r155",
      "r157",
      "r159",
      "r337"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r271",
      "r345"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, to be Paid [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r269",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liability"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r277",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r276",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on investments, net",
        "verboseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Unvested performance restricted stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r1",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r346"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March\u00a031, 2023 and December\u00a031, 2022; no shares issued or outstanding at March\u00a031, 2023 and December\u00a031, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r28",
      "r71"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of common stock options and ESPP"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r43",
      "r118",
      "r119"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r57",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r54",
      "r102"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r56",
      "r91",
      "r316",
      "r346"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Research and development asset acquired other than through business combination, written-off"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r76",
      "r96",
      "r413"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r326",
      "r355",
      "r362"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r60",
      "r89",
      "r323",
      "r325",
      "r346"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r97",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r168",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r249",
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r69",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r51",
      "r98",
      "r121",
      "r166",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r203",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Cancelled or forfeited (in shares)",
        "terseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested restricted common stock, ending balance (in shares)",
        "periodStartLabel": "Unvested restricted common stock, beginning balance (in shares)",
        "terseLabel": "Units outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested restricted common stock, ending balance (in dollars per share)",
        "periodStartLabel": "Unvested restricted common stock, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant\u00a0date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)",
        "terseLabel": "Units vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of units vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Life and Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested or expected to vest, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested or expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested or expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued under share-based compensation plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails",
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, remaining life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, remaining life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested or expected to vest, remaining life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Maximum percent of fair market value of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Surrender of shares for taxes (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r272",
      "r345"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r13",
      "r59",
      "r97",
      "r113",
      "r114",
      "r115",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r147",
      "r168",
      "r196",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r249",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r281",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r147",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r1",
      "r2",
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock related to ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r1",
      "r2",
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r1",
      "r2",
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r59",
      "r60",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercise of common stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r1",
      "r2",
      "r59",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock related to ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r59",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r42",
      "r346",
      "r363",
      "r372",
      "r406"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r274",
      "r345"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r162",
      "r163",
      "r193",
      "r195",
      "r248",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r369",
      "r370",
      "r371",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r334",
      "r341",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r148",
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r273",
      "r345"
     ],
     "calculation": {
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r136",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r135",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
      "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r347": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r348": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r349": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r351": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r352": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r353": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001701541-23-000032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001701541-23-000032-xbrl.zip
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M]6;[[>'NGR_F"/R8]!XO2V_2OE'M=]!^S[Z!W_H5B;]%XNM;)/8:4YPH%R5
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MQ[1%ZE>MHQ:O7]OSUG7CM/[I/0<2M]V_#T;'G^R%)BQN7!]W6M<?4(M\!+:
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MFW?QVV;./#>9+32QW_T2%/%)W@6X%(:[DPU/:K_M-W9^KZDB#5814)PS;<Z
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MF"3$DJ3 I?G <\49^'3^I-[7VP,X%\[> !<&<ZUST4Z+8E'%"<*OG?A\<_>
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M5'/<2)<H%LE$>E!SCD>*61XQJ3VC!&CJ@YICFQ3S%5)S"S)ZU@-6%AO;G;N
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MO$_--N\RYUV6N8!#@8$V:__[:ZK^G<L.3U7F%F+&L#L*CQ5]R7GYG<J:V>%
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M;'3MLE[%OLMC7UK?_HR5)X:&.&258 !Y"8FTD")*!,&::2*MXBND%)O#07\
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M3B+#:VJ0EI8B3QH5NEP6=KL22 &JQ0'5?!<S9X*TCEE$JL+*,K%<."FBW#2
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M$2PX#A:$HW5"/!N?#K@3THY@ZTG0V@*N4M(6<KYKWKWR4!M["*  P-/2K (
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M89PO<'!O;^,S9JK7/>+2D-&%565P8?3M15Y]^^F\&>W.9.GM]%[7"V][LNZ
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M!2K4$WOZGPPS&N=5O'U#G45.S3.%T>L:\?P,AI9NS0^!CC/Q9N8M#B8&1+@
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MK2\B!"$I.A(MY<YZ3:SBQ"D1&&?$I]GU]93X=CVE_^&&_ NP^-;+FO+_VNH
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M7_U"^%RO\I]!IQ_#6!/\!,8R7[4S;A@U<=_KE09\./]H"W3I1W_8;OYG4-Q
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M'GAP?#(<GFN><6PQ\%#=W"6A.YIO^S-6C@;AQZBMF.L,^E<N-QY FWV["9>
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M:C[&A'/<$4TUYBX2$Z,AWG!GL;>4D_'RCV_)9%S#E5]$5OJYH87"]0^,=0%
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MP-U8-F<QE7@;#37.1"6QY%AQ$Y@4V"G)G*3!\FEA!G)5+Q;/J#3<UT3KA=.
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M.BLTA(@YJ.!N1P6W,"I<Y!ORMG:VT(%M-6+WF%YA63 L_H\PZ)Y!X%P"QET
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MPP;7V!$AG(PF\NB4<_![U"SW954VN45/ 9:PL6JP<3Y].E!9-ZP[]8HA3D)
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M22./@!!$1E&?#GZS^A-.V$LGX-K)Y"+*T@0?MD]#2I9G&[W5^=-C,:-):>T
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M-FZ2Z!Z3I%2<4=9XH$JY2",J9A5!^HU.D%; +03-VX(3AE_A8*!UQXZ.2GF
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M2$TXI&%W_ -H2%&^8 K4);2HS V0Q5,MZ$UM"/AICMHREF=JQZRM0?"&;!?
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MGL8!3OI2EUDC)8J_R:#6N,\T$"JFJ\;VE&GYN BD&G@IM#36'@C.!).)'M>
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M!P?OV6;@]Y0(,^FV2TV"<LQ&$.5^G.;4+*_X*,?N4LU*Y771KZH;I7[8.OZ
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MV!^@_&"U(%51G?RFP7<^XI^*:0X">\;SZFS'>(KR\(]WOWW$OS[# 8^3B*P
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MQ[I=:S"X]:?VAEW+=6^SXGK'MN!@SZIZ-^O*^"T6_E?C,!*3- EPMGPFIK*
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MV,^3[^89;=XK".,;"?Y439,$8D<7GT#39\M?!(DY,Q!YQ"9J(T1; >$;<E4
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M XNJY@RC1X&AVSWLL#R$=3H=$&_"G=Y]H?CK+'KI2V]XA')K:9[)"0:N.5M
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M#]><P]LP_8M,?;QZ =;*KO/!;73A#]<3M)63NU;X?/56L;/YF;KN-9LO'.Z
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MQ[4'*W')69.S]^NW2,W__M/_ U!+ P04    " "U/:E6^8C]1=<G  #WN0$
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MTK9>\EKBW]J6;'NV[=R<>[.Y>Y-N9YL4A6ON<LY@=2U*%U4:BC%K=BK'&$1
M[(Z<5\#L;%-W9_18RM--S-3%@;@+.&_#*?WX81R&DY"J=19^["H(.]H;OAO=
MCC:*VYCS*DFZL<5N6.-TEGQ6O9!][=SB%;CL./T5%<WS(4C?/*^T([;<M9>\
M*[*L8X*&))EY@D>?</AK&/^.TPIT$;Z&F(W S$&&NO5I!4)0/H'B)9LDO191
MKN13W_3T'7C1C4TP:JF_AK[SW+4_P4%YCQ_[D^G<D_^6(EF TZDDR9$M<NM2
M22"G3H%(6291;%1.KQ8PW?&FQV7HIGI=.HH[W?/YY>#U^W\>O/GM\-?#@^/?
MWM-_WGXXKLVM\MD 1^67T!_/ZCL/)A.<3L(PO^F'V!_,"N-^Q3 Y&V.N-:+I
M;%Q+HU^&27^RP0Y1EW ZV$_:FO:N[#X%IP73GN8.II2/VO%H92SHG9)>"-WK
M$MAF[L>55Q_<^.JCBU?3%]Z.AN/OD%S$GSPG&D]90A&LGMYE!J)-"B0W!GGP
MC)766UM-!=@X!33#\ W2J_ZD!K"$X"#6.2E->]XZ+)%F,XLL \TW 5R4&;Q,
M-/V(Q-NW&+H3U/97@=VQ[EJJJ*G%NFC&$R8G)'[]3XVD/]/Z.;P1<"_(HKVQ
MM%HJ2ZN;<@E<T JRB$YJ&[B)K<.$E<%MGV*-#7NU%J$3JW007L[W74Z7H;/<
MDZ\;*6P*R9'SJVSM!\K %U\/2"GRB5K7Y]Z.Z+$1I:'^.\@_+Y6]IQ2G*55'
M$-+)VNR%"&R2 <?02!8R-[KYB;)E8!X;)]IHO8,6.RV6Y?D&K\E2I^0M2.D\
M*$WKLO.B@+/<BB01HV[MYC0#OZU<SOXX0;NQ^[[D?;Y)__+K0M;ZU%_&^#]G
M.$Q?9]N+(=%4G&A\%U%4[0 3(>3(:70ZHWQ6I._6&: 58.TJ%[0COBQC;2.[
M=>!]?8-X$\#%=M<J$#O*":T ;S=)H>:F74:=QG;9$86T$S$43MZ'\Z86T9/'
MD"5Y)"ASE"J(=#49\'"I<T>&:!^8LXXYML28R;>Y^'PK7 FI,M. .;JZR6[K
M_GH$Q* EER&8YKT15\&UPZVH5@9=@3 ;6:.#/:9+@^;;C__HXYA><O+U#7[&
MP6S<(#?9LLC *1<)90S@L2!P^E F6K>3[<RIOQ79#S^HL?4ZV&JX<1Q<Q[L8
M<:N W:)3M!3HSMVC9A9?9=IJ:JYMK7S+08=4E)(,DJ^]";QW0%%R+09PT7#'
MBS.M.V3N ;=6]Y_VA%IK6*E+2KT>?CJ;3F8:X.?GS4)P#'F $+VD23L6B-K6
M_MCD)C 6.2^F*P)=A[,?KE,C0RZCS(96Z-)WN@1-G+MUDK'$M -,*8%BM3._
MI) C8'06F=;<MNYS?PN<IT:0^UAA2S.(7$#S,8>0N(6H KE]#AW]Q"5(G5$%
M^E4QVR"(?)H$N8\5NO",^\,P3/TP>#V<3,>S.Q]G:VS,*'AR''2N:VR6"1Q3
M#H++R16M)+>M#Y O@?+$XZL&]ND@63<KG"PXKFJ9]X(DD8_*#6@G'^B1DYM_
MM1A:J\C24;S54HX=A6,M"#+:,^MVL!(VE0FE$)K["&B-!87,0N""YG#+HY1*
M%NE;9^3VGZEW!7?[3M1UC-H!07\=#?'K_*C +V?#?-XJ@-P XU-)((/BH(+0
M%9  B3Y9;Q73LG5ZY68DVW?0=F?=47/3='138KVYJ/:C(;_F[:BV'AV<9<SU
MIH^;BP07R(W&7(3PH(-%4-)F\$E+\"%G%8OB,;?V[NZ/]@D3;TLF[J03V?C3
M:!RF^')4=7C>/_E\VT2D7)).0*XQC1R&"%$;"8S3L/&.(ZT"S?EW"Z G3;%6
MANH@.OWM^.^CSS@>SIR%CTCBX^05QNDUG&B4\.@H,%>I-C-.%$6[4( <"<,X
MH_@KMKX;8U5L3YA;G9AO-_V07K_]Y^'QARM'I^8N08WQ+R3:X,#;VN_HX!3;
M9G)>.9JFBLDV8?+!)EIS2C#.<V:$04,&E=A;^VT;'G=?O..H+._P_^9;42M3
MTJ,/ 0PA!^4Q0LPL0]*.O#[I8FA^GFPM@!O7WU]YQ?<C\^!T-)[.V_Y,IK/-
MK)Y%;DQT#K@R'LB#"."$KVFXXI(0BOO2>I)=%^,.SA1WQJEKE?M=VJN+#J6W
MX[UHD_CW\6@R^6TXQC"H OR=U#Z_7:/>GB$C<TS6LPX)26.D/XCUMJXL91$%
MK6M?S-\$^!-F8@>6[:)CZCV%J#=[7 @1N4VL% -<:A(B2@1GLP,68PA!(1K1
M^@Q;$^ _Z-G2LEV<CENJI._%Z3$M4+$<(3A/#GJJS6<H/ .1E.":84;7^A;*
M5;$])9(UL4\'F;HKY+^">I&@9%9%+PL4703%> $AE'I1CHXB>11,BM9K[ JP
MMM;6<&N<:6V+O3G$MB2UDT56F2D+G)9S4,9DB"IY&@FAIL*9L\WOI-FS(H+F
M%E^Q/& =S>][LG4567Z4!ZR9=5V+(%UF7>]CW7UGK+>6%OVH06K/*?!&!CY)
M6O=]%(A)JN1:I]?VGZGW+ _8&Z*N8]2.KO:Y9RJ0\<!4X:7>=<Y B9+ ):%
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M\)O'I^G\118?:,D?5F$9JW]OBK!F).8DU28Z$EFJ+78H 44A E!EG$,4AX)
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M> 0Y]_KZ%I#XJK9_;*AA:^];*+U3B=_FGLLD?=Y\>\IK WC=,WN2Q7'"$RF
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M7I[ #@)A15.'[W8C(R'SR<VLS,N7G<2?=H1LA& 8*XQ-R'X&,!($$$9B@*#
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MJ'K=[.)I(V^[\475\2)8SG+7;<!#.-MQK@?T>N;+EH3KKM3>CPE.P. KE/3
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MT @C[9QCGJKF[;B9B>_\W5AI,-";(:O_?I>OA9UC/\*)'O 8Y=R H5?ORD[
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M$L;W&^@W&_RH@WNIWL>O[$#H8J/(I15.>OIC-H))%L<)04"2! ($-0%<Y"F
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MYU7P:6*O71*J"E4O-O=;U:K/;MBKDM5KXT/3$=A6*!R)/!500 V8L!N0L8"
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MC:&"%?LUOM\ QXMTS%Y0Y&6L.$.URYY$W;Y\G<^^%>>2]6F&H!)* F. 8Y@
MI&$.&",YB%E"29PSE*;"6[GK<%M#6S.M3(W&&[:V$.8Z JW;>!$(L([)?8W5
MIID=G!0YP!%2I>M(2_TK=36[?%"MZ\0M88IW;]2O?E>6KQ[15$AFZW_DC-B2
M0-A,DS6) 4TRF"$8)U0FYQ3RWF]R:,P1O*CW 91=MSU"8M?Y1L9NL>]?-I&L
M##X>F71VY>_CZ'14!?Q @Q>M"'X<@%/5P1ON;$<TMT6!5TM<9N(S>U%WL^GJ
M*&:48IYCC'*0JA@#I!0'!"8Y$#1.\SS..<%.,;XNC0V-7&ZGIA5CK5T\&U/]
MB*4153=*"855QV2R-C,J[2Q.G%:6AB,1%SP"T4=C4[T2AXO3NY3A=$_;^H1O
MS6/G;'([E>K[?Z@?(X8S(A%6@"D& <I3# B-!2 JER@G$J?,*4W_: M#HX72
MR*BR,BK,C(R=OG4(=X%L)H4@\'3,!-[(M*@W>,3[,^H,[CZQY_J"1QS:KRMX
M[,*6P6CFF7(\>5V.OZFU ."=Z=UWLQ<SX1@E6D+)F0(XI@2@F.6 <[L'CYG6
MB;)1:U[R&Z<:'-IGOFGOEFZG-3GZO33:4XWO).AN$X.04'9,"6>BZ!_;Y@A-
MJ#"W4\WU&_'FZ/Q>\)OK?6?J=Y8"1#;J?C:U^R37W\>+D1!I#H4@P/!-#E!*
M&* XRX"2*20)YDBFK)6<YZ'6AD8RE<C9VLCH=VMF6Y'/@P"[<4HPV+J>8_@B
MUEX)M F)T,*@!]NZC$YHD]M'94,;;VJ94E/KC+WY\5&QQ>N\:.C]7/W7JYJ*
M'\6[35/!F*VV*!)B%A\P2P!+&04ZM?219QIKK^@TAS:'1B$;=D8K0UO1B O@
M;F02&,:.*:45@OZ9-^Z8A$K!<6BQWUP<=PCVDG(\;AV::/'=K-B/4:<5%3_-
M)I/WL[E]ZBC)E9D,<0BT0K:<"M* )20&J4Q(AC 6L5_@[<#\&QJ-KE1C6:4:
M^\5:_[__%\SC_R=M7(OV+,XR4-PO+FK<^=O2\6C1G[3Q"BE73>-.LL4&^B8,
M7N2XG7=_$JGCL[JV/\'C\\P\<UFS,8]9?+*[+O/Q]$L5L:1(CCG-,8BQX@ I
M00 C+ <IA"25N80R]4H,=&ET:"/RRKR6JY@F?#V7,8%0ZWADVBP>M;*R"PT!
M#UA"+V6:FKS,6L8!A*.+&9=[>U[-5,QX\]TJC2YL,9@=;JS^13W,QT*-F,A4
M+A((< [-*B5).##4%8.$&?Y2*58B]5(OZ,GNH7%=97VDUN9?MI:*YVO0\:*B
MN\X=_F)AM1S8\/[ @J!&("H@&,#TOUV?77I:[VGUSS%=;]<5P:;A+9MO.?"M
M"K:?M'=QS."R5IY&><Q);",>T@P@J1%@&#+ :)S2F BMH5^=P5"6#6WPJAVS
M0H<ED?%&PENL&8_O,U[+.H?!NMUQ*+M$9W8]6.WU8_/ M6@<N3HHT1@:\U"#
M33"[^AU.0L.Y-V $;Z"CM=#1UE<CU]?QO+AI<:0XUO9LF' F!-49@"PSBR+,
M$D"D)@#C' F,.%(J#;HH"NS T :8POR^JDN&?AD"+8TNV,4#6",U#S5;BZ05
M#(TU(2^V7.JH'_M:-X4V?U@+J(XZQWLEU94=[6L_O!\O!)O8VN[OS6\6(YYP
ME2K*0$*4!BBFN:V_+H#F.B>"D0RY18<WM#&T46A5W*"T,[*&1H6E_L4?=N%L
M'B0"@=0QC[? IU7UAR,(G%7]8?>9O5=_..+4H>H/QRYM-SF^4TLKBO$PGWT;
M2R7?_/B\L"5@5SJ%UV(Y_E;$@Z^4=A'+>(8H!#2WA5D)U("F20J23$+!$TEI
MPGVFM_XF#(T:"N4</9G]L8AL]VY(F;*5[9XBQRWZQ6VFV2W:'7.,E;(JP*[-
MM_/"7ZP'9K;WZT9=JK47G03%M <QT$2MA0&]3K7: [0[63KC2?[3G;?CY8_K
MN6)O9U*-,)<T355NB T)@)"A.!Y+ E"*,<M8!B7*7><XFP\>''O98#1K7&2M
M<Y_,;(%U>@;3%H*.*<71>Z^IRB%76\U/MA[4VZ3DD/F;,Y&#_]XR#56(^:M9
MX\QG6BT619'S]TK50NPC*G2<:EL[A0BSS)"QM#]!H%.DS&]DFF&O&LS-S0WM
MP]PTLU1I- N^UTDQP&GE*XM^ FJWV4,X #O^K"M#HRT,K:FKV@H!DTZ=0 F5
M<MK<6+\)ITZ.[Z6;NMUU9K+IA_%4W9H?%Z,4*X4ECD%&!0:(P110898OB.M,
M)CJ.%?0BD?TFAD8<*PNCWZV-46%DVZ32-9".6]EGP=/U9K,?,NV31_><#YTQ
MNF[@,FFB>PX>S0W=O[+=I_T7-35S_LGU5%[+E_%T;&?[-F7]YKO=0U4C2&*8
MI9(!JKFMI)1!P#.)@,BACC7-%)5>0=,GVAO:1U^96TP4V);!?A_^*9C=6" @
M>!U3PB9NV[9&E;'AZ,$1E4!<<:JU7HG#T?5=%G&][9R2;*L=-*43S!"W0G>9
M^0_E$M"4)P!"05,-#:40KY"O[<</C3!*Z]K47FM5=&V VXFE81T66>NTNMHE
MRZJYU5,+5$AMZY34RGDOQV72Q+OQ0DQF-H7"\XWT>.* 7M>UF=$;0XMZW-&[
MVP*=4'KY'BWW*W;O#\F>4GV+1PQ6RN#NM<BCTYA21AD"B9EX P0AM+6-$> X
MI3'50@A"!R924%H^M+'X\]1^S+/7Y6)IYJ%V@^^\"O&]]'Z>9)J)F()<)'9W
M5N2 PYP#+%2FN8H)C-'H:Q&>8A:#\^5/_ [L>M'EFU#:&,W7E5G$[.5E9EZ'
MY4S\_2KBZLMX:K6@(\[,K4+]#.]*DE.=YXH"KF4&$$X$(.8W(-$PP[%62NNL
M>E=NIO*G?U-J'R[YGJB22'ZBE\1Q@W&(W=[UON4E5$=*% :02]BVXRZ=3>AM
M][#"84-WQP6$/78,:!DCMZ&?7BJJUWNA28Z8-M\N( B;&1"U8; YPP#E2-,D
MQXBQV*=0X=&6O.:K/=04?+)M5$5LR_((T2^J-/77JVBJ/,NP'$?8;4@(@EO'
M%+YI8U4I(?JE,C-@J9634(2*0#O:3K^!9J?<W8LG.WF#'TEPN?S>(9-=B^>Q
M*NM*W>N/XXEAM=E4+1[F,UZDJT)-91%^3TB2 )1!"5@N.. 9U#%G(I7,Z=#K
MLFX,;3G>WW1K QB;=[N&)JJQ<6/2"[^&S33]\[Q<?YII_)_DO9)5TD/1X)_@
M_=KRYW_X>^8\M1E&]Y;S)FN+G0RE<9K"8D)T8>MZF6T-HP?JJ=Q K#DS0/%>
M/]I].EL\U,QH2JL\CS&=GC6DX6\5?6<E1C8L_N>:;CI1L/5!*7287F.;EXG<
M<X'A:#"?T\UG%WQ8_?AO8[-4FXOG'Q_,%SDI2A! Q+!$@H+4%GY ,<& I00!
MCA)&M"8X]]-E<FMV:"N4#=7GE;%%"-O=]6_G5G]H0M^-F,)CVC$SG0/G.:4@
M'- )7PVBJ=%+%81P **A)H3+W2V'ZU>^&,LQF_]X9(64D66_XDM(%$]QGJ:
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M'(CQ_5!JI'C'1_7'Z7Z^;9&XYZT]:TQ629:_%?(\UU-I5Y16O.QI9G]UOU9
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MPGY[HF.&/)E[5CIRM>J4Z/?"EZB3TY-PT(8*Y3G?H'[#<8(!N!=2$^[)9XI
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M&"MNO@<?S$__^D_U;\Q_K!+_O_[3?P-02P,$%     @ M3VI5B,_S>')60
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MT-E%LT^"9!<Q-X"5UV[ZY6@4RU_'_W4U_.8ND)GIT>RUFTQ^#$>?_^(NKM+
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MBWS*\,EK=O)\2GD,Z%J4N@)I%?A(->!J4XRHR#VM7>OZ$Y+ZO03H!E(UM=
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MIB--S&'\>.6GZ'&ZR8_3R>->NBF5;+G3/#\?>O7C\2]?_]I\-0^\-R9)6;I
M>@+"EB[B3* 0&4T:W>/ =?7[G8KTOX39C9O@^%$8TA<6&G K;MFYP^71]^%T
MD*FDY7@3M(RBE!65UO@AEG'#T7O'7$K=@?H!,?TBM#]\K 3J+LIJ 76WY+]W
ME_CE^<2-IKB.4:-OQI=N.!H8&3GUA*$[5$[?E17H@\V/KI+0BCG'JT="/Z>J
M%1SNI/Z'H*JKBQ[151S% ;K?H\50H\+8;^G2I\G ^:A8BA2XXR@?S1(X84.Y
MB(PJ<"N9YS]S.E<^O6=05%;?N*8L^P;#QR_I(G](GX?%2UA<52\]AR4S,N3
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M%6PK::\E0#[%T#*8E(:A\T4C6&/1=7)>83#)'9A4:M"$8^'A>4L]0*XFJQ%
MUH+"*JA5TDNC4)O>K-CKXP7!N(A$0HJ^E#S:TBTQ>4C)24ZY<XK%/6#M(5V-
M@*T6&-8 VTZ::0EMKW[<?/GG(48!D_#EQ[OT+5W,UVBB*FKB"1AA/'+E'5@D
M&"A^R /N#$%WYAP^2UF_!T'-[;>U=-@2,N^NML?\+==U<B$+@7YUL#&"L-:
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M%12,(!F49#R40WL>:Y]]/DE(O_=Q7:-H=]DW *!WR4W3E_%%/+G\.AE_6[2
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M3"H$'M-:QV](R!TTXG>W2-R5QE:NQ^OA9=R#\GH&Z2H^EJ>:W!JN99F(P'P
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M$$2K8T\?OF)U^Y>_K_CYN)Q?IOG7</&AE'G"S]\6ZT3=::%R40HH,6)UL)>
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M"7Y;:G7\E&#]1?V(%,G^YU]_ U!+ P04    " "U/:E6;+7K AD)  "W,
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MJ4L;_%^?$W(R(G^G%-PWQ)/&GKE7V?__F?*[:)T> UD*,ID"ZO217E\.>)0
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M'_MER._^.\JOQ7+MK?)KE,+*_!YC!=F!_$53=!N+":?DAA9=FJ5++A'@0BQ
MUL$,F,4(QU.4QEJF%"( H6<U'V04HPB>),,<!=B'KR02$>@/+9S=DD%,?:H4
MEE-C$N%;:G$S&U/!=P2<@2FY%8PPAS'PF02!"&8Q=$=6\*!)R !?*C5_YOTG
M5-)L$!- Q!0')6E$Z83I$ )4"?6M@PN ]<48NA$TFBXNPWN$8_WG@2-% 8LA
MX08[\P07 8M@#LURH9W%0$&1E</PV>>I(2  T4(VBP! 9@@L 0P8^!I8<S['
M9P8-]6!JV +$'I:*QB+E8 "@%( <.YVR_OA8A2C@8J)RQ$IZPY2&DY9&V'SI
M_ 8OBPO 4[DS2]Z^1^PU-@Y[PWN)^K"U5_-V#U2&KDQY&.H00<#@T::PC["D
M%BR0?#;BU%8_"@@=<:9"8V[,(J!-0YWFF3#E<Z%2Z&<(50KN4)-(X5,"7RNT
M#2 A%%#GD-"[\T-00!1U@*L&*0<+>S1H;M,=V]6>#<R3>V1&;L8.K69\9 AM
M <0.5,:7M2<*[DT4P$1YE5^$-E@8M?"-E)D]GF\*7/'&P-6KENN[9AU.J(+3
M!63.5KWG854T!=G'J5J_BZF,(PH0R69RM5:D$@8 TAHS9:D0K&ALQS'"?$ZB
MBT0L*<<6<UFQG>.FF)&T:61 J."+$IP1>X6DTI%BA&')3 #,20);&F(S4JI,
MF;9;5-F:;HE3* H.:2!JTRD!L<K\E&/#]Q"6=6)>[J&'$P^+F@<^C:@Q!$J&
M_I2LIN#-Q^UH8W";T^Q]V*[-54OH79_EU@8Q '_,B,$F5B+&ALZQ EP;H6D
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M:[#>,$]>EJSOS;]S&+O\%:MS7RVR7]=K,V[Q*N[7[O9W]T?_ U!+ P04
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M,9U(OUK'N5MW8VP'(8Z'""D[KXJH?_[PK:_JXIEY'=0DOI\3@6LM7L(I3;E
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M !$              ( !     &)D='@M,C R,S S,S$N:'1M4$L! A0#%
M  @ M3VI5LRO#-HH#   IG,  !$              ( !&E$! &)D='@M,C R
M,S S,S$N>'-D4$L! A0#%     @ M3VI5EK$T*."%0  G\8  !4
M     ( !<5T! &)D='@M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0    ( +4]
MJ5;YB/U%UR<  />Y 0 5              "  29S 0!B9'1X+3(P,C,P,S,Q
M7V1E9BYX;6Q02P$"% ,4    " "U/:E6#_: ;7V9  !XH08 %0
M    @ $PFP$ 8F1T>"TR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @ M3VI
M5B,_S>')60  ^A@$ !4              ( !X#0" &)D='@M,C R,S S,S%?
M<')E+GAM;%!+ 0(4 Q0    ( +4]J59LM>L"&0D  +<P   5
M  "  =R. @!E>&AI8FET,S$Q7W$Q,C R,RYH=&U02P$"% ,4    " "U/:E6
MX_/". @)  #2+P  %0              @ $HF ( 97AH:6)I=#,Q,E]Q,3(P
M,C,N:'1M4$L! A0#%     @ M3VI5MQZ]*&'!0  2B0  !4
M ( !8Z$" &5X:&EB:70S,C%?<3$R,#(S+FAT;5!+!08     "0 ) %,"   =
%IP(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
